



The College *on* Problems
of Drug Dependence

85th Annual Scientific Meeting
June 17 - 21, 2023
Denver, CO

PROGRAM BOOK

WWW.CPDD.ORG

HOTEL INFORMATION

SHERATON DENVER DOWNTOWN HOTEL

1550 Court Place, Denver, CO

(303) 893-3333

With a recently completed \$80 million dollar renovation and located on the 16th Street Mall, the hotel offers access to some of the best attractions in Denver. The mile-long 16th Street Mall is a pedestrian promenade with shopping, dining, and entertainment.

REGISTRATION INFORMATION

Please visit the CPDD Registration desk to pick up your name badge and other meeting materials. Registration is located in the Plaza Building, Concourse Level, at the Plaza Registration desk during the following hours:

Saturday, June 17	12:00 pm-7:00 pm
Sunday, June 18	7:00 am-7:00 pm
Monday, June 19	7:00 am-7:00 pm
Tuesday, June 20	7:00 am-7:00 pm
Wednesday, June 21	7:00 am-3:00 pm

CONFERENCE WI-FI

Complimentary internet is available for CPDD attendees in the meeting spaces.

Network Name: MarriottBonvoy_Conference

Password: cpdd2023

TABLE OF CONTENTS

General Information	4
COVID-19 Safety Protocols.....	5
2022-2023 Board of Directors.....	6
2023 Program Committee.....	7
Program Schedule	8
Saturday, June 17	8
Sunday, June 18.....	9
Monday, June 19.....	10
Tuesday, June 20.....	11
Wednesday, June 21.....	12
Plenary Sessions	13
Abstracts	19
Posters	55
Author Index	140
2022-2023 Donors.....	147
2024 Save the Date	Back Cover

GENERAL INFORMATION

QUESTIONS?

If you have questions during the conference, we encourage you to:

- 1) Stop by the registration desk, located in the Plaza Exhibit area in the Plaza Building, Concourse Level.
- 2) Email info@cpdd.org with additional question or concerns, or call (615) 432-0099.
- 3) Visit the Speaker Ready Room, located in Plaza Court 7, for assistance with presentation or presenter questions.

JOIN THE CONVERSATION!

CPDD is on social media, and we invite you to join the online conversation. Please follow/like the CPDD social media accounts:

@CPDDorg



@CPDDmembers



@CPDD



And don't forget to use #CPDD23 if you post pictures or comments about the Meeting.

CPDD'S DISCLAIMER STATEMENT

Information obtained via CPDD channels, including webinars, conferences, websites, etc., is intended only for research and information purposes. CPDD cannot be held liable for the information consumed and information presented may not reflect the opinions of CPDD or its members. The content and information shared should be used at the discretion of the consumer.

Funding for this conference was made possible (in part)
by 5 R13 DA 013182-15
from the National Institute on Drug Abuse.


The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations, imply endorsement by the U.S. Government.

#CPDD23

SAFETY PROTOCOLS

WEAR A MASK

Masks are strongly recommended at all CPDD events. Make sure and pack yours!




WEAR YOUR BADGE

A CPDD badge is required at all times for entry.

GRAB A LANYARD

Red=Keep Your Distance
Yellow=Limited Contact
Green=Handshakes & High Fives



ATTENDEES THAT EXPERIENCE SYMPTOMS OR FEEL ILL
ONSITE SHOULD QUARANTINE IN THEIR GUESTROOM
AND CALL JESSE HOWARD AT 606-233-3049
TO RECEIVE NEXT STEPS.

BOARD OF DIRECTORS

CPDD 2022-2023 BOARD OF DIRECTORS

EXECUTIVE COMMITTEE

Amy Janes, PhD
President

Deborah Hasin, PhD
President-Elect

Jack Bergman, PhD
Treasurer

William Stoops, PhD
Past-President

Sandra Comer, PhD
Public Policy Officer

BOARD MEMBERS

Sudie Back, PhD
Qiana Brown, PhD, MPH, MSW, LCSW
Kelly Dunn, MBA, PhD
Francesca Filbey, PhD
Albert Garcia-Romeu, PhD, MA
Cassandra Gipson-Reichardt, PhD
Angela Heads, PhD
Jermaine Jones, PhD
Wendy Lynch, PhD
Silvia Martins, MD
Angela Moreland, PhD
Marco Pravetoni, PhD
James Rowlett, PhD
Dace Svikis, PhD
Michael Taffe, PhD
Erin Winstanley, PhD

2023 PROGRAM COMMITTEE

Chair: Kevin Freeman, PhD

MEMBERS

Marc Auriacombe, Prof Dr med

Cecilia Bergeria, PhD

Eduardo R. Butelman, PhD

Mance E. Buttram, PhD

Scott E. Hadland, MD, MPH, MS

Abenaa A. Jones, PhD

Jermaine D. Jones, PhD

Mikhail N. Koffarnus, PhD

Catalina Lopez-Quintero, MD, PhD

Carol A. Paronis, PhD

Dustin J. Stairs, PhD

Justin C. Strickland, PhD

Denise C. Vidot, PhD

Heather Burrell Ward, MD

AGENDA

08:00 AM	05:30 PM	ISGIDAR Annual Meeting	Majestic Ballroom
10:00 AM	05:00 PM	Speaker Ready Room	Plaza Court 7
12:00 PM	07:00 PM	Registration	Plaza Registration
01:00 PM	02:30 PM	Workshop: Stressful Environments and Genetic Risk Factors Associated With Early Initiation of Alcohol and Substance Use: Findings From the ABCD Study	Plaza Ballroom A
01:00 PM	02:30 PM	Workshop: Evaluating Pennsylvania's Centers of Excellence on Improving OUD Treatment Access & Patient Care	Plaza Ballroom D
01:00 PM	02:30 PM	Workshop: Sharing Your Scientific Story: Tips and Tricks for Strategically and Effectively Communicating Your Research	Grand Ballroom I
01:00 PM	02:30 PM	Workshop: Pathways to Recovery and Beyond in Native American Communities	Governor's Square 15
01:00 PM	02:30 PM	Workshop: A View Beyond the Horizon: Innovative Methodologies and Approaches in Substance Use Disorder Research and Treatment Utilized Internationally	Grand Ballroom II
02:30 PM	03:00 PM	Break	
03:00 PM	04:30 PM	Workshop: New Approaches to Culturally Appropriate Treatment and Research	Grand Ballroom I
03:00 PM	04:30 PM	Workshop: Standards of Psychedelic Care: Peer & Professional Providers	Plaza Ballroom A
03:00 PM	04:30 PM	Workshop: Epidemiology and Public Health Research Methods	Grand Ballroom II
03:00 PM	04:30 PM	Workshop: Collaboration and Complication: Lessons Learned in Implementing Community-Engaged Research on Substance Use	Plaza Ballroom D
03:00 PM	04:30 PM	Workshop: r/AskAcademia: Special Considerations in the Practice of Using Reddit for Substance Use Research	Governor's Square 15
04:30 PM	06:30 PM	National Drug Early Warning System (NDEWS) Meeting	Governor's Square 16
04:30 PM	07:00 PM	Workshop: NIDA Early Career Workshop	Plaza Ballroom A
05:00 PM	06:00 PM	Closed Abstinence-Based Recovery Meeting (NA/AA)	Silver
05:00 PM	06:00 PM	Committee Chairs Meeting (Invitation Only)	Governor's Square 10
07:00 PM	08:30 PM	Opening Reception	Plaza Ballroom BCEF (Plenary)

07:00 AM	07:00 PM	Registration	Plaza Registration
08:00 AM	10:00 AM	Opening Session: Plenary, NIDA Update, and Eddy Lecture	Plaza Ballroom BCEF (Plenary)
08:00 AM	05:00 PM	Speaker Ready Room	Plaza Court 7
10:15 AM	11:15 AM	Mini-Symposium: Harm Reduction Utilization and Strategies	Grand Ballroom II
10:15 AM	11:15 AM	Oral Communication: ISGIDAR: Again?	Grand Ballroom I
10:15 AM	11:15 AM	Oral Communication: Sexual Minority Health	Plaza Ballroom A
10:15 AM	11:15 AM	Oral Communication: Gapapentin: Friend or Foe?	Governor's Square 15
10:15 AM	11:15 AM	Oral Communication: Criminal Justice: Dangers Upon Release	Plaza Ballroom D
11:30 AM	12:30 PM	Mini-Symposium: 2022 NIDA Craving Challenge	Plaza Ballroom BCEF (Plenary)
11:30 AM	12:30 PM	Oral Communication: Uncertainty as a Driver of SUDs	Governor's Square 15
11:30 AM	12:30 PM	Oral Communication: Alcohol Treatment Development	Plaza Ballroom A
11:30 AM	12:30 PM	Oral Communication: Preclinical Neuro Effects of Methamphetamine	Plaza Ballroom D
11:30 AM	12:30 PM	Oral Communication: Juvenile Justice	Grand Ballroom I
12:15 PM	02:00 PM	NIDA K12 Scholars Lunch	Governor's Square 11
01:00 PM	02:00 PM	Lunch Presentation: Fischman Lecture Presented by Joy Schmitz, Marian W. Fischman Lectureship Award Winner	Plaza Ballroom BCEF (Plenary)
02:15 PM	03:45 PM	Workshop: "Pre-Addiction:" A Starting Point for a Strategic Shift Toward Earlier Intervention in Substance Use Disorders	Plaza Ballroom BCEF (Plenary)
02:15 PM	03:15 PM	Oral Communication: E-Cigarettes: That's Not a Thumb Drive, Mom!	Grand Ballroom I
02:15 PM	03:15 PM	Oral Communication: Cocaine Science in Humans	Plaza Ballroom A
02:15 PM	03:15 PM	Oral Communication: Novel Stimulants and Mechanisms	Plaza Ballroom D
02:30 PM	03:00 PM	ECMC Mentee/Mentor Mixer	Plaza Exhibit Networking Zone
03:15 PM	04:00 PM	Networking Break	Plaza Exhibit Networking Zone
03:30 PM	04:00 PM	CPDD Finance Committee Meeting	Plaza Court 5
03:45 PM	04:45 PM	DAD/DADR Editorial Board Meeting (Invitation Only)	Governor's Square 10
04:00 PM	05:15 PM	Media Forum	Grand Ballroom I
04:00 PM	05:30 PM	Policy Forum	Grand Ballroom II
05:15 PM	06:45 PM	Poster Session 1	Plaza Exhibit
05:30 PM	07:00 PM	CPDD Presidential Reception (Invitation Only)	Governor's Square 17
06:30 PM	07:30 PM	Closed Abstinence-Based Recovery Meeting (NA/AA)	Silver
06:45 PM	07:45 PM	Pre and Post-Doctoral Networking	Plaza Exhibit Networking Zone
07:00 PM	08:30 PM	Movie Screening and Discussion: Swallow THIS: A Documentary about Methadone and COVID-19	Plaza Ballroom BCEF (Plenary)

07:00 AM	07:00 PM	Registration	Plaza Registration
08:00 AM	09:00 AM	NIAAA Update Presented by George Koob, Director of the National Institute on Alcohol Abuse and Alcoholism	Plaza Ballroom BCEF (Plenary)
08:00 AM	05:00 PM	Speaker Ready Room	Plaza Court 7
09:00 AM	10:00 AM	Oral Communication: Novel Strategies for Pain Therapeutics: Still Trying	Plaza Ballroom A
09:00 AM	10:00 AM	Mini-Symposium: Beyond the Dichotomy	Grand Ballroom I
09:00 AM	10:00 AM	Oral Communication: Nicotine Reinforcement	Plaza Ballroom D
09:00 AM	10:00 AM	Oral Communication: Sex and Gender Differences in SUDs	Grand Ballroom II
09:00 AM	10:00 AM	Oral Communication: Cannabis Policy and Regulation	Governor's Square 15
10:00 AM	10:30 AM	Break	
10:30 AM	12:00 PM	Symposium: Measurement of Cannabis Consumption to Determine Risk and Promote Public Health	Plaza Ballroom A
10:30 AM	12:00 PM	Symposium: The Intersection of Aging, Tobacco Use, and Health Equity	Governor's Square 15
10:30 AM	12:00 PM	Symposium: The Intersection of COVID-19 and Substance Use Disorders	Grand Ballroom II
10:30 AM	12:00 PM	Symposium: Stimulation for the Treatment of Stimulant Use Disorder	Plaza Ballroom D
10:30 AM	12:00 PM	Forum: Restructuring the Pathway from Discovery to Dissemination of New Medications in the Academic Environment	Grand Ballroom I
12:30 PM	02:00 PM	CPDD Early Career Investigator Travel Awards Luncheon	Governor's Square 14
12:30 PM	02:00 PM	Lunch Presentation: Presidential Symposium	Plaza Ballroom BCEF (Plenary)
02:00 PM	03:15 PM	Human Forum: Nothing About Us Without Us: Engaging Individuals with Lived Experience of Substance Use Disorders in Substance Use Research Development and Implementation	Grand Ballroom I
02:00 PM	03:15 PM	Animal Forum: The 3Rs Concept of Replacement: Future Tools or Political Strategy?	Grand Ballroom II
03:15 PM	03:45 PM	Break	
03:30 PM	05:00 PM	Symposium: 10 Years Gone: Remembering Bill Woolverton Through His Impact on our Current Research Programs	Plaza Ballroom A
03:30 PM	05:00 PM	Workshop: Early Career Member Committee: Navigating a Career in Addiction Science	Grand Ballroom II
03:30 PM	05:00 PM	Federal Agencies and Cannabis Research: Updates From NIH, FDA and DEA	Grand Ballroom I
03:30 PM	04:30 PM	Oral Communication: PrEP Among Drug Users	Governor's Square 15
05:00 PM	06:30 PM	Poster Session 2	Plaza Exhibit
06:30 PM	07:30 PM	Primm Singleton Reception (Invitation Only)	Governor's Square 17
06:30 PM	09:30 PM	Shuttle to Space Gallery Exhibition: "Art for Hope"	
06:30 PM	07:30 PM	Closed Abstinence-Based Recovery Meeting (NA/AA)	Silver
06:30 PM	07:30 PM	LGBTQIA+ Networking Reception	Governor's Square 16

07:00 AM	07:00 PM	Registration	Plaza Registration
08:00 AM	09:30 AM	Symposium: The Racist Origins and Impact of the War on Drugs	Grand Ballroom II
08:00 AM	09:30 AM	Symposium: The Past, Present, and Future of Reinforcer Pathology Theory in Substance Use Disorder	Plaza Ballroom A
08:00 AM	09:30 AM	Symposium: Dysregulation of the Prefrontal Cortex in Substance Use Disorders	Plaza Ballroom D
08:00 AM	09:30 AM	Symposium: Beyond GWAS: The Genetics and Epigenetics of Addiction	Governor's Square 15
08:00 AM	09:30 AM	Symposium: Not like Other Opioids: How is Fentanyl Unique?	Grand Ballroom I
08:00 AM	05:00 PM	Speaker Ready Room	Plaza Court 7
10:00 AM	11:30 AM	Innovator Symposium: Medication Development for Methamphetamine Use Disorder	Plaza Ballroom A
10:00 AM	11:30 AM	Symposium: The Potential of Psychedelic Therapies for Substance Use Disorders	Grand Ballroom I
10:00 AM	11:30 AM	Symposium: Neuropeptides in Reward, Addiction, and Mental Health	Plaza Ballroom D
10:00 AM	11:30 AM	Symposium: How Neuroimaging Can Be Used in Treatment Development in Drug Addiction: From FDA Standards to Clinical Applications	Grand Ballroom II
10:00 AM	11:30 AM	Workshop: 29th Annual Contingency Management Working Group	Governor's Square 15
12:15 PM	01:15 PM	Symposium: In Memoriam Martin Adler	Plaza Ballroom BCEF (Plenary)
01:15 PM	02:15 PM	Mini-Symposium: Monitoring and Diagnostic Devices for Substance Use Disorders: Challenges and Opportunities	Grand Ballroom I
01:15 PM	02:15 PM	Oral Communication: SUD and Pregnancy	Grand Ballroom II
01:15 PM	02:15 PM	Oral Communication: Minor Cannabinoids: Mild High?	Plaza Ballroom A
01:15 PM	02:15 PM	Oral Communication: Cocaine in Context	Plaza Ballroom D
01:15 PM	02:15 PM	Late-Breaking Oral Session 1	Governor's Square 15
02:15 PM	02:45 PM	Networking Break	
02:45 PM	03:45 PM	Late-Breaking Oral Session 2	Governor's Square 15
02:45 PM	03:45 PM	Mini-Symposium: From Initiation to Addiction: A Measure of the Full Range of Involvement for Opioids, Cannabis, and Alcohol	Grand Ballroom I
02:45 PM	03:45 PM	Oral Communication: Telehealth: Uniform Still Required	Grand Ballroom II
02:45 PM	03:45 PM	Oral Communication: Behavioral Economics	Plaza Ballroom A
02:45 PM	03:45 PM	Oral Communication: Nicotine Clinical Treatments	Plaza Ballroom D
04:00 PM	05:15 PM	CPDD Business Meeting	Governor's Square 15
05:15 PM	06:45 PM	Poster Session 3	Plaza Exhibit
05:30 PM	07:00 PM	Rural Opioid Initiative Meeting (Invite Only)	Governor's Square 10
06:15 PM	07:15 PM	Closed Abstinence-Based Recovery Meeting (NA/AA)	Silver
07:00 PM	09:30 PM	Awards Dinner Celebration	Plaza Ballroom BCEF (Plenary)

07:00 AM	03:00 PM	Registration	Plaza Registration
08:00 AM	09:30 AM	Symposium: Using Big Data to Understand the Role of the Gut Microbiome in Substance Use Disorders	Plaza Ballroom D
08:00 AM	09:30 AM	Symposium: Prevention is Better than Cure: Early Intervention for Substance Use Disorders	Governor's Square 15
08:00 AM	09:30 AM	Symposium: Development of Fentanyl-Targeted Vaccines to Decrease Overdose Fatalities	Grand Ballroom II
08:00 AM	09:30 AM	Symposium: Leaving No One Behind: Ending the HIV Epidemic With Targeted Interventions for People Who Use Drugs	Grand Ballroom I
08:00 AM	09:00 AM	Oral Communication: Methamphetamine Science in Humans	Plaza Ballroom A
08:00 AM	04:00 PM	Speaker Ready Room	Plaza Court 7
08:30 AM	10:00 AM	Brunch with Champions	Governor's Square 14
09:30 AM	10:00 AM	Break	
10:00 AM	11:30 AM	Symposium: Treating SUD in Patients with PTSD and Histories of Victimization	Grand Ballroom I
10:00 AM	11:30 AM	Symposium: Driving Impairment Caused by the Use of Cannabis and Other Drugs: Recent Evidence From Human Laboratory Studies	Grand Ballroom II
10:00 AM	11:30 AM	Symposium: A Gentle Introduction to Data Science Tools for Addiction Research: Use Cases With Examples	Plaza Ballroom A
10:00 AM	11:30 AM	Symposium: Universal Precautions: Considerations When Conducting Clinical Addiction Research in the Acute Care Hospital	Plaza Ballroom D
10:00 AM	11:00 AM	Oral Communication: Emerging Drugs: As If There Weren't Enough Already	Governor's Square 15
12:00 PM	01:00 PM	In Memoriam Mary Jeanne Kreek	Plaza Ballroom BCEF (Plenary)
01:00 PM	02:00 PM	Oral Communication: Online Drug Marketing: Dealing in the Work-From-Home Age	Grand Ballroom I
01:00 PM	02:00 PM	Oral Communication: SUD and Comorbid Anxiety	Grand Ballroom II
01:00 PM	02:00 PM	Oral Communication: Imaging	Governor's Square 15
01:00 PM	02:00 PM	Oral Communication: Opioid-Stimulant Interactions: Speedballs and Goofballs	Plaza Ballroom A
01:00 PM	02:00 PM	Oral Communication: Digital Therapeutics: Harmful if Swallowed!	Plaza Ballroom D
02:00 PM	03:30 PM	Poster Session 4	Plaza Exhibit
03:45 PM	04:45 PM	Oral Communication: SUD and Suicidality	Grand Ballroom I
03:45 PM	04:45 PM	Oral Communication: Understanding SUD Through Narrative Perspectives	Plaza Ballroom A
03:45 PM	04:45 PM	Oral Communication: Delta-8-THC: Mile High?	Governor's Square 15
03:45 PM	04:45 PM	Oral Communication: Decision-Making in SUDs	Plaza Ballroom D
03:45 PM	04:45 PM	Oral Communication: Novel Treatment Targets for Fentanyl and Beyond	Grand Ballroom II
05:00 PM	05:45 PM	Closing Session and Sweepstakes	Plaza Ballroom A

SATURDAY, JUNE 17, 2023

4:30 P.M. - 7:00 P.M.

Workshop: NIDA Early Career Workshop
Plaza Ballroom A

NIDA EARLY CAREER WORKSHOP

Lindsey Friend, National Institute on Drug Abuse

The National Institute on Drug Abuse (NIDA) Early Career Workshop Summer 2023 will be held on Saturday June 17, 2023. This symposium will focus on career development and grantsmanship ideal for graduate students, postdoctoral fellows, and early-stage investigators. NIDA offers a strategic set of funding mechanisms for all early career stages. These awards are designed to facilitate continuous growth of early investigators to become career independence and to strengthen research workforce development of next generation biomedical scientists. The theme for this session is persistence in advancing career and science. Topics covered include National Institutes of Health grant mechanisms and review processes, and strategies to overcome hurdle, master grantsmanship, and tips to secure grant awards. Speakers include Program Officers, Scientific Review Officers, Research Training Officers and the Director of the Office of Diversity and Health Disparities from the National institute on Drug Abuse (NIDA). Extramural speakers include early-stage NIDA awardees and experienced training director and substance use researchers.

SUNDAY, JUNE 18, 2023

8:00 A.M. - 10:00 A.M.

Opening Session: Plenary, NIDA Update, and Eddy Lecture
Plaza Ballroom BCEF (Plenary)

NIDA UPDATE

Nora Volkow, National Institute on Drug Abuse

Scientific advances continue to broaden our understanding of the biological, developmental, and environmental elements underlying drug use and addiction and to accelerate efforts to develop targeted strategies for their prevention and treatment. At the same time, the challenges confronting the addiction field have grown both in number and in magnitude. This presentation will highlight such challenges as the growing use of fentanyl by itself or in combination with other opioids or stimulant drugs like cocaine and methamphetamine and the staggering number of overdose deaths that result. It will also focus on how NIH researchers have been using scientific advances to address the opioid crisis which has been further exacerbated by the COVID pandemic, including the development of new medications and formulations to help treat opioid use disorders and overdoses; prevention strategies to mitigate an individual's vulnerability to addiction; and implementation science to guide optimal deployment of therapeutic interventions including the use of telehealth in diverse settings (healthcare, justice setting, rural communities).

EDDY LECTURE: WHAT HAS BRAIN IMAGING TAUGHT US ABOUT STIMULANT USE DISORDER

Edythe London, University of California Los Angeles

This session will cover scientific findings about stimulant use disorder, obtained from brain imaging research. The research findings will be presented in the historical context of the cocaine/crack epidemic of the 1980s, the surge of methamphetamine use beginning in the late 1990's and the recent surge in stimulant-related deaths. A major focus will be on taking what we know about the circuitry and neurotransmitter systems affected in designing new approaches to treatment.

1:00 P.M. - 2:00 P.M.

Lunch Presentation: Fischman Lecture Presented by Joy Schmitz, Marian W. Fischman Lectureship Award Winner

Plaza Ballroom BCEF (Plenary)

FISCHMAN LECTURE: MY 30-YEAR RESEARCH JOURNEY: HIGH-RISK SITUATIONS, COPING SKILLS, AND LESSONS LEARNED ALONG THE WAY

Joy Schmitz, University of Texas Health Science Center

This session will honor the work of Dr. Marian W. Fischman, recognizing her as an inspiring role model for women in science. The recipient of this year's award will focus on her contributions to the field of drug abuse research and treatment, with a particular focus on her efforts to develop behavioral and pharmacological interventions for cocaine use disorder. She will conclude by highlighting her role in cultivating the next generation of women addiction researchers.

MONDAY, JUNE 19, 2023

8:00 A.M. - 9:00 A.M.

NIAAA Update Presented by George Koob, Director of the National Institute on Alcohol Abuse and Alcoholism

Plaza Ballroom BCEF (Plenary)

George Koob, National Institute on Alcohol Abuse and Alcoholism

Alcohol misuse and alcohol use disorder (AUD) are endemic societal problems that have been willingly absorbed into the social fabric of our society for generations. They cause an enormous amount of medical pathology, human suffering, loss of productivity and cost to our medical care system and the nation's economy. Alcohol misuse accounts for 30 million individuals with alcohol use disorder, 5% of cancers, 50% of liver disease deaths, and up to 25 % of pancreatitis. While efforts to employ screening, brief intervention and referral to treatment have successfully initiated screening in many situations, brief intervention and referral to treatment remain underused. Missed screening opportunities especially for some subgroups and the more widespread lack of follow up after screening contribute to a significant treatment gap: less than 10% of individuals in need of treatment receive treatment for AUD. Less than 2% receive one of the three FDA approved and effective medications for treatment of AUD. In addition, the COVID-19 pandemic has exposed some long-neglected drivers of AUD: increased drinking to cope with stress, interaction of alcohol with mental health, the role of

alcohol in women's health, alcohol and health in older adults, and understanding recovery from AUD. In the face of these challenges, a cultural change is underway as highlighted by movements to reevaluate our relationship with alcohol such as Dry January, Sober October, and the broader Sober Curious movement. Current NIAAA priorities and challenges include providing resources for the public to facilitate prevention among young adults (College Aim), to help individuals evaluate their own relationship with alcohol (Rethinking Drinking), and to assist those seeking treatment (NIAAA Treatment Navigator). Also, the Healthcare Professional Core Resource on Alcohol, launched in 2022, provides healthcare professionals with evidence-based knowledge and resources to address alcohol misuse in clinical practice.

12:30 P.M. - 2:00 P.M.

Lunch Presentation: Presidential Symposium*

Plaza Ballroom BCEF (Plenary)

PRESIDENTIAL SYMPOSIUM: THE CASE AGAINST PURITY: STUDYING THE INTERSECTION OF PSYCHIATRIC AND SUBSTANCE USE DISORDERS

Plaza Ballroom BCEF (Plenary)

Amy Janes, NIDA

The Case Against Purity: Studying the Intersection of Psychiatric and Substance Use Disorders

Anne Eden Evins, Massachusetts General Hospital-Psychiatry

Beginning with the question of what can we do strategically to accelerate progress in the treatment of substance use disorders? This symposium explores from clinical and pre-clinical perspectives whether a concerted effort to study the intersection of psychiatric and substance use disorders could accelerate clinical progress. There will be discussion and Q and A led by Drs. Haney, Koob, Volkow, Evins, Khokhar, and Janes.

Cannabis Use and Schizophrenia: Cracking the Chicken or Egg Question

Jibran Khokhar, Western University

Although cannabis use occurs commonly in patients with schizophrenia and significantly worsen their clinical course, the neurobiological basis of cannabis use in schizophrenia is not well understood. Therefore, there is a critical need to understand the mechanisms underlying cannabis use in schizophrenia in order to identify potential targets for therapeutic intervention. Since cannabis use usually begins in adolescence, it is also important to understand the long-term effects of life-time cannabis exposure on schizophrenia- and reward-related behaviours and circuitry. Lastly, there is a need for exploring the shared genetic susceptibility for these co-occurring disorders. This talk will combine a variety of translational pre-clinical pharmacological, genetic, behavioural, electrophysiological (local field potential recordings) and magnetic resonance imaging (resting-state functional connectivity and magnetic resonance spectroscopy) approaches to study this topic with an eye toward developing better treatment approaches.

Margaret Haney, Columbia University Irving Medical Center

Nora Volkow, National Institute on Drug Abuse

George Koob, National Institute on Alcohol Abuse and Alcoholism

3:30 P.M. - 5:00 P.M.

Federal Agencies and Cannabis Research: Updates From NIH, FDA and DEA

Grand Ballroom I

Steve Gust, Consultant, National Center on Complementary and Integrative Health

Angela Arensdorf, NIH/NCCIH

Cannabis research is subject to rapidly changing legal and regulatory requirements, while evolving findings on its potential therapeutic effects has stimulated significant changes in Federal research support. This panel will provide updates from the key Federal agencies involved in cannabis regulation and research and should provide attendees with up-to-date information relevant to researchers interested in cannabis and related constituents.

Cannabinoid Research at the NIH

David Shurtleff, NCCIH/NIH

The National Institutes of Health (NIH) support of cannabinoid and cannabis research has increased over the past few years. Several NIH Institutes, Centers, and Offices (ICOs) have a growing interest in the therapeutic potential of cannabis, cannabinoids, and related compounds as well as their adverse effects on health and society. The National Center on Complementary (NCCIH) and Integrative Health (NCCIH) has become a focal point for research on the therapeutic potential of the heretofore understudied minor cannabinoids and terpenes found in cannabis for the management of pain. Also, NCCIH has become more actively involved in coordinating activities to stimulate new research programs and coordinating various cannabis-related activities across the NIH. This presentation will provide an update on the broad landscape of cannabis-related research at the NIH, summarize new areas of research interest and investment, including those of NCCIH, and describe a new multi-NIH ICO extramural program coordinating group to foster collaboration, share information, and expand and coordinate NIH cannabis and cannabinoid research activities.

Cannabis Research Priorities at the National Institute on Drug Abuse

Susan Weiss, National Institute on Drug Abuse, National Institutes of Health

NIDA has a wide-ranging cannabis research portfolio and remains the largest funder in the US government. This includes research on the endocannabinoid system, where THC exerts its predominant effects; studies to understand the potential harms of cannabis and cannabinoid exposure throughout the lifespan; therapeutic studies on cannabinoids for treating pain, HIV, and substance use disorders; treatment research for cannabis use disorder; and epidemiology and policy research to better understand the impact of the changing cannabis laws on health outcomes and consumption patterns (e.g., choice of diverse products; multiple routes and patterns of administration).

Research on cannabis is complex and can be difficult because of the inherent variability of the plant; its multiple components with therapeutic potential and distinct mechanisms of action; the difficulty of obtaining a Schedule I registration; and up until very recently, a single source of plant material for research. The latter is expected to change with new manufacturers approved by the DEA, but there are still no assurances that the cannabis that will be available for research will reflect the diversity of products currently available to the public in States where it is legal. Federally funded researchers are prohibited from analyzing products available in state-authorized dispensaries, and therefore, must rely on participant self-report or photos of unverified product labels from dispensaries. Understanding the characteristics of products on the market - including the amount of THC, the concentration of other cannabinoids and components, and potential toxins - is important for determining and differentiating characteristics responsible for health effects.

Federal Agencies and Cannabis Research: Updates from NIH, FDA, and DEA

Matthew Strait, Drug Enforcement Administration (DEA)

Since 2016, DEA has been actively engaged in regulatory activities aimed at improving both the quality and quantity of marijuana utilized for research in the United States. DEA will provide an update of those activities, including successes and ongoing challenges. DEA will explain how it remains focused on ensuring that scientific data and evidence dictates decisions on whether marijuana should remain a schedule I controlled substance under federal law.

FDA Regulation of Cannabis and Cannabis-Derived Compounds

Katherine Bonson, US Food and Drug Administration

FDA has a well-defined role to play in the regulation and development of products containing cannabis and cannabis-derived compounds. This presentation will detail the FDA regulatory oversight of scientific investigation and new drug development with Schedule I cannabis and its derivatives and will provide a brief overview of other FDA regulatory roles for cannabis vs. hemp, particularly as impacted by the 2018 Farm Bill. With regard to potential cannabis drug products, there will be a discussion of FDA Guidance for Industry on cannabis and botanical drug development, therapeutic research areas for cannabis, IND submissions, DEA licensing of Schedule I research, and the federal process for evaluating drugs for abuse potential and scheduling them under the Controlled Substances Act.

TUESDAY, JUNE 20, 2023

12:15 P.M. - 1:15 P.M.

Symposium: In Memoriam Martin Adler

Plaza Ballroom BCEF (Plenary)

Chair: *Scott Lukas, McLean Hospital, Harvard Medical School*

Co-Chair: *Toby Eisenstein, Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University*

Speakers:

William Dewey, Virginia Commonwealth University

Toby Eisenstein, Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University

Scott Lukas, McLean Hospital, Harvard Medical School

Ellen Unterwald, Lewis Katz School of Medicine at Temple University

WEDNESDAY, JUNE 21, 2023

12:00 P.M. - 1:00 P.M.

IN MEMORIAM MARY JEANNE KREEK
Plaza Ballroom BCEF (Plenary Ballroom)

Chair: *Eduardo Butelman, Mount Sinai School of Medicine*

Seminal work performed by Dr. Mary Jeanne Kreek and colleagues demonstrate the important contribution of dysregulation of the stress-responsive hypothalamic-pituitary-adrenal axis to the acquisition and persistence of drug-seeking behaviors. Dr. Ellen Unterwald will highlight Dr. Kreek's key findings from human and animal studies and present her own research on the role of stress-responsive mediators in cocaine seeking and relapse including analysis of sex-specific effects.

Dr. Kreek's clinical research on methadone efficacy and safety led to its FDA indication for the treatment of opioid use disorder and has resulted in life-saving and life-sustaining treatment for millions of people world-wide. Her work was also critical to identifying injection drug use as a risk factor for HIV, spurring public health approaches to drug use. Furthermore, her conceptual models of addictions entailing alterations in stress responsivity have influenced treatment approaches to opioid use disorder and alcohol use disorder and has supported increased interest in the kappa opioid system as a target for pharmacotherapy of alcohol and stimulant use disorders. Dr. Gavin Bart will use highlights from her career to illustrate her impact on contemporary clinical care and research in substance use disorders.

Dr. Brian Reed will share work on diverse kappa opioid receptor ligands in animal models, in an effort to identify candidates with reduced side effect profiles, including sedation and hallucinatory-like effects, which are undesirable characteristics of some of the earlier kappa opioid receptor agonists.

46.1 Stress-Responsive Genes and Their Role in Cocaine-Seeking

Speaker: *Ellen Unterwald, Lewis Katz School of Medicine at Temple University*

46.2 Kappa Opioid Receptor Ligands - Structure and Signaling Relationships

Speaker: *Brian Reed, Marymount Manhattan College*

46.3 The Clinical Impact of Dr. Mary Jeanne Kreek

Speaker: *Gavin Bart, University of Minnesota*

SATURDAY, JUNE 17, 2023

1:00 P.M. - 2:30 P.M.

WORKSHOP: STRESSFUL ENVIRONMENTS AND GENETIC RISK FACTORS ASSOCIATED WITH EARLY INITIATION OF ALCOHOL AND SUBSTANCE USE: FINDINGS FROM THE ABCD STUDY

Plaza Ballroom A

Chair: *Priscila Gonçalves, Columbia University*

Co-Chair: *Rick Cruz, Arizona State University*

Early initiation of alcohol or other substance use can disrupt brain development contributing to negative individual and societal consequences. Stressful environments, including adverse childhood experiences, and high family conflict, coupled with less effective parenting, play an outsized role in the risk for early substance use initiation. This constellation of environmental influences interacts with genetics and behavioral (e.g., decision-making related to delayed reward) factors to transmit risk for early substance use. Better understanding the ecodevelopmental pathways of early substance use risk can inform prevention efforts, which could have powerful downstream effects. This session describes novel research examining biological and environmental factors related to the prediction of early alcohol and other substance use in the large, longitudinal Adolescent Brain Cognitive Development (ABCD) Study®. The symposium is comprised of scholars from the NIDA-funded START program for URM investigators, which aims to enhance diversity among the network of scholars working with ABCD data. First, Skye Bristol will describe family conflict predictors of different alcohol expectancies. Next, Dr. Bounds will explore the combined impact of family conflict and adverse childhood experiences on future alcohol use and related risk behaviors. Dr. Ryan-Pettes will expand beyond parental monitoring and discipline by examining these influences in the context of peer affiliation, neighborhood, and environmental factors. This symposium on risk factors for early substance use will be concluded by Dr. Garcia who extends beyond environmental factors with a focus on the contribution of genetic risk factors and reward-related decision-making to alcohol and substance use risk in early adolescence.

1.1 Family Conflict as a Risk Factor for Problematic Alcohol Expectancy in the ABCD Study

Speaker: *Skye Bristol, University of South Florida*

1.2 Exploring the Impact of Family Conflict and Adversity on Alcohol Use and Risk Behaviors in Youth in the ABCD Study

Speaker: *Dawn Bounds, University of California, Irvine*

1.3 Effects of Parent Monitoring and Inconsistent Discipline on Risk for Alcohol Initiation Through Deviant Peer Affiliation in the Context of Neighborhood Variables

Speaker: *Stacy Ryan-Pettes, Baylor University*

1.4 Innate and Environmental Determinants of Delayed Reward Discounting in Youth Participants in the ABCD Study

Speaker: *Erik Garcia, University of Nebraska Omaha*

Moderator: *Neo Gebru, Brown University*

1:00 P.M. - 2:30 P.M.

WORKSHOP: EVALUATING PENNSYLVANIA'S CENTERS OF EXCELLENCE ON IMPROVING OUD TREATMENT ACCESS & PATIENT CARE

Plaza Ballroom D

Chair: *Renee Cloutier, University of Pittsburgh*

Co-Chair: *Janice Pringle, University of Pittsburgh*

States have developed several responses to address the growing US opioid public health crisis. In 2016, Pennsylvania Governor Tom Wolf introduced the Centers of Excellence to increase access to evidence-based treatment services for OUD, including medications for OUD (MOUD) and care management. Amidst early program successes and planned expansions from 45 pilot treatment sites in 2020, the COVID-19 pandemic incited disruptions to healthcare services and increased overdoses. This Mini-Symposia will present the COE history and empirical results demonstrating: 1) effects of COE care management services on improving patient outcomes, 2) how COVID-19 impacted MOUD service delivery, and 3) lessons learned for future expansion.

Methods and Results:

Symposia 1: A mixed-effects Cox model with $n=15,100$ patients nested within $n=41$ treatment sites indicated an overall median retention rate of 19.4 weeks. Retention rates improved with more patients care management services and declined as sites client caseload ratios increased.

Symposia 2: Correlations between staff-administered organizational health survey scales demonstrated that organizations with greater organizational health pivoted faster ($\rho = -0.360$, $p < 0.001$) to COVID-19 disruptions/policy changes while maintaining higher workplace morale ($r = 0.466$, $p = .002$).

Symposia 3: Qualitative interviews with COE program staff indicated COVID-19 impacts on the processes associated with MOUD implementation, care coordination, and client confidentiality. According to participants, some policy and regulatory changes/adaptations have the potential to improve patient-level MOUD-related outcomes (e.g., telehealth, take home dosing) while others did not (e.g., urine drug screening frequency).

Conclusion: Future research and policy should consider addressing organizational health to improve OUD patient-level outcomes.

2.1 The Effects of Care Management and Provider Capacity on Opioid Use Disorder Treatment Retention

Speaker: *Renee Cloutier, University of Pittsburgh*

2.2 The Relationship Between Organizational Health and Resiliency Among Pennsylvania's Centers of Excellence During the COVID-19 Pandemic

Speaker: *Debra Moore, University of Pittsburgh*

2.3 Response to Impact of COVID-19 on Medications for Opioid Use Disorder Service Delivery at Centers of Excellence in Pennsylvania

Speaker: *Rahul Amruthapuri, University of Pittsburgh, School of Pharmacy Program Evaluation and Research Unit (PERU)*

1:00 P.M. - 2:30 P.M.

WORKSHOP: SHARING YOUR SCIENTIFIC STORY: TIPS AND TRICKS FOR STRATEGICALLY AND EFFECTIVELY COMMUNICATING YOUR RESEARCH

Grand Ballroom I

Chair: *Rachel Evans, DHHS/NIH/NIDA*

Sharing your scientific story: tips and tricks for strategically and effectively communicating your research. “Science is not finished until it’s communicated.” – Sir Mark Walport, former UK Chief scientist
The ability to effectively communicate scientific concepts and research findings to a wide range of audiences is a crucial part of the scientific process. And in a world where misinformation continues to permeate scientific discussions, and trust in science and scientists is declining across many groups, the need to deliver the right message, to the right audience, at the right time, in the right way, has never been more important. In this forum, the speakers will share strategies to help scientists move beyond communicating their findings in academic journals to reach the general public. They will discuss how to work with their research funders and the media to get attention for their scientific findings, and how to structure strong messages that will resonate with the audiences they aim to reach. The speakers will also host a robust Q and A session to answer questions from the audience.

3.1 Sharing Your Scientific Story: Tips and Tricks for Strategically and Effectively Communicating Your Research

Speaker: *Magdalena Cerdá, New York University School of Medicine*

3.2 Sharing Your Scientific Story: Tips and Tricks for Strategically and Effectively Communicating Your Research

Speaker: *Jennifer Hobin, National Institute on Drug Abuse*

3.3 Sharing Your Scientific Story: Tips and Tricks for Strategically and Effectively Communicating Your Research

Speaker: *Carla Johnson, The Associated Press*

1:00 P.M. - 2:30 P.M.

WORKSHOP: PATHWAYS TO RECOVERY AND BEYOND IN NATIVE AMERICAN COMMUNITIES

Governor’s Square 15

Chair: *Anne Skinstad, University of Iowa*

Recovery from substance use disorders (SUD) is a multi-dimensional phenomenon, and over the last two decades multiple definitions with varying overlap have been proposed. Research has also found that recovery definitions vary across social groups, including by race/ethnicity; however, scant research has focused on the ways that Native American individuals define recovery. Thus, current consensus definitions may have limited salience for Native American communities, may result in less efficacious interventions, and may partially explain persistent treatment disparities. To address the gap, this workshop intends to spur development of a culturally appropriate definition of recovery. First, Dr. Paul Gilbert will review findings from a current national US study of people in recovery, highlighting commonalities and differences across key dimensions of gender, race/ethnicity, and treatment exposure. Second, Dr. Anne Helene Skinstad and Steve Steine, MA, will introduce a translation of recovery definition into tribal and urban Indian community contexts, and summarize how results from the Virtual Native Talking Circles (VNTC), a workforce development program, contributed

to a better cultural understanding of the recovery process. Furthermore, VNTC results underscored the importance of peer support and networking, as well as providing additional culturally informed tools, and self-care measures to better prepare providers to support clients' recovery in a culturally informed way. Non-AIAN VNTC participants reported improved cultural understanding and capacity to support their tribal clients with SUD or in recovery. Finally, Dr. Daniel V. Foster will lead a discussion with speakers and audience members on recovery meanings and pathways in an Indigenous cultural context.

4.1 What Does Recovery Mean? Ubiquitous and Unique Elements From a National U.S. Survey of Adults in Recovery
Speaker: Paul Gilbert, University of Iowa

4.2 Behavioral Health Benefits of Virtual Native American Talking Circles
Speaker: Steven Steine, ATTC/ College of Public Health/ University of Iowa

Discussant: Daniel Foster, Included Health

1:00 P.M. - 2:30 P.M.

WORKSHOP: A VIEW BEYOND THE HORIZON: INNOVATIVE METHODOLOGIES AND APPROACHES IN SUBSTANCE USE DISORDER RESEARCH AND TREATMENT UTILIZED INTERNATIONALLY **Grand Ballroom II**

Chair: Laura Brandt, City College of New York

While substance use disorders (SUD) pose a challenge to public health worldwide, context-specific aspects of these challenges require context-specific solutions. Therefore, unique innovations are brought about by unique regional or local challenges. At the same time, owing to political and regulatory barriers, these innovations may not be available in other settings/countries. This workshop, hosted by CPDD's International Committee, brings together researchers with diverse cultural and professional backgrounds with the aim to enrich our shared understanding of SUD-related issues and address inadequacies in the implementation of existing evidence-based approaches into practice.

Towards the goal of providing insight into methodological and treatment innovations from international contexts, this workshop will be structured in two parts. Part 1 will consist of 15-minute panel presentations: (1) Eugenia Oviedo-Joekes will present scientific evidence from Canada on injectable opioid agonist treatment, and injectable hydromorphone in particular, as a promising treatment option for severe opioid use disorder; (2) Thiago Fidalgo will discuss challenges related to collecting epidemiological data in low- and middle-income countries and lessons learned from conducting a longitudinal field survey in Brazil; (3) Min Zhao will describe digital medicine approaches and a Community-based Addiction Rehabilitation Electronic System as alternative/ complementary care models in China, in the context of limited mental health resources; and (4) Suzanne Nielsen will discuss a collaborative prescriber-pharmacist model of care in Australia as a low-threshold approach to improve access to SUD treatment. Part 2 will be an interactive discussion, and we particularly encourage international attendees to share their diverse experiences and regional innovations.

5.1 "Injectable Opioid Agonist Treatment – Implementing Evidence-Based Approaches into Practice for Opioid Use Disorder in Canada"

Speaker: Eugenia Oviedo-Joekes, School of Population and Public Health, University of British Columbia

5.2 Challenges Related to Conducting Epidemiological Surveys in Low- And Middle-Income countries: Lessons Learned from Field Work in Brazil

Speaker: *Thiago Fidalgo, Universidade Federal de Sao Paulo*

5.3 Early learnings from a hybrid implementation-effectiveness study of pharmacist-prescriber collaborative care for opioid dependence, and other clinical innovations in Australia

Speaker: *Suzanne Nielsen, Monash University*

3:00 P.M. - 4:30 P.M.

WORKSHOP: NEW APPROACHES TO CULTURALLY APPROPRIATE TREATMENT AND RESEARCH

Grand Ballroom I

Chair: *A. Kathleen Burlew, University of Cincinnati*

New Approaches to Culturally Appropriate Treatment and Research. A compelling body of research suggests that generic treatments may not adequately address risk, protective, and contextual factors related to substance use treatment among specific racial/ethnic minoritized (REMs) groups. Moreover, novel approaches may be required to promote REM recruitment and retention into research. The mission of the Minority Interest Group (MIG) of NIDA's National Drug Abuse Treatment Clinical Trials Network is to promote research that advances the science of REM substance use. Consistent with that mission, MIG members will present novel strategies for recruiting, retaining, and treating REMs.

Aims: 1) To share culturally-appropriate approaches for engaging/ retaining REMs in substance use research. 2) To describe treatment approaches that incorporate syndemic factors related to the etiology and treatment of substance use among REMs

Both Drs. Obel and Cain will share efforts to increase the recruitment and retention of REMs into substance use research. Dr. Obel's team has developed an evidence-based manual for recruiting and retaining REMs into research. Dr. Cain will describe her team's use of community-engaged culturally appropriate strategies to recruit and retain urban REMs in substance use treatment research.

Both Drs. Moreland and Bryant will share culturally appropriate treatment research. Dr. Moreland will describe research identifying and addressing decision-making about buprenorphine among REMs. Utilizing the ADAPT-ITT framework, Dr Bryant will describe the adaptation of an intervention to more effectively respond to substance use and discrimination distress simultaneously.

Dr. Jordan, the discussant, will address the conclusions and implications for future research.

6.1 The Cultural Adaptation Process of a Substance Use Intervention for Black Justice-Involved Youth Using the Adapt-ITT Model (Phase 1): Lessons Learned

Speaker: *Brittany Bryant, Medical University of South Carolina*

6.2 Culturally Appropriate Approaches for Recruitment and Retention of African Americans in SUD Treatment:

Speaker: *Gloria Cain, Howard University College of Medicine*

6.3 Are Minority Patients With Opioid Use Disorder More Likely to Decline Buprenorphine in the ED? Exploring Reasons That People Accept and Decline Buprenorphine

Speaker: *Angela Moreland, Medical University of South Carolina*

6.4 Innovative Methods for Increasing Recruitment & Retention in Research (RCTs & Non-RCTs) among African American Communities in the United States (US).

Speaker: *Geoffrey Obel, University of Texas Southwestern Medical Center At Dallas*

Discussant: *Caravella McCuistian, Department of Psychiatry and Behavioral Sciences, School of Medicine, University of California San Francisco*

3:00 P.M. - 4:30 P.M.

WORKSHOP: STANDARDS OF PSYCHEDELIC CARE: PEER & PROFESSIONAL PROVIDERS **Plaza Ballroom A**

Chair: *Brian Anderson, University of California, San Francisco*

Co-Chair: *Jennifer Mitchell, University of California San Francisco*

As the use of psychedelics like psilocybin, MDMA, and ayahuasca becomes more prevalent across the US due to the advancement of clinical drug development and drug policy reforms (e.g., decriminalization and legalization), providers of psychedelics and psychedelic-informed care have been developing standards of good practices with these substances. This includes providers from peer-based (12 step recovery fellowships), professional/therapeutic, and religious settings. Three national organizations that have generated standards of care for the safe use of psychedelics in their respective settings present information on their organizations, their processes of generating these standards, and comments specifically on what their memberships have learned about the apparent risks and benefits of using psychedelics as part of the care of persons suffering from addictions.

7.1 Psychedelics in Recovery: Mutual Aid for Psychedelic Integration

Speaker: *Kevin Franciotti, Kevin Franciotti Counseling*

7.2 Developing Standards of Practice Within the American Psychedelic Practitioners Association Part 2

Speaker: *Stephen Xenakis, American Psychedelic Practitioners Association (APPA)*

Discussant: *Peter Hendricks, The University of Alabama At Birmingham*

3:00 P.M. - 4:30 P.M.

WORKSHOP: EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS **Grand Ballroom II**

Chair: *Howard Chilcoat, Indivior, Inc.*

Co-Chair: *Maria Parker, Indiana University - Bloomington*

This proposal is for a continuation of the annual CPDD Epidemiology and Public Health Research Methods evening workshop series that was launched nearly 20 years ago. This year's workshop will focus on geospatial analytical approaches of interest to those conducting epidemiologic, prevention, and clinical research in the field of substance use and related disorders. Topics to be discussed include: 1) Jamie Humphrey, RTI - Spatial heterogeneity in county-level racial residential segregation and overdose mortality rates of opioids, synthetic opioids, and psychostimulants with abuse potential. Using multiscale geographically weighted regression models, spatially-explicit measures of racial residential segregation, and smoothed overdose mortality rates,

this presentation will explore the presence and scale of spatial heterogeneity in the relationship between structural racism and three overdose mortality rates in US counties, 2020: any opioids, synthetic opioids, and psychostimulants with abuse potential. 2) Richard Sadler, Michigan State University - Geospatially-Informed Strategies to Address Mental Health and Substance Use Disparities in Flint, Michigan. This talk will explore the creation of a community-informed GIS-based healthfulness index and the use of standard hot spot analyses to understand and act upon geographic disparities uncovered in the Strengthening Flint Families (SFF) and the Resiliency in Communities After Stress and Trauma (ReCAST) programs. 3) Erik Nelson, Brigham Young University - Placing drug use into context. This presentation will discuss the impact of social and environmental conditions that promote (impede) drug use. It will also explore methods for measuring and analyzing these factors using geospatial techniques.

8.1 Spatial Heterogeneity in County-Level Racial Residential Segregation and Overdose Mortality Rates of Opioids, Synthetic Opioids, and Psychostimulants With Abuse Potential, 2020

Speaker: *Jamie Humphrey, RTI International*

8.2 Geospatially-Informed Strategies to Address Mental Health and Substance Use Disparities in Flint, Michigan

Speaker: *Richard Sadler, Michigan State University College of Human Medicine*

8.3 Placing Drug Use Into Context

Speaker: *Erik Nelson, Brigham Young University*

3:00 P.M. - 4:30 P.M.

WORKSHOP: COLLABORATION AND COMPLICATION: LESSONS LEARNED IN IMPLEMENTING COMMUNITY-ENGAGED RESEARCH ON SUBSTANCE USE

Plaza Ballroom D

Chair: *Devin Banks, University of Missouri--St. Louis*

Advocates, policy makers, patients, and recently, NIDA have called for the inclusion of people with lived experience in the conceptualization and realization of addiction science. Perhaps more than ever, research teams are including patient and community consultants and advisory boards in their research.

However, most research training paradigms do not prepare investigators to effectively collaborate with people with lived experience. This is especially true when working with communities who experience other intersecting forms of stigma, such as racial stigma, who have often been considered “hard to reach” populations.

This symposium will share lessons learned from community-engaged NIH- and foundation-funded research projects with specific focus on minoritized people with lived experience. Presenters will demonstrate how their research designs, data collection, and interpretation of qualitative and quantitative findings developed based on the feedback of people with lived experience with substance use (disorder).

Attendees will increase their knowledge of different approaches to community-engaged research and strategies for addressing common challenges that emerge when collaborating with stakeholders outside the academy. This knowledge will support investigators in not only engaging with minoritized people with lived experience, but developing long-term, bidirectional relationships.

Specifically, presentations will include practical strategies for: 1) building trusted partnerships and developing a Community Advisory Board in communities that have been previously exploited by research and/or policy; 2) recruiting, engaging, and retaining minoritized research participants; 3) developing effective, culturally-appropriate recovery interventions and education; and 4) incorporating insights of community members into data interpretation and clinical and policy recommendations.

9.1 We see the Value in the Hood: Developing Reciprocal Research Partnerships in an Exploited Community
Speaker: Maria Paschke, University of Missouri - St. Louis

9.2 Blind Spots in Ivory Towers: Considerations for Recruiting Black American Research Participants
Speaker: Danelle Stevens-Watkins, University of Kentucky

9.3 The Role of Cultural Humility in Community-Engaged Research
Speaker: Alexandria Bauer, Rutgers University

9.4 From Relapse Prevention to Recovery Planning: Community-Based Participatory Research to Address Substance Use on a Rural American Indian Reservation
Speaker: Monica Skewes, Montana State University

Moderator: Devin Banks, University of Missouri--St. Louis

3:00 P.M. - 4:30 P.M.

WORKSHOP: R/ASKACADEMIA: SPECIAL CONSIDERATIONS IN THE PRACTICE OF USING REDDIT FOR SUBSTANCE USE RESEARCH **Governor's Square 15**

Chair: Savannah Brenneke, Johns Hopkins Bloomberg School of Public Health
Co-Chair: Meredith Meacham, University of California San Francisco

Interest in the use of social media platforms for substance use research has been on the rise, with Reddit emerging as one of the most rapidly growing platforms studied. To date, however, standards for the practice of collecting, analyzing, and disseminating findings from these highly unstructured data are lacking, contributing to concerns around the validity and ethics of using such data in the field. Therefore, there is a need for researchers across the fields of health and social sciences, computer science and engineering, to share lessons learned and work towards establishing best practices. This symposium will focus on phases of the research process using Reddit data, moving from defining Reddit data and conceptualizing research questions, to data collection and management, analysis and inference, and ending at dissemination. Speakers will present their original research, with special attention to a phase of the research process and challenges they face. Dr. Amanda Bunting will discuss the nature of Reddit data and the conceptualization of research questions that can be asked within the data. Ms. Alexandra DeLucia will present on the use of Natural Language Processing (NLP) for the extraction of data from Reddit, providing the perspective of computer science in the application of computational methods for data harvesting and management. Ms. Savannah Brenneke's work will explore analytical approaches commonly found in the literature, including inferences drawn from them. Lastly, Dr. Nicholas Proferes will cover the ethical considerations in the decision to use Reddit for research and their implications for the dissemination of findings.

10.1 Rapid Use of Reddit to Understand Emerging Drug Use Trends
Speaker: Amanda Bunting, New York University School of Medicine

10.2 r/AskAComputerScientist: Processing Reddit Data for the Social Sciences
Speaker: Alexandra DeLucia, Johns Hopkins University

10.3 Harnessing Reddit: The Methods and Their Limitations in Analyzing Unstructured Data From Social Media
Speaker: Savannah Brenneke, Johns Hopkins Bloomberg School of Public Health

10.4 Ethical Responsibility and Reddit Research: How Contextual Integrity Can Help Guide Practice
Speaker: Nicholas Proferes, Arizona State University

SUNDAY, JUNE 18, 2023

10:15 A.M. - 11:15 A.M.

MINI-SYMPOSIUM: HARM REDUCTION UTILIZATION AND STRATEGIES **Grand Ballroom II**

Chair: Mai Pho, The University of Chicago

Co-Chair: Judith Tsui, Department of Medicine, Division of General Internal Medicine, University of Washington

Rural areas experience high rates of drug overdose. While recent surges in overdose deaths are driven largely by highly potent fentanyl and related analogues, the rural opioid crisis is co-occurring and intertwined with evolving methamphetamine use. Overdose deaths involving methamphetamines increased by over 600% between 2007 and 2017. Harm reduction services (HRS) play a vital role in risk reduction and health promotion among rural PWUD by both figuratively and literally meeting individuals where they are in the communities and settings where they live and use drugs. Strategies include sterile equipment, overdose education and naloxone distribution (OEND), product testing for fentanyl, HIV, hepatitis C, and STI screening, sexual health supplies, linkage to substance use disorder treatment and social support. Given limited substance use disorder treatment in rural areas, efforts to improve health outcomes for people who use drugs in these settings hinge on harm reduction strategies. However, the availability of HRS is limited in rural settings compared to urban areas due to funding, marginalization, and vulnerabilities exacerbated by the COVID-19 pandemic and related mitigation strategies. This mini-symposium will explore factors associated with harm reduction practices, including naloxone use and fentanyl product testing from data collected through the Rural Opioid Initiative (ROI), a research consortium funded by NIDA, CDC, SAMHSA, and the Appalachian Regional Commission, as well as present strategies for expanding access and engagement with harm reduction services in rural settings.

11.1 Factors Associated With Possession of Naloxone Among Rural People Who Use Drugs
Speaker: Alex Rains, University of Chicago, Pritzker School of Medicine

11.2 Fentanyl Awareness and Harm Reduction Techniques to Avoid Fatal Overdose: A Qualitative Exploration of Eight Rural Settings in the United States
Speaker: Rebecca Bolinski, Southern Illinois University School of Medicine

11.3 Engagement in Harm Reduction Services through Academic and Community-Based Partnership
Speaker: Mai Pho, The University of Chicago

11:30 A.M. - 12:30 P.M.

MINI-SYMPOSIUM: 2022 NIDA CRAVING CHALLENGE
Plaza Ballroom BCEF (Plenary)

Chair: *G. Andrew James, University of Arkansas for Medical Sciences*

Co-Chair: *Ronald Thompson, University of Arkansas for Medical Sciences*

The National Institute on Drug Abuse (NIDA) issued the “Product Prototypes to Combat Drug Craving” Challenge, which solicited working prototypes of devices intended to reduce drug craving among people with substance use disorders. The Challenge specifically sought prototypes that were easily accessible, minimally invasive, available on-demand, did not require detoxification, could be adapted for different substances, modifiable to provide tailored experiences, and suitable for patients of diverse backgrounds and different stages of recovery. This mini-symposium will discuss the inspiration behind some of the winning entries.

Richard Hanbury MBA (Healthcare) will discuss the winning entry Sana, a neuromodulation platform that provides anxiety relief on-demand and has shown a 45% reduction in anxiety during methadone withdrawal. Josh Israel (Serial Entrepreneur) will discuss the runner-up entry Hale, a vaporizer system to ease nicotine craving and withdrawal by automatically reducing nicotine use over time. Ronald G. Thompson Jr., Ph.D., will discuss the Honorable Mention entry for smartphone app OptiMAT, which seeks to reduce opioid misuse through daily monitoring of mood and craving, personalized feedback, and GPS-driven “just-in-time” intervention when participants enter areas of high contextual risk for relapse. Chair Andrew James, Ph.D., a co-creator of OptiMAT, will lead discussion on the devices’ common and unique approaches for reducing drug craving.

12.1 *The Sana Wearable Neuromodulation Device for Reducing Anxiety and Drug Cravings*

Speaker: *Richard Hanbury, Sana Health, Inc.*

12.2 *Hale: Automated Nicotine Reduction Device*

Speaker: *Josh Israel, Hava Health, Inc.*

12.3 *OptiMAT: A Smartphone Application to Decrease Opioid Cravings and Optimize MAT for Opioid Use Disorders*

Speaker: *Ronald Thompson, University of Arkansas for Medical Sciences*

2:15 P.M. - 3:45 P.M.

WORKSHOP: “PRE-ADDICTION:” A STARTING POINT FOR A STRATEGIC SHIFT TOWARD EARLIER INTERVENTION IN SUBSTANCE USE DISORDERS

Plaza Ballroom BCEF (Plenary)

Chair: *Nora Volkow, National Institute on Drug Abuse*

Co-Chair: *George Koob, National Institute on Alcohol Abuse and Alcoholism*

Discussant: *A Thomas McLellan, University of Pennsylvania Perelman School of Medicine*

Federal efforts to address substance use disorders (SUDs) have focused almost exclusively on those with serious, chronic addictions. Yet treatment penetration rates and treatment outcomes have been disappointing. The far larger population of those who regularly misuse substances and often transition to serious SUDs has

been largely ignored. Facing a similar situation, the diabetes field strategically moved toward identifying and intervening with early-stage diabetes - termed “pre-diabetes.” That strategic change led to better prevention, longer delay in onset of serious diabetes, better treatment penetration and more effective reimbursement policies. This workshop first describes (15 minutes) how the diabetes field developed this strategy, including a commonly understood name to motivate both patients and clinicians, and creation of evidence-based medications and behavioral interventions. Finally, we offer our suggestion of the term “pre-addiction,” initially defined by 2-5 DSM 5 diagnostic criteria as a starting point for the development of this concept for SUDs. The remainder of the workshop will be devoted to audience discussion and suggestions on five important and unresolved issues (12 minutes each) if this concept is to move forward.

1. What promising biological measures may improve the suggested operational definition of pre-addiction?
2. What medications might be appropriate for those with pre-addiction?
3. What behavioral interventions – including social media or internet apps - might be effective with pre-addiction?
4. How can insurers and healthcare systems facilitate studies of effectiveness and value pre-addiction interventions?
5. Are there concerns that the term pre-addiction will promote stigma?

4:00 P.M. - 5:15 P.M.

MEDIA FORUM

Grand Ballroom I

Chair: *Bethea Kleykamp, BAK and Associates*

Mainstream news media disseminates many problematic narratives about drug use and addiction that perpetuate stigma, discrimination, and bad policy. One way to address these shortcomings is to increase the coverage of evidence-based approaches to addiction treatment and recovery, including well-designed research studies, through collaborative efforts with subject matter experts. Unfortunately, many experts are not trained to interact with journalists or the general public about addiction science. This forum is designed to offer customized, in-person training that can help attendees develop effective science communication skills.

The Media Forum will be open to all attendees including graduate-level and early-career CPDD attendees for whom this forum could serve as a valuable career development experience. The 120-minute forum will be broken down into three components: 1) an overview of different types of science and medical writing related to substance use research and treatment (Presenter: Kleykamp; 30min); 2) tips on science communication (Presenter: Jonathan 30min) 3) tips on working with the media to communicate science (Presenter: Ashton; 30minutes); 4) trainer led small-group didactic and practice sessions (30min). The small-group trainer sessions will help attendees become aware of non-traditional avenues of disseminating their research and expertise (science journalism, regulatory writing, clinical guidelines, educational materials), sharing research accurately and concisely with the media, how to disseminate press releases, and how to pitch ideas or op-eds.

14.1 Reporting on Addiction: Science Communication

Speaker: *Jonathan Stoltman, Opioid Policy Institute*

14.2 Communicating Science Effectively Media Forum: Training With Reporting on Addiction

Speaker: *Ashton Marra, Reporting on Addiction*

4:00 P.M. - 5:30 P.M.

POLICY FORUM **Grand Ballroom II**

Chair: *Sandra Comer, Columbia University and NYSP*

Despite a longstanding prohibition on psychedelics dating back to the 1970s, scientific and public interest in these substances is growing as clinical trials suggest their promise for treating mood, anxiety, and substance use disorders. Early reports that people with severe treatment-resistant depression responded to psychedelic treatment created momentum for controlled clinical trials to establish therapeutic efficacy for other indications. The Food and Drug Administration (FDA) has granted breakthrough therapy status for psilocybin and MDMA, which means that intensive FDA guidance is provided for designing the clinical trial programs and expedited timelines are applied when FDA reviews the safety and efficacy data from the completed Phase III studies.

This Forum will present the history of the therapeutic use of hallucinogens (Jack Henningfield), the epidemiology of the current illicit use of hallucinogens (Deborah Hasin), and current regulatory perspectives on psychedelic drug development from the FDA (Marta Sokolwska) and Industry (Beatriz Rocha).

15.1 The History of Therapeutic Use: Lessons Learned From 1960s Studies, and From the Renaissance in Clinical Development Beginning in the First Decade of the 21st Century

Speaker: *Jack Henningfield, Pinney Associates, Inc.*

15.2 The Epidemiology of Hallucinogen/Psychedelic Use in the United States

Speaker: *Deborah Hasin, Columbia University*

15.3 Analyses of U.S. Trends in Non-Medical Use of Hallucinogens

Speaker: *Beatriz Rocha, Fortrea*

15.4 MDMA for PTSD and Psilocybin for Treatment-Resistant Depression Currently in Phase III Trials

Speaker: *Marta Sokolowska, FDA*

MONDAY, JUNE 19, 2023

9:00 A.M. - 10:00 A.M.

MINI-SYMPOSIUM: BEYOND THE DICHOTOMY **Grand Ballroom I**

Chair: *Cara Struble, Geisel School of Medicine at Dartmouth*

Co-Chair: *Jessica Barrington-Trimis, University of Southern California*

Cannabis use and cannabis-related problems remain highly prevalent among adolescents and young adults (AYA). Burgeoning research reveals substantial disparities in problematic cannabis use between LGBTN+ (lesbian, gay, bisexual, transgender, non-binary+) AYA and their cisgender, heterosexual counterparts. However, this research has been limited by a lack of adequate sampling, leading studies to combine individuals from any LGBTN+ subgroup into a single analytic group and obfuscating heterogeneity in cannabis use behaviors across

the diverse range of identities utilized by AYA. This mini-symposium will highlight the need for scientists to expand analyses to explore differences within the LGBTN+ population by describing heterogeneity observed in cannabis use behaviors across subgroups. Talks will examine key individual, interpersonal, and structural mechanisms that may explain observed disparities within and outside the LGBTN+ population of AYA. The first speaker will present on distinct cannabis use patterns among subgroups of LGBTN+ youth from Southern California, and relatedly explore how outness (openness about one's identity) and discrimination experiences might explain disparities in use. The second speaker will examine differences in the effects of depression and anxiety on associations between minority stressors and cannabis problems across subgroups of LGBTN+ young adults. The third speaker will examine LGBTN+ subgroup differences in reported exposure to pro-cannabis marketing, and associations with LGBTN+ disparities in cannabis use. This collection of presentations on LGBTN+ disparities in cannabis use behaviors will highlight implications for future research, treatment, and policy, providing concrete suggestions for research strategies to better understand disparities in substance use behaviors for the LGBTN+ population.

16.1 Addressing the Role of Minority Stressors: A Cross-Sectional Analysis of Cannabis Use Patterns Among LGBTN+ High Schoolers

Speaker: *Tahsin Rahman, University of Southern California*

16.2 Comparing the Impact of Minority Stressors and Co-Occurring Mental Health Factors on Cannabis-Related Problems in a Diverse Sample of LGBTN+ Young Adults

Speaker: *Cara Struble, Geisel School of Medicine at Dartmouth*

16.3 Pro-Cannabis Marketing and LGBTQ+ Disparities in Cannabis Use Among Youth and Young Adults

Speaker: *Evan Krueger, Tulane University*

10:30 A.M. - 12:00 P.M.

SYMPOSIUM: MEASUREMENT OF CANNABIS CONSUMPTION TO DETERMINE RISK AND PROMOTE PUBLIC HEALTH

Plaza Ballroom A

Chair: *Alan Budney, Geisel School of Medicine at Dartmouth*

Co-Chair: *Ashley Linden-Carmichael, Penn State University*

With the escalation of cannabis legalization and commercialization, the need for better public messaging and guidelines about safe vs. risky use patterns has become imperative. Efforts to develop such guidelines are hindered by a lack of valid methods for measuring diverse cannabis products and quantifying consumption of the intoxicating component of cannabis, i.e., THC. This symposium will provide data from a diverse set of studies that help move the field towards resolution of this cannabis quantification impasse. The initial presentation will showcase methods utilized in the International Cannabis Policy Study for measuring novel cannabis product consumption quantities, generating national prevalence estimates, and evaluating consumer understanding of product labels. Next, a community-based study of frequent cannabis consumers that measured quantity, frequency, potency, and dose will demonstrate how those metrics can predict risk of problematic cannabis use. Findings from an intensive ecological momentary assessment study of young adults, will show how quantity reports and their interaction with product type and route of administration relate to subjective intoxication and other adverse consequences. Last, results from a study in which milligrams of THC consumption was calculated using responses from an internet-based survey of frequent cannabis consumers will describe associations between THC amount, pattern of use, and Cannabis Use Disorder severity. A moderated discussion will

highlight how this work advances methods for measuring cannabis dose and determining its relationship to risk, and importantly, generate future innovative studies that will expedite the development of guidelines for safe and unsafe use of cannabis.

17.1 Consumption Patterns for Cannabis Products From a National Sample of Consumers in the United States: Edibles, Extracts, CBD, and Other 'Novel' Products
Speaker: David Hammond, University of Waterloo

17.2 Predicting Problematic Cannabis Use From Estimates of Cannabis Quantity, Frequency, Potency, and Standard Dose
Speaker: Brad Conner, Colorado State University

17.3 Measuring Cannabis Use, Subjective Experiences, and Cannabis-Related Consequences in the Moment: Associations by Cannabis Product, Route of Administration, and Other Substance Use
Speaker: Ashley Linden-Carmichael, Penn State University

17.4 Exploring the Link Between the Amount and Pattern of THC Consumption and CUD Severity in a Large Sample of Adults
Speaker: Jacob Borodovsky, Dartmouth Geisel School of Medicine

Moderator: Alan Budney, Geisel School of Medicine at Dartmouth

10:30 A.M. - 12:00 P.M.

SYMPOSIUM: THE INTERSECTION OF AGING, TOBACCO USE, AND HEALTH EQUITY **Governor's Square 15**

Chair: Bethea Kleykamp, BAK and Associates

Significance: Over the last 20-plus years, combustible cigarette prevalence has dropped to the lowest levels ever recorded for young people in the United States but has not changed for older adults (65 years+). At the same time, novel tobacco products and policies continue to evolve, and the extent to which these shifts will impact older smokers is rarely addressed. For example, although electronic nicotine delivery systems (ENDS) are the fastest-growing tobacco product category, few research studies examine their harm reduction potential among older adults. Yet, these individuals stand to gain the most from stopping their combustible tobacco use as soon as possible. In addition, many people who smoke into later decades of life have been historically minoritized, including individuals who are Black and Hispanic, have a lower socioeconomic status, and/or have more chronic health issues. Thus, aging and tobacco use is a long-standing health equity issue that continues to be overlooked in research, treatment, and policy.

Specific Aims: The primary aim of this symposium is to educate and promote discussion about older adults that use tobacco and nicotine. Four presentations will address four different tobacco products/policy initiatives, including 1) very low nicotine content cigarettes, 2) electronic cigarettes, 3) menthol and non-menthol tobacco flavoring, and 4) lung cancer screening. Given the broad focus of this symposium, we expect that it will be of great interest to clinical researchers, healthcare providers, and health policy organizations that seek to learn about tobacco-related disparities among older adults.

18.1 A Qualitative Analysis of Older Adults' Perspectives on Very Low Nicotine Content Cigarettes

Speaker: Jessica Kulak, University at Buffalo

18.2 Expectations and Patterns of Electronic Nicotine Delivery Systems (ENDS) Use Among Older Adults who Smoke Cigarettes Within a Nationwide RCT

Speaker: Margaret Fahey, Medical University of South Carolina

18.3 Racial and Ethnic Differences in Lung Cancer Screening Eligibility and Health Services Utilization Among Older Smokers in the U.S.

Speaker: Jaqueline Avila, University of Massachusetts Boston

18.4 Representation of Older Adults in Tobacco Flavoring Research

Speaker: Bethea Kleykamp, BAK and Associates

10:30 A.M. - 12:00 P.M.

SYMPOSIUM: THE INTERSECTION OF COVID-19 AND SUBSTANCE USE DISORDERS

Grand Ballroom II

Chair: Carlos Blanco, National Institute on Drug Abuse

Co-Chair: Leonardo Angelone, DHHS/National Institute on Drug Abuse

This symposium will present a variety of epidemiological and health services responses to the intersection of the COVID-19 pandemic and substance use disorders and overdose. Dr. Ramsey will present an overview of changes in overdose deaths in New York State during COVID-19, innovative practices in the delivery of SUD treatment services during that period and lessons learned for the future. Dr. Halden will discuss the use of wastewater-based epidemiology to monitor community levels of SARS-CoV-2 as well as opioids, as well as opportunities and limits of information gleaned from wastewater analysis.

Dr. Jones will discuss a series of analyses examining use of telehealth for opioid use disorder prior to and during the COVID-19 pandemic among the Medicare population. The analyses explore use of telehealth services and impacts on receipt of medications for opioid use disorder (MOUD), MOUD retention, experiencing medically treated overdose, and overdose death.

There will be a discussion among all panelists regarding changes in Federal- and state-level legislation and regulations, innovations to increase access to MOUD, approaches to workforce support and augmentation and innovations to increase access to overdose prevention, such as naloxone distribution, syringe services programs, drug checking, and overdose prevention centers.

Throughout the symposium, there will be multiple opportunities for interaction with the audience to ensure that the approach is participative and inclusive, rather than adopting a top-down didactic approach.

19.1 COVID-19 and Substance Use: Lessons Learned and where Do We Go from Here?

Speaker: Kelly Ramsey, NYS OASAS

19.2 Examining the Relationship between Use of Emergency Authorities to Support Oud Treatment and Outcomes in the Medicare Population during the COVID-19 Pandemic

Speaker: Christopher Jones, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention

10:30 A.M. - 12:00 P.M.

SYMPOSIUM: STIMULATION FOR THE TREATMENT OF STIMULANT USE DISORDER

Plaza Ballroom D

Chair: *Katrina Foster, NIH/NIDA/DTMC*

Co-Chair: *Jennifer Wong, National Institute on Drug Abuse*

Stimulating the Brain to Treat Stimulant Use Disorder: Stimulant use disorder (StUD) is a significant public health concern. In 2020, over 5 million people aged 12 and older reported past year use of stimulants (SAMHSA, 2021). Currently, there are no FDA approved treatments for this devastating disorder despite decades of research focused on developing pharmacotherapies. Neuromodulation provides a new direction for developing treatments for StUDs. This treatment modality has already been authorized by the FDA for smoking cessation and mental health disorders, such as depression. Neuromodulation involves the alteration of nerve activity through targeted delivery of a stimulus, such as electrical or magnetic stimulation to specific brain area(s) to modulate behavior. Examples of neuromodulation include Deep Brain Stimulation (DBS), Transcranial Magnetic Stimulation (TMS) and Low-intensity Focused Ultrasound (LIFU). There are pre-clinical data demonstrating that neuromodulation is effective in reducing drug-seeking behavior (Knapp CM et al., 2009; Friedman A et al., 2010; Fakhrieh-Asl G et al., 2020). Moreover, preliminary data show that neuromodulation reduces alcohol, cocaine and methamphetamine use (da Silva MC et al, 2013; Batra et al., 2017; Hang S et al., 2020). Neuromodulation for the treatment of StUDs is in the early stages but significant advances are being made in clinical studies. This symposium focuses on compelling clinical neuromodulation data for the treatment of StUD and StUD craving from three different types of neuromodulation, as well as having the FDA provide guidance on the authorization pathway for new devices.

20.1 Low Intensity Focused Ultrasound (LIF) as a New Tool to Treat Cocaine Use Disorder

Speaker: *Nassima Ait-Daoud Tiourine, University of Virginia School of Medicine*

20.2 Development of Portable Neuromodulatory Intervention to Reduce Craving in Cocaine Addiction

Speaker: *Abhishek Datta, Soterix Medical*

20.3 Deep Brain Stimulation for Treatment Refractory Methamphetamine Use Disorder

Speaker: *Joseph Sakai, University of Colorado School of Medicine*

20.4 The Approval Process for New Devices and the Data Needed for This Process

Speaker: *Pamela Scott*

10:30 A.M. - 12:00 P.M.

FORUM: RESTRUCTURING THE PATHWAY FROM DISCOVERY TO DISSEMINATION OF NEW MEDICATIONS IN THE ACADEMIC ENVIRONMENT

Grand Ballroom I

Chair: *Charles France, University of Texas Health Science Center*

Co-Chair: *Jennifer Potter, University of Texas Health San Antonio*

Discovery, development, dissemination, and implementation of treatments for substance use disorders (SUD) can be inefficient and ineffective, particularly in academic environments, thereby delaying the availability of medications to patients most in need. Scientific evidence clearly shows that medications can be effective for treating SUD and that with comprehensive care recovery is achievable. Despite the availability of effective medications (e.g., buprenorphine for opioid use disorder), relatively few individuals who need treatment receive a medication. Barriers to uptake of new medications include stigma surrounding SUD, misinformation, and policy regulations surrounding prescribing. One approach to mitigate these barriers is adjusting the manner by which new discoveries become treatments. This forum will discuss the potential value of bidirectional translational conversations across the spectrum of stakeholders, from drug discovery to patients, early and throughout the process of medication development, and from community-oriented solutions back to basic scientists to identify mechanisms of action. Discussion topics will include an adapted translational model for medication development for SUD, including adjusting the typical sequential process of translational science to a parallel interactive process. This model of translational research proposes that activities such as those that are typically conducted in T3 and T4 (e.g., dissemination and implementation research to address potential barriers and discover facilitators) are conducted in parallel with the earlier stages of development, starting with stage T0. Examples of current research will highlight how early engagement of implementation and dissemination research can accelerate the manner by which drugs for treating SUD become available as treatment options.

21.1 Integrated Research to Support Multi-Level Readiness for Evidence-Based Care

Speaker: Tara Karns-Wright, The University of Texas Health Science Center At San Antonio

21.2 Community Engagement to Facilitate Dissemination and Implementation of SUD Innovations

Speaker: Kasey Claborn, The University of Texas At Austin

21.3 The Impact of Physical Activity on Biological Circadian Rhythms in Early Remission From Alcohol Use Disorder

Speaker: Susette Moyers, Oklahoma State University- Center for Health Sciences

21.4 Immune Biomarkers to Accelerate Drug Discovery in Substance Use Disorders

Speaker: Elise Marino, University of Texas Southwestern Medical Center At Dallas

2:00 P.M. - 3:15 P.M.

HUMAN FORUM: NOTHING ABOUT US WITHOUT US: ENGAGING INDIVIDUALS WITH LIVED EXPERIENCE OF SUBSTANCE USE DISORDERS IN SUBSTANCE USE RESEARCH DEVELOPMENT AND IMPLEMENTATION

Grand Ballroom I

Chair: Omayma Alshaarawy, Department of Family Medicine. Michigan State University College of Human Medicine.

Co-Chair: Rachel Luba, New York State Psychiatric Institute

Involving individuals with lived experience of substance use disorders (LESUD) in research is increasingly recognized as a critical strategy to reduce stigma, develop effective personalized interventions, and enhance policy recommendations. Individuals with LESUD are well-positioned to identify research challenges and intended outcomes, perform outreach activities, develop referrals, foster trust, and disseminate findings to the community. Accordingly, several organizations (e.g., SAMHSA and NIDA) now strongly encourage researchers to engage individuals with LESUD and their families in all steps of research process including grant proposal development, implementation, and review. The College of Problems on Drug Dependence Human Research Committee presents a forum focusing on guiding principles to ensure purposeful engagement of individuals

with LESUD in SUD research. Forum speakers will give overviews of effective collaborations with organizations representing individuals with SUD, study planning, data collection methods and analysis, and dissemination of findings. The forum will provide attendees with different perspectives and best practices to collaborate with individuals with LESUD to design effective and responsive research programs and enhance clinical practice and public policy.

22.1 What do we do When Everyone With Lived Experience Wants to Help? Insights From a Recent Research Project of College Students With Histories of Addiction

Speaker: Noel Vest, Boston University

22.2 Qualitative Interviews to Inform Research on and Implementation of Effective Treatments for OUD: How Can the Perspectives of People With LESUD Shape Our Definitions of Clinically-Meaningful Outcomes?

Speaker: Manesh Gopaldas, Columbia University

22.3 Supporting Technology Use and Harm Reduction Within a Housing First Framework

Speaker: Tessa Frohe, University of Washington

2:00 P.M. - 3:15 P.M.

ANIMAL FORUM: THE 3RS CONCEPT OF REPLACEMENT: FUTURE TOOLS OR POLITICAL STRATEGY? **Grand Ballroom II**

Chair: James Rowlett, University of Mississippi Medical Center

The “3Rs” concept was introduced in the 1959 by Russell and Birch, and consists of “Replacement”, “Reduction”, and “Refinement”. At present, these concepts play a central role in animal welfare and regulation of animal research worldwide. However, the concept of “replacement” (originally defined as scientific method using non-sentient material instead of conscious living vertebrates) has been used increasingly to promote the complete abolition of all animal-based research (e.g., US FDA Modernization Act passed Oct 2022 by the Senate). Nevertheless, research on alternatives to animals is a viable and active field. To discuss recent issues in the area of non-animal research alternatives, Dr. James Rowlett will introduce the topic and provide updates from the political arena. Dr. Robert Hester will discuss his use of animals for physiological research and his responsibility serving as IACUC Chair at the University of Mississippi Medical Center. He will then present how computer simulation of physiology was initially used to plan animal experiments, then his work on the development of computer simulation for understanding physiology and how investigators and companies are using physiological simulation for virtual clinical trials. Our primary goal is to provide perspectives (sometimes competing ones) on the realities of replacement, and to provide informed responses to challenges that animal research is outdated, including evidence-based knowledge for when alternatives are available and appropriate.

23.1 Non-Animal Alternatives as Political Strategy

Speaker: James Rowlett, University of Mississippi Medical Center

23.2 Animal Experimentation or Computer Simulations? Both are Needed

Speaker: Robert Hester, University of Mississippi Medical Center Department of Physiology

3:30 P.M. - 5:00 P.M.

SYMPOSIUM: 10 YEARS GONE: REMEMBERING BILL WOOLVERTON THROUGH HIS IMPACT ON OUR CURRENT RESEARCH PROGRAMS

Plaza Ballroom A

Chair: *Sally Huskinson, University of Mississippi Medical Center*

Co-Chair: *Michael Nader, Wake Forest University School of Medicine*

Considerable progress in understanding substance use disorders has been made using nonhuman animal models. This symposium will highlight the profound contributions of such research and its translational impact made by one of CPDD's long-time members, Bill Woolverton, on the 10th anniversary of his passing. Bill was passionate about rigorous experimental designs using operant procedures, with a focus on translating these preclinical findings to clinical applications. Dr. Nader will discuss the use of concurrent food-drug schedules of reinforcement to model vulnerability to substance misuse, which began for Bill during the late 1980's and while at the University of Chicago, and how these models can inform interpretations of reinforcing strength and intervention strategies involving polysubstance use. Dr. Rowlett will explore mechanisms of reinforcement and how they tie into, or are explained by, other pharmacological effects engendered by drugs using examples from his research using nonhuman primates, which originated after joining the Bill Woolverton Band (1993-1997) at the University of Mississippi Medical Center. Dr. Freeman will discuss the study of drugs as punishers and the translational implications of Bill's efforts for the development of abuse-deterrent formulations for prescription drugs. Bill had a deep appreciation for the powerful role of the environment, and Dr. Huskinson will discuss environmental determinants of drug vs. non-drug choice, including delay and variable schedules of reinforcement. The session will conclude with moderated discussion of, and reflection on, Bill's substantial legacy and the growth opportunities stemming from his impressive body of work.

24.1 Bill was Right: For Most Research Questions, Models of Reinforcing Efficacy are the Best

Speaker: *Michael Nader, Wake Forest University School of Medicine*

24.2 Woolverton's "3Ms": Monkeys, Music, and Mississippi

Speaker: *James Rowlett, University of Mississippi Medical Center*

24.3 Bill Woolverton and the Study of Drugs as Punishers: Translational Growth From a Bedrock of Rigor

Speaker: *Kevin Freeman, University of Mississippi Medical Center*

24.4 Looking out Instead of in: How Bill Inspired us to Study Context in Drug Taking

Speaker: *Sally Huskinson, University of Mississippi Medical Center*

3:30 P.M. - 5:00 P.M.

WORKSHOP: EARLY CAREER MEMBER COMMITTEE: NAVIGATING A CAREER IN ADDICTION SCIENCE **Grand Ballroom II**

Chair: *Danielle Davis, Yale University School of Medicine*

Co-Chair: *Denise Vidot, University of Miami School of Nursing and Health Studies*

Despite a wide range of career paths available to scientists in the substance use and addiction fields, knowledge on how to navigate a career can be limited. This gap in knowledge can be a function of limited access to resources, mentorship, and/or institutional knowledge. Opportunities may exist for emerging addiction scientists that are well suited for their skillsets or expertise but are otherwise inaccessible due to a lack of knowledge on how to pursue certain career paths. The purpose of this workshop is to provide early career attendees at CPDD the opportunity to hear from a diverse group of addiction scientists from a range of professions spanning academia, industry, and government agencies. This workshop will provide valuable information to early career scientists about skill sets, expertise, and experiences needed for various careers and the benefits of different career paths. Our speakers include preclinical, clinical, and epidemiological addiction scientists with experience in Industry positions, government agencies, and both research-focused and teaching-focused academic institutions. Presenters will share experiences that prepared them for their careers, describe their day-to-day work, and discuss available growth opportunities. Presentations by speakers will be followed by breakout groups to allow early career attendees to ask directed questions about specific careers. CPDD is successful, in part, because of dedicated scientists with careers in academia, industry, and government who collaborate to advance the understanding of addiction science. This workshop will provide critical insights for early career attendees, facilitate unique networking opportunities, and will ultimately enrich the future membership of CPDD.

25.1 Addiction Science Research at a Primarily Undergraduate Institution: Balancing the Classroom and Laboratory
Speaker: Ryan Lacy, Franklin and Marshall College

25.2 Federal Regulatory Scientist: Evaluating Drug Abuse-Potential
Speaker: Jovita Randall-Thompson, US Food and Drug Administration

25.3 Trading Paces: One Perspective on the Journey From Academia to Industry
Speaker: Erica Peters, Canopy Growth Corporation

25.4 The Role of the Psychiatrist in Academic Research
Speaker: Denis Antoine, Johns Hopkins University School of Medicine

25.5 Navigating Non-Academic Careers in Addiction Science
Speaker: Alexandra Duncan, The Pew Charitable Trusts

TUESDAY, JUNE 20, 2023

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: THE RACIST ORIGINS AND IMPACT OF THE WAR ON DRUGS **Grand Ballroom II**

Chair: Bryon Adinoff, *Doctors for Cannabis Regulation*
Co-Chair: Brenda Curtis, *NIH/NIDA-IRP*

The Black Lives Matter (BLM) movement has raised awareness of the systemic racism embedded in the laws, institutions, and culture of the U.S. A key driver of systemic racism is the War on Drugs. Most U.S. drug laws were promoted to the public using racist arguments and have been used to disenfranchise and incarcerate millions of individuals, particularly people of color. Consequences include arrests, incarcerations, violent policing, and the lifelong effects of an arrest/prison record upon education, employment, housing, and child custody. The criminal

consequences of illicit drug use make our field of medicine unique in that suffering from an addictive illness (e.g. opioid use disorder) is punishable by law, even in the absence of harm. Moreover, criminal punishment can also exacerbate mental illness and contribute to problematic drug use. Nevertheless, addiction-related medical and research organizations by and large continue to either support drug prohibition or remain silent. In this symposium, the speakers will provide an overview of the origins and impact of drug prohibition, the centrality of race and stigma to the prohibitionist structure, and the role of the addiction research community in resolving the inherent conflict between an illicit drug use disorder as a criminal behavior vs. biologic illness. A moderated discussion will allow audience input into the role the CPDD community can play to re-orient society's focus on drug prohibition to evidence-based drug treatment, where appropriate.

26.1 The Racist Origins and Impact of the War on Drugs

Speaker: *Maritza Perez Medina, Office of Federal Affairs*

26.2 The Dehumanization of Substance Users

Speaker: *Brenda Curtis, NIH/NIDA-IRP*

26.3 The Role of Addiction Researchers in Righting the Wrongs of the Drug War

Speaker: *Bryon Adinoff, Doctors for Cannabis Regulation*

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: THE PAST, PRESENT, AND FUTURE OF REINFORCER PATHOLOGY THEORY IN SUBSTANCE USE DISORDER

Plaza Ballroom A

Chair: *Justin Strickland, Johns Hopkins University School of Medicine*

Co-Chair: *Warren Bickel, Fralin Biomedical Research Institute at VTC*

Behavioral economics is an interdisciplinary field that uses psychological, economic, and neuroscience principles to inform behavioral health and decision-making science. Advances in behavioral economic research have culminated in the development of a novel conceptual framework – Reinforcer Pathology Theory. Reinforcer Pathology Theory posits that reinforcers are integrated over a temporal window that determines the relative value of drugs and prosocial alternatives such that brief, immediate, intense, and reliable reinforcers (e.g., substance use) are overvalued compared to alternatives lower in their intensity, variable in their outcome, and delayed in their value accumulation (e.g., employment). This session will trace the past, present, and future of Reinforcer Pathology Theory using data from diverse drug classes and preclinical, human laboratory, and clinical settings. We will first describe the development and evolution of Reinforcer Pathology Theory along with basic science tests of diverse phenomena explained by this theoretical framework (e.g., alternative reinforcer and satiation hypotheses). Speakers will then discuss applications of Reinforcer Pathology Theory to behavioral and medications development work in substance use disorder. These data will demonstrate improved translational potential achieved through Reinforcer Pathology Theory across a pipeline of preclinical rodent studies to the human laboratory to clinical assessment. A public health view of Reinforcer Pathology Theory will then be explained, and how these approaches have rendered novel insights to guide policy development and thus garnered widespread attention outside of academia. The session will conclude with a moderated discussion of future theory refinement and applications for new intervention contexts.

27.1 Reinforcer Pathology: Contemporary Status and Future Directions

Speaker: *Warren Bickel, Fralin Biomedical Research Institute at VTC*

27.2 Understanding the Effects of Visual Exposure to Nature on Substance Demand and Discounting Using Reinforcer Pathology

Speaker: Meredith Berry, University of Florida

27.3 Applying Behavioral Economics and Reinforcer Pathology Theory to Improve Translational Medications Development

Speaker: Justin Strickland, Johns Hopkins University School of Medicine

27.4 The Historical Precedence and Translational Promise of Reinforcer Pathology Theory in Public Health Policy for Substance Use Disorder

Speaker: Derek Reed, University of Kansas

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: DYSREGULATION OF THE PREFRONTAL CORTEX IN SUBSTANCE USE DISORDERS Plaza Ballroom D

Chair: Jacqueline McGinty, Medical University of South Carolina

Co-Chair: Kathryn Cunningham, John Sealy School of Medicine University of Texas Medical Branch

Dysregulation of the medial prefrontal cortex (mPFC) during substance use disorders (SUDs) is a major characteristic of relapse to drug seeking and the cognitive deficits that accompany relapse. However, we know little about the phenotypes that result from structure and functional mPFC deficits in impulse control and executive decision-making during SUD development. Recent evidence indicates that abused drugs disrupt regulation of mPFC pyramidal neurons by fast-spiking, parvalbumin (PV)-expressing interneurons and the perineuronal nets (PNNs) that surround them. In this symposium, a diverse panel of investigators who represent multi-disciplinary perspectives will address these issues and more. To introduce the clinical context, F. Gerard Moeller (VCU) will discuss human brain effective connectivity engaging the mPFC to gain a richer “fingerprint” of the complex neurocircuitry and behavior to develop precise diagnoses and make therapeutic decisions in SUDs. Barbara Sorg (Legacy Research Institute) will discuss the effects of repeated cocaine on PNNs and synaptic excitability of PV interneurons in the mPFC as well as the impact of mPFC PNN removal on communication between the mPFC and hippocampus during consolidation of cocaine-associated memories. Antonieta Lavin (MUSC) will discuss the role of PV-positive interneurons in METH- induced hypofrontality and its resulting cognitive deficits. Kathryn Cunningham (UT Galveston) will highlight preclinical studies of serotonin target-phenotype relationships engaging mPFC circuitry which precipitate SUD risk. Altogether this panel will highlight the importance of the relationship between specific PFC neuronal subpopulations in preclinical and clinical models that expand our understanding of clinical phenotypes of SUDs.

28.1 Human Brain Connectivity as a Fingerprint of Neurocircuitry and Behavior

Speaker: F. Gerard Moeller, Virginia Commonwealth University

28.2 Impact of Perineuronal Nets on Reconsolidation of Cocaine-Associated Memories and Prefrontal-Hippocampal Coupling During Cocaine Cue Acquisition

Speaker: Barbara Sorg, Legacy Research Institute

28.3 Chronic Methamphetamine Administration Produces Cognitive Deficits Through Augmentation of Gabaergic Synaptic Transmission in the Prefrontal Cortex

Speaker: Antonieta Lavin, MUSC, Dept. of Neuroscience

28.4 Prefrontal Cortex 5-HT_{2A} and 5-HT_{2C} Receptors Control Target Behaviors Allied With Cocaine Use Disorder
Speaker: Kathryn Cunningham, John Sealy School of Medicine University of Texas Medical Branch

8:00 A.M. – 9:30 A.M.

SYMPOSIUM: BEYOND GWAS: THE GENETICS AND EPIGENETICS OF ADDICTION
Governor's Square 15

Chair: Jonathan Pollock, National Institute of Drug Abuse, National Institutes of Health
Co-Chair: Arpana Agrawal, Washington University School of Medicine

GWAS studies are rapidly identifying variants underlying addiction and complex psychiatric disorders. These variants are being found within the coding regions of genes and in non-coding regions of the genome. Understanding how these different types of variants contribute to addiction and behaviors associated with addiction requires approaches that identify functional consequences, assess gene x gene interactions within gene networks, and creation of addiction risk scores associated with these variants. In this symposium, we will discuss technologies that uncover the underlying biology of GWAS variants using three different approaches: identifying function through analysis of variant-specific chromatin changes, machine learning, and analysis of short tandem repeats.

29.1 Substance Use Disorders in 3D Genome
Speaker: Hyejung Won, University of North Carolina at Chapel Hill

29.2 Transcriptomic Profiling of the Opioid Exposed Human Ventral Midbrain at Single Nuclei Resolution
Speaker: Shahram Akbarian, Icahn School of Medicine at Mount Sinai

29.3 Systems Biology Integration of Multi-Omic Data Reveals Biological Pathways Underlying Substance Use Disorders
Speaker: Kyle Sullivan, Oak Ridge National Laboratory

29.4 The Contribution of Short Tandem Repeats to Splicing Variation in Humans
Speaker: Yang Li, University of California - San Diego

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: NOT LIKE OTHER OPIOIDS: HOW IS FENTANYL UNIQUE?
Grand Ballroom I

Chair: Kelly Dunn, Johns Hopkins University School of Medicine
Co-Chair: Andrew Huhn, Johns Hopkins University School of Medicine

Illicitly manufactured fentanyl has infiltrated and, in many places, completely replaced the heroin product in the United States and Canada. Fentanyl has many unique characteristics that distinguish it from other opioid agonists and make it a particularly nefarious compound. Specifically, the mechanisms through which fentanyl exerts effects leads to differences in its subjective effect profile and withdrawal experience and increases its lethality relative to other opioids, putting patients at extreme risk and complicating conventional treatment strategies. This symposium brings together researchers from several disciplines to discuss these unique features. First, Dr. Sandra Comer will discuss fentanyl's unique pharmacodynamic profile relative to

other opioids. Next, Dr. Jaime Yanez-Farfan will discuss fentanyl's secondary peaking profile, an effect that is not typically observed in persons using other opioid agonists. Third, Dr. Phillip (Randy) Torralva will review preclinical evidence of the unique lethality of fentanyl-induced vocal cord (glottic) closure (FIVCC) as it relates to fentanyl overdose in humans. Finally, Dr. Kelly Dunn will present data on withdrawal and play recorded (and anonymized) conversations with persons who have lived experience with illicit fentanyl exposure to illustrate patient-reported differences in the experience of withdrawal following fentanyl versus heroin as well as during buprenorphine inductions. A panel discussion, moderated by Dr. Andrew Huhn, will focus on how these distinct features make fentanyl uniquely challenging relative to other opioids and review the epidemiological, clinical, and preclinical research that is needed to help advance the care of patients.

30.1 Pharmacology of Fentanyl and its Implications for Treatment of Opioid Use Disorder and Overdose

Speaker: *Jermaine Jones, Columbia University Irving Medical Center*

30.2 Multiple Peaking Phenomena in Fentanyl Disposition

Speaker: *Jaime Yanez, Universidad Norbert Wiener*

30.3 Preclinical Evidence of Fentanyl-Induced Vocal Cord Closure (FIVCC)- Relevance to Fentanyl Overdose in Humans

Speaker: *Phillip Torralva, Oregon Health and Science University / Torralva Medical Therapeutics, INC.*

30.4 Withdrawal From Fentanyl is Different: Data Presentation and First-Hand Accounts From Persons With Lived Experience

Speaker: *Kelly Dunn, Johns Hopkins University School of Medicine*

Moderator: *Andrew Huhn, Johns Hopkins University School of Medicine*

10:00 A.M. - 11:30 A.M.

INNOVATOR SYMPOSIUM: MEDICATION DEVELOPMENT FOR METHAMPHETAMINE USE DISORDER Plaza Ballroom A

Chair: *Linda Dwoskin, University of Kentucky*

Methamphetamine Use Disorder (MUD) afflicts 2.6 million US citizens, caused >23,000 US deaths in 2020, and imposes an economic burden of >\$600B annually. MUD is the compulsive, chronic use of methamphetamine, causing devastating health consequences (e.g., psychotic behavior, brain and heart damage, death) and harm to communities (e.g., crime, unemployment, child neglect or abuse). There are currently no FDA approved medications to treat MUD. Methamphetamine increases extracellular dopamine by inhibiting cellular uptake and reversing transport at the vesicular monoamine transporter-2 (VMAT2). Blocking methamphetamine's effects at VMAT2, and thus blocking METH-induced reward and relapse, could lead to a MUD pharmacotherapy. Our late lead preclinical candidate VMAT2 inhibitor, UKY-21, potently ($K_i = 31$ nM) inhibits VMAT2 function with minimal interactions at potential off targets (dopamine transporter and hERG, K_i 's >100-fold higher than at VMAT2). UKY-21 evolved from a previously reported series of related VMAT2 inhibitors with poor oral bioavailability and hERG liability. Oral administration of UKY-21 in rats, potently ($ID_{50} = 17$ mg/kg/d) and effectively decreases methamphetamine self-administration without the development of tolerance. In vivo selectivity for UKY-21 is supported by failure to decrease cocaine self-administration at oral doses that decrease METH self-administration. UKY-21 has high oral bioavailability (>65% in rat) and provides durable exposure in plasma and brain, consistent with once daily oral dosing. UKY-21 is well tolerated in vivo in rat and

appears to have an optimal safety pharmacology profile, including no significant hERG inhibition. Successful development of a pharmacotherapy for MUD would have a tremendously beneficial health and socioeconomic impact.

31.1 Mirtazapine for Methamphetamine Use Disorder

Speaker: *Phillip Coffin, San Francisco Department of Public Health*

31.2 Development of Biased Neurotensin Receptor 1 Ligands for the Treatment of Addiction

Speaker: *Lauren Slosky, University of Minnesota*

10:00 A.M. - 11:30 A.M.

SYMPOSIUM: THE POTENTIAL OF PSYCHEDELIC THERAPIES FOR SUBSTANCE USE DISORDERS **Grand Ballroom I**

Chair: *Albert Garcia-Romeu, Johns Hopkins University School of Medicine*

Historically, clinical research with classic psychedelics such as LSD focused heavily on applications treating substance use disorders (SUDs). Meta-analysis of early controlled trials comparing LSD to non-psychedelic control conditions found a single high-dose LSD treatment was associated with significantly greater reductions in alcohol misuse than control. Similarly, a preliminary trial of high-dose LSD with residential treatment in formerly incarcerated men with a history of opioid dependence found significantly greater biologically verified opioid abstinence in the LSD vs. treatment-as-usual control condition up to 12 months post-treatment. These studies and anecdotal and observational reports on indigenous and naturalistic psychedelic use formed the basis for novel research on psychedelic therapies for SUD in the 21st century, with small preliminary trials of psilocybin and ayahuasca for various SUDs showing feasibility and promise. More recently, larger randomized controlled trials of psilocybin for SUD have been conducted. Published data from a placebo-controlled trial in patients with alcohol use disorder showed significantly greater reductions in heavy drinking days and daily alcohol consumption after two high doses of psilocybin with motivational enhancement therapy (MET) compared to placebo with MET. Available data from recently completed controlled trials of psilocybin-assisted treatment for tobacco and cocaine use disorder will also be discussed. Additionally, growing preclinical research is probing biological activity underlying psychedelics' anti-addictive effects. These findings will be examined in the context of investigating psychedelic therapies and their mechanisms and exploring the ramifications for potential psychedelic-assisted treatments for SUD.

32.1 Effects of Psilocybin in Treatment-Seeking Adults With Alcohol Use Disorder

Speaker: *Michael Bogenschutz, New York University Grossman School of Medicine*

32.2 Psilocybin Treatment for Cocaine Use Disorder

Speaker: *Peter Hendricks, The University of Alabama At Birmingham*

32.3 Effects of Psychedelics in Preclinical Models of Substance Use Disorders

Speaker: *Kevin Murnane, Louisiana State University Health Sciences Center - Shreveport*

32.4 Psilocybin-Assisted Smoking Cessation: A Randomized Controlled Trial

Speaker: *Matthew Johnson, Johns Hopkins University School of Medicine*

10:00 A.M. - 11:30 A.M.

SYMPOSIUM: NEUROPEPTIDES IN REWARD, ADDICTION, AND MENTAL HEALTH
Plaza Ballroom D

Chair: *Subramaniam Ananthan, DHHS/NIH/NIDA*

Co-Chair: *Lakshmi Devi, Icahn School of Medicine At Mount Sinai*

Neuropeptides are known to play a central role in physiological and pathological processes relating to reward, learning, memory, stress, addiction, and neurological disorders. Peptidomic studies using mass spectroscopy and single cell transcriptional profiling are revealing a surprising prevalence of neuropeptides in brain that are positioned to broadly modulate neural activity and behavioral functions. These findings offer novel targets for therapeutics development for neurobehavioral disorders. This symposium will feature presentations on innovations and recent advances in the field of neuropeptides and their signaling mechanisms in addiction, mental health, and psychiatric disorders.

33.1 The Role of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Binge-Like Ethanol Drinking and Affective Behavior

Speaker: *Jessica Barson, Drexel University College of Medicine*

33.2 Extended Amygdala Neuropeptide Circuitry of Emotional Arousal

Speaker: *William Giardino, Stanford University*

33.3 Endogenous Opioid Peptides and Novel Neuropeptides in Addiction, Reward, and Mental Health

Speaker: *Lakshmi Devi, Icahn School of Medicine At Mount Sinai*

10:00 A.M. - 11:30 A.M.

SYMPOSIUM: HOW NEUROIMAGING CAN BE USED IN TREATMENT DEVELOPMENT IN DRUG ADDICTION: FROM FDA STANDARDS TO CLINICAL APPLICATIONS
Grand Ballroom II

Chair: *Hamed Ekhtiari, University of Minnesota*

Co-Chair: *Sarah Yip, Yale University*

As a neurobiological process, addiction involves pathological patterns of engagement with substances and a range of behaviors with a chronic and relapsing course. Neuroimaging technologies assess brain activity, structure, physiology, and metabolism at scales ranging from neurotransmitter receptors to large-scale brain networks, providing unique windows into the core neural processes implicated in substance use disorders. Identified aberrations in the neural substrates of reward and salience processing, response inhibition, interoception, and executive functions with neuroimaging can inform the development of pharmacological, neuromodulatory, and psychotherapeutic interventions to modulate the disordered neurobiology. Neuroimaging measures can facilitate the development of a range of biomarkers that may prove useful in the arsenal of addiction treatments in the coming years. There is evidence that these markers of large-scale neural structure and activity may indicate vulnerability or separate disease subtypes, predict response to treatment, or provide objective measures of treatment response or recovery. Neuroimaging biomarkers can also suggest novel targets for interventions. Closed or open loop interventions can integrate these biomarkers with neuromodulation in real-

time or offline to personalize stimulation parameters and deliver precise intervention. Given the sheer diversity and rapid advances in neuroimaging in recent years, this symposium will provide an overview of neuroimaging modalities in addiction, potential neuroimaging biomarkers, and future directions and challenges in bringing these putative biomarkers from the bench to the bedside. At the end, we will discuss an executive pathway to support FDA qualification for neuroimaging biomarkers in certain contexts of use and how other labs can contribute in this collective effort.

34.1 From Neuroimaging Markers to Biomarkers in Treatment Development

Speaker: *Lara Ray, University of California Los Angeles*

34.2 Brain-Based Predictive Modeling of Addiction

Speaker: *Sarah Yip, Yale University*

34.3 Neuroimaging as a Response Biomarker in Drug Development

Speaker: *Joseph Schacht, University of Colorado School of Medicine*

34.4 Neuroimaging as a Target Biomarker in Neuromodulation

Speaker: *Hamed Ekhtiari, University of Minnesota*

10:00 A.M. - 11:30 A.M.

WORKSHOP: 29TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP

Governor's Square 15

Chair: *Matthew Novak, Johns Hopkins University School of Medicine*

Co-Chair: *Diann Gaalema, University of Vermont*

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the discussion and dissemination of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 29th annual meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input and providing opportunities for junior and senior researchers to interact. As the goal for this working group has always been to provide an informal outlet for discussion of CM data, names of presenters are not included with this submission. Rather, participants and topics will be chosen during the Spring of 2023 to capture the most current data in contingency management research for presentation at our annual working group.

1:15 P.M. - 2:15 P.M.

MINI-SYMPOSIUM: MONITORING AND DIAGNOSTIC DEVICES FOR SUBSTANCE USE DISORDERS: CHALLENGES AND OPPORTUNITIES

Grand Ballroom I

Chair: *Stacie Gutowski, National Institute on Drug Abuse, National Institutes of Health*

Co-Chair: *Kelly Dunn, Johns Hopkins University School of Medicine*

Medical devices can serve as tools for monitoring patients and/or diagnosing drug overdose to provide innovative solutions in the management of substance use disorders. New developments in hospital-based monitoring options can provide personalized pain management and medication dosing to reduce opioid exposure. Beyond the clinical environment, novel technological developments have led to monitoring for a wide range of real-time physiologic parameters in daily life including respiratory rate, blood oxygen saturation, heart rate, and electrodermal activity through wearable devices and accompanying mobile phone applications. These devices can be utilized by patients to provide instantaneous monitoring of the patient experience, such as identifying when a person is experiencing stress or anxiety and subsequently providing real-time options for social support, geo-located interventions (e.g., meetings, treatment centers), cognitive behavioral therapies through clinician or chat bot interactions. Additionally, medical devices are being developed to focus on the detection of opioid-induced respiratory depression, to monitor and possible alert bystanders and/or caregivers and allow for a timely administration of naloxone. As these devices are developed, we must discuss and understand the challenges and opportunities about which measures are most useful and the types of data output and alerts that will be accepted in this patient population.

36.1 Monitoring and Diagnostic Devices for Substance Use Disorders: Challenges and Opportunities

Speaker: *David Reeser, OpiAID, Inc.*

36.2 An EEG Biomarker for Opioids: Insights From the Operating Room to aid in the Opioid Crisis

Speaker: *Patrick Purdon, Harvard Medical School*

36.3 Wearable and On-Body Devices for Detection of Opioid Overdose

Speaker: *Michael Hite, Ayuda Medical*

2:45 P.M. - 3:45 P.M.

MINI-SYMPOSIUM: FROM INITIATION TO ADDICTION: A MEASURE OF THE FULL RANGE OF INVOLVEMENT FOR OPIOIDS, CANNABIS, AND ALCOHOL

Grand Ballroom I

Chair: *Ty Ridenour, RTI International*

Co-Chair: *Lisette Saavedra, RTI International*

This mini symposium will present an innovative measure of the full developmental continuum of substance use (SU) involvement from pre-initiation through physiological dependence onto which numerous other SU measures could be mapped. This measure could help delineate which stages of progression from earlier to later involvement are impacted by specific environmental risks, genetic mechanisms, and underlying neurophysiology as well as when and for whom prevention and treatment programs are most impactful. Involvement was tested

using items on initiation, regular use, and SU disorder (SUD) criteria available in many commonly used datasets. Methods: National Survey on Drug Use and Health (NSDUH) datasets 2016-2019 (N=225,622) were analyzed using moderated non-linear factor analysis and traditional psychometric analyses to evaluate “anchor items” for recreating involvement measures in other datasets for alcohol, cannabis, prescription opioids, and heroin. NSDUH data represent noninstitutionalized U.S. civilians, ages 12 or older. Sample composition was 52.2% female; 58.3% non-Hispanic White, 12.8%, non-Hispanic Black and 18.5% Hispanic; and 21.5% with an income below 2 times the poverty level. Results: Psychometrics in the general population and an elevated risk subsample supported involvement measures for each substance and overall SU involvement. Greater involvement with each substance was associated with SUDs of the same or other drugs (e.g., cocaine), major depression, risk taking, criminal behavior, and suicidality. Conclusions: Panelists will present study results; methods to create involvement measures in other datasets illustrated using NIH HEAL datasets; and how involvement could shed light on SUD etiology, prevention, treatment, and recovery.

37.1 Substance Use Involvement Associations With Risk Factors and Psychopathology

Speaker: Barrett Montgomery, RTI International

37.2 Development and Psychometrics of Substance Use Involvement Measures With Nonlinear Moderated Factor Analysis

Speaker: Alexandra Tonigan, RTI International

37.3 Substance Use Involvement Replication in Other Datasets and Potential Research Directions Illustrated With Heal Initiatives Studies

Speaker: Ty Ridenour, RTI International

WEDNESDAY, JUNE 21, 2023

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: USING BIG DATA TO UNDERSTAND THE ROLE OF THE GUT MICROBIOME IN SUBSTANCE USE DISORDERS

Plaza Ballroom D

Chair: Susan Wright, NIDA/NIH

Co-Chair: Kiran Vemuri, National Institute of Drug Abuse/NIH/DHHS

Substance use disorders (SUDs) continue to be a significant public health challenge with negative health, social, and economic consequences. They are known to co-occur at high prevalence with several mental health disorders and can involve several different substances, including cocaine, opiates, cannabinoids, nicotine, and alcohol. While much SUD research has focused on the neurologic and genetic components of usage behavior, there is increasing interest in the role of the gut microbiome in the pathogenesis of SUD. With the continuous collection of large volumes of various data types, researchers are trying to facilitate microbiome research by building large reference data sets to serve as a foundation for new technologies and data analysis tools. This session will explore current research providing evidence that the gut microbiome is involved in SUDs and the challenges and opportunities for understanding the role of the microbiome in health. Accordingly, the symposium will address key knowledge gaps in the field while describing relationships between the gut microbiome and various addiction or addiction-related behaviors. The panel will also discuss relevant models of drug-seeking behavior along with metagenomics, metabolomics, and proteomics approaches to identify

molecular signatures underlying gut microbiome affects, including biomarkers that covary in the context of SUD.

38.1 Using Big Data to Understand the Role of Gut Microbiome in Substance Use Disorder

Speaker: Jason Bubier, The Jackson Laboratory

38.2 The Gut Microbiome in Modulating Binge Drinking

Speaker: Yanjiao Zhou, UConn Health

38.3 Utilizing Multi-Omics Approaches to Identify Molecular Signatures of Gut-Brain Signaling in Models of Fentanyl Use Disorder

Speaker: Drew Kiraly, Wake Forest School of Medicine

38.4 The Microbiome as a Risk Factor in Opioid Use Disorders

Speaker: Jennifer Whistler, Center for Neuroscience

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: PREVENTION IS BETTER THAN CURE: EARLY INTERVENTION FOR SUBSTANCE USE DISORDERS

Governor's Square 15

Chair: Gillinder Bedi, The University of Melbourne

Co-Chair: Carlos Blanco, National Institute on Drug Abuse

Substance use disorders (SUD) commonly emerge during adolescence/young adulthood, a critical period of neurobiological and psychosocial development. Onset of SUD during this period confers risk of harm to the developmental trajectory, setting the stage for a cascade of future difficulties. Without intervention, SUDs can develop into chronic conditions, requiring multiple episodes of care. Yet, delayed treatment remains the norm and most treatments are targeted to the severe end of the SUD spectrum. There is a need to refocus intervention efforts towards the early stages of SUD to disrupt progression to more severe SUD and prevent adverse health outcomes. This symposium will provide an overview of the current limited evidence guiding early intervention strategies for SUD. We will review the clinical staging model in psychiatry and developments in early intervention psychiatry, assessing the utility of these frameworks for clinical addiction science. Early intervention depends on the presence of well-delineated early clinical phenotypes: the second speaker will use epidemiological data to assess whether clinical high-risk states for SUD can be identified. The second section of the symposium will present emerging evidence on early intervention methods. This will include data on implementation of screening, brief intervention and referral to treatment for adolescents in pediatric medical and school settings, and opportunistic early intervention in college students and youth presenting for emergency care. Speakers will highlight the potential for early intervention to modify negative effects of SUD across the life course, and the clear need for further research to enable these impacts to be realised.

39.1 Early Intervention for Substance Use Disorders: Lessons From Clinical Staging and Early Intervention Psychiatry

Speaker: Gillinder Bedi, The University of Melbourne

39.2 Is There a Clinical High Risk State for Substance Use Disorder? An Epidemiological Perspective

Speaker: Carlos Blanco, National Institute on Drug Abuse

39.3 Implementing SBIRT for Adolescent Substance Use in Pediatric Medical and School Settings

Speaker: Christopher Hammond, Johns Hopkins University School of Medicine

39.4 Opportunistic Early Intervention for Problematic Substance Use in Young People via University and Emergency Services

Speaker: Leanne Hides, University of Queensland

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: DEVELOPMENT OF FENTANYL-TARGETED VACCINES TO DECREASE OVERDOSE FATALITIES

Grand Ballroom II

Chair: Drew Townsend, NIDA DTMC

Co-Chair: Jason Sousa, National Institute on Drug Abuse

Opioid-related fatalities have become the most common cause of death for Americans between 18-45 years of age. This surge in deaths may be attributable to the adulteration of illicit drugs (heroin, cocaine, methamphetamine) with fentanyl, leading to the unintentional exposure of illicit drug users to this highly potent opioid. Recent findings suggest that fentanyl-targeted vaccines can confer robust protection against fentanyl and structurally similar opioids. However, it is critical that the durability of fentanyl-targeted vaccines is closely examined preclinically to identify the most promising candidates for clinical testing. The aims of this symposium, organized by NIDA's Division of Therapeutics and Medical Consequences, include 1) educating the audience on the mechanisms of the leading anti-opioid vaccination strategies, 2) provide the current state of the science of opioid-targeted vaccines, and 3) discuss practical considerations of opioid vaccine development (e.g., preclinical vs. clinical endpoints, gaining IND approval, manufacturing). These goals will be accomplished by highlighting three approaches for vaccination under preclinical consideration and conclude with a preview of how these vaccines may be tested under human-laboratory conditions. The first speaker will share findings with a fentanyl-conjugated vaccine, a conventional and well-established approach for vaccination. The second speaker will share findings with a monoclonal vaccination approach for fentanyl. The third speaker will share data related to a novel "nanoparticle vaccine" approach. Finally, potential challenges to the forward translation of opioid-targeted vaccines towards clinical evaluation will be discussed.

40.1 Translation of Vaccines and Antibody Based Strategies Against Fentanyl and its Analogs

Speaker: Marco Pravetoni, University of Washington School of Medicine

40.2 Development of CSX-1004 Monoclonal Antibody for Treatment and Prevention of Fentanyl Overdose

Speaker: Paul Bremer, Cessation Therapeutics

40.3 Hybrid Nanoparticle as a Platform for Vaccine Development Against Opioids and Other Psychoactive Compounds

Speaker: Chenming Zhang, Virginia Tech

40.4 Clinical Testing of Opioid Vaccines: Lessons Learned

Speaker: Sandra Comer, Columbia University and NYSPI

Co-Presenter: Rachel Luba, New York State Psychiatric Institute

8:00 A.M. - 9:30 A.M.

SYMPOSIUM: LEAVING NO ONE BEHIND: ENDING THE HIV EPIDEMIC WITH TARGETED INTERVENTIONS FOR PEOPLE WHO USE DRUGS

Grand Ballroom I

Chair: *Joy Schmitz, University of Texas Health Science Center*

Co-Chair: *Angela Heads, The University of Texas Health Science Center At Houston*

In 2019, the US announced a plan to End the HIV Epidemic by 2030. People who use drugs (PWUD) are disproportionately affected by the epidemic, due in part to low rates of HIV testing and insufficient access to HIV prevention and care services. Consequently, many PWUD do not benefit from highly efficacious HIV prevention and treatment interventions, such as pre-exposure prophylaxis (PrEP) and antiretroviral therapies (ART). Effectively ending the HIV epidemic involves improving HIV prevention and treatment outcomes for PWUD so that no one is left behind. In this symposium, speakers will present progress being made in the development of integrated interventions, encompassing a range of substances of abuse, treatment delivery modalities, and affected populations. Dr. Christopher Kahler will present findings from a factorial randomized controlled trial of telehealth interventions to reduce substance use in men who have sex with men (MSM) living with HIV. Dr. Glenn-Milo Santos will discuss the use of intermittent naltrexone with an in-the-moment ecological momentary intervention to increase PrEP and ART adherence in MSM who use methamphetamine. Research presented by Dr. Adam Carrico will focus on optimizing contingency management to improve HIV prevention and care with sexually minority men who use stimulants. Finally, Dr. Jennifer Jain will present an intervention approach that addresses stigma-related barriers to HIV care engagement among racially diverse women living with HIV who use drugs. Drs. Joy Schmitz and Angela Heads will summarize the talks and moderate a discussion on research priorities for addressing the intersection of substance use and HIV.

41.1 Leaving No One Behind: Ending the HIV Epidemic With Targeted Interventions for People who Use Drugs

Speaker: *Christopher Kahler, Brown University School of Public Health*

41.2 Pharmacotherapy With an Ecological Momentary Intervention to Increase Pre-Exposure Prophylaxis and Anti-Retroviral Therapy Adherence Among Men who Have Sex With Men who Use Methamphetamine

Speaker: *Glenn-Milo Santos, University of California San Francisco*

41.3 Optimizing the Benefits of Contingency Management for HIV Prevention and Care With Sexual Minority Men who Use Stimulants

Speaker: *Adam Carrico, University of Miami*

41.4 WISH: Women, Intersectionality, Substance Use, and HIV

Speaker: *Jennifer Jain, University of California, San Francisco*

10:00 A.M. - 11:30 A.M.

SYMPOSIUM: TREATING SUD IN PATIENTS WITH PTSD AND HISTORIES OF VICTIMIZATION **Grand Ballroom I**

Chair: *Carrie Mulford, National Institute on Drug Abuse, National Institutes of Health*

PTSD and SUD commonly co-occur, with approximately 30% of youth and 50% of adults with PTSD also meeting criteria for SUD. Traumatic experiences are risk factors for the development of SUD. Moreover, the co-occurrence of PTSD and SUD is associated with more severe symptoms and worse clinical outcomes. This panel will present research demonstrating that integrated treatment of comorbid PTSD and SUD, is feasible and effective in reducing symptoms of both disorders. The first presentation will identify neurobiology and symptomatology common to comorbid PTSD and SUD and review the clinical impact of co-occurring disorders. The second presenter will summarize results from the Collaboration Leading to Addiction Treatment and Recovery from Other Stresses (CLARO) study, a randomized controlled trial comparing the effectiveness of collaborative care for patients with co-occurring OUD, PTSD and/or depression. In this presentation, the authors will describe and compare adult patients who have OUD and co-occurring PTSD with and without traumatic experiences of victimization. The third presentation will provide an overview of research on Risk Reduction through Family Therapy (RRFT), including preliminary findings from an ongoing effectiveness implementation trial in adolescent outpatient clinics. RRFT is an integrative, exposure-based treatment for youth that incorporates best-practice interventions for PTSD, SUD, and related health risk behaviors. The final presentation will present preliminary outcomes from an RCT examining the efficacy Concurrent Treatment of PTSD and Substance Use Using Prolonged Exposure - Adolescent (COPE-A), a 16-session intervention, on substance use and PTSD outcomes for adolescents and young adults.

42.1 Comorbid Ptsd and Substance Use disorders: Shared Symptomatology and Neurobiology

Speaker: *Jesse Hinckley, University of Colorado School of Medicine*

42.2 Challenges in Addressing Victimization for People who Have Opioid Use Disorder and Probable PTSD

Speaker: *Lisa Meredith, RAND*

Co-Presenter: *Grace Hindmarch, RAND Corporation*

42.3 Advancing Treatment for Adolescents with Co-Occurring Substance Use Disorders (SUDs) and Posttraumatic Stress Disorder (PTSD): Risk Reduction through Family Therapy

Speaker: *Zachary Adams, Indiana University School of Medicine*

Moderator: *Devin Banks, University of Missouri--St. Louis*

10:00 A.M. - 11:30 A.M.

SYMPOSIUM: DRIVING IMPAIRMENT CAUSED BY THE USE OF CANNABIS AND OTHER DRUGS: RECENT EVIDENCE FROM HUMAN LABORATORY STUDIES

Grand Ballroom II

Chair: *Tory Spindle, Johns Hopkins University School of Medicine*

Co-Chair: *Carlos Zamarripa, Johns Hopkins University School of Medicine, Department of Psychiatry*

The global expansion of cannabis legalization for medical and “recreational” purposes has created an urgent need for research on cannabis-induced driving impairment. Controlled studies demonstrate that cannabis can impair driving performance and epidemiological evidence shows that: 1) driving under the influence of cannabis is increasing, and 2) cannabis-positive drivers have an increased crash risk. However, there are currently no validated methods to detect cannabis-impaired drivers and novel approaches are sorely needed. Further, many novel cannabis products (e.g., edibles) have emerged that remain understudied. Finally, given the heterogeneity in cannabis users, there is a need to characterize impairment among different groups (e.g., medical vs recreational users) and to evaluate individual differences in impairment. This symposium includes four presentations describing data from human laboratory studies featuring sophisticated driving simulators. Dr. Austin Zamarripa will present a study evaluating the individual and interactive effects of cannabis edibles and alcohol on driving performance. Dr. Thomas Arkell will present research on the effects of real-world medical cannabis use on driving/cognitive performance. Dr. Jan Ramaekers will present data showing neural mechanisms underlying individual differences in cannabis-induced impairment. Lastly, Dr. Amie Hayley will describe a novel impairment-detection approach (Driver Monitoring Systems, DMS) that evaluates fitness to drive using eye-tracking; the effectiveness of DMS at detecting drug/alcohol-induced impairment and future applications of this technology will be discussed. Dr. Tory Spindle will synthesize findings from these studies and facilitate an interactive discussion, with an emphasis on U.S. and global policy implications and possible future directions in the driving impairment field.

43.1 Individual and Interactive Effects of Oral Cannabis Products (i.e., “Edibles”) and Alcohol on Driving Impairment

Speaker: *Carlos Zamarripa, Johns Hopkins University School of Medicine, Department of Psychiatry*

43.2 Acute Effects of Medicinal Cannabis on Driving and Cognitive Function: Real-World Evidence

Speaker: *Thomas Arkell, Centre for Human Psychopharmacology, Swinburne University of Technology*

43.3 Neural Mechanisms Underlying Cannabis-Induced Driving Impairment: The Impact of Tolerance and Individual Differences

Speaker: *Jan Ramaekers, Maastricht University*

43.4 Driver Monitoring Systems (DMS): Next Generation Methods to Manage Driver Impairment

Speaker: *Amie Hayley, Swinburne University of Technology*

Moderator: *Tory Spindle, Johns Hopkins University School of Medicine*

10:00 A.M. - 11:30 A.M.

SYMPOSIUM: A GENTLE INTRODUCTION TO DATA SCIENCE TOOLS FOR ADDICTION RESEARCH: USE CASES WITH EXAMPLES

Plaza Ballroom A

Chair: *Gabriel Odom, Florida International University*

Co-Chair: *Raymond Balise, University of Miami*

Discussant: *Daniel Feaster, University of Miami Miller School of Medicine*

Writing and publishing fully replicable scientific analyses is the goal for addiction research, but because of limitations in common software (e.g., copying and pasting numbers between SAS/Excel and Word) researchers do not have the easy-to-use tools to build fully reproducible workflows. In this workshop, participants will be shown how to use free (open source) software tools, including REDCap, R/RStudio, Quarto, and Zotero, to build a completely reproducible pipeline from data collection to manuscript publication. We will present general-purpose software add-ons (the Tidyverse, tidyREDCap, and rUM R Packages) in addition to other user-friendly software tools designed to aid addiction science researchers (R Packages including DOPE, ctn0094data, ctn0094DataExtra, and CTNote). We will give examples of how we write our manuscripts: starting with data curation in REDCap; data wrangling, preprocessing, and engineering in RStudio with tidyREDCap and the Tidyverse; specific tasks related to addiction data with DOPE, ctn0094DataExtra, and CTNote; managing our research bibliographies with Zotero, and creating publication-ready manuscripts with Quarto and rUM. Some of our examples will use the data sets from the Clinical Trials Network, namely CTN-0027, CTN-0030, and CTN-0051, as harmonized during the CTN-0094 project.

10:00 A.M. - 11:30 A.M.

SYMPOSIUM: UNIVERSAL PRECAUTIONS: CONSIDERATIONS WHEN CONDUCTING CLINICAL ADDICTION RESEARCH IN THE ACUTE CARE HOSPITAL

Plaza Ballroom D

Chair: *Michelle Lofwall, University of Kentucky, College of Medicine*

Co-Chair: *Laura Fanucchi, University of Kentucky, College of Medicine*

Hospitalizations for consequences of opioid use disorder (OUD), such as overdose and severe infections associated with injection drug use, are increasing with the opioid epidemic. Persons with OUD hospitalized with significant medical consequences are a unique population with complex needs both during and after hospitalization. Though there has been recent attention to the need to screen, diagnose, and initiate medications for OUD in hospitals, and also facilitate linkage to continued care in the community, there is a lack of evidence informing best practices, and major gaps in the care continuum post-discharge. Clinical research that involves persons with OUD and other substance use disorders in acute care hospitals, and that addresses the specific implementation issues in that setting is challenging but urgently needed. Investigators must navigate myriad factors that affect recruitment, enrollment, and adverse event monitoring, such as changes in clinical care and participant medical complexity. In addition, to be successful, research teams must frequently communicate with and coordinate among various multidisciplinary members of clinical teams and hospital administration. Furthermore, stigma related to persons with OUD and medications for OUD is common in general healthcare settings, and complicates interactions between researchers and the clinical team. During this session we will explore challenges, successes, and lessons learned in initiating, recruiting, enrolling, and randomizing medically

complex, hospitalized patients with opioid use disorder through the lens of two ongoing clinical trials. We will also discuss a hybrid implementation-effectiveness trial evaluating the roll-out of an addiction consultation service in a large health care system.

45.1 Conducting a Randomized Controlled Trial in Hard to Control Hospital Settings: Lessons Learned From the B-OPAT Trial (Buprenorphine plus Outpatient Parenteral Antibiotic Therapy)

Speaker: Laura Fanucchi, University of Kentucky, College of Medicine

45.2 Inpatient and out of Treatment: The Ins and Outs of Addiction Research in Hospitals

Speaker: Gavin Bart, University of Minnesota

45.3 Understanding the Implementation and Effectiveness of Addiction Consult Services: Partnering With a Large Public Hospital System to Conduct a Pragmatic Trial of Addiction Consult Services in 6 Urban Hospitals

Speaker: Jennifer McNeely, New York University Grossman School of Medicine

SUNDAY, JUNE 18, 2023

POSTER SESSION 1

S1. Substance Use Patterns and Impulsivity Among Bariatric Surgery Patients

Rachel Arnold¹, Dace Svikis¹

¹Virginia Commonwealth University

S2. Sex Differences in Acute Pharmacological Stress-Induced Mood and Opioid-Seeking Behavior

Tabitha Moses¹, Mark Greenwald²

¹Wayne State University School of Medicine, ²Wayne State University, Dept of Psychiatry and Behavioral Neurosciences

S3. Sex Differences in Adversity and Risk for Future Alcohol Use in Youth in the ABCD Study

Dawn Bounds¹, Sarah Rodrigues¹, Sanghyuk Shin¹

¹University of California, Irvine

S4. Amyloid Pet and Diffusion Kurtosis Imaging for Alcohol Use Disorder

Kyoji Okita¹, Noriko Sato¹, Yoko Shigemoto¹, Mitsuru Syakadou¹, Yumi Saito¹, Toshihiko Matsumoto¹

¹National Center of Neurology and Psychiatry

S5. Alcohol Cue Reactivity in Virtual, Video Game Environments

Timothy Regan¹, Deicy De la Ossa Brown², Christopher Burrows³, Hart Blanton³, Sherece Fields²

¹Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, ²Department of Psychological and Brain Sciences, Texas A and M University, ³Department of Communication, Texas A and M University

S6. Investigating the Association Between Discrimination, Internalizing Symptoms, and Alcohol Use Among Latino/a Immigrant Parent in the United States

Miracle Macias¹, Tara Bautista¹, Sumeyra Sahbaz², Yesenia Cruz Carrillo¹, Seth Schwartz³, Pablo Montero-Zamora³

¹Northern Arizona University, ²Oklahoma State University, ³University of Texas at Austin

S7. Realist Evaluation of the Impact, Viability, and Transferability of an Alcohol Harm Reduction Support Program Based on Mental Health Recovery: The Vitae Study: First Results

Sarah Moriceau¹, Marc Auriacombe¹, Fuschia Serre¹, Judith Martin-Fernandez¹, Nolwenn Stevens¹, Linda Cambon¹

¹Universite de Bordeaux

S8. SBI Tech Michigan: Optimizing Implementation of Screening and Brief Intervention for Excessive Alcohol Use Among Women of Reproductive Age

Amy Loree¹, Hsueh-Han Yeh¹, Farah Elsis¹, Celeste Zabel¹, Logan Zelenak¹, Sarah Moore¹, Gregory Goyert¹, Jessica Beatty², Poonam Yadav³, Melissa Riba³, Steven Ondersma⁴

¹Henry Ford Health, ²Wayne State University, ³Center for Health and Research Transformation, ⁴Michigan State University

S9. Modes of Marijuana Use by Secondary School Students in 2019–20, Findings From a California Statewide Survey

Jijiang Wang¹, Yue-Lin Zhuang¹, Anthony Gamst¹, Katherine Braden¹, Shu-Hong Zhu¹

¹UC San Diego

S10. Provider-Patient Alliance and Trauma Among Pregnant People With Opioid Use Disorder

Gustavo Angarita¹, Kathryn Gilstad-Hayden², Kimberly Yonkers², Ariadna Forray¹

¹Yale School of Medicine, ²Yale University Department of Psychiatry

S11. Cannabis Use and Mental Health Coping Behavior Among Minority Women During the COVID-19 Pandemic: Results From the COVID-19 Cannabis Health Study

Bria-Necole Diggs¹, Ranya Marrakchi El Fellah¹, Cynthia Lebron², Sitara Weerakoon³, Sarah Messiah⁴, Denise Vidot²

¹University of Miami Miller School of Medicine, ²University of Miami School of Nursing and Health Studies,

³Yale University School of Medicine, ⁴University of Texas Health Science Center

S12. Trends in the Co-Use of Cannabis and Prescription Psychotherapeutic Drugs in the United States

Hosam Elbaz¹, Omayma Alshaarawy²

¹Department of Pharmacology and Toxicology. Michigan State University College of Osteopathic Medicine.,

²Department of Family Medicine. Michigan State University College of Human Medicine.

S13. Trends in Prevalence of Cannabis Use Disorders Among U.S. Veterans With Psychiatric Disorders Between 2005 and 2019

Ofir Livne¹, Carol Malte², Yoanna McDowell², Mark Olfson³, Melanie Wall³, Katherine Keyes⁴, Magdalena Cerda⁵, Silvia Martins¹, Andrew Saxon⁶, Zachary Mannes⁷, David Fink⁸, Salomeh Keyhani⁹, Deborah Hasin¹

¹Columbia University, ²VA Puget Sound Health Care System, ³Columbia University and NYSPI, ⁴Columbia University Mailman School of Public Health, ⁵Department of Population Health, NYU School of Medicine,

⁶Veterans Affairs Puget Sound Healthcare System, ⁷Columbia University, Mailman School of Public Health,

⁸New York State Psychiatric Institute, ⁹University of California, San Francisco

S14. Aerobic Exercise During Adolescence Protects Against Anxiety Disorders in the United States

Whitney Cordoba-Gruesso¹, Karla I. Galaviz², Maria A. Parker²

¹Indiana University, ²Indiana University - Bloomington

S15. Factors Related to Cannabis Use in Individuals Over 65

Lauren Russell¹, Alison Oliveto¹

¹University of Arkansas for Medical Sciences

S16. Factors Associated With Risk for Cannabis Use Disorder Among Adults Using Medical Marijuana in Florida

Robert Cook¹, Hannah J Fechtel¹, Ruba Sajdeya¹, Gabriel Spandau¹, Yan Wang¹

¹University of Florida

S17. Evaluation of the Pharmacokinetic and Pharmacodynamic Profile of Cannabigerol (CBG) in Human Subjects

David Wolinsky¹, Elise Weerts², Marcel O. Bonn-Miller Bonn-Miller³, Matthew Feldner³, Ryan Vandrey², Cecilia Bergeria²

¹Johns Hopkins University School of Medicine, Department of Psychiatry, ²Johns Hopkins University School of Medicine, ³Canopy Growth Corporation

S18. Neural Correlates of Controllable Negative Life Events and Their Relationships With Cannabis and Alcohol Use Initiation

Yihong Zhao¹, Marc Potenza², Susan Tapert³, Martin Paulus⁴

¹Columbia School of Nursing, ²Yale University School of Medicine, ³University of California San Diego,

⁴Laureate Institute for Brain Research

S19. Neural Reward Reactivity to Delta-9-Tetrahydrocannabinol (THC) among Young Adults as a Function of Lifetime Cannabis Use Frequency

Julia Brooks¹, Zoa Glab², Rebecca Denson¹, Natania Crane²

¹University of Illinois At Chicago, ²Psychiatric Institute, University of Illinois At Chicago

S20. Identifying Brief Intervention Factors to Improve Cannabis Related Outcomes in Adolescents and Emerging Adults: A Systematic Review

Kathryn Gex¹, Ruschelle Leone², Jenna Aungst³, Kevin Branson¹, Kevin Gray¹, Rachel Tomko¹

¹Medical University of South Carolina, ²Georgia State University, ³Lincoln Memorial University

S21. A Human Laboratory Study Investigating the Influences of Sex on the Acute Pharmacological Effects of a Range of Smoked Cannabis Doses

Madison Wright¹, Justin Matheson², Bernard Le Foll¹, Bruna Brands³

¹University of Toronto, ²Centre for Addiction and Mental Health, ³Health Canada

S22. Results of Pilot Randomized Controlled Trial of Cognitive Behavioral Therapy for Insomnia to Reduce Cannabis Use

Mark Ilgen¹, J. Todd Arnedt¹, Deirdre Conroy¹, Emily Yeagley¹, Kipling Bohnert²

¹University of Michigan, ²Michigan State University

S23. Adolescents' Online Searches for Marijuana Information: Results From a Random Sample of Middle and High School Students in Los Angeles County

Shuwen Li¹, Yue-Lin Zhuang¹, Adam Cole², Shu-Hong Zhu¹

¹University of California - San Diego, ²Ontario Tech University

S24. Domestic Cannabis Cultivation: Results of the Georgian (country) Sample of the Transnational Online Survey of Cannabis Growers

Irma Kirtadze¹

¹Ilia State University

S25. Differences in Immediate Memory Performance Between Individuals Living With and Without Cannabis Use Disorder in Young Adult HBCU Undergraduates

Emma Quarles¹, Larry Keen¹

¹Virginia State University

S26. Cannabis Retail Staff Perspectives on Trustworthiness of Social Media Information: A Qualitative Study

Meredith Meacham¹, Danielle Schell², Coye Cheshire²

¹University of California San Francisco, ²University of California Berkeley

S27. THC/CBD Vapor Self-Administration in Female Rats Results in Spatial Memory Deficits and Increases Methamphetamine Self-Administration

Jordan Carter¹, Samuel Wood¹, Caroline Limbaker¹, Ayteria Crow¹, Carmela Reichel¹

¹Medical University of South Carolina

S28. Open Board

S29. Cigarillo Purchasing and Pack Sizes by Their Use as Blunts

Brian Fairman¹

¹University of Arkansas for Medical Sciences

S30. Likelihood and Duration of Breastfeeding by Maternal Smoking and Drinking Change During Pregnancy

Yukiko Washio¹, Ashton Raines², Mengxi Li³, Shaopeng Pei⁴, Shantae Taylor¹, Zugui Zhang⁵

¹RTI International, ²Drexel University, ³University of Delaware, ⁴University of Delaware, ⁵Christiana Care

S31. Sex-Specific Associations Between Childhood Trauma and Tobacco Use Outcomes

Alexandra Palmisano¹, Elizabeth Schwartz², Mehmet Sofuoglu³

¹Yale University School of Medicine, ²West Haven VA, Yale School of Medicine, and Yale University, ³Yale University

S32. The Impact (or Lack Thereof) of Moving to Remote Study Procedures on Quit Attempts in an NRT Sampling Intervention

Elizabeth Hawes¹, Andrew Bontemps¹, Andres Azuero¹, Matthew Carpenter², Peter Hendricks¹, Adrienne Lahti¹, Karen Cropsey¹

¹The University of Alabama At Birmingham, ²Medical University of South Carolina

S33. Tobacco Use and Sleep Problems in the Population Assessment of Tobacco and Health (PATH) Study

Jocelyn Hansson¹, Halle Thomas¹, Samantha Bauer¹, Leslie Lundahl², David Ledgerwood¹

¹Wayne State University, ²Wayne State University School of Medicine

S34. Optimizing the Training Conditions of Rats in Nicotine Drug Discrimination Studies

Nana Kofi Kusi-Boadum¹, Nathalie Sumien¹, Michael Forster¹

¹University of North Texas Health Science Center

S35. Is Resilience Enough? Resilience Processes to Intersectional Stigma Among People who Inject Drugs (PWID) in Appalachia Ohio

Kathryn Lancaster¹, Anna D. Sucaldito², Stacy Endres-Dighe¹, Renee McDowell¹, Ashleigh LoVette¹, William C. Miller¹, Vivian F. Go³

¹The Ohio State University, ²Wake Forest University, ³University of North Carolina at Chapel Hill

S36. Examining Population Trends in the Association Between Mental Health and Psychedelic Use

Daniel Grossman¹, Melissa Bradley¹, Alex Clain², Greg Pavela¹, Peter Hendricks¹

¹The University of Alabama At Birmingham, ²Northwestern University

S37. Prevalence of Comorbid Substance Use Disorders Among People With Opioid Use disorder: A Systematic Review and Meta-Analysis

Thomas Santo¹, Gabrielle Campbell², Natasa Gisev¹, Lucy Thi Tran¹, Daniel Martino-Burke¹, Jack Wilson³, Samantha Colledge-Frisby⁴, Brodie Clark¹, Louisa Degenhardt¹

¹National Drug and Alcohol Research Centre, UNSW Sydney, ²School of Psychology, University of Queensland, ³Matilda Centre, The University of the Sydney, ⁴National Drug Research Institute, Curtin University

S38. State-Level Synthetic Opioid Arrests in the United States: Overall and Race-Specific Trends, 1990-2016

Erin Annunziato¹, John Pamplin¹, Seth Prins¹, Pia Mauro¹

¹Columbia University

S39. Overdose Death Rates Among Racial Minority Women in Wisconsin: Changes During the COVID-19 Pandemic

Alexa Lopez¹, Jeneile Luebke², Hanan Abusbaitain¹

¹University of Wisconsin-Milwaukee, ²University of Wisconsin-Madison

S40. Syndemic Profiles and Opioid-Related Mortality among People Initiating Chronic Episodes of Prescription Opioid Use in BC, Canada

Mohammad Karamouzian¹, Younathan Abdia², James Wilton², Naveed Janjua², Jane Buxton³, Roy Purssell²

¹Centre of Drug Policy Evaluation, St. Michael's Hospital, ²BC Centre for Disease Control, Vancouver, British Columbia, ³School of Population and Public Health, UBC

S41. Sex Differences in Non-Fatal Overdose Rates: A Population-Based Administrative Health Records Study in British Columbia, Canada

Megan Marziali¹, Katherine Kooij², Jason Trigg³, Michael Budu³, Viviane Lima³, Julio Montaner³, Robert Hogg²

¹Columbia University Medical Center, ²Simon Fraser University, British Columbia, Canada, ³British Columbia Centre for Excellence in HIV/AIDS, British Columbia, Canada

S42. Oud Treatment, Harm Reduction Service Engagement, and Sexually Transmitted Infection Risk Among Men and Women who Use Illicit Opioids in New York City

Joy Scheidell¹, Muthoni Mahachi², Maria Khan³, Holly Hagan², Alex S. Bennett², Luther Elliott²

¹University of Central Florida, ²New York University, ³New York University Grossman School of Medicine

S43. Open Board

S44. Prescription Opioid Tapering Patterns Prior to Discontinuation of Long-Term, High-Dosage Treatment Episodes Among Adult Medicaid Enrollees

Hillary Samples¹, Nicole Kennelly², Arthur Robin Williams³, Mark Olfson⁴, Stephen Crystal⁵

¹Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, ²Rutgers Institute for Health, Health Care Policy and Aging Research, ³Columbia University Division on Substance Use Disorders, ⁴Columbia University and NYSPI, ⁵Rutgers University

S45. Transition Strategies to Link Patients With Substance Use Disorders From Acute Care to Community-Based Treatment Settings: A Scoping Review

Noa Krawczyk¹, Bianca Rivera², Ji Chang³, Margaux Grivel³, Yu-Heng Chen⁴, Suhas Nagappala², Honora Englander⁵, Jennifer McNeely²

¹NYU Grossman School of Medicine, ²New York University Grossman School of Medicine, ³NYU Global School of Public Health, ⁴Temple University, ⁵Oregon Health and Science University

S46. Impact of Oat Initiation During Acute Hospitalization on Readmission, Overdose, and Mortality Among People With Opioid Use Disorder

Tamara Mihic¹, Nadia Fairbairn¹, Janet Mok², Michelle Cui², Seonaid Nolan¹, Eugenia Socias¹

¹University of British Columbia, ²British Columbia Centre on Substance Use

S47. Trends in Buprenorphine Dosage and Days Supplied for New Treatment Episodes, 2010-2019

Alyssa Tilhou¹, Eleanor Murray², Jiayi Wang³, Benjamin Linas, MD MPH³, Laura White², Jeffrey Samet³, Marc Larochelle³

¹Boston Medical Center, ²Boston University School of Public Health, ³Boston University School of Medicine

S48. Barriers and Facilitators to Integrating Medications for Opioid Use Disorder (MOUD) and HIV Pre-Exposure Prophylaxis (PrEP) for Adolescents and Young Adults (AYA)

Maria Herrera¹, Kaja Darien¹, Sarah Wood², Scott Hadland³, David Metzger², Nadia Dowshen²

¹Children's Hospital of Philadelphia, ²Perelman School of Medicine at the University of Pennsylvania,

³Harvard Medical School

S49. Removal of Medicaid Prior Authorizations for Buprenorphine did Not Result in a Substantial Change in Prescriptions

Paul Christine¹, Marc Larochelle², Lewei (Allison) Lin³, Jonathon McBride³, Renuka Tipirneni³

¹Boston Medical Center, ²Boston University School of Medicine, ³University of Michigan

S50. Effectiveness of Rapid Inpatient Initiation of Methadone for Pregnant Women With Opioid Use Disorder

Dennis Hand¹, Amulya Raju¹, Ryan Sholes¹, Neel Iyer¹, Vanessa Short¹, Meghan Gannon¹, Diane Abatemarco¹, Rupsa Boelig¹

¹Thomas Jefferson University

S51. Qualitatively Exploring Pharmacist and Patient Needs to Design a Patient-Centered Pharmacy-Based Opioid Misuse Screening and Brief Intervention

Deepika Rao¹, Olayinka Shiyanbola², James Ford²

¹Dartmouth College, ²University of Wisconsin - Madison

S52. Opioid Prescribing Trajectories in Veterans With and Without Substance Use Disorder

Anne Black¹, Sydney Axson², Jessica Merlin³, Karl Lorenz⁴, William Becker²

¹VA Connecticut Healthcare System, ²Yale University, ³University of Pittsburgh School of Medicine, ⁴Stanford University

S53. Investigation of Life Events Associated With Development of OUD in Young Adults: A Longitudinal Study of a High-Risk Clinical Population

Grace Blake¹, Jarrod Ellingson¹, Kristen Raymond², Soo Rhee³, Michael Stallings², Tamara Wall⁴, Christian Hopfer⁵, Jesse Hinckley⁵

¹University of Colorado Anschutz Medical Campus, ²University of Colorado, ³University of Colorado Boulder,

⁴University of California San Diego, ⁵University of Colorado School of Medicine

S54. Social Determinants of Health and Quality of Care Among Patients With Opioid Use Disorder Receiving Treatment in Rural Primary Care Settings

Huyen Pham¹, Allison Ober², Yuhui Zhu¹, Zhe Fei³, Laura-Mae Baldwin⁴, Larissa Mooney⁵, Yih-Ing Hser⁵

¹Semel Institute - UCLA, ²RAND Corporation, ³University of California, Los Angeles, ⁴University of Washington Department of Family Medicine, ⁵Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles

S55. Prevalence of Opioid Use Disorder and Overdose Rates Among People With Mental Illness in New York State

Felipe Castillo¹, Qingxian Chen², Nancy Covell¹, Manesh Gopaldas¹, Emily Leckman-Westin², Edward V Nunes¹, Frances R Levin¹, Molly Finnerty²

¹Columbia University and New York State Psychiatric Institute, ²New York State Office of Mental Health, New York

S56. Changes in Buprenorphine Prescribing After X-Waiver Exemptions: An Interrupted Time Series Analysis

Payel Roy¹, Katie Suda², Jing Luo¹, MyoungKeun Lee², Joel Anderton², Donna Olejniczak², Jane Liebschutz¹

¹UPMC/University of Pittsburgh, ²University of Pittsburgh

S57. Assessment of Treatment Retention Rates and Factors Affecting Retention on Opioid Agonist Maintenance Treatment Among Adolescents: A Retrospective Cohort Study From India

Pooja Shakya¹, Jaswant Jangra², Roshan Bhad³, Ravindra Rao⁴

¹All India Institute of Medical Sciences New Delhi, ²All India Institute of Medical Science New Delhi,

³Department of Psychiatry and National Drug Dependence Treatment Centre (NDDTC), AIIMS, New Delhi, INDIA, ⁴National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi

S58. Examining the Relationship Between Childhood Trauma and Behavioral Economic Indices Among Individuals who use Opioids

Andrea Vasquez Ferreiro¹, Shahar Almog¹, Meredith Berry¹

¹University of Florida

S59. Fentanyl Concentrations and Withdrawal in Illicit Fentanyl Exposure

Helen Bird¹, William Clarke¹, Melanie Baime¹, Prem Umang Satyavolu¹, Rachel Burns¹, Kelly Dunn¹, Andrew Huhn¹

¹Johns Hopkins University School of Medicine

S60. Prolonged Exposure Therapy for Individuals with Co-Occurring Posttraumatic Stress Disorder and Opioid Use Disorder: A Randomized Clinical Trial

Kelly Peck¹, Jillian Giannini¹, Rebecca Cole¹, Gary Badger¹, Letizia Mosca¹, Stacey Sigmon¹

¹University of Vermont

S61. Racial/Ethnic Differences in Treatment-Related Barriers and Facilitators Among Patients Initiating Medication for Opioid Use Disorder (MOUD) as Part of Comprehensive Patient Navigation Programs

Caravella McCuistian¹, Maria Olivas¹, Alexandra Haas¹, Emily Dauria², Valerie Gruber¹, Paula Lum³, J. Konadu Fokuo⁴, D. Andrew Tompkins¹

¹Department of Psychiatry and Behavioral Sciences, School of Medicine, University of California San Francisco, ²Department of Behavioral and Community Health Sciences, University of Pittsburgh, School of Public Health, ³Department of Medicine, School of Medicine, University of California, San Francisco, ⁴Department of Psychiatry, College of Medicine, University of Illinois at Chicago

S62. Implementation of a “Tele-Peer” Model to Expand Access to Medications for Opioid Use Disorder (MOUD) in a Rural Emergency Department (R-ED) in South Carolina

Sarah Gainey¹, Lindsey Jennings¹, Suzanne Lane¹, Angela Moreland¹, Karen Hartwell², Louise Haynes¹, Kathleen Brady¹

¹Medical University of South Carolina, ²Medical University of South Carolina; Ralph H. Johnson VAMC

S63. Effects of a Comprehensive Patient Navigation Program on High-Cost Healthcare Utilization Among Patients Enrolled in Project HOUDINI LINK (Hospital Opioid Use Disorder treatment INItiation and LINKage to Care)

Kendall Islam¹, Maria Olivas¹, Alexandra Haas¹, Alexander Bazazi¹, D. Andrew Tompkins¹

¹University of California San Francisco School of Medicine

S64. Preliminary Evidence of Lower Kappa Opioid Receptor Availability in Opiate Use Disorder: An Exploratory 11C-EKAP Positron Emission Tomography Study in Humans

Henrique Oliva¹, Ansel Hillmer², Marcella Mignosa¹, Yiyun Henry Huang², Richard Carson², Sarah Yip¹, David Matuskey², Gustavo Angarita¹

¹Yale University School of Medicine, ²Yale University

S65. Data-Driven Selection of Regions of Interest (ROIs) for fMRI Opioid Cue Reactivity: Using Systematic Review, Bold Signal Intensity and Test-Retest Reliability Data

Hamed Ekhtiari¹, Arshiya Sangchooli², Sara Jafakesh³, Rayus Kuplicki⁴

¹University of Minnesota, ²Melbourne University, ³University of Shiraz, ⁴Laureate Institute for Brain Research

S66. The Substance Abuse Self-Stigma Scale: Reliability Among Veterans With Co-Occurring Chronic Pain and Opioid Use Disorder

Verlin Joseph¹, Frank Schwebel², Zachary Schmidt³, Juliana Bondzie⁴, Brian Bosari⁵, Joannalyn Delacruz⁶, David Moniz-Lewis¹, Megan Kirouac², Kevin Vowles¹, Katie Witkiewitz²

¹University of New Mexico, ²Center on Alcohol, Substance Use, and Addictions (CASAA), ³New Mexico Veterans Affairs, ⁴VA Puget Sound Health Care System, ⁵San Francisco Veterans Affairs Health Care System, ⁶University of California San Francisco

S67. Transition to Antagonist Treatment in the Age of Fentanyl

George Woody¹, Sabrina Poole¹, Evgeny Krupitsky², Kyle Kampman³

¹Perelman School of Medicine at the University of Pennsylvania, ²V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, ³University of Pennsylvania

S68. Within-Subject Variations in Opioid Sensitivity Across Patient-Reported Outcomes, Observer-Ratings, Physiological Endpoints, and Analgesic Responses

Caitlyn Durgin¹, Andrew Huhn², Cecilia Bergeria², Patrick Finan³, Claudia Campbell², Denis Antoine², Kelly Dunn²

¹Pinney Associates, ²Johns Hopkins University School of Medicine, ³University of Virginia

S69. Sociodemographic Differences in Engagement With a Mobile Application to Support Recovery From Opioid and Stimulant Use Disorders in Missouri

Hannah Szlyk¹, Lindsey Filiatreau², Xiao Li³, Alex Ramsey³, Patricia Cavazos⁴

¹Washington University School of Medicine, Department of Psychiatry, ²Washington University in St. Louis, ³Washington University School of Medicine, ⁴Washington University St. Louis

S70. Open Board

S71. Association Between Ongoing Illicit Fentanyl Use and Risk for Non-Fatal Overdose Among Patients Treated With Opioid Agonist Therapy in Canada

Kenneth Lee¹, Sophie Zhao², Tazmin Merali³, Chris Fraser⁴, Jan Kozicky⁵, Brian Conway⁶

¹University of Western Ontario Faculty of Medicine, ²Indivior, Inc., ³Drug Intelligence Inc, Toronto, ON Canada, ⁴COOL-AID Community Health Centre, ⁵Indivior Canada, ⁶Vancouver Infectious Diseases Center and Simon Fraser University, Vancouver BC, Canada

S72. The Association of Self-Report Adherence to Hepatitis C (HCV) Direct-Acting Antiviral (DAA) Therapy With Measured Adherence and Sustained Virologic Response Among People Who Inject Drugs (PWID) Receiving Opioid Agonist Therapy

Snehal Lopes¹, Irene Pericot-Valverde¹, Julia Arnsten², Paula Lum³, Lynn Taylor⁴, Shruti H Mehta⁵, Judith Tsui⁶, Judith Feinberg⁷, Arthur Kim⁸, Brianna Norton⁹, Kimberly Page¹⁰, Moonseong Heo¹, Alain Litwin¹¹

¹Clemson University, ²Montefiore Medical Center, ³University of California San Francisco School of Medicine, ⁴University of Rhode Island, ⁵Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, ⁶Department of Medicine, Division of General Internal Medicine, University of Washington, ⁷West Virginia University School of Medicine, ⁸Massachusetts General Hospital, ⁹Albert Einstein College of Medicine and Montefiore Medical Center, ¹⁰University of New Mexico, ¹¹University of South Carolina School of Medicine

S73. Prevalence of Secondary Health Diagnoses Among Persons Presenting in Texas Hospitals With an Opioid or Stimulant Diagnosis Compared to General Population

J. Michael Wilkerson¹, Cecilia M Ganduglia Cazaban¹, Regina M Hansen¹, Caroline M Schaefer¹, Elizabeth M Caballero¹, David Adzrago¹, Kathryn R. Gallardo¹, Sheryl McCurdy²

¹The University of Texas Health Science Center at Houston, ²University of Texas Health Science Center

S74. Sex Trafficking Experiences and Substance Use Patterns Among Incarcerated Women Who Use Opioids

Martha Tillson¹, Jaxin Annett¹, Megan Dickson¹, Matt Webster¹, Carrie Oser¹, Michele Staton²

¹University of Kentucky, ²University of Kentucky, College of Medicine

S75. Rapid Jail-Based Implementation of Overdose Education and Naloxone Distribution (OEND) in Response to the COVID-19 Pandemic

Carrie Oser¹, Margaret McGladrey², Marisa Booty¹, Hilary Surratt¹, Hannah Knudsen¹, Patricia Freeman¹, Danelle Stevens-Watkins¹, Monica Roberts¹, Michele Staton³, April Young⁴, Emma Draper⁵, Sharon Walsh¹

¹University of Kentucky, ²University of South Florida, ³University of Kentucky, College of Medicine,

⁴University of Kentucky, College of Public Health, ⁵Williams College

S76. A Consistent Decrease of Opioid Misuse Among Young Americans: A Pseudo-Cohort Analysis of Use Patterns From the National Household Survey on Drug Use and Health

Georgiy Bobashev¹, Lauren Warren¹, Joella Adams¹

¹RTI International

S77. Exploring the Relationship Between Readiness to Change and Engagement with Substance Use Disorder Treatment Among People who Inject Drugs

Lauren Crimmins¹, Edward Suarez Jr.², Renae Schmidt², Viviana Horigian²

¹Brigham and Women's Hospital, ²University of Miami Miller School of Medicine

S78. Adoption and Reach of Overdose Education and Naloxone Distribution in Kentucky During Wave 1 of the Healing Communities Study

Hannah Knudsen¹, Patricia Freeman¹, Carrie Oser¹, Doug Oyler¹, Sharon Walsh¹

¹University of Kentucky

S79. A Qualitative Study Examining Factors Influencing Access to Opioid Agonist Treatment Among a Sample of People who Use Drugs in Rural and Remote Canada

Kate Hodgson¹, Manal Mansoor², Ellery Cleaveland³, Thomas Kerr¹, Geoff Bardwell⁴

¹University of British Columbia, ²University of British Columbia Faculty of Medicine, ³Lift Community Services, ⁴University of British Columbia, BC Centre on Substance Use

S80. Using Implementation Facilitation to Implement Interim Methadone in Opioid Treatment Programs

Shannon Mitchell¹, Karen Burruss-Cousins¹, Julia Jester², Jan Gryczynski¹, Melanie Whitter³, Douglas Fuller³, Caroline Halsted³, Robert Schwartz¹

¹Friends Research Institute, ²Mid Shore Pro Bono, ³National Association of State Alcohol and Drug Abuse Directors, Inc.

S81. Factors Associated With Patient Referral From Rural Primary Care Clinics to Vendor-Based Telemedicine for Opioid Use Disorder Treatment

Chunqing Lin¹, Yuhui Zhu², Megan Black³, Sarah Clingan⁴, Huyen Pham², Larissa Mooney⁴, Yih-Ing Hser⁴

¹David Geffen School of Medicine at UCLA, ²Semel Institute - UCLA, ³Semel Institute for Neuroscience and Human Behavior at UCLA, ⁴Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles

S82. Predictors and Correlates of Hepatitis C Incidence Among Young People who Inject Drugs in the Chicago Metropolitan Area

Mary Mackesy-Amiti¹, Basmattee Boodram²

¹University of Illinois at Chicago, School of Public Health, ²University of Illinois at Chicago

S83. Calcium Imaging of Central Amygdala Activity After Escalation of Fentanyl Self-Administration

Samantha Malone¹, Pavel Ortinski², Michael Bardo¹

¹University of Kentucky College of Arts and Sciences, Department of Psychology, ²University of Kentucky College of Medicine, Department of Neuroscience

S84. Lived Experiences of Addiction Counselors: A Protocol Exploring Stigma in a Time of Regulatory Change Within Opioid Treatment Programs

Kathryn Eggert¹, Lynn Madden¹, Beth Mabry², Ermonda Gjoni-Markaj¹, Kim Hoffman³, Kimberly DiMeola⁴, Erica Cannata¹, Scott Farnum¹, Gretchen Hermes⁵, Declan Barry⁵

¹APT Foundation, Inc., ²Antioch University, ³Oregon Health and Science University, ⁴APT Foundation, ⁵Yale University School of Medicine

S85. Pharmacy-Level Barriers to Buprenorphine Dispensing: Evidence From the Medicaid Distributed Research Network in Five States

Patricia Freeman¹, Lindsey Hammerslag², Michael Sharbaugh³, Katherine Ahrens⁴, Anna Austin⁵, Adam Gordon⁶, Lindsay Allen⁷, Andrew Barnes⁸, Julie Donohue³, Jeffery Talbert²

¹University of Kentucky, ²College of Medicine, University of Kentucky, ³University of Pittsburgh, ⁴Muskie School of Public Service, University of Southern Maine, ⁵Injury Prevention Research Center, Gillings School of Public Health, University of North Carolina, ⁶University of Utah School of Medicine and VASLCHCS, ⁷Feinberg School of Medicine, Northwestern University, ⁸School of Medicine Health Behavior and Policy, Virginia Commonwealth University

S86. Changes in Opioid and Other Analgesic Prescribing Following Voluntary and Mandatory Prescription Drug Monitoring Program Implementation: A Time Series Analysis

Suzanne Nielsen¹, Louisa Picco¹, Grant Russell¹, Christopher Pearce², Nadine Andrew¹, Dan Lubman³, Simon Bell¹, Rachel Buchbinder¹, Ting Xia¹

¹Monash University, ²Outcome Health, ³Turning Point

S87. Naloxone Distribution in the Emergency Department: Program Evaluation of the University of Washington Harborview Medical Center Emergency Department's Response to Washington State Bill 5195

Sophie Morse¹, Canada Parrish, PhD², Callan E. Fockele, MD MS³, Chris Craft², Sarah Leyde, MD², Arvin R. Akhavan, MD MPA², Elinor Sveum, MD², Timothy Fredrickson, RN², Lauren Whiteside, MD MSc²

¹University of Washington School of Medicine, ²University of Washington, ³University of Washington at Harborview Medical Center

S88. Photovoice – a Methodology to Engage People With Lived Experience in Order to Understand Contextual Drivers of the Opioid Epidemic and Promote Community Activism

Peter Balvanz¹, Alyssa Curran², Anna Martin¹, Carolyn Damato-MacPherson¹, Randy Gratton³

¹Boston Medical Center, ²WMTC, ³BHN

S89. Perceptions of Racism's Impact on Drug Use Among African Americans Using Opioids

Natalie Malone¹, Gabriella Pitcher¹, Danelle Stevens-Watkins²

¹University of Kentucky, ²University of Kentucky, Center on Drug and Alcohol Research

S90. Referral Appointment Wait-Times and Arrival for Patients Accessing Medication for Opioid Use Disorder (MOUD) in an Emergency Department (ED)

Suzanne Lane¹, Lindsey Jennings¹, Sarah Gainey¹, Angela Moreland¹, Karen Hartwell², Louise Haynes¹, Kathleen Brady¹

¹Medical University of South Carolina, ²Medical University of South Carolina; Ralph H. Johnson VAMC

S91. Advantages and Disadvantages of Online Networking Among Those Engaged in Opioid Misuse

Erin Kasson¹, Hannah Szlyk¹, Xiao Li¹, Aishwarya Rajamahanty¹, Nina Kaiser¹, Patricia Cavazos-Rehg¹

¹Washington University School of Medicine Department of Psychiatry

S92. Pain in Opioid Use Disorder Recovery: Is Pain Severity or Chronicity a Stronger Predictor of Health Outcomes?

William Craft¹, Allison Tegge¹, Candice Dwyer¹, Devin Tomlinson¹, Diana Keith², Liqa Athamneh¹, Jeffrey Stein¹, Anne Le Moigne³, Angela DeVeaugh-Geiss³, Howard Chilcoat³, Warren Bickel¹

¹Fralin Biomedical Research Institute at Virginia Tech Carilion, ²Behavioral Psychopharmacology Research Laboratory, McLean Hospital, Belmont, MA; Department of Psychiatry, Harvard Medical School, Boston, MA,

³Indivior, Inc.

S93. Open Board

S94. Patient Perspectives on an Open Access Model for Methadone Treatment: A Research and Process Improvement Protocol

Lynn Madden¹, Scott Farnum², Kathryn Eggert², Erica Cannata², Gretchen Hermes³, Kimberly DiMeola¹, Kim Hoffman⁴, Declan Barry³

¹APT Foundation, ²APT Foundation, Inc., ³Yale University School of Medicine, ⁴Oregon Health and Science University

S95. Mobile Units Improve Access to Medications for Opioid Use Disorder: A Qualitative Implementation Study

Avik Chatterjee¹, Trevor Baker¹, Maria Rudorf¹, Galya Walt², Caroline Stotz¹, Anna Martin¹, Elizabeth Kinnard¹, Ann McAlearney¹, Julie Bosak¹, Bethany Medley³, Jeffrey Samet⁴, Karsten Lunze⁴

¹Boston Medical Center, ²Harvard T.H. Chan School of Public Health, ³Columbia School of Social Work, ⁴Boston University School of Medicine

S96. The Pharmacist-Integrated Medication Treatment for Opioid Use Disorder (PrIMO) Model: Operationalizing an Effective Clinical Care Model to Assess Feasibility in Diverse Care Settings

Felicity Homsted¹, Trip Gardner², Noah Nesin², Frank R. McGrady², David Fiellin³, Paul Joudrey⁴, Bethany McLeman⁵, Phoebe Gauthier⁵, Sarah K. Moore⁵, Lisa Marsch⁵, Udi Ghitza⁶, Deepika Rao⁷

¹FQHC 340B Compliance, ²Penobscot Community Health Care, ³Yale University School of Medicine, ⁴University of Pittsburgh, ⁵Geisel School of Medicine at Dartmouth College, ⁶National Institute of Drug Abuse, National Institutes of Health, ⁷Dartmouth College

S97. Initiation and Retention in Medications for Opioid Use Disorder (MOUD) Among Women: A Multi-Paneled Qualitative Study of Women in Recovery, Women who Terminated Treatment, and the Professionals who Serve Them

Hannah Apsley¹, Robert Schwartz², Hobart Cleveland¹, Eric Harrison¹, Kristina Brant¹, Sarah Brothers¹, Abenaa Jones¹

¹Pennsylvania State University, ²Friends Research Institute

S98. More Stress Than You Know: A Qualitative Study of Client Experiences Navigating MOUD Treatment

Jodie Dewey¹, Dennis Watson², Monte Staton³

¹Chestnut Health System's Lighthouse Institute, ²Chestnut Health Systems, ³University of Illinois at Chicago

S99. Patient Perceptions of Integrating Meditation-Based Interventions in Office-Based Opioid Treatment With Buprenorphine: A Mixed-Methods Survey

Babak Tofighi¹, Christina Marini¹, Joshua D. Lee¹, Eric Garland²

¹New York University School of Medicine, ²University of Utah

S100. Vulnerability to Hyperalgesia and Hyperkatifeia Drives Addiction-Like Behaviors

Renata Marchette¹, Emma Frye¹, Lyndsay Hastings¹, Erika Carlson¹, Leandro Vendruscolo¹, Hugo Tejeda², George Koob¹

¹National Institute on Drug Abuse, Intramural Research Program, ²National Institute of Mental Health, Intramural Research Program

S101. Ventilatory Effects of Fentanyl, Heroin, and D-Methamphetamine, Alone and in Mixtures, in Male Rats

Takato Hiranita¹, Nicholas Ho¹, Charles France¹

¹UT Health San Antonio

S102. NMRA-140, a Novel and Selective Kappa Opioid Receptor Antagonist: Mode of Action Profiling Studies Demonstrate No Opioid Agonist Properties Implicated in Opioid-Related Abuse

Filomene Morrison¹, Lori Jean Van Orden², Karla Zeitz², David Heal³, Sharon Smith³, Tanya Wallace²

¹Neumora Therapeutics, ²Neumora Therapeutics Inc., ³DevelRx Ltd.

S103. Extended Access to Fentanyl Self-Administration During Pregnancy: Effects on Dams and Offspring

Barrett Aldridge¹, Isaac Johnson², DONNA Platt², Daniela Rüedi-Bettschen²

¹University of Mississippi Medical Center, ²University of Mississippi Medical Center, Dept. of Psychiatry and Human Behavior

S104. Estradiol Enhances the Development of Addition-Like Features in a Female Rat Model of Opioid Use Disorder

Eleanor Towers¹, Ben Setaro¹, Wendy Lynch¹

¹University of Virginia

S105. Acute Effects of Oral 3,4-Methylenedioxymethamphetamine (MDMA) and Delta-9-Tetrahydrocannabinol (THC) on Intrinsic Functional Connectivity

Tonisha Kearney-Ramos¹, Xuejun Hao¹, Margaret Haney², Gillinder Bedi³

¹Columbia University Medical Center, ²Columbia University Irving Medical Center, ³The University of Melbourne

S106. Reduced Demand for Substances Following Visual Exposure to Natural Versus Built Stimuli

Shahar Almog¹, Andrea Vásquez Ferreiro¹, Ali Yurasek¹, Meredith Berry¹

¹University of Florida

S107. Anger Across Substance Use Disorders: Results From the National Epidemiologic Survey on Alcohol Use and Related Conditions-III

Krista Miloslavich¹, Margaret Wardle¹

¹University of Illinois Chicago

S108. Drug Decriminalization in the United States: Emerging Models, Implementation Experiences and Implications for Health and Racial Equity

Saba Rouhani¹, Leanne Zhang², Abigail Winiker², Catherine Tomko², Bradley Silberzahn³, Susan Sherman⁴, Sachini Bandara²

¹New York University School of Global Public Health, ²Johns Hopkins Bloomberg School of Public Health, ³University of Texas at Austin, ⁴Department of Health, Behavior and Society, Bloomberg School of Public Health

S109. Cross-Spouse Relationships Between Drug Use and Marital Functioning Among Reserve and National Guard Soldiers and Their Spouses

Bonnie Vest¹, Rachel Hoopsick², D. Lynn Homish¹, Gregory Homish¹

¹State University of New York at Buffalo, ²University of Illinois Urbana-Champaign

S110. Brandeis/Harvard Spire Center: SUD Systems Performance Improvement Research and Engagement

Sharon Reif¹, Haiden Huskamp², Constance Horgan³

¹Brandeis University, Heller School for Social Policy and Management, Institute for Behavioral Health,

²Harvard Medical School, Department of Health Care Policy, ³Brandeis University, Heller School for Social Policy and Management

S111. Regional Differences of Self-Reported Past-12-month Marijuana, Psilocybin, and Cocaine Use: Results From NDEWS Rapid Street Reporting 2021-2022

Nae Won¹, Anna Wang¹, Joseph Palamar², Nicole Fitzgerald¹, MeLisa Creamer³, Catherine Striley¹, Linda Cottler¹

¹University of Florida, ²New York University School of Medicine, ³National Institute on Drug Abuse

S112. Toxicology Testing Inequities During the Birthing Hospitalization and Impact of an Institutional Intervention

Leah Habersham¹, Angela Bianco¹, Candice Woolfolk², Toni Stern¹, Joanne Stone¹, Yasmin Hurd¹

¹Icahn School of Medicine At Mount Sinai, ²Washington University in St. Louis

S113. Provider Perspectives on Facilitators and Barriers to Providing HIV Pre-Exposure Prophylaxis (PrEP) in Hospital-Based Addiction Treatment Bridge Clinics to Women Sex Workers who Use Drugs

Miriam Harris¹, Emma Weinberger², Mary Althoff³, Samantha Paltrow-Krulwich⁴, Jessica Taylor⁵, Abigail Judge⁶, Jeffrey Samet⁵, Christine Gunn⁵, Alexander Walley⁵

¹Boston University, ²Boston Medical Center, ³AIDS Action Committee, ⁴Harvard School of Public Health,

⁵Boston University School of Medicine, ⁶Massachusetts General Hospital

S114. Initial Results of the First Momentary-Assessment Study of U.S. Adults who Use Kratom

Kirsten Smith¹, Leigh Panlilio², Jeffrey Feldman², Kelly Dunn³, Albert Garcia-Romeu³, Oliver Grundmann⁴, Abhishek Sharma⁵, Jeffrey Rogers⁶, Christopher McCurdy⁵, David Epstein²

¹National Institute on Drug Abuse, Intramural Research Program, ²NIDA Intramural Research Program,

³Johns Hopkins University School of Medicine, ⁴College of Pharmacy, Dept. Medicinal Chemistry, Univ. FL,

⁵University of Florida, ⁶SDSU/UCSD Joint Program in Clinical Psychology

S115. Screening Test for Drug Abuse Among Blood Donors in the West Bank, a Cross-Sectional Study

Ashraf Awad¹, Maytham Khatatbeh¹, Mahmoud Matar¹, Saed Abed¹, Majdi Dwikat¹, Basma Damiri²

¹An-Najah National University, ²School of Medicine and Health Sciences, An-Najah National University

S116. Laws Limiting Access to SNAP Benefits for People With Felony Drug Convictions

Hridika Shah¹, Alex McCourt¹, Sachini Bandara¹

¹Johns Hopkins Bloomberg School of Public Health

S117. Exploring Substance Use Among LGB Adults Through the National Institutes of Health All of Us Research Program

Stephen Lippi¹, Matthew Perez¹, Jennifer Potter¹, Tara Karns-Wright¹

¹The University of Texas Health Science Center At San Antonio

S118. Untargeted Umbilical Cord Testing to Detect Novel Psychoactive Substances

Marcela Smid¹, Joseph Worden², Melissa Hughes³, Gwen McMillin⁴

¹University of Utah Health, ²University of Utah School of Medicine, ³ARUP Lab, ⁴ARUP

S119. Safety and Tolerability of Ascending Doses of ENA-001: A Novel Respiratory Stimulant, for the Intended Management of Pharmacologically-Induced Respiratory Depression

Errol Gould¹, Thomas Miller¹, Joseph Pergolizzi¹

¹Enalare Therapeutics

S120. Sociodemographic Correlates of a Substance-Related Diagnosis and Associations With the Number of Emergency Department Visits Using Electronic Health Record Data From 2012-2019

Wayne Kepner¹, Natasia Courchesne², Carla Marienfeld²

¹SDSU/UCSD Joint Program, ²University of California San Diego

S121. The Application of Positive Psychology to Substance Use, Addiction, and Recovery Research: An Updated Systematic Review

Hannah Carlon¹

¹University of New Mexico

S122. Caregiver Recommendations for Contingency Management in Juvenile Probation

Logan Jackson¹, Meghan Morrison¹, Phillippe B. Cunningham², Jeff Randall², Colleen Halliday-Boykins², David Ledgerwood³, Stacy Ryan-Pettes¹

¹Baylor University, ²Medical University of South Carolina, ³Wayne State University

S123. Associations Between Daily Coffee Consumption and Personal and Family Alcohol, Drug and Mental Health Problems in College Students: Looking Separately at Rapid and Slow Caffeine Metabolizers

Dace Sviki¹, Pamela Dillon¹, Alexis Edwards¹, Kathryn Polak¹, Leroy Thacker¹, David Pomm¹, Danielle Dick², Kenneth Kendler¹

¹Virginia Commonwealth University, ²Rutgers University

S124. Characteristics of People With Early Psychosis and Substance Use Problems

Megan Liew¹, Mary Grace Shinnors¹, Justin Shepherd², Roger Weiss³, Julie McCarthy³

¹McLean Hospital, ²McLean Hospital, University of Houston, ³McLean Hospital, Harvard Medical School

S125. Socioeconomic Marginalization and Overdose Risk: A Gender-Stratified Repeated Measures Latent Class Analysis Among Men and Women who Use Drugs

Sanjana Mitra¹, Lindsey Richardson², Michelle Cui³, Mark Gilbert⁴, Kanna Hayashi⁵, M-J Milloy⁶, Thomas Kerr³

¹Centre on Drug Policy Evaluation, ²University of British Columbia, BC Centre on Substance Use, ³British Columbia Centre on Substance Use, ⁴BC Centre for Disease Control, ⁵Simon Fraser University, ⁶BC Centre on Substance Use

S126. Exploring Future Research Needs for Pharmaceutical Pain Management Among Black/Hispanic Populations With Opioid Use Disorder and Liver Disease

Autumn Barnes¹, Lissette Saavedra¹, Ty Ridenour¹, Amber Jarnecke²

¹RTI International, ²Medical University of South Carolina

S127. Substance Co-Exposure Among Women With Opioid Use During Pregnancy

Michael Kuzniewicz¹, Cynthia Campbell¹, Sandra Comer², Monique Hedderson¹, Lisa Croen¹, Eileen Walsh¹, Sherian Li¹, Sam Pimentel³, Lena Sun⁴

¹Kaiser Permanente Northern California, ²Columbia University Irving Medical Center and the New York State Psychiatric Institute, ³University of California, Berkeley, ⁴Columbia University

S128. How Common is Fentanyl Contamination of Methamphetamine? Attitudes, Self-Reported Exposures, and Toxicology Data From Persons who Use Methamphetamine

Raminta Daniulaityte¹, Lance Ruhter¹, Matthew Juhascik², Sydney Silverstein³

¹Arizona State University, ²Montgomery Co. Coroner's Office, ³Boonshoft School of Medicine Wright State University

S129. Combinations of Drugs Among Maryland Overdose Decedents

Catherine Tomko¹, Kristin Schneider¹, Masoumeh Amin-Esmaeili¹, Ryoko Susukida¹, Taylor Parnham¹, Ju Nyeong Park², Renee Johnson¹

¹Johns Hopkins Bloomberg School of Public Health, ²Alpert Medical School, Brown University

S130. Characterizing Methamphetamine Use Among Opioid Agonist Therapy-Seeking Adults With Prescription-Type Opioid Use Disorder in Canada

Jenna Langlois¹, Nadia Fairbairn¹, Didier Jutras-Aswad², Bernard Le Foll³, Ron Lim⁴, M. Eugenia Socias¹

¹University of British Columbia, ²Université de Montréal, ³University of Toronto, ⁴University of Calgary

S131. The Interplay of Temporal Contexts With Social and Physical Contexts on Alcohol and Marijuana Use and Related Consequences

Brooke Arterberry¹, Brian Calhoun², Christine Lee², Megan Patrick¹

¹University of Michigan, ²University of Washington

S132. HIV Pre-Exposure Prophylaxis Awareness, Use, Willingness, and Physician Engagement Across Sexually and Gender Diverse Veterans who Use Drugs

Ariana Gross¹, Olivia V. Fletcher², Amy J. Kennedy³, Emily C. Williams⁴

¹University of Washington School of Medicine, ²Health Services Research and Development Center of Innovation for Veteran-Centered and Value-Driven Care, VA Puget Sound Health Care System, 1660 S Columbia Way, Seattle, WA, 98108, USA, ³Veterans Affairs Puget Sound Health Care System, 1660 S Columbia Way, Seattle WA, 98102, ⁴University of Washington School of Public Health, Department of Health Systems and Population Health

S133. Time-To-COVID-19 Vaccination by HIV Viral Load Among People who Inject Drugs in Baltimore, Maryland

Pieter Baker¹, Javier Cepeda¹, Becky Genberg¹, Shruti H Mehta¹, Gregory Kirk¹, Kenneth Feder¹, Jing Sun¹, Jacqueline Rudolph¹, Jacquie Astemborski¹

¹Johns Hopkins Bloomberg School of Public Health

S134. A Pilot Trial of Integrated Intervention Strategies to Optimize Prep Care Among PWID in Rural Kentucky

Hilary Surratt¹, Cole Derosssett¹, Laura Fanucchi², Christie Green³, Jennifer Havens², Rebecca Rains⁴, Michele Staton², Philip Westgate¹

¹University of Kentucky, ²University of Kentucky, College of Medicine, ³Cumberland Valley District Health Department, ⁴Knox County Health Department

S135. Differences in Hepatitis C Virus (HCV) Testing and Treatment by Opioid, Stimulant, and Polysubstance Injection Among People who Inject Drugs (PWID) in Rural U.S. Communities

Angela Estadt¹, William C. Miller², David Kline³, Judith I. Tsui⁴, April M. Young⁵, Hannah Cooper⁶, P. Todd Korthuis⁷, Judith Feinberg⁸, Gordon Smith⁹, Mai T. Pho¹⁰, Wiley Jenkins¹¹, Peter D. Friedmann¹², Ryan P. Westergaard¹³, Vivian F. Go¹⁴, L. Sarah Mixson¹⁵, Daniel Brook¹⁶, Kelsa Lowe¹³, Christopher B. Hurt¹⁷, Dylan Rice¹⁸, Kathryn E. Lancaster²

¹College of Public Health, The Ohio State University, ²The Ohio State University, College of Public Health, Division of Epidemiology, ³Wake Forest University School of Medicine, Division of Public Health Sciences, Department of Biostatistics and Data Science, ⁴University of Washington, Division of General Internal Medicine, ⁵University of Kentucky, Department of Epidemiology, Center on Drug and Alcohol Research, ⁶Emory University, Rollins School of Public Health, ⁷Oregon Health and Science University, Department of Medicine, Section of Addiction Medicine, ⁸West Virginia University School of Medicine, Departments of Behavioral Medicine and Psychiatry and Medicine/Infectious Diseases, ⁹West Virginia University School of Public Health, Department of Epidemiology and Biostatistics, ¹⁰University of Chicago, Department of Medicine, ¹¹Southern Illinois University, School of Medicine, ¹²University of Massachusetts Medical School-Baystate and Baystate Health, ¹³University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Division of Infectious Disease, ¹⁴University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Health Behavior, ¹⁵University of Washington, Department of Medicine, ¹⁶The Ohio State University, College of Medicine, ¹⁷University of North Carolina at Chapel Hill School of Medicine, Institute for Global Health and Infectious Diseases, ¹⁸University of Massachusetts Chan School of Medicine

S136. Trends in Past-Month Alcohol and Tobacco Co-Use Among Older Adults in the US Between 2002-2019

Pia Mauro¹, Sarah Gutkind¹, Benjamin Han², Guadalupe Antonio-Lopez³, Silvia Martins¹, Katherine Keyes¹, Daniel Giovenco¹

¹Columbia University, ²University of California - San Diego, ³Mount Holyoke College

S137. Examining Polysubstance Overdose Patterns and Demographic Correlates: A Latent Class Analysis in St. Louis, Missouri

Julia Richardson¹, Kanila Brown¹, Melissa Nance¹, Devin Banks¹, Ryan Carpenter¹, Rachel Winograd¹

¹University of Missouri-St. Louis

S138. Preferences for Abstinence-Based Recovery and Public Stigma Toward Substance Use

Diamond Meadows¹, Bruce Taylor², Kelly Moore¹

¹East Tennessee State University, ²NORC at the University of Chicago

S139. The Effect of Opioid-Stimulant Co-Use on Tonic and Cue Induced Cravings

Martin Hochheimer¹, Andrew Huhn²

¹Department of Psychiatry, Johns Hopkins University School of Medicine, ²Johns Hopkins University School of Medicine

S140. I Crave Not to Feel Uncomfortable: Craving for Opioids and Cannabis Among Patients With Chronic Pain

Johannes Thrul¹, Courtney Nordeck², Janardan Devkota¹, Chung Jung Mun³, Kelly Dunn⁴, Vadim Zipunnikov¹, Ryan Vandrey⁴, Patrick Finan⁵

¹Johns Hopkins Bloomberg School of Public Health, ²Friends Research Institute, ³Arizona State University,

⁴Johns Hopkins University School of Medicine, ⁵University of Virginia

S141. Trajectories of Substance Abuse Treatment Usage: A 9-Year Longitudinal Approach Using Latent Class Growth Analysis and Multichannel Sequence Analysis

Ignacio Borquez¹, Magdalena Cerda¹, Andrés Gonzáles-Santa Cruz², Ignacio Madero-Cabib³, Alvaro Castillo-Carniglia²

¹Department of Population Health, NYU School of Medicine, ²Universidad Mayor, ³Instituto de Sociología and Departamento de Salud Pública, Pontificia Universidad Católica de Chile

S142. Delay Discounting, Pain Catastrophizing, and Quality of Life Among Individuals in Recovery From Substance Use Disorder: A Reinforcer Pathology Perspective

Candice Dwyer¹, William Craft², Liqa Athamneh³, Yu-Hua Yeh², Warren Bickel⁴

¹Virginia Tech, ²Fralin Biomedical Research Institute at Virginia Tech Carilion, ³Fralin Biomedical Research Institution, ⁴Fralin Biomedical Research Institute at VTC

S143. Traumatic Events, Chronic Pain, and Multiple Substance Use in Women With Poly-Substance Use Disorder

Nia Fogelman¹, Marshall Tate¹, Stephanie Wemm¹, Erin Vacey², Suraj Bera², Gretchen Hermes¹, James Swain², Helen Fox², Rajita Sinha¹

¹Yale University School of Medicine, ²Stony Brook University School of Medicine

S144. Motivation to Seek Mental Health Services Young Black Men

Carolyn Bazan¹, Alexandria Bauer¹

¹Rutgers University

S145. The Potential of Virtual Reality to Treat Substance Use Disorders

Sarah Clingan¹, Lin Chunqing¹, Guo Freeman², Larissa Mooney¹, Yih-Ing Hser¹

¹Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles, ²Human-Centered Computing Division, School of Computing, Clemson University

S146. A Multi-Phased Study to Develop a Novel Measure of Polysubstance Use

Amanda Bunting¹

¹New York University School of Medicine

S147. Characteristics of Substance Use Disorder Treatment Facilities That Provide Tailored Mental Health Treatment

Orrin Ware¹, Kelly Dunn²

¹University of North Carolina at Chapel Hill, ²Johns Hopkins University School of Medicine

S148. Changes in Cannabis Use, Nicotine Dependence, and Cigarette Cessation Among U.S. Adult Cigarette Smokers by State-Level Legalization of Non-Medical Cannabis, 2013-2019

Peter Driezen¹, Karin Kasza², Shannon Gravely³, Andrew Hyland², David Hammond⁴, Richard O'Connor², Geoffrey Fong¹, Mary Thompson¹, Nicolas Schlienz⁵, Danielle Smith²

¹University of Waterloo, ²Roswell Park Comprehensive Cancer Center, ³University of Waterloo, Canada,

⁴Universtiy of Waterloo, ⁵State University of New York at Buffalo

S149. Perceived Stigma on the Emotional Wellbeing Among Latinx With Substance Use Disorders: The Mediated Roles of Self-Stigma and Self-Efficacy

Coralee Perez-Pedrogo¹, Bianca Y. Planas-Garcia², Jose Noel Caraballo³, Carmen E. Albizu-Garcia³

¹University of Puerto Rico, Medical Sciences Campus and Albizu University, ²University of Puerto Rico, Medical Sciences Campus and Albizu University, ³University of Puerto Rico, Medical Sciences Campus

S150. Barriers to Enrolling Monolingual Spanish-Speaking Primary Care Patients in a Screening and Brief Intervention (SBI) RCT to Reduce Risky Drug Use: Lessons Learned From the Quit-Mobile Study

Leticia Cazares¹, Dallas Swendeman², Lillian Gelberg³, Stephanie Sumstine⁴, Amanda Sirisoma², Cristina Batarse², Cristina Hernandez², Melvin Rico¹, Mani Vahidi¹, Andrea Bañuelos Mota¹

¹David Geffen School of Medicine at UCLA, ²University of California Los Angeles, ³University of California Los Angeles, Department of Family Medicine, ⁴University of California Los Angeles, Department of Psychiatry and Biobehavioral Sciences

S151. Optimizing Recovery Funding: A National Look at Strategies for State Funding of Recovery Support Services for Substance Use Disorders

Zoe Murphy¹, Rebecca Boss², Neil Campbell², Victor Capoccia², Colette Croze², Jordan Gulley², Crystal Jeffers³, Adam Viera³, Laurie Krom³

¹University of Missouri- Kansas City, ²Technical Assistance Collaborative, ³University of Missouri-Kansas City

S152. Associations of Sleep Quality and Perceived Stress With Discounting and Quality of Life in Substance Use Disorder Recovery

Yu-Hua Yeh¹, Michelle Zheng², Allison Tegge¹, Liqa Athamneh¹, Roberta Freitas-Lemos¹, Candice Dwyer¹, Warren Bickel¹

¹Fralin Biomedical Research Institute at Virginia Tech Carilion, ²Civil and Environmental Engineering Department, University of California, Los Angeles

S153. Examining Quality of Life in a Sample of U.S. Veterans Seeking Treatment for Substance Use

Cory Stanton¹, Austin Hahn², Stefan Kertesz³, Elizabeth Santa Ana⁴

¹Ralph H. Johnson VA Medical Center, ²Medical University of South Carolina, ³Birmingham VA Medical Center, ⁴Medical University of South Carolina and Charleston VAMC

S154. Health Justice Coordination for Increased Access to Health and Social Services for People With Drug Use Disorders in Contact With the Criminal Justice System

Anja Busse¹, Sanita Suhartono¹, Nicola Singleton², Dagmar Hedrich³, Jee Aei Lee¹, Sven Pfeiffer¹, Giovanna Campello¹

¹United Nations Office on Drugs and Crime, ²King's College London, ³Freelance Consulting Drug Policy and Demand Reduction

S155. Recovery Support Services Research Priorities Developed by People With Lived Expertise

Eden Buell¹, Patrick Hibbard¹, Ashli Sheidow¹, Michael McCart¹, Tess Drazdowski¹

¹Oregon Social Learning Center

S156. Lifetime Depression and Psilocybin Mushroom Use in U.S. Adults, 2008–2019

Lauren Gorfinkel¹, Julia Bujno², Claire Walsh², Dvora Shmulewitz³, Deborah Hasin³

¹The University of British Columbia, ²New York State Psychiatric Institute, ³Columbia University

S157. Developing Core Consensus Measures for Assessment of Psilocybin Services

P. Todd Korthuis¹, Kim Hoffman¹, Adrienne Wilson-Poe², Jason Luoma³, Alissa Bazinet⁴, David Morgan⁵, Sarann Bielavitz¹, Dennis McCarty¹, Christopher Stauffer⁶

¹Oregon Health and Science University, ²Legacy Research Institute, Legacy Health, ³Portland Psychotherapy Clinic, Research, and Training Center, ⁴Sequoia Center, ⁵Department of Sociology, Portland State University, ⁶Portland VA Medical Center; Oregon Health and Science University

S158. Psychedelic Drug Abuse Potential Assessment Challenges to Scientific Validity and Real World Predictiveness: Current Approaches and Research Gaps

Jack Henningfield¹, August Buchhalter², Caitlyn Durgin³, Ryan Lanier⁴, Judy Ashworth¹

¹Pinney Associates, Inc., ²PinneyAssociates, Inc., ³PinneyAssociates, Inc., ⁴Pinney Associates

S159. Ayahuasca-Assisted Addiction Treatment in Peru: Results, Challenges, and Promises From a Multi-Year, Mixed-Methods Study at Takiwasi Center

Olivia Marcus¹, Sara García Arce², Ariane Spitalier³, Anja Loizaga-Velder⁴, Fernando Mendive⁵, Brian Rush⁶

¹New York University, ²Independent researcher, ³Autonomous University of Barcelona, ⁴National Autonomous University of Mexico, ⁵Independent Researcher, ⁶University of Toronto

S160. Sex Differences Are Associated With Perceived Changes in Baseline and Post-Acute Religious Beliefs Among Ayahuasca Users

Yitong Xin¹, Roland Griffiths², Alan K. Davis¹

¹The Ohio State University, ²Johns Hopkins University

S161. Physical Dependence-Like Effects of Acute Benzodiazepine Treatment in Rhesus Monkeys

Eliseu Moreira¹, Joseph T. Talley Talley², Heather H. Hembree Hembree², Lais Berro², James Rowlett²

¹University of Mississippi Medical Center, Dept. of Psychiatry and Human Behavior, ²University of Mississippi Medical Center

S163. A Comparison of Non-Fatal Opioid Overdose, Acute Methamphetamine Toxicity, and Mixed Stimulant/Opioid Overdose Presentations: Implications for Measurement of Methamphetamine-Related Morbidity

Karla Wagner¹, Phillip Coffin², Phillip Fiuty³, Leo Beletsky⁴, Kimberly Page⁵

¹University of Nevada School of Public Health, ²San Francisco Department of Public Health, ³The Mountain Center Harm Reduction Center, ⁴Northeastern University, ⁵University of New Mexico

S164. Comparison Between Original and Adaptive Form of Cocaine Purchase Task

Fatima Quddos¹, Devin Tomlinson¹, Kirstin Gatchalian¹, Warren Bickel¹

¹Fralin Biomedical Research Institute at VTC

S165. Resting-State Electroencephalogram Markers of Sleep Quality in Cocaine Use Disorder

Heather Webber¹, Danielle Kessler², Joy Schmitz¹, Robert Suchting¹, Scott Lane¹

¹University of Texas Health Science Center, ²Drexel University College of Medicine at Tower Health

S166. Randomized Controlled Trial Testing the Efficacy of a Remote Caffeine Reduction Intervention

Dustin Lee¹, Labos Breanna¹, Roland Griffiths²

¹Johns Hopkins University School of Medicine, ²Johns Hopkins University

S167. Resilience as a Mediator of Amphetamine Dependence and Psychiatric Symptoms in Deferred Prosecuted Individuals who Use Amphetamine in Taiwan

Chia-Chun Hung¹, Ming-Chyi Huang², Lian-Yu Chen², Kuen-Hong Wu³, Cheng-Yi Huang⁴, Yung-Lien Lai⁵, Su-Chen Fang⁶, Chuan-Hsi Chen⁷, Chun Lin², Yang-Lin Lin³, Yi-Jia Wu², En Chao¹, Lien-Wen Su⁸, Tony Szu-Hsien Lee¹

¹National Taiwan Normal University, ²Taipei City Hospital, ³Taoyuan Psychiatric Center, ⁴Bali Psychiatric Center, ⁵Central Police University, ⁶Mackay Medical College, ⁷National Taipei University, ⁸Taipei Medical University-Shuang Ho Hospital

S168. Estimating Human Doses of Stimulant-Like New Psychoactive Substances Based on Invitro Monoamine Transporter Data

Matthew Baggott¹, Donna Walther², Dino Luethi³, Jeremy Coyle¹, Matthias Liechti⁴, Michael Baumann⁵
¹Tactogen Inc, ²NIDA Intramural Research Program, ³University Hospital Base, University of Basel, and Medical University of Vienna, ⁴University Hospital Basel and University of Basel, ⁵NIDA, Intramural Research Program

S169. Vitamin D Deficiency in a Series of Heavy Drinkers Admitted for Hospital Treatment

Daniel Fuster¹, Julia Casado², Anna Hernández-Rubio², Xavier Garcia-Calvo², Robert Muga¹, Paola Zuluaga²
¹Hospital Universitari Germans Trias i Pujol, ²Internal Medicine Service. Hospital Universitari Germans Trias i Pujol

S162. Open Board

MONDAY, JUNE 19, 2023

POSTER SESSION 2

M1. Increased Risk of Mortality From Polysubstance Use Among Hospitalized Patients With Opioid Use Disorder

Karli Hochstatter¹, Courtney Nordeck¹, Shannon Mitchell¹, Robert Schwartz¹, Christopher Welsh², Jan Gryczynski¹
¹Friends Research Institute, ²University of Maryland School of Medicine

M2. Pupillometer to Predict Postoperative Opioid-Induced Respiratory Depression in Children

Jeffrey Oliver¹, Charles Abramson¹, Claudio Privitera¹, Senthilkumar Sadhasivam²
¹NeuroOptics Inc, ²UPMC, University of Pittsburgh

M3. A Virtual Reality Recovery Support Intervention for Opioid Use DISORDER: Efficacy Testing and Development

Brandon Oberlin¹, Andrew Nelson², Megayn Lewandowski¹, Yitong Shen¹
¹Indiana University School of Medicine, ²Half Full Nelson, LLC; Relate XR, LLC

M4. Small Business Program: Implementation of a Technological Solution to Support Treatment for Opioid Use Disorder in the Primary Care Setting

Mariah Kalmin¹, Bengisu Tulu², Omar Nieto³, Alycia Quick⁴, Allison Rosen⁵, Li Li⁵, Dominic Trupiano⁴, Steve Jenkins⁴, Steve Shoptaw⁵
¹RAND Corporation, ²Worcester Polytechnic Institute, ³UCLA, ⁴Q2i, ⁵University of California Los Angeles

M5. Transcutaneous Auricular Neurostimulation (tAN): An Emerging Treatment Strategy to Combat the Opioid Crisis

Navid Khodaparast¹, Melanie McWade¹, Caroline Benner¹, Alejandro Covalin¹
¹Spark Biomedical, Inc.

M6. Proof of Concept of Regional Oximetry to Detect Opioid Induced Respiratory Depression, Signifying Possible Overdose

Desislava Hite¹, Michael Hite¹
¹Ayuda Medical

M7. Development and Validation of a Reasons for Electronic Cigarette Use Questionnaire

David Ledgerwood¹, Danishi Bedi¹, Mannat Bedi¹, Ciara Cannoy¹, Krithika Prakash², Alanna Foulon¹, ShayLin Excell¹, Leslie Lundahl¹

¹Wayne State University, ²Eastern Michigan University

M8. Digital Motivation and Prediction Platform to Improve Treatment Retention and Reduce Relapse in Opioid Use Disorder

Jeremy Guttman¹, Debarati Bhanja², Jane Liebschutz³, Carolanne Semancik⁴, Kamaneeya Kalaga⁵, Bilal Stambouli¹

¹Biomotivate, ²Penn State College of Medicine, ³University of Pittsburgh, ⁴Glenbeigh Hospital, ⁵Carnegie Mellon University

M9. Reduce Return to Use: Personalized AI for Individuals in Recovery

Ellie Gordon¹, Whitney Menarcheck¹

¹Behavior

M10. Small Business Program: Scalable Cue-Induced Craving Neurofeedback for Opioid Use Disorder Treatments

Scott Burwell¹, Flavio Da Silva¹, Justin Anker²

¹Neurotype Inc., ²University of Minnesota

M11. OpiAID: A Data Driven Approach to Treating Opioid Dependence

Christopher Evonko¹, David Reeser², Tyler Sugden², Jesse Shaw², Wendy Washington¹, David MacQueen¹

¹University of North Carolina Wilmington, ²OpiAID

M12. Development, Calibration, and Delivery of Personalized Cognitive-Behavioral Interventions Through Software

Gregg Siegel¹, Richard Priesmeyer², Leslie Siegel¹, Tara Karns-Wright³, Van King⁴, Katherine Dondanville⁴, Jennifer Potter⁴

¹Biomedical Development Corporation, ²St. Mary's University, ³The University of Texas Health Science Center At San Antonio, ⁴University of Texas Health San Antonio

M13. Innovations in Small Business Telehealth Technologies for Opioid Use Disorder: Automated Assessments, Electronic Health Record integrations, and Medication Shipping

Cynthia Jimes¹, Marlene Lira¹, M. Justin Coffey¹

¹Workit Health

M14. NIDA-Funded Small Business Companies Successfully Contribute to NIH Heal Initiative

Jia Bei Wang¹, Leonardo Angelone¹, Stacie Gutowski¹, Tam Nguyen¹, Yordan Kostov¹, Elena Koustova¹, Sara Lioi¹

¹NIDA, NIH

M15. A Digital Health App for Opioid Treatment Programs: The Sonara Health Platform for Video Observed Methadone Take-Homes

Michael Giles¹, Kshitij Verma¹, Omer Kaplan¹, Dongseok Choi², Kim Hoffman², Katharina Wiest³, Dennis McCarty²

¹Sonara Health, ²Oregon Health and Science University, ³Pacific Vascular Specialists

M16. Wearable Immunosensor Array for Rapid Opioids Detection

Igor Ilevitsky¹, Nantaniel Cady², Natalia Tokranova³, Albert Lampher¹

¹Emitech, Inc., ²Albany Polytechnic Institute, ³Albany Polytechnic Institute

M17. Development of a Community-Based Wastewater Surveillance System to Measure Opioid, Stimulant and Medications for Opioid Use Disorder in the COVID-19 Pandemic

Peter Chai¹, Gordon Getzinger², Joji Suzuki¹, Alex Buben², Matthew Boyce², Kait Hess², Kelly Wahl², Mariana Matus², Timothy Erickson¹

¹Brigham and Women's Hospital, Harvard Medical School, ²Biobot Analytics

M18. Targeting a Non-Opioid Signaling Pathway to Reverse Opioid-Induced Respiratory Depression

Andy Chang¹, Alexandra Scharr², Ethan Garcia¹, Terra Lin¹, Deomar Arizabal¹

¹University of California, San Francisco, ²Olfa Thera, Inc.

M19. Novel Maintenance Therapeutic for Opioid Use Disorder

Don Gehlert¹, Douglas Crawford¹, William Schmidt¹, Neil Schwartz¹

¹Epiodyne

M20. Brief Xenon Gas Inhalation Attenuates Naltrexone-Precipitated Morphine Withdrawal Symptoms in Morphine-Dependent Mice

Marc Kaufman¹, Edward Meloni¹, Dilin Meloni¹, Carol Paronis¹, Vlad Bogin²

¹McLean Hospital, Harvard Medical School, ²Nobilis Therapeutics, Inc., Portland OR

M21. Development of Dual MOR Agonist/DOR Antagonists as Novel Treatments for Opioid Use Disorder

Annie Pasternak¹, Jeffrey Reich²

¹Sparian Biosciences, ²Sparian Biosciences, Inc.

M22. Incentivized Collaborative Care to Disseminate Contingency Management via Buprenorphine Treatment

Sean Regnier¹, Rosemarie Davidson², Hayley Brown², David Gastfriend³, Anthony DeFulio²

¹University of Kentucky, College of Medicine, ²Western Michigan University, ³DynamiCare Health, Inc.

M23. Trends of Prenatal Substance Exposure: A 10 Year Evaluation of Umbilical Cord Test Outcomes

Joseph Jones¹

¹United States Drug Testing Laboratories

M24. A Novel Hand-Held Personalized Dual Biometrically Controlled Device for At-Home Dispensation of Methadone

John Timberlake¹, Kenneth Stoller², Thomas King¹, Christy Corey¹

¹Berkshire Biomedical, ²Johns Hopkins University School of Medicine

M25. The Computerized Oral Prescription Administration System (COPA™): An Innovative Hand-Held Oral Liquid Medication Dispensing Device With Remote Monitoring and Dual Biometrics With the Potential to Streamline Clinical Trials

Thomas King¹, Christy Corey¹, Kenneth Stoller², John Timberlake¹

¹Berkshire Biomedical, ²Johns Hopkins School of Medicine

M26. Identification of Epigenetic Biomarkers Associated With Prenatal Exposure to Substances of Abuse

Aileen Baldwin¹, Joseph Jones¹

¹United States Drug Testing Laboratories, Inc.

M27. The NIDA Cause of Death Elucidated (CODE) Initiative: Developing Innovative Postmortem Toxicology Testing Devices to Reduce the Undercounting of Drug Overdose Deaths

Tam Nguyen¹, Yordan Kostov¹, Sara Lioi¹, Leonardo Angelone¹, Elena Koustova¹

¹DHHS/National Institute on Drug Abuse

M28. RAE cHealth: A Digital Tool to Support Peer Recovery-Based Treatment for Substance Use Disorder and to Reduce Digital Inequity

Stephanie Carreiro¹, Rebecca Leach¹, Melissa Taylor¹, Joshua Stapp², Nicole Gilbertson², Megan Reinhardt², Premananda Indic³

¹University of Massachusetts Medical School, ²RAE Health, ³Department of Electrical Engineering, The University of Texas at Tyler

M29. The Vox Venturi Device: Portable Breath-Based THC and Opioid Detection

Jake Golde¹, Scott Lukas², Arash Aslani¹, Ken Markoski¹, Joe Santos³, Jane McNeil²

¹Vox Biomedical, ²McLean Hospital, Harvard Medical School, ³DRAPER

M30. A Three Phase Program of Research Investigating a Digital Intervention for Substance Use Delivered via a Relational Agent, "Woebot"

Athena Robinson¹, Maddison Pirner¹, Sarah Pajarito¹, Amy Chieng², Erin Vogel², Jessie Moore², Alison Darcy¹, Judith Prochaska²

¹Woebot Health, ²Stanford University Stanford Prevention Research Center

M31. Novel 'Agnostic' Pharmacologic Approach to Polysubstance Overdose

Thomas Miller¹, Amanda Bunting², Michael Schatman³, Joseph Pergolizzi¹, Alfred Schweikert¹, Frank Diana¹, Robert Colucci⁴, Herm Cukier¹, Daniel Motto¹, Marty Lutz¹, Errol Gould¹, Robert Raffa¹

¹Enalare Therapeutics, ²NYU Langone Health, ³NYU Grossman School of Medicine, ⁴NEMA Research

M32. A Novel Approach to Treat Fentanyl Intoxication

Shekar Shetty¹, Xinhua Li², Mitchell Zakin², Piercen Oliver²

¹Clear Scientific Inc., ²Clear Scientific Inc

M33. Using MegaSyn Generative Machine Learning to Identify Psychoplastogens for Opioid Abuse Treatment

Joshua Harris¹, Jacob Gerlach¹, Fabio Urbina¹, Sean Ekins¹

¹Collaborations Pharmaceuticals, Inc.

M34. AI/ML-Driven in Silico Identification of Blood-Brain Barrier Permeable Compounds

Maksim Khotimchenko¹, Kaushik Chakravarty¹, Courtney Miller², Yogesh Bunday¹, Roshan Bhawe¹, Szczepan Baran¹, Jyotika Varshney¹

¹Verisim Life, ²The Scripps Research Institute, Department of Neuroscience

M35. Facilitating Supervised Self-Management of Stimulant Medications Among Adolescents: Improving Adherence, Supporting Caregivers, and Reducing the Risk of Misuse

Artin Perse¹, Catherine Stanger², Bridget Skidmore³, Erin Winstanley⁴

¹Levl, ²Dartmouth College, Geisel School of Medicine, Department of Psychiatry, ³West Virginia University, WVU Medicine Children's Hospital, ⁴West Virginia University, Department of Behavioral Medicine and Psychiatry

M36. Novel Neurotheranostic for MR Imaging of Dopamine Transporters (DAT) and Treatment of Dopaminergic Neurodegeneration in Methamphetamine Use Disorder (MUD)

Gordana Vitaliano¹, Christopher Adam², Gonzalo Zeballos², Kyoko Ohashi¹, Franco Vitaliano³

¹McLean Hospital, Harvard Medical School, ²McLean Hospital, ³EXQOR

M37. Development of Dual "Atypical" DAT Inhibitor/Sigma Receptor Antagonists as Novel Treatments for Stimulant Use Disorder

Jeffrey Reich¹, Christopher McCurdy²

¹Sparian Biosciences, Inc., ²University of Florida

M38. You Can See that the Culture is Definitely Changing: Peer-Facilitated Telemedicine Hepatitis-C Treatment for People who Use Drugs

Kim Hoffman¹, Soomin Shin², Gillian Leichtling², Hunter Spencer¹, Tonhi Gailey¹, Andrew Seaman¹, P. Todd Korthuis¹

¹Oregon Health and Science University, ²Comagine Health

M39. Patient- And Clinician-Level Factors for Virtual and In-Person Substance Use Disorder Treatment Retention

Michael Parks¹, Justine Welsh², Lance Waller³, Siara Sitar⁴, Jackie Braughton¹, Samantha Patton⁵, Quyen Ngo¹

¹Hazelden Betty Ford Foundation, ²Emory University School of Medicine Department of Psychiatry and Behavioral Services, ³Emory University Rollins School of Public Health Department of Biostatistics and Bioinformatics, ⁴Emory University School of Medicine, Department of Psychiatry and Behavioral Services, ⁵Emory University, Department of Psychiatry and Behavioral Sciences

M40. Persistent Anxiety is Associated With Reporting At-Risk Drinking During COVID-19 Among Women in a Community Setting

Alyssa Berger¹, Linda Cottler¹

¹University of Florida

M41. Open Board

M42. Substance Use Patterns and Access to Services in Humanitarian Settings: A Formative Research Study

Stephanie Haddad¹, Mbaita Shawa², Jeremy Kane¹, Bertha Bwalya³, Megan Sienkiewicz¹, Grace Kilbane¹, Veronica Chibemba², Princess Chiluba², Nkumbu Mtongo², Kristina Metz⁴, Mildred Chibwe², Namuchana Mushabati², Allan Zulu³, Ravi Paul⁵, Zaliwe Banda⁶, Henry Loongo³, Muzi Kamanga², M. Claire Greene¹

¹Columbia University Mailman School of Public Health, ²Women in Law and Development in Africa, Lusaka, Zambia, ³CARE Zambia, Lusaka, Zambia, ⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, ⁵University of Zambia, ⁶Zambia Ministry of Health, Lusaka, Zambia

M43. Preliminary Evidence That Individuals With Remitted Alcohol Use Disorder and Major Depressive Disorder Exhibit Enhanced Neural Responses to Reward: An EEG Study

Natania Crane¹, Lilian Li², Julia Brooks³, Stewart Shankman²

¹Psychiatric Institute, University of Illinois At Chicago, ²Northwestern University, ³University of Illinois At Chicago

M44. Fluoxetine in the Relapse Prevention of Alcoholism

John Sullivan¹, Donald Jasinski²

¹none, ²Johns Hopkins Bayview Medical Center

M45. Differences in Psychopathology, Substance Use, and Social Support Among Adolescents With Versus Without Lifetime Alcohol Use

Carol Vidal¹, Caroline Brooks², Eric Strain³

¹Department of Psychiatry, Johns Hopkins University School of Medicine, ²Department of Psychiatry, Johns Hopkins University, ³Johns Hopkins University School of Medicine

M46. Ageing With an Alcohol Problem is Not What I Envision: Reclaiming Agency in Shaping Personal Ageing Trajectory and Recovery From an Alcohol Problem

Wossenseged Birhane Jemberie¹, Fredrik Snellman¹, Malin Eriksson¹, Anders Hammarberg²

¹Umea University, Faculty of Social Sciences, ²Karolinska Institutet, Department of Clinical Neuroscience

M47. Parent Influence and Alcohol Use by Youth With Chronic Medical Conditions

Jessica Calihan¹, Machiko Minegishi², Elissa Weitzman³

¹HHMI, Children's Hospital - Boston, ²Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, ³Department of Pediatrics, Harvard Medical School, Boston, Massachusetts; Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts; Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts.

M48. Chronic Alcohol Self Administration Induces Extracellular Matrix Abnormalities in the Hippocampus of Non-Human Primates

Jake Valeri¹, Charlotte Stiplosek¹, Donna Platt¹, Kathleen A Grant², Barbara Gisabella¹, Harry Pantazopoulos¹

¹University of Mississippi Medical Center, ²Oregon National Primate Research Center

M49. Molecular Signaling Pathways in the Hippocampus of Rhesus Monkeys With Chronic Alcohol Use

Tanya Pareek¹, Donna Platt¹, Kathleen Grant², Barbara Gisabella¹, Harry Pantazopoulos¹

¹University of Mississippi Medical Center, ²Oregon Health and Science University

M50. Common and Distinct Associations Between Baseline Impulsivity and Longitudinal Development of Positive and Negative Alcohol Expectancies in the Adolescent Brain Cognitive Development (ABCD) Cohort

Faith Adams¹, Iliyan Ivanov¹, Muhammad Parvaz¹

¹Icahn School of Medicine At Mount Sinai

M51. Gender, Mental Health, and Cannabis Use Amongst Students in the United States During the Pandemic: Results From the COVID-19 Cannabis Health Study

Ana Borja¹, Marvin Reid², Layan Ibrahim³, Nicole O'Dell⁴, Deanna Uddin⁵, Denise Vidot⁵

¹Syracuse University, ²The University of the West Indies, Mona, ³Vanderbilt University School of Medicine, ⁴University of Miami Miller School of Medicine, ⁵University of Miami School of Nursing and Health Studies

M52. Effects of Cannabidiol and Morphine on Antinociception Across Multiple Modalities

Leslie Lundahl¹, Mark Greenwald²

¹Wayne State University School of Medicine, ²Wayne State University, Dept of Psychiatry and Behavioral Neurosciences

M53. White Matter Structural Organization Alterations in People Living With HIV With Heavy Cannabis Use

Ryan Bell¹, Sheri Towe¹, Syam Gadde¹, Amelia Costello², Christina Meade¹

¹Duke University School of Medicine, ²Duke University

M54. Chronic Disease Symptoms Self-Managed with Cannabis during the COVID-19 Pandemic: Results From the COVID-19 Cannabis Health Study

Nicole O'Dell¹, Marvin Reid², Jessica Islam³, Marlene Camacho-Rivera⁴, Denise Vidot⁵

¹University of Miami Miller School of Medicine, ²The University of the West Indies, Mona, ³Moffitt Cancer Center, ⁴SUNY Downstate Health Sciences University, ⁵University of Miami School of Nursing and Health Studies

M55. Primary Form of Cannabis Use and Recent Negative Affect Symptoms

Anita Cservenka¹

¹Oregon State University

M56. Characteristics Associated With Cannabis Dispensary Purchasing Among a Representative Sample of Adults in the United States who Use Cannabis

Matthew Myers¹, Kipling Bohnert²

¹Michigan State University College of Human Medicine, ²University of Michigan and Department of Veterans Affairs

M57. Age and Pandemic-Related Stress among Cannabis Consumers in First Year of COVID-19 Pandemic: Preliminary Results from the COVID-19 Cannabis Health Study

Layan Ibrahim¹, Marvin Reid², Nicole O'Dell³, Audrey Harkness⁴, Denise Vidot⁴

¹Vanderbilt University School of Medicine, ²The University of the West Indies, Mona, ³University of Miami Miller School of Medicine, ⁴University of Miami School of Nursing and Health Studies

M58. Applying the Observational-Implementation Hybrid Approach to Collect Implementation Data on the Use of Evidence-Based Practices to Support Reductions in Cannabis Use among Black Sexual Minority Men and Transgender Women

Justin Knox¹, Silvia Martins¹, Elvin Geng²

¹Columbia University, ²Washington University in St Louis

M59. Cannabis Use in Adolescence and the Later Onset of Bipolar Disorder: A Systematic Review and Meta-Analysis of Prospective Cohort Studies

Naonori Yasuma¹, Kotaro Imamura², Kazuhiro Watanabe³, Mako Iida⁴, Ayumi Takano⁵

¹Ageonomori clinic, ²Department of Digital Mental Health, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ³Department of Public Health, Kitasato University School of Medicine, Sagami-hara, Kanagawa, Japan, ⁴Department of Psychiatric Nursing, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁵Department of Mental Health and Psychiatric Nursing, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan

M60. Cannabis Use Disorder Symptom Profiles Among Individuals Reporting Past-year Cannabis Use in the United States

Angela DeVeauh-Geiss¹, John Mariani², Beth Reboussin³, Howard Chilcoat⁴

¹Indivior, Inc., ²Columbia University Irving Medical Center, New York State Psychiatric Institute, ³Wake Forest University School of Medicine, ⁴Indivior, Inc; Johns Hopkins Bloomberg School of Public Health

M61. Sex Differences in Prospective Trajectories of Alcohol but Not Marijuana Use Following Trauma

Robyn Ellis¹, R. Kathryn McHugh¹, William Davie², Charis Wiltshire², Samuel McLean³, Kerry Ressler¹, Tanja Jovanovic², Antonia Seligowski¹

¹McLean Hospital - Harvard Medical School, ²Wayne State University School of Medicine, ³University of North Carolina-Chapel Hill

M62. Pilot Trial of a Behavioral Economic Intervention to Promote Cannabis-Free Activities for Non-Treatment Seeking Adults With Cannabis Use Disorder

Lara Coughlin¹, Erin Bonar¹, Joshua Wieringa¹, Alyssa Augustiniak¹, Grant Goodman¹, Rachel Girard², Lewei (Allison) Lin¹

¹University of Michigan, ²University of Rhode Island

M63. Mobile EEG Correlates of Frequent Cannabis Use are Sex- and Age-Dependent

Conor Murray¹, Ziva Cooper¹

¹University of California, Los Angeles

M64. Cannabis Reduction is Associated With Improved Functional Outcomes: An Aggregated Analysis From Seven Cannabis Treatment Trials

Erin McClure¹, Brian Neelon¹, Rachel Tomko¹, Kevin Gray¹, Aimee McRae-Clark¹, Nathaniel Baker¹

¹Medical University of South Carolina

M65. Examining the Effects of Marijuana Use on Cognition in Persons With and Without HIV

Sheri Towe¹, Christina Meade¹

¹Duke University School of Medicine

M66. Hippocampal Subfield Volume as a Function of Cannabis Use and Cannabis Use Disorder

Alexandre Guerin¹, Xuejun Hao², Margaret Haney³, Suzette Evans⁴, Gillinder Bedi⁵

¹University of Melbourne, ²Columbia University Medical Center, ³Columbia University Irving Medical Center,

⁴NYSPI and Research Foundation for Mental Hygiene, ⁵The University of Melbourne

M67. Open Board

M68. Individuals with Cannabis Use Disorder Display Altered Parasympathetic Hrv during Waking and Sleeping Hours Relative to Light Cannabis Users.

Morgan Pearlman¹, Stephanie Wemm¹, Morgan Pearlman¹, Jennifer Liston¹, Rajita Sinha¹

¹Yale University School of Medicine

M69. Extended-Release Mixed Amphetamine Salts for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder: A Pilot, Randomized Double-Blind, Placebo-Controlled Trial

Frances Levin¹, John Mariani², Martina Pavlicova³, C. Jean Choi⁴, Cale Basaraba⁴, Amy Mahony⁴, Daniel Brooks⁴, Christina Brezing⁵, Nasir Naqvi⁵

¹Columbia University Irving Medical Center/ New York State Psychiatric Institute, ²Columbia University and New York Psychiatric Institute, ³Columbia University, ⁴New York State Psychiatric Institute, ⁵Columbia University and NYSPI

M70. Cannabis Use Frequency's Positive Associations With Blood Pressure Among Young Adult African American Students

Alexis Morris¹, Larry Keen¹

¹Virginia State University

M71. Marijuana Use Among Asian American Adolescents: An Analysis of Specific Ethnic Groups

Ting Luo¹, Jijiang Wang¹, Yue-Lin Zhuang¹, Shu-Hong Zhu¹

¹University of California - San Diego

M72. State Cannabis Legalization and Changes in Cannabis Use as Determined by Biologic Testing in Emergency Department Patients in the U.S. Veterans Health Administration, 2008 to 2019

David Fink¹, Hillary Samples², Andrew Saxon³, Carol Malte⁴, Melanie Wall⁵, Deborah Hasin⁶

¹New York State Psychiatric Institute, ²Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, ³Veterans Affairs Puget Sound Health Care System, Seattle, ⁴Center of Excellence in Substance Abuse Treatment and Education, Veterans Affairs Puget Sound Health Care System, ⁵Columbia University and NYSPI, ⁶Columbia University

M73. Preliminary Evidence for Altered Sleep Patterns in Cannabis Users

Tracy Brown¹, Alessandra Stagni¹, Shakti Anand¹, Mihir Shah¹, Francesca Filbey¹

¹University of Texas at Dallas

M74. The Adolescent Path? Anhedonia and Cannavaping Use

Cynthia Ortiz¹, Peter Hendricks¹

¹The University of Alabama At Birmingham

M75. Co-Occurrence of Cannabis Use and Cigarette Smoking Accelerates Epigenetic Age

Brooklyn Bradley¹, Youshu Cheng¹, Xiaoyu Liang², Rajita Sinha¹, Ke Xu¹

¹Department of Psychiatry, Yale University, New Haven, CT, ²Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

M76. Place Conditioning With $\Delta 9$ -THC Following Chronic $\Delta 9$ -THC Exposure During Adolescence

Sarah Withey¹, Stephen Kohut¹, Brian Kangas¹, Jack Bergman¹

¹McLean Hospital / Harvard Med School

M77. An Overview of New Psychoactive Substances (NPS) Analysis and Trends in Taiwan, 2008-2022

Kai-Hsiang Kang¹, Wei-Ting Chen², Yuan-Chun Liao², Wei J. Chen³

¹Center for Neuropsychiatric Research, National Health Research Institutes, Taiwan, ²Division of Controlled Drugs, Food and Drug Administration, Taiwan, ³National Taiwan University College of Public Health

M78. Emotion Regulation Expectancies and Smoking Cessation Factors: An Ecological Momentary Assessment Study During a Practice Quit Attempt

Raina Pang¹, Shirlene Wang¹, Chyna Tucker¹, Lori Zadoorian¹, Andrea Weinberger², Lina D'Orazio¹, Matt Kirkpatrick¹

¹University of Southern California, ²Yeshiva University

M79. Pharmacological Manipulation of Temporal Brain State Dynamics During Rest

Justine Hill¹, Betty Jo Salmeron¹, Thomas Ross¹, Amy Janes²

¹National Institute on Drug Abuse, Neuroimaging Research Branch, ²National Institute on Drug Abuse

M80. Opioid Withdrawal Symptoms and Reasons for Discontinuation of Low-Dose Buprenorphine Induction for Treatment of Opioid Use Disorder in Hospitalized Patients

Catherine Chen¹, Chelsea Markle¹, Judith Tsui¹, Elenore Bhatraju¹

¹University of Washington/Harborview Medical Center

M81. Examining the Relationship of Concurrent Obesity and Tobacco Use Disorder on the Development of Substance Use Disorders and Psychiatric Conditions: Findings From the NESARC-III

Logan Fields¹, Walter Roberts², Isabella Schwing¹, Michael McCoy¹, Sherry McKee³

¹Arcadia University, ²Yale University School of Medicine, ³Yale School of Medicine

M82. Preference for Waterpipes Among Female Patrons of Open-Air Bars in Lagos, Nigeria

Olanrewaju Onigbogi¹, Omobola Ojo², Modupe Onigbogi³

¹University of Lagos, College of Medicine, ²Federal Medical Center Abeokuta, ³University of Texas Health Sciences Houston

M83. Effects of Nicotine Dose in Cigarettes on Symptoms of Depression and Anxiety

Diann Gaalema¹, Jennifer Tidey², Stacey Sigmon¹, Sarah Heil¹, Dustin Lee³, Michael DeSarno¹, Stephen Higgins¹

¹University of Vermont, ²Brown University, ³Johns Hopkins University School of Medicine

M84. Latinx Combustible Cigarette Smokers Versus Dual Users: Differences in Alcohol and Drug Use Problem Severity

Justin Shepherd¹, Bryce Clausen¹, Michael Zvolensky¹

¹University of Houston

M85. Gender Differences in Smoking Dependence Motives

Dominique Black¹, Andrew Bontemps¹, Karen Gamble¹, S. Justin Thomas¹, Karen Cropsey¹

¹The University of Alabama At Birmingham

M86. Identifying Vape-Related Content on TikTok Using Automatic Clustering

Grace Kong¹, Tanvi Anand², Rachel Ouellette¹, Juhan Lee¹, Dhiraj Murthy³

¹Yale University School of Medicine, ²Cockrell School of Engineering, University of Texas at Austin, ³School of Journalism and Media, University of Texas at Austin

M87. Relationships Between Socioeconomic Position and Quitting Smoking Among Pregnant Women: A Longitudinal Assessment From Waves 1-5 of the Population Assessment of Tobacco and Health Study

Loren Kock¹, Stephen Higgins¹, Fang Fang Chen¹, Sarah Heil¹

¹University of Vermont

M88. Chronic Nicotine Use Induces a Unique Neuroimmune Landscape That Critically Impacts Aberrant Accumbens Synaptic Plasticity

Emma Bondy¹, Shailesh Khatri¹, Percell Kendrick², Michael Scofield³, Cassandra Gipson-Reichardt¹

¹University of Kentucky, ²University of Kentucky, College of Medicine, ³Medical University of South Carolina

M89. Nicotine Self-Administration Differentially Modulates Ventral Tegmental and Medial Habenular Neuronal Excitability

Nathan Olszewski¹, Brandon Henderson¹

¹Joan C. Edwards School of Medicine, Marshall University

M90. Incidence of Opioid Misuse by Cigarette Smoking Status in the United States

Maria Parker¹, Raul Cruz¹, Joanna Streck², Andrea Weinberger³

¹Indiana University - Bloomington, ²Harvard Medical School/Massachusetts General Hospital, ³Yeshiva University

M91. Proximity to Low Barrier Resources for Alabamians Hospitalized With Injection Drug Use

Kelly Gagnon¹, John Bassler², Ariann Nassel³, Emma Kay⁴, Ellen Eaton¹

¹Division of Infectious Diseases, The University of Alabama At Birmingham, ²School of Public Health, The University of Alabama At Birmingham, ³Lister Hill Center for Health Policy, The University of Alabama At Birmingham, ⁴Magic City Research Institute

M92. Patient Characteristics Associated With Retention on XR-NTX in the CTN-0051 Trial

Onumara Opara¹, Kaitlyn Ohrtman¹, Miranda Greiner¹, Matisyahu Shulman², Tse-Hwei Choo³, Martina Pavlicova⁴, Aimee Campbell⁵, John Rotrosen⁶, Edward Nunes⁷

¹NYSPI/Columbia University, ²Columbia University and New York State Psychiatric Institute, ³Columbia University Mailman School of Public Health, ⁴Columbia University, ⁵Columbia University Irving Medical Center and New York Psychiatric Institute, ⁶New York University School of Medicine, ⁷Columbia University and New York State Psychiatric Institute

M93. Changes in Mentalization, Cognition, and Catastrophizing Scores During Methadone Maintenance Treatment

Einat Peles¹, Shlomit Zorani², Miriam Adelson²

¹Tel Aviv Sourasky Medical Center, ²Adelson Clinic, Tel Aviv Medical Center

M94. Examining Protective Behavioral Strategies and Harm Reduction Service Utilization Among Individuals who Use Opioids

Rachel Luba¹, Suky Martinez², Manesh Gopaldas¹, Sandra Comer³

¹New York State Psychiatric Institute, ²Columbia University and New York State Psychiatric Institute, ³Columbia University and NYSPI

M95. Early Non-Adherence Among Individuals Initiating Low Barrier Buprenorphine Treatment in an Office-Based Setting

Karen Dugosh¹, Michelle Lent², Brook Burkley¹, Conor Millard¹, James McKay³, Kyle Kampman³

¹Public Health Management Corporation, ²Philadelphia College of Osteopathic Medicine, ³University of Pennsylvania

M96. Predictors of Study Treatment Attendance Among Individuals With Opioid Use Disorder Reporting Perceived Social Isolation

Lisham Ashrafioun¹, Nicholas Allan², Jonathan Umansky¹, Tamara Bilinski¹, Tracy Stecker³

¹University of Rochester, ²Ohio State University, ³VA Center of Excellence for Suicide Prevention; Medical University of South Carolina

M97. Explainable Machine Learning Elucidates the Affective, Cognitive, and Social Factors Driving Non-Medicinal Opioid Use in Young Adults

Andrea Maxwell¹, Gregory Niklason², Sisi Ma³, Anna Zilverstand²

¹University of Minnesota, Medical Scientist Training Program, Graduate Program in Neuroscience, ²University of Minnesota, Department of Psychiatry, ³University of Minnesota, Institute for Health Informatics

M98. Comparisons Between Prescription Opioid Formulations and Risk for New-Onset Affective Disorders in Chronic Pain Patients

David Houghton¹, Christopher Lewis¹

¹University of Texas Medical Branch

M99. An Implementation Science Framework to Contextualize an Innovative Intervention Integrating Medications for Opioid Use Disorders in the Probation System

Amelia Bailey¹, Siena Napoleon², Augustine Kang², Rosemarie Martin²

¹Brown University, ²Brown University School of Public Health

M100. History of Traumatic Events and Opioid Use Among Justice Involved Mothers

Michele Staton¹, Martha Tillson², Mary Levi², Carl Leukefeld², Matt Webster², Carrie Oser²

¹University of Kentucky, College of Medicine, ²University of Kentucky

M101. Comparison of Symptom Networks in Younger Adults vs. Middle and Older Adults With Past 12-Month Non-Medical Use of Prescription Pain Relievers

Alyssa Falise¹, Sara Nutley¹, Catherine Striley¹, Catalina Lopez-Quintero¹

¹University of Florida

M102. Characteristics of Adults Who Used Opioids Nonmedically From the NDEWS Rapid Street Reporting, 2021 to 2022

Anna Wang¹, Nae Won¹, Nicole Fitzgerald¹, Joseph Palamar², MeLisa Creamer³, Catherine Striley¹, Linda Cottler¹

¹University of Florida, ²New York University School of Medicine, ³National Institute on Drug Abuse

M103. Naloxone Usage Over Time as Reported to the National Poison Data System (NPDS)

Evelyn Fox¹, Richard Dart¹, Alicia Dalton¹, Jennifer Jewell¹, Joshua Black¹

¹Rocky Mountain Poison and Drug Safety

M104. Screening for Co-Morbid OUD, PTSD, and Depression in a Primary Care Setting: Recruitment Results From a Randomized Clinical Trial

Christina Crowley¹, Jessica Anderson², Cristina Murray-Krezan³, Mary Carmody², Lina Tarhuni², Christina Phillips², Kirsten Becker⁴, Lauren Kelly⁴, Colleen McCullough⁴, Beth Ann Griffin⁴, Kimberly Page², Michael Schoenbaum⁵, Miriam Komaromy⁶, Katherine E. Watkins⁴

¹Frederick S. Pardee RAND Graduate School, RAND Corporation, ²Department of Internal Medicine, University of New Mexico Health Sciences, ³Department of Medicine, University of Pittsburgh School of Medicine, ⁴RAND Corporation, ⁵National Institute of Mental Health, ⁶Grayken Center for Addiction, Boston Medical Center, Boston University

M105. Racial Disparities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women With Opioid Use Disorder: An Analysis of Multi-State Insurance Claims in the USA (2006-2016)

Kevin Xu¹, Davida Schiff², Hendree Jones³, Caitlin Martin⁴, Jeannie Kelly¹, Laura Bierut¹, Ebony Carter¹, Richard Gruzca⁵

¹Washington University School of Medicine, ²Mass General Hospital for Children, ³University of North Carolina at Chapel Hill, ⁴Virginia Commonwealth University, ⁵St Louis University School of Medicine

M106. Reduction in Substance Use-Related Harms Among a Cohort of People Receiving Injectable Opioid Agonist Treatment in Ontario, Canada

Tinkhani Mbichila¹, Mohammad Karamouzian², Zachary Bouck¹, Ahmed Bayoumi³, Bijan Rafat¹, Carman Brown¹, Shaun Hopkins⁴, Ayden Scheim⁵, Dan Werb¹

¹Centre on Drug Policy Evaluation, ²Centre of Drug Policy Evaluation, St. Michael's Hospital, ³MAP Centre for Urban Health Solutions, ⁴Toronto Public Health, ⁵Dornsife School of Public Health, Drexel University

M107. Attitudes Toward Naloxone Uptake for Opioid Overdose Prevention Among People who Use Opioids in the Southeastern U.S.

Mylinh Le¹, Tanja Laschober², Susan Tross³, Margaret Paschen-Wolff⁴, Melissa Ertl⁵, Lynette Wright⁶, Mary Hatch⁷

¹University of Washington School of Medicine, ²University of Washington, Addictions, Drug and Alcohol Institute, ³Columbia University, ⁴Columbia University Medical Center, ⁵Columbia University and New York State Psychiatric Institute, ⁶University of Washington Alcohol and Drug Abuse Institute, ⁷University of Washington, Department of Psychiatry and Behavioral Sciences

M108. Screening for Opioid Use Disorder at Public Sexual Health Clinics

Jan Gryczynski¹, Courtney Nordeck¹, Kristi Dusek¹, Anjalee Sharma¹, Mishka Terplan¹, Elizabeth Gilliams²

¹Friends Research Institute, ²Baltimore City Health Department

M109. Feasibility and Outcomes of a Community-Pharmacist Led Program to Treat Hepatitis C Virus Among Persons who Inject Drugs

Judith Tsui¹, Alex J. Gojic¹, Kathleen A. Pierce², Elyse L. Tung³, Nancy C. Connolly¹, Andrea C. Radick¹, John D. Scott¹, Ryan N. Hansen⁴, Joanne D. Stekler⁵, Sarah V. Marchetti⁶, Robert H. Kubinieć⁷, Regan R. Hunt⁸, Elizabeth J. Austin⁹, Emily C. Williams¹⁰, Sara N. Glick¹¹

¹Department of Medicine, Division of General Internal Medicine, University of Washington, ²Kelley-Ross Pharmacy Group, ³Kelley-Ross Pharmacy Group; Department of Pharmacy, University of Washington, ⁴Kelley-Ross Pharmacy Group; Department of Pharmacy, University of Washington; Department of Health Systems and Population Health, University of Washington, ⁵Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, ⁶Hepatitis Education Project, ⁷Evergreen Treatment Services, ⁸Des Moines University College of Osteopathic Medicine, ⁹Department of Health Systems and Population Health, University of Washington, ¹⁰Department of Health Systems and Population Health, University of Washington; Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services Research and Development, VA Puget Sound, ¹¹Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington; HIV/STD Program, Public Health - Seattle and King County

M110. Performance of a Brief Substance Use Symptom Checklist (SUSC) for Identifying Substance Use Disorder Among Primary Care Patients With or at Elevated Risk for Opioid Use Disorder

Emily Williams¹, Theresa Matson², Kevin Hallgren³, Malia Oliver², Katharine Bradley²

¹Veterans Affairs Puget Sound Health Services Research and Development, ²Kaiser Permanente Washington Health Research Institute, ³University of Washington

M111. A Retrospective Chart Review of Hormonal Contraceptives and Compliance With Medication for Opioid Use Disorder in Adolescents and Young Adults

Stephanie Mallahan¹, Andrea Bonny², Brittney Manos², Erin Mcknight², Alicia Allen¹

¹University of Arizona, College of Medicine, ²Nationwide Children's Hospital

M112. Emergency Department and Hospital Admissions With Injecting-Related Infections in a Cohort of People who Inject Drugs

Samantha Colledge-Frisby¹, Stephanie Curtis², Andrew Stewardson², Joe Doyle², Peter Higgs³, Matthew Hickman⁴, Lisa Maher⁵, Mark Stooze³, Paul Dietze¹

¹National Drug Research Institute, Curtin University, ²Monash University, ³Burnet Institute, ⁴Bristol University, ⁵Kirby Institute

M113. The Relationship Between Medical and Recreational Cannabis Legalization With Opioid Misuse Among Individuals Reporting Medically Recommended Cannabis Use

Silvia Martins¹, Emilie Bruzelius¹, Christine Mauro¹, Julian Santaella-Tenorio², Anne Boustead³, Magdalena Cerdá²

¹Columbia University, ²New York University, ³University of Arizona

M114. Punitive Policies and Stigma in Health and Social Service Settings as Drivers of Perinatal Overdose: A Qualitative Exploration in New York City

Brooke West¹, Bethany Medley¹, Jaih Craddock², Talia Z. Nadel¹, Morgan Philbin³, Pia Mauro¹

¹Columbia University, ²University of California, ³University of California San Francisco

M115. Sex and Age Differences in Suicide Attempts Among Opioid Overdose-Related 911 Dispatches

Andrew McCabe¹, Linda Cottler¹

¹University of Florida

M116. Assessment of Risky Sexual Practices Among Married Males Seeking Treatment for Opioid Dependence in India

Ankita Chattopadhyay¹, Mahadev Sen², Nishtha Chawla³, Ragul Ganesh⁴, Suraj Verma³, Siddharth Sarkar⁵, Atul Ambekar⁶

¹All India Institute of Medical Sciences, New Delhi, ²Institute of Human Behaviour and Allied Sciences (IHBAS), New Delhi, ³All India Institute of Medical Sciences (AIIMS), New Delhi, ⁴All India Institute of Medical Sciences (AIIMS), Jammu, ⁵National Drug Dependence Treatment Centre, AIIMS, New Delhi, India, ⁶National Drug Dependence Treatment Centre

M117. The Interaction Between Anhedonia and Impulsivity in Opioid Use Disorder

Nicole Kouri¹, Tabitha Moses², Leslie Lundahl², Mark Greenwald³

¹Wayne State University, ²Wayne State University School of Medicine, ³Wayne State University, Dept of Psychiatry and Behavioral Neurosciences

M118. Patient Characteristics of Fentanyl Positive Individuals With Opioid Use Disorder

Miranda Greiner¹, Mei-Chen Hu², Matisyahu Shulman³, Kathryn Hefner⁴, Onumara Opara⁵, Kenzie Potter⁵, Kaitlyn Ohrtman⁵, Udi Ghitza⁶, Edward Nunes¹, Adam Bisaga⁷

¹Columbia University and New York State Psychiatric Institute, ²Columbia University and NYSPI, ³Columbia University and New York State Psychiatric Institute, ⁴Emmes Data and Statistics Center, NIDA CTN, ⁵NYSPI, ⁶National Institute of Drug Abuse, National Institutes of Health, ⁷Columbia University Division on Substance Use Disorders

M119. Predictors of Treatment Drop-Out and Termination Among Those With Opioid Use Disorder

Nicholas Weaver¹

¹The University of Texas At Austin

M120. Examining Predictors of the Routes of Administration of Opioids Among Adolescents in the United States

Enya Vroom¹, Skye Bristol², Micah Johnson²

¹University of Florida, ²University of South Florida

M121. Opioid-Related Poisoning in Kentucky Medicaid Beneficiaries Receiving Buprenorphine, Methadone or Naltrexone

Lindsey Hammerslag¹, Svetla Slavova², Feitong Lei², Emily Slade², Michelle Lofwall³, Laura Fanucchi³, Heather Bush², Patricia Freeman⁴, Sharon Walsh³, Jeffery Talbert³

¹University of Kentucky, ²University of Kentucky, College of Public Health, ³University of Kentucky, College of Medicine, ⁴University of Kentucky, College of Pharmacy

M122. Patient Reported Insights to Guide Development and Implementation of Sleep Interventions in the Opioid Use Disorder Treatment Setting

Michelle Eglovitch¹, Anna Beth Parlier-Ahmad¹, Sajanee Chithranjan¹, Saisriya Kolli¹, Catherine Legge¹, Stephanie Violante¹, Joseph Dzierzewski², Caitlin Martin¹

¹Virginia Commonwealth University, ²National Sleep Foundation

M123. Neural and Longitudinal Mechanisms Mediating Drug-Related Optimism Bias in Opioid Addiction

Emmanuel Alvarez¹, Maëlle Gueguen², Syed Sawar³, Julia Kong², Sahar Hafezi², Darla Bonagura⁴, Anna Konova²

¹Rutgers Robert Wood Johnson Medical School, ²Department of Psychiatry, UBHC, and Brain Health Institute, Rutgers University – New Brunswick, ³Rutgers University Center for Cognitive Science, Rutgers University–New Brunswick, NJ, ⁴Department of Psychology, University of Tennessee – Knoxville

M124. Associations Between Suvorexant and Biological and Self-Reported Stress in a Randomized Trial in Persons With Opioid Use Disorder

Greer McKendrick¹, Charlotte Clapham², Vadim Zipunnikov², Patrick Finan², Kelly Dunn¹, Andrew Huhn¹

¹Johns Hopkins School of Medicine, ²Johns Hopkins University

M125. Cannabis Use Disorder Treatment Preferences: A Pilot Survey in People who Currently Use Cannabis

Joshua Lile¹, David Cox¹, Marcel O. Bonn-Miller Bonn-Miller², Thomas Shellenberg¹, William Stoops¹, Justin Strickland³

¹University of Kentucky, College of Medicine, ²Canopy Growth Corporation, ³Johns Hopkins University School of Medicine

M126. Safety and Subjective Reinforcing Effects of Lorcaserin on Oxycodone in Adults With Opioid Use Disorder

Taylor Ochalek¹, Kathryn Polak¹, Lori Keyser-Marcus¹, Kathryn Cunningham², Caitlin Martin¹, F. Gerard Moeller¹

¹Virginia Commonwealth University, ²University of Texas Medical Branch

M127. Preliminary Effectiveness of Remote Opioid Overdose and Naloxone Administration Training and Impact of Naloxone Possession on Opioid Use

Karen Cropsey¹, Michelle Sisson¹, Andres Azuero¹, Keith Chichester¹, Michael Businelle², Richard Shelton¹, Matthew Carpenter³

¹University of Alabama at Birmingham, ²University of Oklahoma Health Sciences Center, ³Medical University of South Carolina

M128. Impact of an Addiction Consultation Team on the Initiation of Medication for Opioid Use Disorder and Readmissions for Patients With Substance Use Disorders

Adrianne Kehne¹, Colin Macleod², Michelle Brauner², Jillian DiClemente², Emily McCall², Yolanda Preston², Nathan Menke², Pooja Lagisetty²

¹University of Michigan/VA Ann Arbor Healthcare System, ²University of Michigan

M129. Reasons for Past Abortions Among Women in Treatment for Opioid Use Disorder

Roxanne Harfmann¹, Sarah Heil¹, Lindsay Cannon², Yasamin Kusunoki³, Vanessa Dalton³, Lauren MacAfee¹

¹University of Vermont, ²University of Wisconsin, ³University of Michigan

M130. Successful Integration of Care for Patients With Serious Injection-Related Infections and Substance Use Disorder in a Tertiary Care Hospital.

Clinton Cooper¹, Judith Feinberg²

¹West Virginia Univ. School of Medicine, ²West Virginia University School of Medicine

M131. Connection, Navigation, Engagement in Care and Treatment (ConNECT) for Opioid Use Disorder

Alia Al-Tayyib¹, Ryan Loh¹, Joshua Blum¹, Deborah Rinehart¹, Scott Simpson¹, Sarah Rowan¹, Jason Haukoos¹

¹Denver Health and Hospital Authority

M132. Depression Profiles and Hepatitis C Treatment Outcomes Among Persons who Inject Drugs: The Hero Study
Snehal Lopes¹, Irene Pericot-Valverde¹, Judith Feinberg², Shadi Nahvi³, Paula Lum⁴, Lynn Taylor⁵, Judith Tsui⁶, Shruti H Mehta⁷, Brianna Norton⁸, Arthur Kim⁹, Julia Arnsten⁸, James Thrasher¹⁰, Kimberly Page¹¹, Moonseong Heo¹, Alain Litwin¹²

¹Clemson University, ²West Virginia University School of Medicine, ³Montefiore Medical Center, ⁴University of California San Francisco, ⁵University of Rhode Island, ⁶Department of Medicine, Division of General Internal Medicine, University of Washington, ⁷Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, ⁸Montefiore Medical Center, ⁹Massachusetts General Hospital, ¹⁰University of South Carolina, ¹¹University of New Mexico, ¹²University of South Carolina School of Medicine

M133. Iron Depositions in Prefrontal Cortex Influences the Effectiveness of Cortical Paired Associative Stimulation in Heroin-Dependent Patients: A Randomized Sham-Controlled Study

Tianzhen Chen¹, Haoye Tan², Hang Su¹, Haifeng Jiang¹, Min Zhao³

¹Shanghai Mental Health Center, ²Heidelberg University, ³Shanghai Jiao Tong University School of Medicine

M134. A Novel 3 mg Naloxone Nasal Spray for the Over-the-Counter Market

Judy Ashworth¹, Vicki G Davis², Richard Mannion², Michael Hufford³

¹Pinney Associates, Inc., ²Harm Reduction Therapeutics, Inc., ³Harm Reduction Therapeutics

M135. Counselor Terminological Preferences for “Craving,” “Euphoria,” and “Withdrawal” Among Patients Receiving Methadone Treatment

Marina Gaeta Gazzola¹, Mark Beitel², Kendall Buck³, Katharine Cammack³, Gul Saeed⁴, Kathryn Eggert⁵, Teresa Roehrich⁵, Lynn Madden⁶, Declan Barry⁷

¹NYU Langone Medical Center/NYC Health and Hospitals Bellevue Hospital Center, ²Yale University, APT Foundation, ³The University of the South, ⁴APT Foundation, Inc., Yale University School of Medicine, ⁵APT Foundation, Inc., ⁶APT Foundation, ⁷Yale University School of Medicine

M136. Psychosocial and Drug Use Characteristics in Persons With Opioid Use Disorder and Chronic Pain

Kaylin Sweeney¹, Ramzi W. Nahhas², Sydney Silverstein³, Chung Jung Mun⁴, Raminta Daniulaityte¹

¹Arizona State University, ²Wright State University, ³Boonshoft School of Medicine Wright State University, ⁴Johns Hopkins Bayview Medical Center

M137. Substance Use Stigma and Abstinence Self-Efficacy Among Justice-Involved Women Who Use Opioids

Matt Webster¹, Martha Tillson¹, Michele Staton²

¹University of Kentucky, ²University of Kentucky, College of Medicine

M138. Neighborhood Racial and Ethnic Segregation is Associated With Opioid Deaths, With or Without Access to Facilities Offering Affordable Medication for Opioid Use Disorder

Michael Williams¹, Justin Manjourides¹, Danielle Haley¹

¹Northeastern University

M139. Non-Fatal Drug Overdose Among Persons who Inject Drugs During First Two Years of the COVID-19 Pandemic in New York City: Prevalence, Risk

Jonathan Feelemyer¹, Chenziheng (Allen) Weng², Courtney McKnight², Don Des Jarlais³

¹New York University School of Medicine, ²New York University College of Global Public Health, ³New York University School of Global Public Health

M140. Trends in Use of Prescribed “Safer Supply” Opioids Among People Living with HIV and Opioid Use Disorder in Vancouver, Canada

Neasa Coll¹, Hudson Reddon², M-J Milloy³

¹University of British Columbia Faculty of Medicine, ²BCCSU, ³BCCSU, University of British Columbia

M141. EMS Calls for Naloxone Administration and Implementation of EMS-Specific Overdose Prevention Strategies Across Maryland

Catherine Tomko¹, Masoumeh Amin-Esmaili¹, Ryoko Susukida¹, Taylor Parnham¹, Ju Nyeong Park², Renee Johnson¹

¹Johns Hopkins Bloomberg School of Public Health, ²Alpert Medical School, Brown University

M142. Opioid Use Disorder Treatment in Medicaid Managed Care Plans

Amanda Myers¹, Christina Andrews², Dominic Hodgkin³, Constance Horgan³, Cindy Thomas¹, Maureen Stewart¹, Sharon Reif⁴

¹Brandeis University, ²University of South Carolina, ³Brandeis University, Heller School for Social Policy and Management, ⁴Brandeis University, Heller School for Social Policy and Management, Institute for Behavioral Health

M143. Characteristics Associated With Opioid Use Disorder Care Post-COVID-19 Public Health Emergency: A Cohort Study

Steffani Bailey¹, Jennifer Lucas¹, Shuling Liu¹, Miguel Marino¹, Rebecca Cantone¹, Brian Garvey¹, Laurel Hallock-Koppelman¹

¹Oregon Health and Science University

M144. Challenges Linking Clients to Medication for Opioid Use Disorder (MOUD) From Emergency Department (ED) Settings

Molly Gallivan¹, Anna Ross², Amanda Fallin-Bennett³, Christopher Cook¹, Michelle Lofwall⁴, Devin Oller⁴, John Lauckner¹, Shelley Elswick², Sharon Walsh³, Laura Fanucchi⁴

¹University of Kentucky, Substance Use Priority Research Area, ²Voices of Hope, ³University of Kentucky, ⁴University of Kentucky, College of Medicine

M145. Assessing Provider Readiness to Implement Pre-Exposure Prophylaxis for HIV Prevention and Medications for Opioid Use Disorder Among People who Inject Drugs

Eleanor Pickering¹, Minhee Sung², Genie Bailey³, Marianne Buchelli⁴, Daniel Davidson¹, Mark Jenkins⁵, Betsey John⁶, Jennifer Kolakowski⁷, Leah Maier⁸, Elizabeth Porter⁹, Oscar Rojas Perez¹⁰, Carla Rash¹¹, E. Jennifer Edelman⁹, Adam Viera¹

¹Yale School of Public Health, ²Yale University School of Medicine and VACHS, ³Stanley Street Treatment and Resources, Inc., ⁴Connecticut Department of Public Health, ⁵Connecticut Harm Reduction Alliance, ⁶Massachusetts Department of Public Health, ⁷Recovery Network of Programs, Inc., ⁸Apex Community Care, ⁹Yale University School of Medicine, ¹⁰Yale School of Medicine, ¹¹UConn School of Medicine

M146. Effectiveness of Family Intervention Addressing Expressed Emotions in Recipients of Opioid Substitution Therapy: A Randomised Controlled Study

Vasudha Singh¹, Gauri Kaloia¹, Atul Ambekar¹, Ravindra Rao², Ashwani Mishra¹

¹National Drug Dependence Treatment Centre, ²National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi

M147. Assessing the Impact of Medical Expenditure Supplements Program on the Enrolling and Retention of Patients Attending Methadone Maintenance Treatment Clinics in Taiwan: An Interrupted Time Series Analysis

Yu-Chu Chung¹, Yu-Chi Tung², Sheng-Chang Wang¹, Wei J. Chen¹

¹Center for Neuropsychiatric Research, National Health Research Institutes, ²Institute of Health Policy and Management, National Taiwan University

M148. State Licensure Policy as an Innovative Tool for Mainstreaming Medications for Opioid Use Disorder

Alene Kennedy-Hendricks¹, Minna Song¹, Alex McCourt¹, Matthew Eisenberg¹, Brendan Saloner¹

¹Johns Hopkins Bloomberg School of Public Health

M149. Attitudes and Beliefs About Vermont's 2021 Buprenorphine Decriminalization Law Among Residents who Use Illicit Opioids

Kenneth Feder¹, Samantha Harris¹, Lauren Byrne¹, Samantha Miller¹, Shereen Sodder¹, Vanessa Berman², Amy Livingston², Jessica Edwards², Shane Hartman², Olivia Sugarman², Hridika Shah¹, Justin Xu¹, Jewyl Raikes¹, Sabrina Gattine¹, Brendan Saloner¹

¹Johns Hopkins Bloomberg School of Public Health, ²Pacific Institute for Research and Evaluation

M150. Self-Identified Stage in Recovery and Substance Use Behaviors Among Pregnant and Postpartum Women and People With Opioid Use Disorder

Patricia Cavazos¹, Xiao Li², Hannah Szlyk², Anna Constantino-Petit², Erin Kasson³, Devin Banks⁴

¹Washington University St. Louis, ²Washington University School of Medicine, Department of Psychiatry,

³Washington University School of Medicine Department of Psychiatry, ⁴University of Missouri--St. Louis

M151. Life Still Exists: Describing the HIV Risk Environment for Women who Inject Drugs-Living With HIV in Kenya

Myla Lyons¹, John Saucedo², Brandon L. Guthrie³, Loice Mbogo⁴, Betsy Sambai⁵, Jane M. Simoni⁶, Aliza Monroe-Wise⁷, David Bukusi⁸, William Sinkele⁹, Esther Gitau⁹, Helgar Musyoki¹⁰, Rose Bosire¹¹, Joshua Herbeck¹², Carey Farquhar¹³, Natasha Ludwig Barron¹⁴

¹University of Michigan/VA Ann Arbor Healthcare System, ²Department of Medicine, Division of Prevention Science, University of California, San Francisco, ³Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA; Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA, ⁴Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA; University of Washington Global Assistance Program-Kenya, Nairobi, Kenya, ⁵University of Washington Global Assistance Program-Kenya, Nairobi, Kenya, ⁶Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA; Department of Psychology, University of Washington, Seattle, WA, USA; Department of Gender, Women and Sexuality Studies, University of Washington, Seattle, WA, USA, ⁷Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA, ⁸VCT and HIV Care, Kenyatta National Hospital, Nairobi, Kenya, ⁹Support for Addictions Prevention and Treatment in Africa (SAPTA), Nairobi, Kenya, ¹⁰National AIDS and Sexually Transmitted Infection Control Programme (NASCOP), Kenyatta Ministry of Health, Nairobi, Kenya, ¹¹Centre for Public Health Research, Kenya Medical Research Institute, Nairobi, Kenya, ¹²Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA, ¹³Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA; Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA, ¹⁴Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA

M152. Transgenerational Effects of Parental Fentanyl Dependence on Sleep and Cognition During Adolescence

Marissa Jones¹, Brooke Schmeichel¹

¹East Tennessee State University, James H. Quillen College of Medicine

M153. Discriminative Stimulus and Antinociceptive Effects of Six Novel Fentanyl Analogs

Michael Gatch¹, Jeanne Priddy¹, Ritu Shetty¹

¹University of North Texas Health Science Center

M154. Abstinence Following Paternal Morphine Exposure Mitigates Increased Morphine Reinforcing Efficacy in Offspring

Dana Zeid¹, Andre B. Toussaint¹, Mathieu Wimmer¹

¹Temple University

M155. Effects of Opioids on the Synaptic Density in Rodents: A Systematic Review and Meta-Analysis

Henrique Oliva¹, Tiago Paiva Prudente², Marc Potenza¹, Gustavo Angarita¹

¹Yale University School of Medicine, ²Universidade Federal de Goias

M156. Buprenorphine Decreases Fentanyl Vapor Self-Administration More Effectively in Opioid Dependent Rats

Emma Frye¹, Lyndsay Hastings¹, Renata Marchette¹, Caroline Smith¹, Brendan Tunstall², Janaina Vendruscolo¹, George Koob¹, Leandro Vendruscolo¹

¹National Institute on Drug Abuse, Intramural Research Program, ²University of Tennessee Health Science Center - Memphis

M157. The Creation of a Web-Based, Interactive, Cost-Effectiveness Calculator for Bystander Naloxone Distribution Programs

Hannah Wang¹, Margaret Moore¹, Sierra Castedo de Martell¹, H. Shelton Brown, III¹

¹UTHealth School of Public Health

M158. The Growth Hormone Secretagogue Receptor Inverse Agonist/Antagonist PF5190457 Suppresses Fentanyl Intake and Seeking in Rats

Noelle Anastasio¹, Robert Fox¹, F. Gerard Moeller², Kathryn Cunningham¹

¹John Sealy School of Medicine University of Texas Medical Branch, ²Virginia Commonwealth University

M159. Opposing Genetic Influences on Opioid Overdose and Self-Administration in Rats

Ken Grasing¹, Alok De¹

¹Kansas City VA Medical Center

M160. The Impact of Heroin Self-Administration on CRF1 and CRF2 Expression Within the Nigrostriatal and Mesocorticolimbic Systems

Ewa Galaj¹, Eddy Barrera², Hayley Lenhard¹, Apoorva Vashisht², Zhi-Bing You³, Robert Rinaldi⁴

¹Colgate University, ²CUNY Graduate Center, ³NIDA IRP, ⁴Queens College

M161. Modulation of Estradiol Signaling in the Amygdala Impacts Heroin Extinction Memory Recall in a Sex-Specific Manner

Jordan Carter¹, Caitlyn Costa², Carmela Reichel²

¹Department of Neuroscience, Medical University of South Carolina, ²Medical University of South Carolina, Department of Neurosciences

M162. Phytochemical Composition of Fresh Kratom Leaves Collected in the Northern Region of Malaysia

Thiruventhan Karunakaran¹, Vicknasingam Kasinather¹, Marek Chawarski²

¹Center for Drug Research, Universiti Sains Malaysia, ²Yale School of Medicine

M163. Acceptability of Psychedelic Therapy Differs Among Social workers, Psychiatrists, and Psychologists in the United States

Stacey B. Armstrong¹, Adam Levin², Yitong Xin¹, Jordan Horan³, Jason Luoma⁴, Paul Nagib², Brian Pilecki⁴, Alan Davis¹

¹The Ohio State University, ²Ohio State University, College of Medicine, ³Independent Researcher, ⁴Portland Psychotherapy Clinic, Research, and Training Center

M164. Experimental Approaches to Screen for Efficacy of Novel Psychedelics

Sharon Smith¹, Jane Gosden¹, David Heal¹

¹DevelRx Ltd

M165. Physiological Effects of Psilocybin, Psilocetin, and DOI in Rats

Shelby McGriff¹, Grant Glatfelter¹, David Manke², Andrew Chadeayne³, Charles Schindler¹, Michael Baumann¹

¹NIDA, Intramural Research Program, ²University of Massachusetts Dartmouth, ³CaaMTech, Inc.

M166. Involvement of 5-HT_{2A} and 5-HT_{1A} Receptors in the Pharmacological Effects of 5-MeO-DMT Analogs in Male C57BL/6J Mice

Grant Glatfelter¹, Antonio Landavazo², Bruce Blough², Michael Baumann¹

¹NIDA, Intramural Research Program, ²RTI International

M167. Adverse Childhood Experiences, Substance Use, and Mental Health Conditions Among Men who Have Sex With Men

Lian-Yu Chen¹, Li-Yuan Chen², Yung-Hsiang Chen¹, Ming-Chyi Huang¹, Nai-Ying Ko³

¹Taipei City Hospital, ²Changhua Christian Children's Hospital, ³National Cheng Kung University

M168. Severity of Stimulant Use Disorder by Type of Stimulant

Ty Schepis¹, Kennedy S. Werner², Olivia Figueroa², Vita McCabe³, John Schulenberg⁴, Philip Veliz², Timothy Wilens⁵, Sean Esteban McCabe²

¹Texas State University, ²Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing, ³St. Joseph Mercy Hospital, ⁴University of Michigan, ⁵Massachusetts General Hospital

M169. Valid and Invalid Designs for Conducting Drug-Discrimination Experiments in Abuse Potential Evaluations

David Heal¹, Jane Gosden¹, Sharon Smith¹

¹DevelRx Ltd

TUESDAY, JUNE 20, 2023

POSTER SESSION 3

T1. Alcohol Use and Substance Use Treatment Engagement Among Patients With Alcohol-Associated Cirrhosis in Three Hospital-Based Hepatology Practices

Hannah Snyder¹, Derek Satre², Martha Shumway², Steven Batki³, Michael Ostacher⁴, D. Andrew Tompkins⁵, Alexander Monto⁵, Robert Wong⁴, Ramsey Cheung⁴, Priti Parekh⁶, William Hua⁷, Denissa Widiarto⁸, Seo Yoon Eli Oh⁸, Meimei Liao⁶, Mandana Khalili⁹

¹University of California, San Francisco Department of Family and Community Medicine, ²Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, ³UCSF and San Francisco VA Medical Center, ⁴Stanford University School of Medicine and Palo Alto VA Medical Center, ⁵University of California, San Francisco, School of Medicine, ⁶Palo Alto VA Medical Center, ⁷UCSF Weill Institute for Neurosciences, ⁸University of California, San Francisco, ⁹University of California San Francisco

T2. Recreational Cannabis Legislation and Binge Drinking in U.S. Adolescents and Adults between 2008-2019

Priscila Gonçalves¹, Emilie Bruzelius¹, Natalie Levy¹, Luis Segura¹, Ofir Livne¹, Sarah Gutkind¹, Anne Boustead², Deborah Hasin¹, Pia Mauro¹, Diana Silver³, James Macinko⁴, Silvia Martins¹

¹Columbia University, ²University of Arizona, ³New York University, ⁴University of California, Los Angeles

T3. Hepatitis C and HIV Among Substance Users in Mizoram, Northeast India

Lalchhanhima Ralte¹

¹Presbyterian Hospital

T4. Evaluation of a Functional Assessment Tool for Alcohol Use

Haily Traxler¹, Mark Rzeszutek¹, Sean Regnier¹, Mikhail Koffarnus¹

¹University of Kentucky, College of Medicine

T5. fMRI and Eye-Tracking During Pavlovian Conditioned Approach: Measuring Sign- And Goal-Tracking in Humans

Lora Cope¹, Ryan Klaus¹, Mary Soules¹, Ha Jung¹, Scott Peltier¹, Jonathan Morrow¹

¹University of Michigan

T6. Results From a Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study of Sunobinop in Subjects who are Experiencing Insomnia During Recovery From Alcohol Use Disorder

Nelson Sessler¹, Stephen Harris¹, Mingyan Zhou¹, Garth Whiteside¹, Ellie He¹, Valentine Pascale¹, Alessandra Cipriano¹, Steven Ripa¹, Russell Rosenberg²

¹Imbrium Therapeutics, ²Neurotrials Research

T7. Body Mass Index in Alcohol Withdrawal: Predictive or Protective?

Alice Ely¹, Krystal Hunter², Brian Schonewald², Matthew Salzman³

¹Cooper Medical School of Rowan University, ²Cooper University Health Care, ³Addiction Medicine, Cooper University Health Care

T8. Association of Baseline Fentanyl Use and Opioid Withdrawal Symptoms During Inpatient Buprenorphine Initiation in a Large Multisite Detoxification Trial

Matisyahu Shulman¹, Miranda Greiner², Mei-Chen Hu³, Onumara Opara⁴, Kenzie Potter⁵, Kaitlyn Ohrtman⁵, Edward Nunes², Adam Bisaga⁶

¹College of Physicians and Surgeons, Columbia University/NYSPI, ²Columbia University and New York State Psychiatric Institute, ³Columbia University and NYSP, ⁴NYSP/Columbia University, ⁵NYSP, ⁶Columbia University Division on Substance Use Disorders

T9. Auditing Measures of Harmful Alcohol Use in Transgender and Non-Binary Communities: A Systematic Review

Ana Chapa Motemayor¹

¹VCU Medical College

T10. Age of Onset of Cannabis Use Predicts Anxiety, Psychoticism, and Anger-Hostility Mental Health Symptoms in Severe Concurrent Disorder Inpatients

Karina Thiessen¹, Tannis Teale², Karling R. Luciani¹, Chris Schütz¹

¹University of British Columbia, ²University of British Columbia, Faculty of Medicine

T11. Correlates of Resilience in Transitional Age Youth Experiencing Homelessness

Colin Burke¹, Sylvia Lanni¹, Maura DiSalvo¹, Peter Ducharme², Timothy Wilens¹

¹Massachusetts General Hospital, ²Bridge Over Troubled Waters

T12. Characterizing Medical Cannabis Use Among Medical Users in Florida Using Cannabis for Sleep Reasons and Reporting Poor Sleep.

Juan G Perez-Carreno¹, Robert L Cook¹, Yan Wang¹, Krishna Vaddiparti¹, Ruba Sajdeya¹, Hannah J Fechtel¹, Catalina Lopez-Quintero¹

¹University of Florida

T13. Marijuana Use and Marijuana Use Disorder: Patterns of Prevalence by Service Status, 2004-2019

Andrew Derminassian¹, Matthew Nickel², Karl Alcover³

¹Keck School of Medicine, University of Southern California, ²College of Arts and Sciences, Gonzaga University, ³Uniformed Services University of the Health Sciences

T14. The Relationship Between High-Potency Cannabis Use and Health-Related Factors: A Systematic Review of Experimental and Observational Studies

Stephanie Lake¹, Conor Murray¹, Beau Kilmer², Ziva Cooper¹

¹University of California, Los Angeles, ²RAND Drug Policy Research Center

T15. Cannabis Use for Medical Symptoms: Patterns Over the First Year of Use

Jodi Gilman¹, Kevin Potter², Randi Schuster³, Anne Eden Evins¹, Bettina Hoepfner²

¹Massachusetts General Hospital-Psychiatry, ²Massachusetts General Hospital/Harvard Medical School,

³Harvard Medical School, Massachusetts General Hospital

T16. A Cohort Sequential Analysis of Developmental Changes in Cannabis Use Practices and Problematic Cannabis Use Among Young Adult Users From Age 18 to 22 in Los Angeles

Carolyn Wong¹, Omolola Odejimi², Bridgid Conn¹, Janna Ataiants³, Ekaterina Fedorova³, Meagan Suen², Alisha Osornio², Susie Choi², Stephen Lankenau³

¹Children's Hospital Los Angeles and University of Southern California, ²Children's Hospital Los Angeles,

³Drexel University Dornsife School of Public Health

T17. Sex Differences in the Prospective Association of Intra-Individual Reaction Time Variability in Stroop and Hazardous Cannabis Use at Six Months

'Elsie' Xu Yan¹, Margaret Bedillion¹, Eric Claus¹, Cynthia Huang-Pollock¹, Emily Ansell¹

¹Penn State University

T18. Is Drowsiness After Cannabis Use Predictive of Magnitude of Driving Impairment

Timothy Brown¹, Thomas Burt¹, Rose Schmitt¹, Gary Gaffney¹, Gary Milavetz¹

¹The University of Iowa

T19. Relationship Between Blood THC and Metabolite Concentrations and Rapidly Collected and Analyzed Breath Samples in Healthy Volunteers After Smoking Marijuana

Scott Lukas¹, Mia Brousseau¹, Samantha Kalmar¹, Jane McNeil¹, Gordana Vitaliano¹, Jake Golde², Joe Santos³, Arash Asiani², Ken Markoski²

¹McLean Hospital, Harvard Medical School, ²Vox Biomedical, ³DRAPER

T20. Factors Associated With Self-Reported Cannabis Use Problems Among People With HIV Screened in Primary Care

Maha Mian¹, Varada Sarovar², Tory Levine², Alexandra Lea², Amy Leibowitz², Mitchell Luu², Kelly Young-Wolff³, Michael J. Silverberg², Derek Satre³

¹University of California - San Francisco, Department of Psychiatry, ²Division of Research, Kaiser Permanente Northern California, Oakland CA, ³Division of Research, Kaiser Permanente Northern California, Oakland CA; University of California - San Francisco, Department of Psychiatry

T21. Post-Stress Late Positive Potential Prospectively Predicts Cannabis Use Disorder Severity in Cannabis Using Women

Thomas Preston¹, Richard Macatee¹

¹Auburn University

T22. Emerging Sex Differences in Current Tobacco and Marijuana Use Trends Among Members of a Community Engagement Program in Florida

Vijaya Seegulam¹, Catherine Striley¹, Linda Cottler¹

¹University of Florida

T23. Sex Differences in Cortical Thickness in Cannabis Use Disorder

Erin Martin¹, Laura Campbell¹, Kathryn Thorn¹, Gregory Sahlem², Aimee McRae-Clark¹, Andreana Benitez¹

¹Medical University of South Carolina, ²Stanford University

T24. Cannabis Use Effects on Reaction Time in Daily Versus Occasional Users

Alexis Krause¹, Samantha Bothwell², Julia Wrobel², Tim Brown³, Sarah Limbacher², Ashley Brooks-Russell²

¹University of Colorado Anschutz Medical Campus, Children's Hospital, ²University of Colorado Anschutz Medical Campus, ³University of Iowa

T25. A Prospective Investigation of Emergency Department Patients With Suspected Cannabinoid Hyperemesis Syndrome

Rachel Wightman¹, Jane Metrik², Timmy Lin³, Yu Li², Adina Badea⁴, Alexandra Collins², Francesca Beaudoin²

¹Rhode Island Hospital/Alpert Medical School of Brown University, ²Brown University School of Public Health, ³Brown Emergency Medicine, ⁴Rhode Island Hospital

T26. Alcohol First, Cannabis Last: Identification of an Especially Risky Use Pattern Among Individuals who Co-Use Alcohol and Cannabis

Hollis Karoly¹, Mark Prince¹, Bradley Conner¹

¹Colorado State University

T27. Positive Association Between Self-Reported Autonomic Symptoms and Hazardous Cannabis Use Scores in a Community-Based Sample of Adults

Larry Keen¹

¹Virginia State University

T28. Common Barriers to Risky Cannabis Use Reduction Among Adult FQHC Primary Care Patients in Los Angeles County

Quynh Vo¹, Amanda Sirisoma², Maria Vasquez², Cristina Batarse², Ishika Seth², Stephanie Sumstine³, Leticia Cazares¹, Melvin Rico¹, Dallas Swendeman³, Lillian Gelberg¹

¹University of California Los Angeles, Department of Family Medicine, ²University of California Los Angeles,

³University of California Los Angeles, Department of Psychiatry and Biobehavioral Sciences

T29. Puff Puff Pass: The Impact of Social Context on Momentary Subjective Cannabis Effects

Margaret Bedillion¹, Emily Ansell¹

¹Penn State University

T30. Prevalence and Correlates of Self-Reported Novel Psychoactive Substance Use Among Adults in 13 US Cities, 2021–2022: Results From National Drug Early Warning System (NDEWS) Surveillance

Nicole Fitzgerald¹, Nae Won¹, Anna Wang¹, Joseph Palamar², Melisa Creamer³, Catherine Striley¹, Linda Cottler¹

¹University of Florida, ²New York University School of Medicine, ³National Institute on Drug Abuse

T31. Towards the Understanding of Smoking Reduction in a Home Use Test Paradigm

Hui Cheng¹, Joshua Karelitz², Elizabeth Becker²

¹Altria Client Services, LLC, ²Altria Client Services

T32. Associations Between Cigarette Smoking, Weight Status, and Mortality Among U.S. Adults

Luis Mestre¹, Maria Parker²

¹Indiana University, ²Indiana University - Bloomington

T33. Investigating Sex Differences in the Relations Between Parent/Guardian Promotion of Tobacco Abstinence, and Tobacco Use in a Nationally Representative Sample of Black Adolescents

Wynta Alexander¹, Adriana Espinosa¹, Lesia M. Ruglass², Fiona N. Conway³, Christine Sheffer⁴

¹The Colin Powell School at The City College of New York, ²The City College of New York, CUNY, ³Steve Hicks School of Social Work at The University of Texas at Austin, ⁴Roswell Park Comprehensive Cancer Center

T34. Cigarette Smoking and Executive Function: Experimental Effects of Very-Low-Nicotine-Content Cigarettes

Brian Katz¹, William Middleton¹, Diann Gaalema¹, Jennifer Tidey², Stacey Sigmon¹, Sarah Heil¹, Dustin Lee³, Michael DeSarno¹, Stephen Higgins¹

¹University of Vermont, ²Brown University, ³Johns Hopkins University School of Medicine

T35. Modeling Common and Patient-Specific Resting-State Connectivity to Predict Craving and Smoking Cessation Treatment Response

Laura Murray¹, Blaise Frederick², Amy Janes³

¹McLean Hospital/Harvard Medical School, ²McLean Hospital, Harvard Medical School, ³National Institute on Drug Abuse

T36. Feasibility and Acceptability of an Ecological Momentary Intervention of Implementation Intentions Delivered by Text Message to Reduce Cigarette Smoking

Elizabeth Saunders¹, Jesse Boggis¹, Lisa Marsch¹, Nico Agosti¹, Shea Lemley¹

¹Geisel School of Medicine at Dartmouth

T37. Fine-Grained Patterns of Combusted Cigarette and E-Cigarette Use Among Dual Users Who Intend to Quit Smoking

Rhiannon Wiley¹, William Middleton¹, Shannon O'Connor¹, Joan Skelly¹, Stacey Sigmon¹, Elias Klemperer²

¹University of Vermont, ²University of Vermont College of Medicine

T38. Differential Reward Processing Across Adolescent Temperamental Profiles Associated With Increased Risk of Substance Use

Patricio Viera Perez¹, Sarah Hartmann¹, Timothy Hayes¹, Elisa Trucco¹, Matthew Sutherland¹

¹Department of Psychology, Florida International University, Miami, FL

T39. Study of Impulsiveness and Aggression in Patients With Opioid Dependence: Comparison With Healthy Controls

Rahul Mathur¹, Siddharth Sarkar², Muzaffar Ahmad Pandit³, Raka Jain⁴, Yatan Pal Singh Balhara²

¹MBBS, MD, ²National Drug Dependence Treatment Centre, AIIMS, New Delhi, India, ³All India Institute of Medical Sciences New Delhi, India, ⁴All India Institute of Medical Sciences

T40. Trauma-Related Shame Predicts Daily Non-Medical Prescription Opioid Use and Motives for Use Among Individuals with PTSD

Tanya Saraiya¹, Teresa Lopez-Castro², Alyssa Jones³, Caitlyn Hood⁴, Jessica Flores⁴, Christal Badour⁴

¹Rutgers University, ²The City University of New York, ³Ralph H. Johnson Veterans Affairs Medical Center, ⁴University of Kentucky

T41. Access to Medications for Opioid Use Disorders: A Multi-Site Comparison of Qualitative Evidence With Stakeholders

Augustine Kang¹, Anthony Surace¹, Lauren Perron², Jennifer Wood², John Fritsche¹, Alice Cates³, Lauren Brinkley-Rubenstein³, Rosemarie Martin¹

¹Brown University School of Public Health, ²Temple University, ³Duke University

T42. Treatment Setting Among Individuals With Opioid Use and Criminal Legal Involvement, Housing Instability, or Medicaid Insurance, 2015-2020

Riley Shearer¹, Benjamin Howell², Utsha Khatri³, Tyler Winkelman⁴

¹The University of Minnesota, ²Yale University School of Medicine, ³Icahn School of Medicine at Mount Sinai, ⁴Health, Homelessness, and Criminal Justice Lab, Hennepin Healthcare Research Institute

T43. Women and Medications for Opioid Use Disorder: Contributors to Treatment Success From the Perspectives of Women in Recovery, Women With Past Attempts in Drug Treatment, and Health and Criminal Justice Professionals

Emma Skogseth¹, Robert Schwartz², Eric Harrison¹, Kristina Brant³, D. Max Crowley¹, Abenaa Jones¹

¹Pennsylvania State University, ²Friends Research Institute, ³Department of Agricultural Economics, Society, and Education, Pennsylvania State University

T44. Geographic Variations in Fentanyl Positive Urine Drug Screens in the United States, 2021

Erin Winstanley¹, Brian Hendricks², Jane Liebschutz³, Cristina Murray-Krezan⁴, Jeremiah Bertz⁵, Yanping Liu⁶, Galen Switzer³, Sarah Kawasaki⁷

¹West Virginia University, Department of Behavioral Medicine and Psychiatry, ²West Virginia University, ³University of Pittsburgh, ⁴University of Pittsburgh School of Medicine, ⁵National Institute on Drug Abuse, Intramural Research Program, ⁶NIH, ⁷Penn State College of Medicine

T45. Changing Characteristics of HIV/AIDS Epidemic in Malaysia

Vicknasingam Kasinather¹, Ravi Ramadah², Darshan Singh¹, Weng-Tink Chooi¹, Norzarina Mohd Zaharim¹, Marek Chawarski³

¹Universiti Sains Malaysia, ²National Anti-Drugs Agency Malaysia, ³Yale School of Medicine

T46. A Longitudinal Analysis of Time in Buprenorphine Treatment States and Stratification by Hazardous Alcohol Use, Cocaine Use and Alcohol or Cocaine Use Disorders Among People with HIV

Jarratt Pytell¹, Anthony Fojo², Jeanne Keruly², LaQuinta Snow², Sean Falade-Nwulia², Richard Moore², Geetanjali Chander³, Catherine Lesko⁴

¹University of Colorado Denver School of Medicine; Department of General Internal Medicine, ²Johns Hopkins University School of Medicine, ³University of Washington Seattle, School of Medicine, ⁴Johns Hopkins Bloomberg School of Public Health

T47. Assessing the Add-On Impact of Accessibility Enhancement Program on the Alleviation of Participant Reduction in Methadone Maintenance Treatment Clinics in Taiwan: An Interrupted Time Series Analysis

Wei J. Chen¹, Yu-Chu Ella Chung², Yu-Chi Tung³, Sheng-Chang Wang¹

¹National Health Research Institutes, ²Center for Neuropsychiatric Research, National Health Research Institutes, Taiwan, ³Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan and Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan

T48. Naloxone Expansion is Not Associated With Increases in Adolescent Heroin Use and Injection Drug Use: Evidence From 44 U.S. States

Emilie Bruzelius¹, Magdalena Cerdá², Corey Davis³, Victoria Jent², Katherine Wheeler-Martin², Christine Mauro⁴, Stephen Crystal⁵, Katherine Keyes¹, Hillary Samples⁶, Deborah Hasin⁴, Silvia Martins⁴

¹Columbia University Mailman School of Public Health, ²New York University School of Medicine, ³Network for Public Health Law, ⁴Columbia University, ⁵Rutgers University, ⁶Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research

T49. Neighborhood and Individual Disparities in Community-Based Naloxone Access

Elizabeth Nesoff¹, Silvia Martins²

¹University of Pennsylvania Perelman School of Medicine, ²Columbia University

T50. Receipt of Prescribed Opioids and Benzodiazepines After Non-Fatal Overdose and Risk of Subsequent Overdose

Benjamin Howell¹, Anne Black², Hsiu-ju Lin³, Grau Laurretta⁴, Robert Heimer⁵, Kathryn Hawk⁶, Gail D'Onofrio¹, David Fiellin¹, William Becker⁵

¹Yale University School of Medicine, ²VA Connecticut Healthcare System, ³State of Connecticut, ⁴Yale School of Public Health, ⁵Yale University, ⁶Yale University School of Medicine, Department of Emergency Medicine

T51. Evaluating Changes in Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder Before and During the COVID-19 Pandemic

Anh Nguyen¹, Ingrid Binswanger², Komal Narwaney¹, Stanley Xu³, David McClure⁴, Deborah Rinehart⁵, Jason Glanz¹

¹Kaiser Permanente Colorado, ²Kaiser Permanente Colorado/Colorado Permanente Medical Group, ³Kaiser Permanente Southern California, ⁴Marshfield Clinic Research Institute, ⁵Denver Health and Hospital Authority

T52. Implementing a Patient-Centered, Rapid-Access Substance Use Treatment Program in Primary Care

Scott Jeanson¹, Alex R. Dopp², Christina Phillips³, Marion Cook¹, Laura Brown⁴, Miriam Komaromy⁵, Kimberly Page³, Katherine Watkins²

¹First Choice Community Healthcare, ²RAND Corporation, ³Department of Internal Medicine, University of New Mexico Health Sciences, ⁴University of New Mexico Health Sciences Center, ⁵Grayken Center for Addiction, Boston Medical Center

T53. Disparities in the Hepatitis C Virus Cascade of Care Among Reproductive Age Women With Opioid Use Disorder

Breanne Biondi¹, Benjamin Buzzee², Claudine Lavarin¹, Sara Lodi³, Rachel Epstein⁴

¹Boston University School of Public Health, ²Boston Medical Center, Section of Infectious Diseases, ³Boston University School of Public Health, Dept of Biostatistics, ⁴Boston University School of Medicine, Department of Medicine, Section of Infectious Diseases

T54. Prescribed Opioids and Neurocognitive Status Among Elderly American Indians: Data From the Strong Heart Study

Che Ross¹, Judith Tsui¹, Andrea C. Radick MPH¹, Jason Deen¹, Dedra Buchwald², Astrid Suchy-Dicey²

¹University of Washington School of Medicine, ²Washington State University

T55. Open Board

T56. Prospective Acceptability of Digital Phenotyping Among Pregnant and Parenting People With Opioid Use Disorder

Elizabeth Charron¹, Ashley White², Kristi Carlston², Walitta Abdullah³, Jacob Baylis², Stephanie Pierce¹, Adam Gordon⁴, Elizabeth Krans⁵, Marcela Smid⁶, Gerald Cochran⁷

¹University of Oklahoma Health Sciences Center, ²University of Utah School of Medicine, ³University of Pittsburgh School of Medicine, ⁴University of Utah SoM and VASLCHCS, ⁵University of Pittsburgh, ⁶University of Utah Health, ⁷University of Utah

T57. Toward a More Complete Comparative Epidemiology of Heroin Use: Female-Male Variations in Using Once and Only Once

Barrett Montgomery¹, Olga Vsevolozhskaya², James Anthony³

¹RTI International, ²University of Kentucky, ³Michigan State University

T58. Initiations of Safer Supply Hydromorphone Increased During the COVID-19 Pandemic in Ontario: An Interrupted Time-Series Analysis

Samantha Young¹, Tara Gomes², Gillian Kolla³, Daniel McCormack⁴, Zoë Dodd⁵, Janet Raboud⁶, Ahmed Bayoumi⁵

¹British Columbia Centre on Substance Use, ²Li Ka Shing Knowledge Institute, St. Michael's Hospital,

³University of Victoria, ⁴ICES, ⁵MAP Centre for Urban Health Solutions, ⁶University of Toronto

T59. Initial Validation and Characterization of a Measure to Assess Attitudes Toward Medications for Opioid Use Disorder for Outpatient Populations

Michael Bushey¹, Kurt Kroenke¹

¹Indiana University School of Medicine

T60. Opioid Agonist Treatment Modifications During COVID-19 Pandemic

Beth Sproule¹, Jessica Stovel¹, Julia Saragosa², Helen Huynh², Francesca Di Paola¹, Bruna Brands³, Maria Zhang¹

¹Centre for Addiction and Mental Health, ²University of Toronto, ³Health Canada

T61. Utilization of Medication for Opioid Use Disorder for Hospitalized Patients at 6 New York City Public Hospitals With an Addiction Consultation Service

Yasna Rostam Abadi¹, Carla King², Noa Appleton³, Medha Mazumdar³, Jasmine Fernando³, Adetayo Fawole³, Roopa Kalyanaraman Marcello⁴, Caroline Cooke⁴, Johanna Dolle⁴, Charles Barron⁴, Jennifer McNeely³

¹NYU School of Medicine, ²NYU Grossman School of Medicine - NYC Health + Hospitals, ³NYU Grossman School of Medicine, ⁴NYC Health + Hospitals

T62. An Emulated Trial of Buprenorphine-Naloxone Versus Extended-Release Naltrexone Following Medically Managed Opioid Withdrawal

Marc Larochelle¹, Shapei Yan², Paul Christine², Heather Hsu², Benjamin Bovell-Ammon², Radhika Puppala², Dana Bernson³, Jane Liebschutz⁴, Alexander Walley¹, Patricia Novo⁵, Joshua Lee⁶, John Rotrosen⁷, Sara Lodi⁸

¹Boston University School of Medicine, ²Boston Medical Center, ³Massachusetts Department of Public Health, ⁴University of Pittsburgh, ⁵New York University School of Medicine, ⁶New York University Grossman School of Medicine, ⁷Department of Psychiatry, NYU Langone School of Medicine, New York, NY, United States, ⁸Boston University School of Public Health

T63. Association of Prescribed Oral Stimulants on Cocaine Use Among Patients Enrolled in Opioid Agonist Treatment: A Retrospective Longitudinal Cohort Study

Mark Tatangelo¹, Farah Tahsin², Kristen Morin³, David Marsh³

¹ICES North, ²University of Toronto, ³Northern Ontario School of Medicine

T64. Patient Navigation Promotes Substance Use Disorder Treatment Retention Among Hospital Patients Experiencing Homelessness

Courtney Nordeck¹, Johannes Thrul², Christopher Welsh³, Shannon Mitchell¹, Robert Schwartz¹, Kevin O'Grady⁴, Jan Gryczynski¹

¹Friends Research Institute, ²Johns Hopkins Bloomberg School of Public Health, ³University of Maryland School of Medicine, ⁴University of Maryland, College Park

T65. Developing a Novel High-Fidelity Overdose Simulation Model

Laura Brandt¹, Gabriella Horton², Allen Yang³, Suky Martinez⁴, Samantha Chong⁴, Kellie Bryant⁵

¹City College of New York, ²Johns Hopkins University School of Medicine, ³Geisel School of Medicine at Dartmouth, ⁴Columbia University and New York State Psychiatric Institute, ⁵Columbia School of Nursing

T66. Impact of Cannabidiol on Reward- And Stress-Related Neurocognitive Processes Among Individuals with Opioid Use disorder: A Pilot, Double-Blind, Placebo-Controlled, Cross-Over Trial

Joji Suzuki¹, Sara Prostko¹, Veronica Szpak¹, Peter Chai², Primavera Spagnolo¹, Saeed Ahmed³, Roger Weiss⁴

¹Brigham and Women's Hospital, ²Brigham and Women's Hospital, Harvard Medical School, ³Rutland Regional Medical Center, ⁴McLean Hospital

T67. Preliminary Evidence of Heterogeneity in the Opioid Withdrawal Syndrome

Suky Martinez¹, Laura Brandt², Andrew Huhn³, Jermaine Jones¹, Kelly Dunn³

¹Columbia University Vagelos College of Physicians and Surgeons, ²City College of New York, ³Johns Hopkins University School of Medicine

T68. Clinical Profiles of Individuals With Primary Heroin and Primary Prescription Opioid Use

Sara Witcraft¹, Tanya Saraiya², Charli Kirby¹, Amber Jarnecke¹

¹Medical University of South Carolina, ²Rutgers University, Medical University of South Carolina

T69. Open Board

T70. Bystander Preference for Naloxone Products

Katherine Marks¹, Doug Oyler¹, Feitong Lei¹, Justin Strickland², Jody Jagers³, Monica Roberts¹, Chase Barnes⁴, Patricia Freeman¹

¹University of Kentucky, ²Johns Hopkins University School of Medicine, ³Kentucky Pharmacy Education and Research Foundation, ⁴Kentucky Department for Public Health

T71. Open Board

T72. Impact of Medication-Based Treatment on Healthcare Utilization Among Individuals With Opioid Use Disorder: A Secondary Analysis of the X:BOT Clinical Trial

Manesh Gopaldas¹, Kevin Wenzel², Aimee Campbell³, Ali Jalali⁴, Marc Fishman², John Rotrosen⁵, Edward Nunes⁶, Sean Murphy⁴

¹Columbia University, ²Mountain Manor Treatment Center/Maryland Treatment Centers, ³Columbia University Irving Medical Center and New York Psychiatric Institute, ⁴Weill Cornell Medical College, ⁵New York University School of Medicine, ⁶Columbia University and New York State Psychiatric Institute

T73. Application of the Multiphase Optimization Strategy (MOST) to Optimize HIV Prevention Targeting People on Medication for Opioid Use Disorder (MOUD) who Have Cognitive Dysfunction: A Study Protocol

Michael Copenhaver¹, Colleen Mistler¹, Roman Shrestha¹

¹University of Connecticut

T74. Patient Navigation for Pregnant Persons With Opioid Use Disorder: Results of a Multisite Pilot Study

Gerald Cochran¹, Marcela Smid², Elizabeth Krans³, Ziji Yu¹, Elizabeth Charron⁴, Akiko Okifuji¹, Adam Gordon⁵, Brad Lundahl¹, John Silipigni⁶, Benjamin Haaland⁷, Ralph Tarter³

¹University of Utah, ²University of Utah Health, ³University of Pittsburgh, ⁴University of Oklahoma HCS,

⁵University of Utah SoM and VASLCHCS, ⁶University of Pittsburgh School of Medicine, ⁷University of Utah School of Medicine

T75. Greater Ethnic Identity and Lower Perceived Stigmatization Relate to Lower Compulsive Craving Behaviors in Individuals in Recovery From Opioid Use Disorder

Chrysanthia Davis¹, Breanna McNaughton¹, Abigail Pleiman¹, Megan Posey², Rayus Kuplicki¹, Hun-Wen Yeh¹, Natosha Markham¹, Martin Paulus¹, Jennifer Stewart²

¹Laureate Institute for Brain Research, ²Laureate Institute for Brain Research and The University of Tulsa

T76. Development and Clinical Feasibility of an Abbreviated Addiction-Focused Phenotyping Battery Piloted in a Female OUD Sample Receiving Buprenorphine Treatment

Anna Parlier-Ahmad¹, Michelle Eglovitch¹, Catherine Legge¹, Lori Keyser-Marcus¹, James Bjork¹, Amanda Adams¹, Tanya Ramey², F. Gerard Moeller¹, Caitlin Martin¹

¹Virginia Commonwealth University, ²NIDA

T77. Open Board

T78. The Effect of Prolonged Exposure Therapy on Posttraumatic Stress Disorder Symptom Clusters in Individuals With Opioid Use Disorder

Jillian Giannini¹, Rebecca Cole¹, Gary Badger¹, Letizia Mosca¹, Stacey Sigmon¹, Kelly Peck¹

¹University of Vermont

T79. Engagement in OUD Treatment 6 Months After Community-Based Intervention

Cecile Denis¹, Peter Smith¹, Kyle Kampman¹, Jose Benitez², Karen Dugosh³, David Metzger⁴

¹University of Pennsylvania, ²Prevention Point Philadelphia, ³Public Health Management Corporation,

⁴University of Pennsylvania, Department of Psychiatry

T80. Outcomes of the Community-Based Medication-First Program for Opioid Use Disorder: A Multisite Hybrid Implementation Study

Caleb Banta-Green¹, Mandy Owens¹, Jason Williams¹, Anthony Floyd¹, Jeanne Sears¹, Wendy Williams-Gilbert¹, Susan Kingston¹

¹University of Washington

T81. Characterization of Peer Support Services for Substance Use Disorders in 11 U.S. Emergency Departments in 2020: Findings From a NIDA Clinical Trials Network Study Site Selection Process

Angela Moreland¹, Lindsey Jennings¹, Laura Lander², Tricia Lawdahl³, Erin McClure¹, Jenna McCauley¹, Louise Haynes¹, Tim Matheson⁴, Richard Jones⁵, Thomas Robey⁶, Sarah Kawasaki⁷, Phillip Moschella⁸, Amer Raheemullah⁹, Suzette Miller¹⁰, Gina Gregovich¹¹, Deborah Waltman¹², Kathleen Brady¹, Kelly Barth¹

¹Medical University of South Carolina, ²West Virginia University Rockefeller Neurosciences Institute,

³FAVOR Upstate, ⁴San Francisco Department of Public Health, ⁵Heritage Health Solutions, ⁶Washington

State University, ⁷Penn State College of Medicine, ⁸Prisma Health, ⁹Stanford Health Care, ¹⁰Mercy Health,

¹¹University of Utah, ¹²Deaconess Hospital

T82. Buprenorphine Versus Methadone for the Treatment of Opioid Dependence: A Systematic Review and Meta-Analysis of Randomised and Observational Studies

Louisa Degenhardt¹, Brodie Clark², Georgina Macpherson², Oscar Leppan², Suzanne Nielsen³, Emma Zahra², Briony Larance⁴, Jo Kimber², Daniel Martino-Burke², Matthew Hickman⁵, Michael Farrell¹

¹National Drug and Alcohol Research Centre, ²National Drug and Alcohol Research Centre, UNSW Sydney,

³Monash University, ⁴University of Wollongong, ⁵University of Bristol

T83. Effects of Intervention on Methamphetamine Use and Mental Health Outcomes Among Patients on Methadone who Use Methamphetamine in Vietnam

Diep Bich Nguyen¹, Trang Thu Nguyen¹, Thuy Thi Thanh Dinh¹, Huy Duc Do¹, Van Thi Hai Hoang¹, Vi Thi Tuong Vu², Truc Thanh Thai², Dung Van Do², Michael Li³, Steven Shoptaw³, Giang Minh Le¹

¹Hanoi Medical University, ²Hochiminh City University of Medicine and Pharmacology, ³University of California, Los Angeles

T84. Effects of Co-morbid Health Conditions on Health-Related Quality of Life Among Recovery Residents With an Opioid Use Disorder in Texas

Elizabeth Obekpa¹, Sheryl McCurdy², David Adzrago³, Kathryn R. Gallardo³, J. Michael Wilkerson³

¹The University of Texas Health Science Center At Houston, ²University of Texas Health Science Center, ³The University of Texas Health Science Center at Houston

T85. Aspects of Interorganizational Collaboration in Linking Justice-Involved Persons With Opioid Use Disorder Treatment: A Qualitative Exploration of the Community Supervision and Treatment Provider Relationship

Lauren Perron¹, Gerald Stahler¹, Jennifer Wood¹, Steven Belenko¹

¹Temple University

T86. Effects of Chronic Naltrexone Treatment on Relapse-Related Behavior and Neural Responses to Fentanyl in Awake Squirrel Monkeys

Sarah Withey¹, Harshawardhan Deshpande², Lei Cao³, Jack Bergman⁴, Stephen Kohut¹

¹McLean Hospital, Harvard Medical School, ²Harvard Medical School McLean Hospital, ³McLean Hospital,

⁴McLean Hospital / Harvard Med School

T87. Long-Term Relationship Between Opioid Use and Change in HIV Disease Severity: A Prospective Cohort Study

Fiona Bhondoeckhan¹, Coraline Danieli², Michal Abrahamowicz², Brandon D.L. Marshall¹, M-J Milloy³

¹Brown University School of Public Health, ²McGill University Health Centre, ³University of British Columbia

T88. Harm Reduction in the Field: First Responders' Perceptions of Opioid Overdose Interventions

Callan Fockele¹, Tessa Frohe², Owen McBride¹, David Perlmutter³, Brenda Goh³, Will Williams⁴, Courteney Wettemann⁴, Nathan Holland⁴, Jenna van Draanen⁵

¹University of Washington Department of Emergency Medicine, ²University of Washington Department of Psychiatry and Behavioral Sciences, ³University of Washington Department of Health Systems and Population Health, ⁴Research with Expert Advisors on Drug Use (READU), ⁵University of Washington Department of Health Systems and Population Health and Department of Child, Family, and Population Health Nursing

T89. Take-Home Methadone Research From 2020 Through 2022: A Narrative Review

Javier Ponce Terashima¹, Kim Hoffman², Ximena Levander², Dennis McCarty²

¹Yale University School of Medicine Department of Psychiatry, ²Oregon Health and Science University

T90. Impact of an Opioid Use Disorder Treatment Implementation Intervention Among Patients With and Without Co-Occurring Substance Use Disorders in the Veterans Health Administration

Madeline Frost¹, Carol Malte², Eric Hawkins², Joseph Glass³, Kevin Hallgren⁴, Emily Williams⁵

¹VA Puget Sound Health Services Research and Development, ²Center of Excellence in Substance Addiction Treatment and Education, Veterans Affairs Puget Sound Health Care System, ³Kaiser Permanente Washington Health Research Institute, ⁴University of Washington School of Medicine, Department of Psychiatry and Behavioral Sciences, ⁵University of Washington School of Public Health, Department of Health Systems and Population Health

T91. Justice Community Opioid Innovations Network Linkage Facilitation

Lynda Stein¹, Linkage Facilitation Group¹

¹University of Rhode Island

T92. COVID-19 Vaccination and HIV Transmission Among Persons who Inject Drugs During the First Two Years of the COVID-19 Pandemic in New York City

Don Des Jarlais¹, Chenziheng (Allen) Weng², Jonathan Feelemyer³, Courtney McKnight²

¹New York University School of Global Public Health, ²New York University College of Global Public Health,

³New York University School of Medicine

T93. Readiness to Implement Contingency Management to Promote PrEP Initiation and Adherence Among People who Inject Drugs

Adam Viera¹, Eleanor Pickering¹, Minhee Sung², Genie Bailey³, Marianne Buchelli⁴, Daniel Davidson¹, Mark Jenkins⁵, Betsey John⁶, Jennifer Kolakowski⁷, Leah Maier⁸, Elizabeth Porter⁹, Oscar Rojas Perez¹⁰, E. Jennifer Edelman⁹, Carla Rash¹¹

¹Yale School of Public Health, ²Yale University School of Medicine and VACHS, ³Stanley Street Treatment and Resources, Inc., ⁴Connecticut Department of Public Health, ⁵Connecticut Harm Reduction Alliance, ⁶Massachusetts Department of Public Health, ⁷Recovery Network of Programs, Inc., ⁸Apex Community Care, ⁹Yale University School of Medicine, ¹⁰Yale School of Medicine, ¹¹UConn School of Medicine

T94. A Summary of Opioid Recovery Funds: Settlements Between Pharmaceutical Companies and Governments Regarding Their Role in the Opioid Epidemic

Jermaine Jones¹, Sara Calvin², Nathan Driskill³, Holly Hagle³, Kerri Hayes³, Sazid Khan², Michael Knabel³, Kiersten Johnson², Brent Moore⁴, Zoey Logan³, Zuleyma Serpas³, Shelby Webb³, Camara Wooten², Frances Levin¹, Kathryn Cates-Wessel³

¹Columbia University Irving Medical Center, ²RTI International, ³Opioid Response Network, American Academy of Addiction Psychiatry, ⁴Yale University School of Medicine

T95. A Time Series Analysis of Nonfatal and Fatal Drug Overdose Outcomes for the Surveillance of Drug Overdose Outbreaks

Thomas Patton¹, Christos Lazarou², Sharon Trillo-Park¹, Steffanie Strathdee¹, Annick Borquez¹, Annick Borquez³

¹University of California, San Diego, ²University of York, ³University of California San Diego

T96. Changes in Opioid Agonist Treatment Initiation Following Voluntary and Mandatory Prescription Drug Monitoring Program Implementation: A Time Series Analysis

Louisa Picco¹, Ting Xia¹, Simon Bell¹, Dan Lubman², Rachelle Buchbinder¹, Suzanne Nielsen¹

¹Monash University, ²Turning Point

T97. Policies Relevant to the Healing Communities Study Kentucky Site Implementation

Anita Silwal¹, Jeffery Talbert², Christopher Cook³, Daniel R. Harris⁴, Daniel T. Redmond⁵, Molly Gallivan³, Drew Speer⁶, Patricia R. Freeman⁷, Katherine R. Marks⁸, Laura Fanucchi⁹, Sharon Walsh¹⁰, Michelle Lofwall¹⁰

¹University of Kentucky, College of Communication and Information, Substance Use Priority Research Area,

²University of Kentucky, Division of Biomedical Informatics, College of Medicine, Institute for Biomedical Informatics, Center for Clinical and Translational Sciences, ³University of Kentucky, Substance Use Priority Research Area, ⁴University of Kentucky, Center for Clinical and Translational Sciences, Department of Pharmacy Practice and Science, College of Pharmacy, ⁵University of Kentucky, Institute for Biomedical Informatics, ⁶University of Kentucky, Substance Use Priority Research Area (SUPRA), ⁷University of Kentucky, Department of Pharmacy Practice and Science, College of Pharmacy, ⁸University of Kentucky, Department of Behavioral Science, ⁹University of Kentucky, Department of Internal Medicine, Center on Drug and Alcohol Research, ¹⁰University of Kentucky, Department of Behavioral Science, College of Medicine, Center on Drug and Alcohol Research

T98. Open Board

T99. Perceptions of Syndromic Surveillance to Prevent Overdose in Lowell, Massachusetts: Qualitative Perspectives of Community Leaders and People who Use Drugs

Kevin Cyr¹, Shikhar Shrestha¹, Thomas Stopka¹, Jennifer Pustz¹

¹Tufts University School of Medicine

T100. Preparing Recovery Coaches to Discuss Medication for Opioid Use Disorder (MOUD): An Interactive Training and Competency

Trevor Moffitt¹, Amanda Fallin-Bennett², Anna Ross³, Molly Gallivan⁴, Jeremy Byard⁵, Jimmy Chadwell³, Christopher Cook⁴, John Lauckner⁴, Laura Fanucchi⁶, Devin Oller⁶, Sharon Walsh¹, Michelle Lofwall⁶

¹University of Kentucky, ²University of Kentucky, Voices of Hope, ³Voices of Hope, ⁴University of Kentucky, Substance Use Priority Research Area, ⁵Louisville Recovery Community Connection, ⁶University of Kentucky, College of Medicine

T101. The Primary Care Opioid Use Disorders Treatment (PROUD) Trial

Paige Wartko¹, Abigail Matthews², Jennifer Bobb³, Denise Boudreau⁴, Jennifer McCormack⁵, David Qiu⁶, Onchee Yu¹, Noorie Hyun¹, Amy Lee¹, Cynthia Campbell⁷, Andrew Saxon⁸, David Liu⁹, Andrea Altschuler⁷, Jeffrey Samet¹⁰, Angela Stotts¹¹, Jordan Braciszewski¹², Mark Murphy¹³, Julia Arnsten¹⁴, Viviana Horigian¹⁵, Jose Szapocznik¹⁶, Joseph Glass¹⁷, Ryan Caldeiro¹⁸, Rebecca Phillips³, Mary Shea³, Katharine Bradley³

¹Kaiser Permanente Health Research Institute, ²The Emmes Company, ³Kaiser Permanente Washington Health Research Institute, ⁴Genetech, ⁵The Emmes Company, LLC, ⁶Wharton School, University of Pennsylvania, ⁷Kaiser Permanente Northern California, ⁸Veterans Affairs Puget Sound Healthcare System, ⁹National Institute on Drug Abuse, National Institutes of Health, ¹⁰Boston University School of Medicine, ¹¹University of Texas Health Science Center, ¹²Henry Ford Health System, ¹³MultiCare Institute for Research and Innovation, ¹⁴Montefiore Medical Center, ¹⁵Miller School of Medicine, University of Miami, ¹⁶University of Miami, ¹⁷Kaiser Permanente Washington Health Research Institute, ¹⁸Kaiser Permanente Washington

T102. Understanding the Needs of Women in Treatment for Opioid Use Disorder to Inform the Development of a Gender-Specific Digital Intervention

Dawn Sugarman¹, Emily A. Levine², Callie Wang³, Lisa Marsch⁴, Roger Weiss¹, Shelly Greenfield¹

¹McLean Hospital - Harvard Medical School, ²McLean Hospital, ³University of Central Florida, ⁴Geisel School of Medicine at Dartmouth

T103. Implementation of Virtual Contingency Management Within a Statewide Opioid Treatment Program Provider Network in Texas

Carma Deem Bolton¹, Michele Green², Tara Karns-Wright¹, Jennifer Potter³

¹The University of Texas Health Science Center At San Antonio, ²WEconnect Health Management, ³University of Texas Health San Antonio

T104. Facilitators of and Barriers to Buprenorphine-Naloxone Initiation for People With Opioid Use Disorder in the Emergency Department: A Scoping Review

Nikki Bozinoff¹, Erin Grennell², Charlene Soobiah³, Christine Bucago⁴, Terri Rodak⁵, Michelle Klaiman⁶, Brittany Poynter⁴, Dominick Shelton⁷, Elizabeth Schoenfeld⁸, Csilla Kalocsai⁹

¹Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, ²Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, ³Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada, ⁴Department of Emergency Medicine, Centre for Addiction and Mental Health, Toronto, Ontario, Canada, ⁵CAMH Library, Department of Education, Centre for Addiction and Mental Health, Toronto, Ontario, Canada, ⁶Department of Emergency Medicine, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada, ⁷Department of Emergency Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, ⁸Department of Emergency Medicine, University of Massachusetts Medical School - Baystate Campus, Springfield, Massachusetts, USA, ⁹Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

T105. Prescription Opioid Dose Reductions and Potential Adverse Events: A Multi-Site Study in Eight U.S. Health Systems

Verena Metz¹, Thomas Ray¹, Vanessa Palzes¹, Ingrid Binswanger², Andrea Altschuler¹, Susan Andrade³, Robin Clark⁴, Irina Haller⁵, Rulin Hechter⁶, Douglas Roblin⁷, Steffani Bailey⁸, Dennis McCarty⁹, Kari Stephens¹⁰, Andrea Rubinstein¹¹, Ruchir Karmali¹², Cynthia Campbell¹

¹Kaiser Permanente Northern California, Division of Research, Center for Addiction and Mental Health Research, Oakland, CA, United States, ²Kaiser Permanente Colorado, ³Meyers Primary Care Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, ⁴Department of Family Medicine and Community Health, University of Massachusetts Chan School of Medicine, Worcester, Massachusetts, ⁵Essentia Institute of Rural Health, Duluth, Minnesota, ⁶Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, ⁷Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland, ⁸Department of Family Medicine, Oregon Health and Science University, Portland, Oregon, ⁹OHSU-PSU School of Public Health, Portland, Oregon, and Division of General and Internal Medicine, School of Medicine, Oregon Health and Science University, Portland, Oregon, ¹⁰Department of Family Medicine, University of Washington, Seattle, Washington, ¹¹Department of Pain Medicine, The Permanente Medical Group, Santa Rosa, California, ¹²Mathematica, Oakland, California

T106. Barriers to Retention in Inpatient and Residential Drug Treatment Among Persons who Use Opioids in the Rural U.S.

Lyndsey Mixson¹, Thomas Stopka², Minh Powell³, Gillian Leichtling⁴, Angela Estadt⁵, John Bressett⁶, William Zule⁷, John Pearce³, Eric Romo⁸, Peter Friedmann⁹, Suzan Walters¹⁰, Joseph Delaney¹¹, Heidi Crane¹², Rob Fredericksen³

¹University of Washington/Harborview Medical Center, ²Department of Public Health and Community Medicine, Tufts University, ³University of Washington, ⁴Comagine Health, ⁵Ohio State University, ⁶Department of Public Health and Recreations Professions Southern Illinois University at Carbondale, ⁷RTI International, ⁸University of Massachusetts Medical School, ⁹Baystate Health, ¹⁰New York University, ¹¹University of Manitoba, ¹²University of Washington at Harborview Medical Center

T107. Perceived Importance of Counseling Among Patients Receiving Methadone Treatment

Mark Beitel¹, Gul Saeed², Marina Gaeta Gazzola³, Kathryn Eggert⁴, Teresa Roehrich⁴, Lynn Madden⁵, Declan Barry⁶

¹Yale University, APT Foundation, ²APT Foundation, Inc., Yale University School of Medicine, ³NYU Langone Medical Center/NYC Health and Hospitals Bellevue Hospital Center, ⁴APT Foundation, Inc., ⁵APT Foundation, ⁶Yale University School of Medicine

T108. Exploring Long-Term Trajectories of Quality of Life for People who are Treated With Methadone

Anjalee Sharma¹, Jan Gryczynski², Trenette Goings³, Robert Schwartz²

¹Johns Hopkins School of Medicine, ²Friends Research Institute, ³University of North Carolina at Chapel Hill

T109. Substance Use Screening Rates and Screening Results Among Adult Primary Care Patients With Mental Health Conditions and Substance Use-Related Medical Conditions

Jennifer McNeely¹, Aimee Wahle², Margaret Kline², Clayton Snyder³, Sarah E. Wakeman⁴, Timothy Wilens⁴, Joseph Kannry⁵, Richard Rosenthal⁶, Noa Appleton¹, Sarah Farkas¹, Carmen Rosa⁷, Seth Pitts², Martina Pavlicova⁸, John Rotrosen¹, Leah Hamilton⁹

¹New York University Grossman School of Medicine, ²The Emmes Company, ³New York State Psychiatric Institute, ⁴Massachusetts General Hospital, ⁵Icahn School of Medicine at Mount Sinai, ⁶Renaissance School of Medicine, Stony Brook University, ⁷National Institute of Drug Abuse, National Institutes of Health, ⁸Mailman School of Public Health, Columbia University, ⁹Kaiser Permanente, Washington Health Research Institute

T110. Socioeconomic Status Differences in U.S. Multiracial Adolescents' Substance Use and Mental Health Problems

Audrey Hai¹, Catalina Lopez-Quintero², Amanda Elton², Juan Perez-Carreño²

¹Tulane University, ²University of Florida

T111. The ATTC Network: 30 Years of Supporting EBP Implementation in SUD Treatment and Recovery Services

Maxine Henry¹, Lena Marceno², Holly Hagle¹, Laurie Krom¹

¹University of Missouri-Kansas City, ²Altarum Institute

T112. State Laws Regulating Provision of Incentives Related to Substance Use

Barbara Andracka-Christou¹, Michelle Williams¹, Scott Buksbaum¹, Josie Karkkainen¹, Bradley Stein², Sydney Batchelder³, Kelly Peck³, Sarah Heil³, Richard Rawson⁴, Sarah Jacobs⁵, Stephen Higgins³, Stacey Sigmon³

¹University of Central Florida, ²RAND Corporation, ³University of Vermont, ⁴UCLA Integrated Substance Abuse Programs, ⁵Parthenon Management

T113. Comparing mHealth Use and Acceptability in Individuals Engaged in Treatment for Substance Use Disorders Prior to and After the Start of COVID-19

Emily A. Levine¹, Hannah Shapiro¹, R. Kathryn McHugh², Roger D. Weiss², Shelly F. Greenfield², Dawn E. Sugarman²

¹McLean Hospital, ²McLean Hospital, Harvard Medical School

T114. Introducing a Socio-Ecological Model of Collegiate Recovery Programs

Noel Vest¹, Sierra Castedo de Martell², Emily Hennessy³

¹Boston University, ²UTHealth School of Public Health, ³Massachusetts General Hospital and Harvard Medical School

T115. An Intervention Module for Methamphetamine Use in Youths Utilizing Mobile Smartphone Technology
Suzaily Wahab¹, Amirul Danial Azmi¹, Mohammad Faidzul Nasrudin², Muhamad Afiq Zulkifly¹, Nor Ba'yah Abdul Kadir³, Norhayati Ibrahim⁴, Normah Mustaffa³, Siti Rahmah Awang⁵, Noor Alaudin Abdul Wahab⁴, Mohd Juzaidin Ab Aziz²

¹Universiti Kebangsaan Malaysia Medical Centre, ²Faculty of Information Science and Technology, Universiti Kebangsaan Malaysia, ³Faculty of Social Sciences and Humanities, Universiti Kebangsaan Malaysia, ⁴Faculty of Health Sciences, Universiti Kebangsaan Malaysia, ⁵Azman Hashim International Business School, Universiti Teknologi Malaysia

T116. Inclusion of Community Members in Initial Design Stages of Technology-Based Interventions Addressing Topics Including Substance Use and HIV: A Systematic Review

Mary-Andrée Ardouin-Guerrier¹, German Rivera-Castellar², Juan Esteban Baus¹, Alex S. Bennett¹, Brent Gibson³, Selena A. Gilles⁴, Ian Aronson²

¹NYU School of Global Public Health, ²New York University, ³Community Research, ⁴NYU Rory Meyers College of Nursing

T117. Long-Term Mortality After Drug Use-Associated Endocarditis is High and Differs by Race and Sex: Results of a Statewide Study

Asher Schranz¹, Mary Figgatt¹, Vivian Chu², Li-Tzy Wu², David Rosen¹

¹University of North Carolina at Chapel Hill, ²Duke University School of Medicine

T118. Kratom Use and Adverse Events: Findings From the NDEWS Rapid Street Reporting Study

Catherine Striley¹, Anna Wang¹, Nae Won¹, Nicole Fitzgerald¹, Linda Cottler¹

¹University of Florida

T119. Familiarity With Substances and Adolescent Substance Use

Devika Bhatia¹, Benjamin Lewis², Hugh Farrior², Andrew Moore², Sara Jo Nixon²

¹University of Colorado School of Medicine, ²University of Florida College of Medicine

T120. Patterns and Clinical Correlates of Depressive Symptoms, Pain Impact, and Sleep Disturbance Among Patients in Residential Substance Use Treatment

Jennifer Ellis¹, Jill Rabinowitz², Patrick Finan³, Neha Skandan¹, Justin Strickland¹, J. Greg Hobelmann⁴, Andrew Huhn¹

¹Johns Hopkins University School of Medicine, ²Johns Hopkins Bloomberg School of Public Health, ³Johns Hopkins Hospital, ⁴Ashley Treatment Center

T121. Black Market Drug Purchases as Reported to Real-Time Monitoring Website, StreetRx

Brooke E. Kritikos¹, Kyle A. Beekman¹, Annika M. Czizik¹, Richard C. Dart¹, Joshua C. Black¹

¹Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO, USA

T122. The Controlled Substances Act Regulations on Schedule I Researcher Registrations and the Need to Investigate New Substances of Abuse

Theresa Carbonaro¹, William Heuett¹, Terry Boos¹

¹The United States Department of Justice

T123. Open Board

T124. Assessing Amygdala Habituation as it Relates to Substance-Use Disorder Vulnerability, Using Data From the ABCD Study®

Paul Regier¹, Yousef Khan², Virgilio Gonzenbach², Elizabeth Sweeney², Russell Shinohara², Anna Rose Childress²

¹University of Pennsylvania, ²University of Pennsylvania Perelman School of Medicine

T125. Marijuana Vaping Exceeds Nicotine Vaping Among California Youth: Results of a Statewide Survey

Angelina Van Dyne¹, Jijiang Wang², Shu-Hong Zhu²

¹UCSD, ²University of California - San Diego

T126. High Blood Pressure Among Psilocybin and Cannabis Consumers During the COVID-19 Pandemic: An Analysis of the COVID-19 Cannabis Health Study

Denise Vidot¹, Bria-Necole Diggs², Amrit Baral², Michaela Larson², Sitara Weerakoon³, Moudou Baquai⁴, Ramessu Iyi⁴, Michelle Weiner⁵, Marlene Camacho-Rivera⁶, Sarah Messiah⁷

¹University of Miami School of Nursing and Health Studies, ²University of Miami Miller School of Medicine, ³Yale University School of Medicine, ⁴TaMerrian Institute, ⁵Spine and Wellness Centers of America, ⁶SUNY Downstate Health Sciences University, ⁷University of Texas Health Science Center

T127. Opioid and Stimulant-Attributed Treatment Admissions and Fatal Overdoses Among Women: Using National Surveillance Data to Examine Racial/Ethnic Differences, 1992-2020

Abenaa Jones¹, Riley Shearer², Joel Segel³, Alexis Santos-Lozada¹, Tyler Winkelman⁴

¹Pennsylvania State University, ²The University of Minnesota, ³Penn State, ⁴Health, Homelessness, and Criminal Justice Lab, Hennepin Healthcare Research Institute

T128. Unmet Social Gender Affirmation as a Driver of Drug Use Among Transgender Women: The Need for Policy and Protections

Tiffany Glynn¹, Don Operario², Conall O'Cleirigh³, Adam Carrico⁴, Steven Safren⁵

¹Harvard Medical School/Massachusetts General Hospital/Brigham and Women's Hospital, ²Rollins School of Public Health at Emory University, ³Harvard Medical School/Massachusetts General Hospital, ⁴University of Miami Miller School of Medicine, ⁵University of Miami

T129. Prevalence of Psilocybin and Cannabis Concurrent Use During the COVID-19 Pandemic: An Analysis of the COVID-19 Cannabis Health Study

Denise Vidot¹, Amrit Baral², Bria-Necole Diggs³, Sitara Weerakoon⁴, Moudou Baquai⁵, Ramessu Iyi⁵, Michelle Weiner⁶, Sarah Messiah⁷

¹University of Miami School of Nursing and Health Studies, ²Miller School of Medicine, University of Miami, ³University of Miami Miller School of Medicine, ⁴Yale University School of Medicine, ⁵TaMerrian Institute, ⁶Spine and Wellness Centers of America, ⁷University of Texas Health Science Center

T130. Open Board

T131. Injecting Partnership Interpersonal Factors Predict Partnership Needle Sharing

Maia Scarpetta¹, Yea-Hung Chen¹, Torstein Neilands¹, Judy Tan¹, Julie Bruneau², Kimberly Page³, Meghan D. Morris¹

¹UCSF, ²Université de Montréal, ³University of New Mexico

T132. Poly-Substance Use Characterization in an Urban Cohort of Substance Users in Philadelphia, PA

Livio Azzoni¹, David Metzger², Amy Jessop³, Rachel Holbert³, Madison Scialanca³, Karam Mounzer⁴, Emily Hiserodt⁴, Cecile Denis⁵, Luis J. Montaner¹

¹The Wistar Institute, ²University of Pennsylvania, Department of Psychiatry, ³Prevention Point, Philadelphia,

⁴Philadelphia FIGHT, ⁵University of Pennsylvania

T133. Cigarette and E-Cigarette Use Trajectories and Prospective Prescription Drug Misuse Among Adolescents and Young Adults

Moriah Harton¹, Dong-Chul Seo¹, Rebecca Evans-Polce², Ivana Nguyen¹, Maria Parker¹

¹Indiana University, ²University of Michigan

T134. Disparities in Use of Syringe Services Programs in King County, WA

Katheryn Salow¹, Sara Glick²

¹University of Washington School of Medicine, ²University of Washington

T135. The Association Between Psychosocial Syndemic Conditions and Chemsex Among Men who Have Sex With Men Seeking PrEP in Thailand

Awirut Oon-arom¹, David Grelotti², Kriengkrai Srithanaviboonchai³, Sung-Jae Lee⁴, Chaisiri

Angkurawaranon⁵, Sherry Larkins⁶

¹Department of Psychiatry, Faculty of Medicine, Chiang Mai University, ²Department of Psychiatry, University of California San Diego, USA, ³Research Institute of Health Science, Chiang Mai University, ⁴Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (UCLA) David Geffen School of Medicine, USA, ⁵Department of Family Medicine, Faculty of Medicine, Chiang Mai University, ⁶Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), USA

T136. Missed Opportunities for HIV Prevention and Treatment for Hospitalized People who Inject Drugs

Ellen Eaton¹, John Bassler², Myles Prados³, KeDarius Ingram³, William Bradford³, Kelly Gagnon³

¹UAB, ²School of Public Health, The University of Alabama At Birmingham, ³Division of Infectious Diseases, The University of Alabama At Birmingham

T137. Health and Social Service Providers' Perspectives on Peer Distribution of HIV Self-Test Kits With Pre-Exposure Prophylaxis Information Among People who Inject Drugs in San Diego County, California

Angela Bazzi¹, Chad Valasek², William Eger², Tara Stamos-Buesig³, Alicia Harvey-Vera⁴, Carlos Vera⁴, Jennifer Syvertsen⁵, Erik Storholm⁶, Steffanie Strathdee⁴, Heather Pines⁴

¹University of California, San Diego, ²University of California - San Diego, ³Harm Reduction Coalition of San Diego, ⁴University of California San Diego, ⁵University of California, Riverside, ⁶San Diego State University

T138. Am I in Recovery? Bayesian Network Analysis to Understand Mental Models of Adolescent Recovery

Janaka Kosgolla¹, Doug Smith¹, Reinhart Crystal¹, Evans Jennifer¹

¹University of Illinois Urbana-Champaign

T139. Identifying Neurocognitive Mechanisms Underlying the Effects of Structural Racism on Risk for Substance Misuse Using the ABCD Study

Micah Johnson¹, Wesley Thompson²

¹University of South Florida, ²University of California, San Diego

T140. The Effect of Mental Illness on High-Risk Opioid Prescribing for Clients With Comorbid Pain and Alcohol Use Disorder in New York State

Zackary Falls¹, Chi-Hua Lu², Gail Jette³, Walter Gibson², Edward Bednarczyk², David Jacobs², Peter Elkin¹, Kenneth Leonard⁴

¹University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, ²University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, ³Division of Outcomes, Management, and Systems Information, Office of Addiction Services and Supports, ⁴Clinical and Research Institute on Addictions, University at Buffalo

T141. Evaluation of the Risk of Psychoactive Substance Use and Eating Attitudes and Behaviors Among Palestine Refugees in the North of the West Bank

Ali Shakhshir¹, Nashat Khelfeh², Adnan Mousa², Ibraheem AbuAlrub², Ali Hamad², Marah Hunjul², Faye Mahamid³, Basma Damiri⁴

¹Department of Medicine, Faculty of medicine and health Sciences, An-Najah National University, Nablus, 44839, Palestine, ²Medicine and Health Sciences Faculty, Department of Medicine, An-Najah National University, Nablus, 00970, Palestine, ³Department of Psychology, An-Najah National University, Nablus, Palestine, ⁴Medicine and Health Sciences Faculty, Drug, and Toxicology Division, An-Najah National University, Nablus, 00970, Palestine

T142. Polysubstance Use Among Patients With Opioid Use Disorder in Rural Primary Care Clinics

Yuhui Zhu¹, Laura-Mae Baldwin², Larissa Mooney³, Andrew Saxon⁴, Emily Kan⁵, Yih-Ing Hser³

¹Semel Institute - UCLA, ²University of Washington Department of Family Medicine, ³Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles, ⁴Veterans Affairs Puget Sound Health Care System, Seattle, ⁵University of California, Los Angeles

T143. Abuse Potential Similarities Between Hypnotic Classes: Real-World Data

Margaret Moline¹, Jocelyn Cheng¹, Caitlyn Durgin², Steve Pype², August Buchhalter², Jack Henningfield²

¹Eisai, Inc., ²Pinney Associates, Inc.

T144. Open Board

T145. Self-Perception of Smoking Status and Co-Use of Cannabis and Narcotic Pain Medication

Andrew Bontemps¹, S. Justin Thomas¹, Karen Gamble¹, Karen Cropsey¹

¹The University of Alabama At Birmingham

T146. The Role of Past Substance Use on ART Adherence Among Black People with HIV

Vanessa Serrano¹, Jessica Montoya², Elizabeth Pasipanodya³, David Moore²

¹University of California, San Diego, ²University of California, San Diego, La Jolla, CA, USA, ³Rehabilitation Research Center, Santa Clara Valley Medical Center, San Jose, CA, USA

T147. Evaluating Patient Perspectives on Mixed Virtual and In-Person Group Settings

Tyler Oesterle¹, Victor Karpyak¹, Scott Breitingner¹

¹Mayo Clinic, Dept. Psychiatry and Psychology

T148. Results from a Randomized Clinical Trial to Optimize Community Wise to Reduce Alcohol and Substance Misuse (ASM) Among Formerly Incarcerated Men in Urban Communities

Liliane Windsor¹, Ellen Benoit², Carol Lee³

¹The University of Illinois at Urbana-Champaign, ²North Jersey Community Research Initiative, ³University of Michigan Medical School

T149. Motivation and Context of Concurrent Stimulant and Opioid Use Among Persons who Use Drugs in the Rural United States: A Multi-Site Qualitative Inquiry

Rob Fredericksen¹, David Colston², Adams Sibley², Robin Baker³, Sarah Mixson¹, Angela Estadt⁴, Suzan Walters⁵, John Bresett⁶, Ximena Levander³, Gillian Leichtling⁷, Minh Powell¹, John Pearce¹, Thibaut Davy-Mendez², Bridget Whitney¹, Joseph Delaney⁸, Heidi Crane¹, Judith Tsui¹

¹University of Washington, ²University of North Carolina, ³Oregon Health Sciences University, ⁴Ohio State University, ⁵New York University, ⁶Southern Illinois University, ⁷Comagine Health, ⁸University of Manitoba

T150. Substance Use, Psychiatric Disorders, and the COVID-19 Vaccine: A Quality Improvement Project

Zoe Karavolis¹, Emily Thacker², Maureen Reynolds³, Ralph Tarter³, Antoine Douaihy⁴

¹University of Pittsburgh Medical Center, ²UPMC Western Psychiatric Hospital, ³University of Pittsburgh, ⁴UPMC-Western Psychiatric Hospital

T151. Understanding Ketamine Use in Treatment-Seeking Persons With Opioid Use Disorder

Corinne Chandler¹, Matthew Ellis², Mance Buttram¹

¹University of Arkansas, ²Washington University in St. Louis

T152. HIV and Hepatitis C Virus-Related Misinformation Remains a Challenge to Improved Clinical Outcomes Among Persons who use Drugs During the U.S. Opioid Overdose Crisis

Alejandro De La Hoz Gomez¹, Kristin Graves, BA², Judith A. Bernstein, PhD³, Sabrina A. Assoumou, MD, MPH²

¹Boston Medical Center, ²Boston University School of Medicine, ³Boston University School of Public Health

T153. Open Board

T154. Optimizing Recovery Funding: Barriers to Acquiring Funding Among Organizations in the Ecosystem of Recovery

Stephanie Spitz¹, Tyler Myroniuk², Enid Schatz², Deena Murphy³, Stephanie Bage³, Laurie Krom³, Adam Viera⁴

¹Peer Recovery Center of Excellence, ²University of Missouri-Columbia, Department of Public Health,

³University of Missouri-Kansas City, ⁴Yale School of Public Health

T155. Changes in Prevalence of Substance Use Among Patients of Community Health Centers in Los Angeles Over Time: Comparative Analysis From 2013 to 2022

Daisy Hernandez-Casas¹, Melvin Rico², Stephanie Sumstine³, Amanda Sirisoma¹, Maria Vasquez¹, Jack Tsai⁴, Armen Arshakyan⁵, Dallas Swendeman¹, Lillian Gelberg²

¹University of California, Los Angeles, ²University of California, Los Angeles, Department of Family Medicine,

³University of California, Los Angeles, Department of Psychiatry and Biobehavioral Sciences, ⁴TCC Family Health, ⁵Saban Community Clinic

T156. Momentary Latent Class Membership to Predict Self-Efficacy and Subsequent Substance Use

Danny Wang¹, Samuel Stull¹, Michael Dennis², Christy Scott², Stephanie Lanza³

¹The Pennsylvania State University, ²Chestnut Health Systems, ³The Pennsylvania State University, Department of Biobehavioral Health

T157. Applying Theory of Planned Behavior to Predict Online Addiction Treatment Intention During COVID-19

Hagit Bonny-Noach¹, Dudi Gold², Ariel Caduri³

¹Department of Criminology, Ariel University and Board member of ILSAM-The Israeli Society of Addiction Medicine, ²M.A., Director of "Gold Center"- An outpatient treatment center and Board member of ILSAM-The Israeli Society of Addiction Medicine, ³Ph.D, Head of Knowledge Development, Israel Authority for prevention of Violence, Alcohol and Drug Abuse - National Authority for Community Safety-Ministry of Public Security

T158. Differences in Acute and Enduring Effects of MDMA vs. Classic Psychedelics in People With Eating Disorders

Natalie Gukasyan¹, Erin Wang¹, Alan K. Davis², Colleen Schreyer¹, Angela Guarda¹, Roland Griffiths³

¹Johns Hopkins Hospital, ²Ohio State University, ³Johns Hopkins University

T159. Open Board

T160. Acute Psychedelic Effects and Clinical Outcomes Are Associated With Therapeutic Alliance Among Participants Receiving Psilocybin Therapy

Alan Davis¹, Adam Levin², Rafaelle Lancelotta³, Nathan Sepeda⁴, Natalie Gukasyan⁵, Sandeep Nayak⁵, Frederick Barrett⁶, Roland Griffiths⁴

¹The Ohio State University, ²Ohio State University, College of Medicine, ³Ohio State University, ⁴Johns Hopkins University, ⁵Johns Hopkins Hospital, ⁶Johns Hopkins University School of Medicine

T161. Essential Experimental Screening to Evaluate the Safety of Novel Psychedelics

Jane Gosden¹, Sharon Smith¹, Christopher Atterwill¹, David Heal¹

¹DevelRx Ltd

T162. Drug Overdose Risk Following Benzodiazepine Treatment in Young Adults With Depression or Anxiety Disorders

Greta Bushnell¹, Moira Rynn², Deborah Hasin³, Katherine Keyes³, Tobias Gerhard¹, Magdalena Cerda⁴, Mark Olfson³

¹Rutgers University, ²Duke University, ³Columbia University, ⁴New York University

T163. Latent Class Analysis of Psychosocial Factors Among People Living with HIV who Use Substances

Daniel Feaster¹, Renae Schmidt¹, Rui Duan², Sharleen Traynor³, Carly Davis⁴, Sophia Gonzalez⁴, Derrick Forney¹, Lisa Metsch⁵, Daniel Feaster¹

¹University of Miami Miller School of Medicine, ²University of Miami, ³Durham Technical Community College, ⁴Miller School of Medicine, University of Miami, ⁵Columbia University

T164. Care Utilization Among Patients With Stimulant Use Disorder During COVID-19: A National Cohort Study of US Veterans

Lewei (Allison) Lin¹, Madeline Frost², Lan Zhang¹, Lara Coughlin¹

¹University of Michigan, ²University of Washington School of Public Health, Department of Health Systems and Population Health

T165. The Development of a Knowledge, Attitude, and Practice Questionnaire for Methamphetamine Use

Amirul Danial Azmi¹, Suzaily Wahab¹, Nor Ba'yah Abdul Kadir², Noor Alaudin Abdul Wahab³, Rogayah Abdul Razak⁴

¹Universiti Kebangsaan Malaysia Medical Centre, ²Faculty of Social Sciences and Humanities, Universiti Kebangsaan Malaysia, ³Faculty of Health Sciences, Universiti Kebangsaan Malaysia, ⁴Faculty of Social Science and Liberal Arts, UCSI University

T166. Treatment Outcomes From Computerized CBT for Substance Use Disorders Among People With Criminal Justice Involvement

Jennifer Loya¹, Theresa Babuscio¹, Charla Nich¹, Brian Kiluk¹

¹Yale University School of Medicine

T167. Impact of Methamphetamine Use on Cardiovascular Risk and Deprivation: Objective Assessment Using Wearable Activity Tracker and Mobile Application

Ayumi Takano¹, Koki Ono², Makito Sato³, Masaki Onuki³, Jun Sese³, Toshihiko Matsumoto⁴

¹Department of Mental Health and Psychiatric Nursing, Tokyo Medical and Dental University, ²Department of Clinical Information Engineering, The University of Tokyo, Tokyo, ³Humanome Lab., Inc., ⁴Department of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry

T168. An Evaluation of the "Critical Period" in Contingency Management

Sean Regnier¹, Thomas Shellenberg¹, Mikhail Koffarnus¹, Joshua Lile¹, Craig Rush¹, William Stoops¹

¹University of Kentucky, College of Medicine

T169. Correlates of Methamphetamine Use for Self-Treatment of Attention Deficit/Hyperactivity Disorder

Patricia Timmons¹, Sydney Silverstein², Raminta Daniulaityte¹

¹Arizona State University, ²Boonshoft School of Medicine Wright State University

WEDNESDAY, JUNE 21, 2023

POSTER SESSION 4

W1. Historical Trauma, Racial Identity, and Binge Drinking Among Black Young Adults

Chantel Ebrahimi¹, Lillian Polanco-Roman¹, Denise Hien²

¹The New School, ²Rutgers Center of Alcohol and Substance Use Studies, Graduate School of Applied and Professional Psychology

W2. Open Board

W3. Is the Whole Greater Than the Sum of Its Parts? Examining How Dosage of Intervention Components From the Sacramento Neighborhood Alcohol Prevention Project Affect Child Abuse and Neglect

Bridget Freisthler¹, Yun Ye¹

¹The Ohio State University

W4. A Therapeutic Workplace for Adults With Alcohol Use Disorder who are Experiencing Homelessness

Matthew Novak¹, August Holtyn¹, Forrest Toegel², Kenneth Silverman³

¹Johns Hopkins University School of Medicine, ²Northern Michigan University, ³Johns Hopkins University

W5. Association of Phosphatidylethanol (PEth) Levels With Severity of Alcohol Dependence in Treatment Seeking Patients of Alcohol Dependence: An Exploratory Study

Abhishek Gupta¹, Raka Jain², Biswadip Chatterjee³

¹AIIMS DELHI, ²All India Institute of Medical Sciences, ³National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences, New Delhi - 110029

W6. Mediation Effect of the Alcohol Reinforcement Value on the Association Between Poor Sleep Quality and Problematic Drinking Among Adolescents

Clara Sancho-Domingo¹, Jose Luis Carballo¹, Ainhoa Coloma-Carmona¹, Antonia Pelegrín Muñoz¹, Carlos Van-der Hofstadt Román¹

¹Miguel Hernández University

W7. Combined Multiomics of Comorbid Alcohol Use Disorder and Depression

Eric Vallender¹, Jon Person¹, Gouri Mahajan¹, James Overholser², George Jurjus³, Lesa Dieter², Grazyna Rajkowska¹, Craig Stockmeier¹

¹University of Mississippi Medical Center, ²Case Western Reserve University, ³Louis Stokes Cleveland VA Medical Center

W8. Increasing Capacity of International Researchers and Universities Through Collaboration

Carly Searcy¹, Stephen Asatsa²

¹International Consortium of Universities for Drug Demand Reduction, ²The Catholic University of Eastern Africa

W9. The Potential Moderating Effects of Alcohol Use Severity and Reinforcer Valuation on Suicidal Thoughts and Behaviors

Mark Rzeszutek¹, Mikhail Koffarnus¹

¹University of Kentucky, College of Medicine

W10. Exploring the Relationships Between Dimensions of Adverse Childhood Experiences and Cannabis Use Outcomes

Catalina Lopez-Quintero¹, Martha Castañeda¹, Juan Perez-Carreño¹

¹University of Florida

W11. A Prospective Study on Changes in Alcohol, Cannabis, and Tobacco Use From Before to During the COVID-19 Pandemic

J. Megan Ross¹, Jesse Hinckley¹, Jarrod Ellingson¹, Stephanie Zellers², Matt McGue², Robin Corley³, Scott Vrieze², Soo Rhee⁴, Sylvia Wilson², John Hewitt⁵, William Iacono², Christian Hopper⁶

¹University of Colorado Anschutz Medical Campus, ²University of Minnesota, ³Institute for Behavioral Genetics, ⁴University of Colorado Boulder, ⁵University of Colorado, ⁶University of Colorado School of Medicine

W12. An Analysis of Gender Differences in Cannabis Use Frequency Among People With Mental Health Disorders Pre- And Post-Recreational Cannabis Use Legalization: A Repeated Cross-Sectional Survey

Maryam Sorkhou¹, Elle Wadsworth², Faith Rodas³, David Hammond⁴, Tony George⁵

¹University of Toronto and CAMH, ²University of Waterloo, ³McMaster University, ⁴University of Waterloo, ⁵University of Toronto

W13. Using Self-Reported Hits and Grams to Estimate Cannabis Consumption in Milligrams of THC

Mohammad Habib¹, Jacob Borodovsky², Cara Struble³, Deborah Hasin⁴, Dvora Shmulewitz⁴, Claire Walsh⁵, Ofir Livne⁶, Efrat Aharonovich⁷, Alan Budney³

¹Dartmouth College, ²Dartmouth Geisel School of Medicine, ³Geisel School of Medicine at Dartmouth, ⁴Columbia University, ⁵New York State Psychiatric Institute, ⁶Mailman School of Public Health, Columbia University, ⁷Columbia University Irving Medical Center

W14. Behavioral and Psychosocial Predictors of Cannabis Use Among Youth During the COVID-19 Pandemic

Kerry Flannagan¹, Marushka Silveira², Colm Everard¹, Heather Kimmel³, Satoko Kuramoto-Crawford⁴, Daniela Marshall¹, Wilson Compton⁴, MeLisa Creamer⁴

¹National Institute of Drug Abuse, National Institutes of Health; Kelly Government Solutions, ²National Institute of Dental and Craniofacial Research, National Institutes of Health; Kelly Government Solutions, ³National Institute of Drug Abuse, National Institutes of Health, ⁴National Institute on Drug Abuse, National Institutes of Health

W15. Increasing Risk of Cannabis Use Disorder Among U.S. Veterans With Chronic Pain: 2005-2019

Zachary Mannes¹, Carol Malte², Andrew Saxon³, Deborah Hasin⁴

¹Columbia University, Mailman School of Public Health, ²Center of Excellence in Substance Abuse Treatment and Education, Veterans Affairs Puget Sound Health Care System, ³Veterans Affairs Puget Sound Healthcare System, ⁴Columbia University

W16. Rising Solitary Cannabis Use Among Young Adults Over Time: Investigating Cannabis Practices, Motivations, and Demographic Factors

Stephen Lankenau¹, Ekaterina Fedorova¹, Janna Ataiants¹, Bridgid Conn², Carolyn Wong³

¹Drexel University Dornsife School of Public Health, ²Children's Hospital Los Angeles, ³Children's Hospital Los Angeles and University of Southern California

W17. Social Role Protective Factors in Risky Substance Use Among a Community Sample of Emerging Adults

Melissa Fenton¹, Piyush Chaudhari¹, Linda Cottler¹, Catherine Striley¹

¹University of Florida

W18. The Left Dorsolateral Prefrontal Cortex Modulates the Perception of Low Dose THC Effects in Individuals With Problematic Cannabis Use

Miranda Ramirez¹, Preston Tolbert², Brady Stamper², Caroline Sumner¹, Joshua Lile², Michael Wesley²

¹University of Kentucky, College of Arts and Sciences, ²University of Kentucky, College of Medicine

W19. Investigating the Simultaneous Effects of Cannabidiol Isolate and Caffeine

Morgan Ferretti¹, Noah Gustin², Rachel Zindler², Caroline Sokol², Avery Knowlton², Kate Porter², Olivia Carmack², Ethan Hoffman², Matthew Feldner³, Marcel Bonn-Miller³, Jessica Irons²

¹University of Arkansas, ²James Madison University, ³Canopy Growth Corporation

W20. Modular-Level Alterations in Functional Brain Connectivity Associated With Cannabis Use

Christina Meade¹, Ryan Bell¹, Sheri Towe¹, Kareem Al-Khalil¹, Jessica Cohen², Syam Gadde¹, Shana Hall¹

¹Duke University School of Medicine, ²University of North Carolina at Chapel Hill

W21. Concurrent and Prospective Relations Between Aberrant Stress-Induced Frontal Alpha Asymmetry and Cannabis Use Disorder

Brandon Schermitzler¹, Richard Macatee¹

¹Auburn University Department of Psychological Sciences

W22. Attitudes and Beliefs of Prenatal Cannabis Use: Assessing the Reliability of the Perceptions of Prenatal Cannabis Use Measure and Comparing Perceptions Between Locations

Anna Wiese¹, Judy Chang², Jeanelle Sheeder³, Nancy jallo¹, Lisa Brown¹, Nicole Karjane¹, Divya Sharma¹, Enkelejda Ngjelina¹, Dace Svikis¹

¹Virginia Commonwealth University, ²University of Pittsburgh, ³University of Colorado Denver

W23. Effect of Acute THC, Sex, and Lifetime Cannabis Use on Neural Reward Activation

Rebecca Denson¹, Zoa Glab², Julia Brooks¹, Natania Crane²

¹University of Illinois At Chicago, ²Psychiatric Institute, University of Illinois At Chicago

W24. A Preliminary Investigation of Repetitive Transcranial Magnetic Stimulation Applied to the Left Dorsolateral Prefrontal Cortex in the Treatment of Cannabis Use Disorder

Gregory Sahlem¹, Nathaniel Baker², Brian Sherman², Amanda Wagner², Brendan Wong¹, Margaret Caruso³, Lauren Campbell², Irakli Kaloani¹, TJ Ford¹, Haroon Musli¹, Andrew Geoly¹, Nolan Williams¹, Ian Kratter¹, Andrew Manett², Suzanne Kerns², E. Baron Short², Robert Malcolm², Therese Killeen², Mark George², Aimee McRae-Clark²

¹Stanford University, ²Medical University of South Carolina, ³Auburn University

W25. Motives Behind Frequency of Cannabis Use – a Comparison of Regular and Occasional Young Adult Cannabis Users

Anna Li¹, Zoa Glab², Rebecca Denson³, Shahd Smadi², Julia Brooks³, Natania Crane²

¹University of Illinois At Chicago College of Medicine, ²Psychiatric Institute, University of Illinois At Chicago,

³University of Illinois At Chicago

W26. Measuring Cannabis Reinforcement Among Young Adults: A Mixed Methods Examination

Neo Gebru¹, Tyler G. James², Ricarda Foxx³, Michelle Castro⁴, Ali Yurasek³

¹Brown University, ²University of Michigan, ³University of Florida, ⁴University of Colorado

W27. Changes in State Medical Cannabis Registration and in Daily Medical Cannabis Sales from 2018-2021

Benjamin Roman¹, Eve Barton¹, Savannah Poling¹, Madeline Meier¹

¹Arizona State University

W28. It's Just, Like, a Younger Guy Thing to Smoke Weed: Gendered Cannabis Norm Perceptions Among Treatment-Seeking Adults

Justin Matheson¹, Madison Wright¹, Tara Marie Watson¹, Beth Sproule¹, Bernard Le Foll¹, Bruna Brands²

¹Centre for Addiction and Mental Health, ²Health Canada

W29. Prevalence of Cannabis Use Disorder Among Primary Care Patients who Use Cannabis for Medical Only, Nonmedical Only, or Both Reasons

Gwen Lapham¹, Theresa Matson¹, Jennifer Bobb¹, Casey Luce¹, Malia Oliver¹, Leah Hamilton¹, Katharine Bradley¹

¹Kaiser Permanente Washington Health Research Institute

W30. Hair Testing: From Drug Monitoring to Harm Reduction Tool

Daniel Martins¹, Alberto Salomone², João Matias³

¹Kosmicare/University of Porto, ²University of Turin, ³EMCDDA

W31. The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis

Lamia Haque¹, David Fiellin², Kendall Bryant³, E. Jennifer Edelman², Amy Justice⁴, Joseph Lim⁵, Vincent Lo Re III⁶, Brandon Marshall⁷, Tamar Taddei⁵, Janet Tate⁵, Jeanette Tetrault¹, Emily Williams⁸, Kathleen McGinnis⁹, E. Jennifer Edelman¹⁰

¹Yale School of Medicine, ²Yale School of Medicine, Yale School of Public Health, ³National Institute of Drug Abuse, National Institutes of Health, ⁴Yale School of Medicine, Yale School of Public Health, VA Connecticut Healthcare System, ⁵Yale School of Medicine, VA Connecticut Healthcare System, ⁶Perelman School of Medicine, University of Pennsylvania, ⁷Brown University School of Public Health, ⁸University of Washington School of Public Health, Department of Health Systems and Population Health, ⁹VA Connecticut Healthcare System, ¹⁰Yale University School of Medicine

W32. How Did the Removal of IQOS® Tobacco Heating System (THS) from the Market Impact Tobacco Harm Reduction?

Brendan Noggle¹, Andrea Vansickel¹

¹Altria Client Services LLC

W33. Open Board

W34. Treatment Engagement, Cigarette Smoking, and Quit Attempts One Month After a Randomized Controlled Trial of E-Cigarette Reduction Among Dual Users

Marc Jerome Feinstein¹, Joan Skelly², Stephen Higgins³, Elias Klemperer⁴

¹Univ. of Vermont College of Medicine, ²Vermont Center on Behavior and Health, ³University of Vermont,

⁴University of Vermont College of Medicine

W35. Nicotine Use and Metabotropic Glutamate Receptor 5 (mGluR5) in Individuals With Major Depressive and Post Traumatic Stress Disorders

Stephen Baldassarri¹, Ruth Asch¹, Ansel Hillmer¹, Robert Pietrzak¹, Nicole DellaGioia¹, Irina Esterlis¹, Margaret Davis¹

¹Yale University

W36. Cooling Flavors Use and E-Cigarette Nicotine Dependence Among Youth

Wei Li¹, Danielle Davis¹, Krysten Bold¹, Deepa Camenga¹, Asti Jackson¹, Grace Kong¹, Juhan Lee¹, Meghan Morean¹, Akshika Sharma¹, Suchitra Krishnan-Sarin¹

¹Yale University School of Medicine

W37. Actual Use Study of Nicotine Pouches Among U.S. Adult Smokers

Tiffany Parms¹, Erin Evans¹, Patrudu Makena¹, Mandara Shetty², Rachel Hart², Peter Chen¹, Kristen Prevette¹, Christine Campbell¹, Krishna Prasad², Sarah Baxter-Wright¹, Kristen Jordan¹

¹RAI Services Company, ²British American Tobacco

W38. Open Board

W39. Self-Reported Opioid Overdose via 120-Day Timeline Follow-Back and Documented Overdose Medical Encounters Among Opioid Overdose Survivors

Rachel Smith¹, Nicole C. McCann², Adam Majeski¹, Vanessa M. McMahan³, Sarah Kosakowski¹, Sarah L. Johns¹, Shae Wolfe¹, Sarah Brennan³, Phillip Coffin³, Alexander Walley¹

¹Grayken Center for Addiction and Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine; Boston University School of Medicine and Boston Medical Center, Boston MA,

²Boston University School of Public Health, Department of Health Law, Policy and Management, Boston, MA,

³Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, CA

W40. High Threshold Prescribing Practices Associated with Increased Termination of Care: Results From a Survey of Michigan Buprenorphine Prescribers

Omeid Heidari¹, Valencia Lyle², Samantha Harris³, Eric Hulsey², Kate Boulton², Brendan Saloner³, Jason Gibbons³

¹University of Washington, ²Vital Strategies, ³Johns Hopkins Bloomberg School of Public Health

W41. Cumulative Vulnerabilities: An Investigation of Lifetime Substance Use Among Individuals in Recovery From Opioid Use Disorder

Devin Tomlinson¹, Allison Tegge², Roberta Freitas-Lemos¹, William Craft³, Anne Le Moigne⁴, Angela DeVaugh-Geiss⁴, Howard Chilcoat⁴, Stephen Higgins⁵, Warren Bickel⁶

¹Fralin Biomedical Research Institute at Virginia Tech Carilion, ²Virginia Tech Carilion Research Institute,

³Fralin Biomedical Research Institute at VTC, Roanoke, VA, ⁴Indivior, Inc., ⁵University of Vermont, ⁶Fralin Biomedical Research Institute at VTC

W42. Criminal Justice Involvement as Trauma: The Role of Recidivism and Reentry on Substance Use Trajectories Among Women With Substance Use Disorders

Sienna Strong-Jones¹, Derek Kreager², Jennie Noll¹, Samantha Ellner³, Amanda Ferrara⁴, Miranda Kaye⁴, Kristina Brant⁵, Melissa Kusi-Amponsah⁶, Abenaa Jones¹

¹Department of Human Development and Family Studies, Pennsylvania State University, ²Department of Sociology and Criminology, Pennsylvania State University, ³Department of Educational Psychology, Counseling, and Special Education College of Education, Pennsylvania State University, ⁴Survey Research Center, Pennsylvania State University, ⁵Department of Agricultural Economics, Society, and Education, Pennsylvania State University, ⁶Department of Psychology, Northwestern University

W43. The Impact of CDC's Opioid Prescribing Guideline on Racial Disparities in Discontinuation of Opioid Treatment in the United States

Huiru Dong¹, Erin Stringfellow¹, Mohammad Jalali¹

¹Harvard Medical School

W44. Association of Medications for Mood/Anxiety Disorders With Fatal and Non-Fatal Opioid Overdose

Nadia Fairbairn¹, Alexis Crabtree², Christian Schutz³, Tae Woo Park⁴, Eugenia Socias⁵, Janet Mok⁶, Zishan Cui⁶, Lianping Ti⁵

¹University of British Columbia, ²BC Centre for Disease Control, ³Institute of Mental Health, Department of Psychiatry, Faculty of Medicine, University of British Columbia, ⁴Department of Psychiatry, Boston University School of Medicine, Boston Medical Center, United States of America; Grayken Center for Addiction, Boston Medical Center, United States of America, ⁵Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, British Columbia, Canada, ⁶British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada

W45. Risk Factors for Misuse Versus Abuse of Opioids and Sedatives

Nicole Schow¹, Elizabeth Bemis², Karilynn Rockhill², Joshua Black¹, Richard Dart²

¹Rocky Mountain Poison and Drug Safety, ²Rocky Mountain Poison and Drug Center

W46. Examining Drug Overdose Mortality Ratios and Their Intersection With Substance Use Disorder-Related Services Across Diverse Communities in a Segregated Metropolitan Area

Fahimeh Mohebbi¹, Rina Ghose², Amir Masoud Forati³, John Mantsch⁴

¹University of Wisconsin-Milwaukee, ²Department of Geography, University of Wisconsin - Milwaukee,

³University of Wisconsin - Milwaukee, ⁴Medical College of Wisconsin, Pharmacology and Toxicology

W47. Using Spatial Social Network Analysis to Study the Journey to Overdose Deaths

Amir Masoud Forati¹, Rina Ghose², Fahimeh Mohebbi³, John Mantsch⁴

¹University of Wisconsin - Milwaukee, ²Department of Geography, University of Wisconsin - Milwaukee,

³University of Wisconsin-Milwaukee, ⁴Medical College of Wisconsin, Pharmacology and Toxicology

W48. The Development of a Conceptual Model to Assess Intersectional Stigma's Role in Shaping Rural Primary Care Providers' Decisions to Implement Harm Reduction, Buprenorphine, and HIV Prevention

Phil Marotta¹, Kaileigh Backes¹, Miryam Baied¹, Lindsey Filiatreau¹, Rachel Winograd², Hilary Reno¹, Katie Wang³, Robert Heimer³, Cindy McDannold⁴, Patricia Cavazos¹

¹Washington University in St. Louis, ²University of Missouri St. Louis, ³Yale University, ⁴Missouri Primary Care Association

W49. Estimating the Impact of Diverted Buprenorphine on Population Opioid Overdose Incidence Using an Agent-Based Model

Joella Adams¹, Michael Duprey¹, Sazid Khan¹, Jessica Cance¹, Donald Rice², Georgiy Bobashev¹

¹RTI International, ²Brown University

W50. Perceptions of Overdose Response Hotlines Among a Sample of People in Treatment for Substance Use Disorder

Rachel Gicquelais¹, Rachel Chenoweth¹, Nora Jacobson¹, Caitlin Conway¹, Carmen Skarlupka², Oona Krieg³, Gina Bryan¹

¹University of Wisconsin - Madison, ²Never Use Alone, ³Brave co-op

W51. The Impact and Evolution of Structural Vulnerabilities Throughout Substance Use Initiation, Treatment, and Recovery: Perspectives From Providers and Women With Opioid Use Disorder

Eric Harrison¹, Kristina Brant¹, Hobart Cleveland¹, Marinda Kaye¹, Hannah Apsley¹, Emma Skogseth¹, Abenaa Jones¹

¹Pennsylvania State University

W52. They Don't Care who you are, They're Only There to Help you: Barriers and Facilitators to Accessing Syringe Service Programs (SSPs) Among People who Inject Drugs (PWID) in Appalachia Ohio

Stacy M. Endres-Dighe¹, Ana D. Sucaldito², Renee McDowell¹, Cathy Neal¹, Anyssa Wright¹, William C. Miller¹, Vivian F. Go³, Kathryn E. Lancaster¹

¹The Ohio State University, ²Wake Forest University, ³University of North Carolina

W53. Socioeconomic Status and HIV Severity Among People With HIV who Inject Drugs in St. Petersburg, Russia
Bulat Idrisov¹, Jenna Van Draanen¹, Sara Lodi², Karsten Lunze³, Simeon Kimmel³, Emily Quinn², Ve Truong³, Elena Blokhina⁴, Natalia Gnatienko⁵, Evgeny Krupitsky⁴, Jeffrey Samet³, Emily Williams¹

¹University of Washington, ²Boston University School of Public Health, ³Boston Medical Center, ⁴Pavlov University, ⁵Boston Medical Center

W54. Frequency of Fentanyl Injection is Associated with Hepatitis C Status: A Cross-Sectional Study

Ahmed Bayoumi¹, Khuloud Aldaheri¹, Kolla Gillian², Flores Brian³, Kenny Kathleen⁴

¹University of Toronto, ²University of Victoria, ³Unity Health Toronto, ⁴University of Manitoba

W55. Fentanyl Route of Administration and Overdose Risk: A Preliminary Analysis of Baseline Data From a Cohort of Overdose Survivors in San Francisco and Boston

Phillip Coffin¹, Vanessa McMahan¹, Sarah Brennan¹, Mackenzie Robinson¹, Andrew Rolles², Sarah Kosakowski², Miriam Harris³, Alexander Walley⁴

¹San Francisco Department of Public Health, ²Boston Medical Center, ³Boston University, ⁴Boston University School of Medicine

W56. An Observational Study of Medication for Opioid Use Disorder Prescribing Practices During Pregnancy

Camille Cioffi¹, Anne Martinez Acevedo², Menolly Kauffman², Miguel Marino², Kea Parker², Mishka Terplan³, Stephan Linder²

¹University of Oregon, ²Oregon Health and Science University, ³Friends Research Institute

W57. Characterizing Empirically-Derived Sub-Groups of Latinx PWID Living Along the US-Mexico Border for HIV and HCV Prevention

Natasha Ludwig-Barron¹, John Saucedo¹, Jorge Salazar², Jorge Puentes³, Lidia Rodriguez-Garcia¹, Rebeca Ramos⁴, Maria Elena Ramos Rodríguez⁵, Julia Lechuga³

¹Department of Medicine, Division of Prevention Science, University of California, San Francisco,

²Department of Medicine, Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, ³Department of Public Health Sciences, University of Texas, El Paso, ⁴Alliance of Border Collaboratives, ⁵Programa Compañeros, A.C.

W58. Benzodiazepine, Z-Drug, and Sleep Medication Prescriptions in Male and Female People With Opioid Use Disorder and Comorbid Insomnia: An Analysis of Multi-State Insurance Claims

Caitlin Martin¹, Hetal Patel², Joseph Dzierewski³, F. Gerard Moeller¹, Laura Bierut⁴, Richard Grucza⁵, Kevin Xu⁴

¹Virginia Commonwealth University, ²Washington University, ³National Sleep Foundation, ⁴Washington University School of Medicine, ⁵St Louis University School of Medicine

W59. Trauma and Craving Among Those Reentering From the Criminal Justice System With Opioid Use Disorder: Treatment Implications

Michael Fendrich¹, Cindy Dubuque-Gallo², Beth Russell², Crystal Park²

¹Advocate Aurora Research Institute, ²University of Connecticut

W60. Neurofunction and Insomnia Symptoms Among Women in Treatment for Opioid Use Disorder

Augustus White¹, Michelle Eglovitch¹, Anna Beth Parlier-Ahmad¹, Joseph Dzierewski², F. Gerard Moeller¹, Caitlin Martin¹

¹Virginia Commonwealth University, ²National Sleep Foundation

W61. Absorption of Naloxone in Patients Prescribed Buprenorphine/Naloxone – a Retrospective Analysis

Domenic Ochal¹, Tyler Oesterle²

¹Mayo Medical School, ²Mayo Clinic, Dept. Psychiatry and Psychology

W62. Opioid Use and Treatment Retention Outcomes Among Patients Initiating Methadone Versus Buprenorphine Treatment in Rural Practices

Lisa Khairy¹, Leslie Kenefick¹, Luke Hall¹, Kibeom Kwon¹, Nicole Limberg¹, Sterling McPherson¹, Andre Miguel¹

¹Elson S. Floyd College of Medicine

W63. Impact of Covid-Related Policy Changes on Retention and Adverse Events Amongst new Methadone Maintenance Intakes

Arthur Robin Williams¹, John Rotrosen², Noa Krawczyk³, Mei-Chen Hu⁴, Lexa Harpel⁵, Nicole Aydinoglu⁵, Magdalena Cerda⁶, Edward Nunes⁷

¹Columbia University Division on Substance Use Disorders, ²Department of Psychiatry, NYU Langone School of Medicine, New York, NY, United States, ³NYU Grossman School of Medicine, ⁴Columbia University and NYSPI, ⁵Research Foundation for Mental Hygiene, ⁶Department of Population Health, NYU School of Medicine, ⁷Columbia University and New York State Psychiatric Institute

W64. Nondrug Reward and Recovery From Addiction: Socio-Spatial Contexts, Interindividual Heterogeneity, and Change Over Time

Samuel Stull¹, Stephanie Lanza², David Epstein³

¹The Pennsylvania State University, ²The Pennsylvania State University, Department of Biobehavioral Health,

³NIDA Intramural Research Program

W65. Trends in Buprenorphine Prescribing in a National Network of Community Health Centers

Daniel Hartung¹, Robert Voss², Steffani Bailey³, Nathalie Huguet³, Irina Chamine³, John Muench³

¹Oregon State University, ²OCHIN, ³Oregon Health and Science University

W66. The Dynamics of Craving and Willingness-To-Pay for Drugs and Food in Daily Life

Sergej Grunevski¹, Emmanuel Alvarez¹, Emma Schweitzer¹, Julia Kong¹, Sahar Hafezi¹, Maelle Guegen¹, Anna Konova¹

¹Department of Psychiatry, UBHC, and Brain Health Institute, Rutgers University – New Brunswick

W67. Pain Catastrophizing Moderates the Relationship Between Chronic Pain and Insomnia Severity in Persons With Opioid Use Disorder

Melanie Baime¹, Prem Umang Satyavolu¹, Andrew S Huhn¹, Jennifer D Ellis¹

¹Johns Hopkins Bayview Medical Center

W68. Greater Coupling of Pain Intensity and Opioid Craving After Delaying Methadone Dose Among Veterans With Opioid Use Disorder

Robert MacLean¹, Suzanne Spinola¹, Brian Pittman², Julia Meyerovich¹, Sara Szollosy¹, Noah Wolkowicz³, Mehmet Sofuoglu⁴

¹VA Connecticut Healthcare System, ²Yale University School of Medicine, ³VA Connecticut Healthcare, Yale Medical School, ⁴Yale University

W69. An Intervention to Reduce the Stigma of Substance Use and Criminal Involvement Among Criminal Legal Staff: Feasibility, Acceptability, and Preliminary Effectiveness

Kelly Moore¹

¹East Tennessee State University

W70. Gender Differences in Substance Use Treatment Interest

Bailey Pridgen¹, Andrew Bontemps¹, Michelle Sisson¹, Karen Cropsey¹

¹The University of Alabama At Birmingham

W71. Adapting to the Fentanyl Epidemic: Rapid Qualitative Observations and Derived Protocol Modifications From the Emergency Department Longitudinal Integrated Care (ED-LINC) Randomized Clinical Trial

Lauren Whiteside¹, Kayla Lovett¹, Lawrence Palinkas², Field Craig³, Mark McGovern⁴, Caleb Banta-Green¹, Douglas Zatzick¹

¹University of Washington, ²University of Southern California, ³University of Texas, El Paso, ⁴Stanford University School of Medicine

W72. The Cost Effectiveness of Interim Buprenorphine Treatment Vs. Waitlist Control for Opioid Use Disorder: An Analysis of Three Randomized Trials

Sydney Batchelder¹, Eric Ross², Kelly Peck¹, Stacey Sigmon¹

¹University of Vermont, ²University of Vermont Health Network

W73. Effects of Opioid Use Disorder and Withdrawal on Striatal Reward Prediction Errors During Decision-Making

Michael Wesley¹, Joshua Beckmann¹, Shanna Babalonis², Joseph Alcorn¹, Kevin Hatton², Hays Lon¹, Miranda Ramirez³, Craig Rush¹, William Stoops², Joshua Lile²

¹University of Kentucky, ²University of Kentucky, College of Medicine, ³University of Kentucky, College of Arts and Sciences

W74. A Mobile Health Tool to Capture Social Determinants of Health and Their Impact on HIV Treatment Outcomes Among People Who Use Drugs

Caitlin Conway¹, Ryan Westergaard¹, Olivia Vjorn¹, Andrew Genz², Gregory Kirk², Rachel Gicquelais¹

¹University of Wisconsin - Madison, ²Johns Hopkins Bloomberg School of Public Health

W75. Association Between Social Exposure and Substance Use Among Youth in the Legal System

Yang Yang¹, Danica Knight¹

¹Texas Christian University

W76. Open Board

W77. Peer Intervention to Link Overdose Survivors to Treatment (PILOT): Study Protocol of a Multi-Site, Randomized Controlled Trial in the National Institute on Drug Abuse Clinical Trials Network

Carrie Papa¹, Erin McClure¹, Louise Haynes¹, Tim Matheson², Jenna McCauley¹, Rich Jones³, Tricia Lawdahl⁴, Kathleen Brady¹, Kelly Barth¹

¹Medical University of South Carolina, ²San Francisco Department of Public Health, ³YouTurn Health, ⁴FAVOR Upstate

W78. Nomi™ SMRxT Bottles Track Daily Medication Intake Patterns in Chronic Pain Patients Prescribed Opioids

Christina Merritt¹, Sierra Miller¹, Jonathan Hommel¹, Denise Wilkes¹, Kathryn Cunningham¹, David Houghton¹

¹John Sealy School of Medicine University of Texas Medical Branch

W79. Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I Feasibility, Usability, and Efficacy Randomized Clinical Trial

Sterling McPherson¹, Crystal Smith¹, Luke Hall¹, Andre Miguel¹, Theresa Bowden², Abigail Keever¹, Alex Schmidt¹, Katie Olson³, Nicole Rodin⁴, Michael McDonell¹, John Roll¹, Jeff LeBrun⁵

¹Washington State University Elson S. Floyd College of Medicine, ²Washington State University College of Nursing, ³Ideal Option, ⁴Washington State University College of Pharmaceutical Sciences and Pharmacy, ⁵Optimize Health

W80. Buprenorphine-Naloxone vs. Extended-Release Naltrexone for Opioid Use Disorder in People With Recent Criminal Legal Involvement: A Secondary Analysis of the X:BOT Randomized Controlled Trial

Dylan Balter¹, Lisa Puglisi¹, James Dziura², David Fiellin¹, Benjamin Howell¹

¹Yale University School of Medicine, ²Yale University School of Public Health

W81. Implementation Facilitation Improves Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine in Four Urban Academic Centers

Kathryn Hawk¹, Gail D'Onofrio², Marek Chawarski², Edouard Coupet², Ethan Cowan³, Leslie Curry⁴, Caroline Freiermuth⁵, Michael Lyons⁶, Alexandra Murphy⁷, Patrick O'Connor², Lynne Richardson³, Richard Rothman⁸, Lauren Whiteside⁹, Joseph Williams⁴, David Fiellin², E. Jennifer Edelman²

¹Yale University School of Medicine, Department of Emergency Medicine, ²Yale University, School of Medicine, ³Ichlan School of Medicine at Mount Sinai, Department of Emergency Medicine, ⁴Yale University, School of Public Health, ⁵University of Cincinnati, Department of Emergency Medicine, ⁶University of Cincinnati, College of Medicine, ⁷Yale University, Department of Emergency Medicine, ⁸Johns Hopkins University School of Medicine, Department of Emergency Medicine, ⁹University of Washington

W82. Variation in Psychosocial Symptom Change: A Preliminary Examination of Veterans in Early Medication Treatment for Opioid Use Disorder

Noah Wolkowicz¹, Mehmet Sofuoglu², Joao De Aquino³, Robert MacLean⁴

¹VA Connecticut Healthcare, Yale Medical School, ²Yale University, ³Yale University School of Medicine, ⁴VA Connecticut Healthcare System

W83. Ethical and Methodological Challenges in Studying Discontinuation of Medications for Opioid Use Disorder

Roger Weiss¹, Edward Nunes², Patricia Novo³, Matisyahu Shulman⁴, Genie Bailey⁵, Scott Provost¹, Sarah Meyers-Ohki³, David Liu⁶, John Rotrosen⁷

¹McLean Hospital, ²Columbia University and New York State Psychiatric Institute, ³New York University School of Medicine, ⁴College of Physicians and Surgeons, Columbia University/NYSPI, ⁵Stanley Street Treatment and Resources, Inc., ⁶National Institute on Drug Abuse, National Institutes of Health, ⁷Department of Psychiatry, NYU Langone School of Medicine, New York, NY, United States

W84. Profiles of Risk and Protection Among People who Use Illicit Opioids in NYC: A Latent Class Analysis

Luther Elliott¹, Alex S. Bennett², Joy Scheidell³

¹New York University, ²New York University College of Global Public Health, ³University of Central Florida

W85. The Role of Law Enforcement Officers in Overdose Response: Insights From a Qualitative Study With People who Use Drugs and Law Enforcement Officers

Sydney Silverstein¹, Tasha Perdue², Darwin Baluran², Ejuan Kendrick², Kaylee Larsen¹, Nathaniel Mack², Russell Hassan²

¹Boonshoft School of Medicine Wright State University, ²The Ohio State University

W86. A Care Cascade Analysis of Opioid Use Disorder Services Provided in Jail

Daniel Hoover¹, Alicia Feryn¹, Melanie Menear², Lee Eby², Elizabeth Waddell³

¹Oregon Health and Science University, ²Clackamas County Jail, ³OHSU-Portland State University School of Public Health

W87. Community Focused Technical Assistance: A Multifaceted Approach to Address Opioid-Related Overdoses

John Lauckner¹, Michelle Lofwall², Laura Fanucchi², Christopher Cook¹, Sharon Walsh³, Molly Gallivan¹, Jordan Kelsch⁴, Devin Oller²

¹University of Kentucky, Substance Use Priority Research Area, ²University of Kentucky, College of Medicine,

³University of Kentucky, ⁴University of Kentucky Substance Use Research Priority Area (SUPRA)

W88. Factors Associated With Sleep Health Among Community Recruited People who Inject Drugs in Los Angeles, CA and Denver, CO, 2021-22

Avaion Ruth¹, Karen Corsi², Kelsey Simpson³, Patricia Wilkins², Jesse Goldshear⁴, Eric Kovalsky², Dustin Duncan⁵, Ricky Bluthenthal³

¹University of Southern California, ²Department of Psychiatry, University of Colorado Denver School of Medicine, ³University of Southern California, Keck School of Medicine, ⁴Keck School of Medicine University of Southern California, ⁵Department of Epidemiology, Mailman School of Public Health, Columbia University

W89. Fentanyl Test Strip Knowledge and Attitudes Among Patients in the Emergency Department who Use Drugs

Megan Reed¹, Anne Siegler², Tracy Esteves Camacho¹, Kory London¹, Kevin Schaeffer¹, Kristin Rising¹

¹Thomas Jefferson University, ²Independent Researcher

W90. Open Board

W91. Patient Experiences With Buprenorphine Following Discontinuation of Long-Term Opioid Therapy

Jessica Wyse¹, Sarah Ono¹, Belle Zaccari², Jennette Lovejoy³, Noah Jacobson², ayushi gulati², Tiona Wu⁴, Taylor Ilevine², Amie Goerlich², Travis Lovejoy²

¹Oregon Health and Science University, ²VA Portland Health Care System, ³University of Portland, ⁴VA Potland Health Care System

W92. Primary Care Team Perspectives on Approaches to Engaging Patients in Treatment for Opioid Use Disorder

Elizabeth Austin¹, Jessica Chen¹, Elena Soyer¹, Bulat Idrisov¹, Elsa Briggs¹, Anna Ratzliff², Monica Ruiz³, Emily Williams¹, Ulrich Koch⁴

¹University of Washington School of Public Health, Department of Health Systems and Population Health,

²University of Washington School of Medicine, Department of Psychiatry, ³George Washington University, Milken Institute School of Public Health, ⁴George Washington University School of Medicine and Health Sciences, Department of Clinical Research and Leadership

W93. The Relationship between Substance Use and Remote Hiv Testing among Men at Risk for Hiv

Bethany McLeman¹, Kathleen Bell¹, Kyle Moon¹, Chantal Lambert-Harris¹, Haiyi Xie¹, Lisa Marsch¹

¹Geisel School of Medicine at Dartmouth College

W94. Intersectional Stigma and Aging Among Older Adults With Opioid Use Disorder

Benjamin Han¹, Mirella Orozco¹, Mari Miyoshi¹, Heidi Doland¹, Alison Moore¹

¹University of California - San Diego

W95. Hopelessness and Impulsivity and Recent Non-Fatal Overdose Among Overdose Survivors who Actively Use Nonprescribed Opioids in San Francisco and Boston

Vanessa McMahan¹, Xochitl Luna Marti¹, Emily Pope¹, Shae Wolfe², Adam Majeski², Gabriela Reed², Alexander Walley², Phillip Coffin¹

¹Center on Substance Use and Health, San Francisco Department of Public Health, ²Grayken Center for Addiction and Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Boston Medical Center and Boston University School of Medicine

W96. Scaling up Opioid Agonist Therapies in Ukraine Before the War: Implementation Factors Related to Disruptions From Legislative Reform and COVID-19

Lynn Madden¹, Roman Ivasiy², Maxim Polonsky³, Scott Farnum⁴, Samy Galvez³, Anna Meteliuk⁵, Daniel J. Bromberg⁶, Frederick Altice³

¹APT Foundation, ²Yale Medical School, ³Yale University School of Medicine, ⁴APT Foundation, Inc., ⁵Alliance for Public Health of Ukraine, ⁶Yale School of Public Health

W97. Open Board

W98. Effects of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain: A Scoping Review

Katherine Warren¹, Sooyeon Kho², Scott G. Weiner³, Carol Mita¹, Molly Franke¹, Shelly Greenfield⁴

¹Harvard Medical School, ²Brigham and Women's Hospital, ³Brigham and Women's Hospital, Harvard Medical School, ⁴McLean Hospital, Harvard Medical School

W99. Barriers and Facilitators to the Prescription Monitoring Program in Harris County, TX: Preliminary Findings

Alejandro Betancur¹, J. Michael Wilkerson², Niles Zoschke², David Adzrago²

¹The University of Texas Health Science Center At Houston, ²The University of Texas Health Science Center at Houston

W100. Impact of a Brief Educational Intervention on Preferences for Medications for Opioid Use Disorder

Pooja Lagisetty¹, Adrienne Kehne², Stephanie Slat¹, Colin Macleod¹, Amy Bohnert¹

¹University of Michigan, ²Center for Clinical Management and Research, Ann Arbor Veterans Health Administration

W101. Moderate-Vigorous Physical Activity and Opioid Use Status

Elizabeth Lee¹, Andrew Bontemps¹, S. Justin Thomas¹, Karen Gamble¹, Karen Cropsey¹

¹The University of Alabama At Birmingham

W102. What Makes an Emergency Department Peer? Characteristics of Effective Peer Recovery Support Specialists in an Ed-Based Post-Overdose Intervention

Mia Kirk¹, Karla Wagner²

¹University of Nevada, Reno School of Public Health, ²University of Nevada School of Public Health

W103. Feasibility of Ecological Momentary Assessment With People who Inject Drugs: A Pilot Study

Kristina Phillips¹, Trent Lalonde², Michael Phillips³, Catherine Erickson¹, Jonathan Lai¹, Michael Stein⁴

¹Kaiser Permanente Hawaii, Center for Integrated Health Care Research, ²Colorado Department of Early Childhood, ³University of Hawai'i – Manoa, Office of Public Health Studies, ⁴Boston University, School of Public Health

W104. Open Board

W105. Exploring the Impact of the COVID-19 Pandemic on MOUD Retention in a Sample of Rural Primary Care Patients

Stacy Calhoun¹, Huiying Guo², Zhe Fei¹, Laura-Mae Baldwin³, Allison Ober⁴, Megan Black², Sarah Clingan², Emily Kan¹, Chunqing Lin⁵, Huyen Pham⁶, Yuhui Zhu⁶, Larissa Mooney², Yih-Ing Hser²

¹University of California, Los Angeles, ²Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles, ³University of Washington Department of Family Medicine, ⁴RAND Corporation, ⁵David Geffen School of Medicine at UCLA, ⁶Semel Institute - UCLA

W106. Peer Support for Individuals Presenting in Emergency Departments Following Opioid Overdose: Association of Program Implementation With Drug Treatment Initiation and Repeat Overdose

Peter Treitler¹, Anna Kline¹, Nina Cooperman², Stephen Crystal¹, Kristen Lloyd¹, Sujoy Chakravarty¹, Joel Cantor¹, Cory Morton¹, Kristen Powell³

¹Rutgers University, ²Rutgers Robert Wood Johnson Medical School, ³Rutgers, The State University of New Jersey

W107. Access to Tablet Injectable Opioid Agonist Therapy in Rural and Smaller Urban Settings in British Columbia: A Qualitative Study

Geoff Bardwell¹, Jeanette Bowles², Manal Mansoor², Dan Werb³, Thomas Kerr²

¹University of Waterloo, ²British Columbia Centre on Substance Use, ³University of California San Diego

W108. Expanding Medication for Opioid Use Disorder (MOUD) Treatment in Rural Health Care Systems: A Case Example

Christopher Cook¹, Lisa Childress², Stacy Caudill², Wes Romanello², Debbie Duckworth³, Jennifer Miles¹, Sharon Walsh⁴, Laura Fanucchi⁴, Devin Oller⁴, Michelle Lofwall⁴

¹University of Kentucky, Substance Use Priority Research Area, ²King's Daughters Medical Center, ³University of Kentucky, Specialty Pharmacy and Infusion Services, ⁴University of Kentucky, College of Medicine

W109. Barriers and Facilitators to Expanding Buprenorphine Treatment for Opioid Use Disorder in Jail Settings

Jordan Kelsch¹, Margaret McGladrey², Carrie Oser³, Laura Fanucchi⁴, Sharon Walsh⁵, Marisa Booty¹, Michelle Lofwall⁵

¹University of Kentucky Substance Use Research Priority Area (SUPRA), ²University of South Florida, Department of Mental Health Law and Policy, College of Behavioral and Community Sciences, ³University of Kentucky, Dept. of Sociology, College of Arts and Science, Center on Drug and Alcohol Research, ⁴University of Kentucky, Dept. of Internal Medicine, Center on Drug and Alcohol Research, ⁵University of Kentucky, Dept. of Behavioral Science, Center on Drug and Alcohol Research

W110. Associations Between Receipt of Government Assistance and Past-Year Substance Use Treatment Utilization Among People With Alcohol or Drug Use Disorders in the United States, 2015-2019

Sarah Gutkind¹, Morgan Philbin², Pia Mauro¹

¹Columbia University, ²University of California San Francisco

W111. Craving Persistence Over 3 Months: An Early and Predictive Marker of Addiction?

Emmanuelle Baillet¹, Cassandre Romao¹, Fuschia Serre², Sarah Moriceau², Marc Auriacombe¹

¹University of Bordeaux, ²Universite de Bordeaux

W112. Drug Checking in the Fentanyl Era: Awareness, Interest, and Utilization Among People who Inject Drugs in San Diego County, California

Katie Bailey¹, Annick Borquez², Daniela Abramovitz², Irina Artamanova², Peter Davidson², Tara Stamos-Buesig³, Carlos Vera², Thomas Patterson², Jaime Arredondo⁴, Jessica Kattan⁵, Sayone Thihalolipavan⁵, Steffanie Strathdee²

¹University of California San Diego and San Diego State University, ²University of California San Diego, ³Harm Reduction Coalition of San Diego, ⁴British Columbia Centre on Substance Use, ⁵County of San Diego Health and Human Services

W113. Psychosocial Functioning and Health Service Utilization Among Psychiatric Subgroups in a Substance-Using Homeless Population: A Cluster Analysis of the at Home/Chez Soi Study in Vancouver, BC

Thomas Wen-Chi Chao¹, Suky Martinez², Jane J. Kim¹, Christian G. Schütz¹

¹University of British Columbia, ²Columbia University Vagelos College of Physicians and Surgeons

W114. Transcultural Translation and Adaptation of the Universal Treatment Curriculum for Fostering Professional Treatment Workforce for Substance Use Disorders in Taiwan

An-Nie Chung¹, Li-Ching Wang¹, Yu-Chu Ella Chung¹, Pei-Hsuan Lin¹, Kai-Hsiang Kang¹, Ya-Wen Yang¹, Yi-Ya Lai¹, Yen-Feng Lin¹, Sheng-Chang Wang¹, Wei J. Chen²

¹Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Miaoli County, Taiwan, ²Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Miaoli County, Taiwan; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan; Department of Psychiatry, College of Medicine and National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan

W115. Prevalence of Cannabis, Nicotine, and Alcohol Use and Associations With Psychological and Diabetes Distress Among Young Adults With Type 1 Diabetes

Enzo Plaitano¹, Catherine Stanger¹

¹Dartmouth College

W116. Emotion Dysregulation Fully Mediates the Relationship between Stress and Impulsivity in Inpatients With Co-Occurring Substance Use and Mental Health Disorders

Stefanie Todesco¹, Thomas Wen-Chi Chao¹, Chris Schütz¹

¹University of British Columbia

W117. Dynamic Modeling on the Health Outcomes for People With First-Time Offense of Different Illicit Drugs in Taiwan With Implications for Policy

Chi-Ya Chen¹, Shang-Chi Wu¹, Lian-Yu Chen², Hsien-Ho Lin³, Yu-Chi Tung⁴, Wei J. Chen⁵

¹Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan, ²Taipei City Hospital, ³National Taiwan University, K3 and Preventive Medicine, ⁴Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan and Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan, ⁵National Taiwan University College of Public Health

W118. Co-Use of Harm Reduction and Addiction Treatment Services Associated With Decreased Non-Fatal Overdose in Catalonia

Todd Korthuis¹, Ibrahim Sonmez², Xavier Majó³, Albert Espelt⁴, Mercè Meroño⁵, Francina Fonseca⁶, Joan Colom³, Jordi Casabona⁷, Cinta Folch⁷, REDAN Study Group⁸

¹Oregon Health and Science University, Portland, OR USA, ²CEEISCAT, ³Sub-direcció General de Drogodependències, Agència de Salut Pública de Catalunya, Barcelona, Spain, ⁴Departament de Psicobiologia i Metodologia en Ciències de la Salut, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain, ⁵Fundació Àmbit Prevenció, Barcelona, Spain, ⁶Institut de Neuropsiquiatria i Addiccions (INAD)- Hospital del Mar Medical Research Institute-IMIM, Barcelona, Spain / Medicine and Health Sciences Department. Universitat Pompeu Fabra, Barcelona, Spain, ⁷CEEISCAT; Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Departament de Salut, Generalitat de Catalunya, Badalona, Spain; Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, ⁸-

W119. Associations Between Kratom-Related State Policy Environments and Kratom Use in a Nationally Representative Population in the United States

Mance Buttram¹, Matthew Ellis², Joshua Black³

¹University of Arkansas, ²Washington University in St. Louis, ³Rocky Mountain Poison and Drug Safety

W120. Adaptation of a Digital Intervention to Reduce Substance Use and Increase Contraceptive Access Among Women Involved in Criminal Legal Systems

Melissa Slavin¹, Chermaine Black¹

¹Columbia University School of Social Work

W121. Earlier Substance Use and Differential Rates by Substance Class for Youth With Combined Externalizing Disorders and Family History of Substance Use Disorders

Michael Smoker¹, Olivia Murray¹, Michael Peck¹, Leslie Hulvershorn¹

¹Indiana University School of Medicine

W122. Diabetes Management in Patients With Substance Use Disorder Served in a Network of Federally Qualified Health Centers in Florida: A Retrospective Analysis Using EHR Data

Viviana Horigian¹, Renae Schmidt¹, Rui Duan¹, Daniel Parras², Katherine Chung-Bridges², Jacob Batycki³, Kevin Espinoza¹, Peyman Taghioff¹, Sophia Gonzalez¹, Carly Davis¹, Daniel Feaster¹

¹Miller School of Medicine, University of Miami, ²Health Choice Network, ³Ross School of Medicine

W123. Enhancing Integration of Substance Use Research Among BIRCWH Scholars: The BIRCWH Scholars Innovation Program (BSIP) Needs Assessment

Karen Hartwell¹, Jacqueline McGinty², Constance Guille², Aimee McRae-Clark¹, Amanda Wagner², Jenna McCauley², Kathleen Brady²

¹Medical University of South Carolina; Ralph H. Johnson VAMC, ²Medical University of South Carolina

W124. A Preliminary Evaluation of the Cost-Effectiveness of Long-Term Post-Treatment Peer Recovery Support Services in the United States

Sierra Castedo de Martell¹, Margaret Brannan Moore², Hannah Wang², H. Shelton Brown, III²

¹JEAP Initiative, ²UTHealth School of Public Health

W125. California's Drug Medi-Cal Organized Delivery System Implementation: Substance Use Services Evolution From 2017-2021, Key Lessons Learned and Systems Improvements From the 1115 Demonstration Project

Rama Khalsa¹, Vandana Joshi², Samantha Fusselman³, Patrick Zarate³

¹UCLA, ²University of California - Los Angeles, ³Behavioral Health Concepts

W126. Understanding Cannabis Use Among Teens who Vape Nicotine

Danielle Davis¹, Ran Wu¹, Krysten Bold¹, Grace Kong¹, Meghan Morean¹, Suchitra Krishnan-Sarin¹

¹Yale University School of Medicine

W127. Supportive Services Program Utilization Among Substance Use Treatment Clients Using Big Data

Vandana Joshi¹, Tina Kim², Rama Khalsa¹, Brittany Bass¹

¹University of California - Los Angeles, ²Los Angeles County, Dept of Public Health, Substance Abuse Prevention and Control

W128. Using an Environmental Scan to Organize Substance Use Prevention Resources to Address the Social Determinants of Health

Holly Hagle¹, Cara Alexander², Ingrid Donato², Thia Walker², Rachel Witmer³, Rory McKeown³

¹UMKC, ²SAMHSA, CSAP, ³UMKC, PTTC

W129. Avoidance of Racial Trauma Exposure and Concurrent Substance Use Among Racial/Ethnic Minoritized Young Adults

Kaytryn Campbell¹, Devin Banks², Kari Thompson³, Kathryn Howell³

¹University of Missouri - St. Louis, ²University of Missouri--St. Louis, ³University of Memphis

W130. Illicit Drug Use in Adolescents Versus Adults Among Those With Use of Other Psychoactive Substance or Depressive Symptoms: A Conditional Prevalence Analysis of the 2014 and 2018 National Survey of Substance Use in Taiwan

Shang-Chi Wu¹, Lian-Yu Chen², Po-Chang Hsiao¹, Te-Tien Ting³, Cheng-Fang Yen⁴, Shu-Sen Chang⁵, Chung-Yi Li⁶, Hao-Jan Yang⁷, Chia-Feng Yen⁸, Chuan-Yu Chen⁹, Jiun-Hau Huang⁵, Yu-Kang Tu¹, Wei J. Chen¹⁰

¹Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan, ²Department of Addiction Psychiatry and Kunming Prevention and Control Center, Taipei City Hospital, Taipei, Taiwan, ³School of Big Data Management, Soochow University, Taipei, Taiwan, ⁴Department of Psychiatry, Kaohsiung Medical University Hospital and School of Medicine and Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, ⁵Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan and Institute of Health Behaviors and Community Sciences, College of Public Health, National Taiwan University, Taipei, Taiwan, ⁶Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ⁷Department of Public Health, College of Health Care and Management, Chung Shan Medical University, Taichung, Taiwan, ⁸Department of Public Health, College of Medicine, Tzu Chi University, Hualien, Taiwan, ⁹Institute of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan, ¹⁰Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan

W131. Polygenic Risk for Alcohol, Cannabis, and Opioid Use Disorder as Predictors of Age of Initiation in a Community Sample

David Sosnowski¹, Jill Rabinowitz¹, Kenneth Feder¹, Nicholas Lalongo¹, Brion Maher¹

¹Johns Hopkins Bloomberg School of Public Health

W132. Changes in Use of Cigarettes, e-Cigarettes, Alcohol, and Cannabis Among U.S. Adults According to State-Level Legalization of Non-Medical Cannabis, 2013-2019

Danielle Smith¹, Pete Driezen², Shannon Gravely², Nicolas Schlienz¹, David Hammond², Andrew Hyland¹, Richard O'Connor¹, Geoffrey Fong², Mary Thompson², Karin Kasza¹

¹Roswell Park Comprehensive Cancer Center, ²University of Waterloo

W133. Polysubstance-Use Trends in a Large Urine Drug Testing (UDT) Database: A Latent Class Analysis

Barrett Bolin¹, Penn Whitley¹, Eric Dawson¹, Kelly Olson¹, Steven Passik¹, Angela Huskey¹

¹Millennium Health, LLC

W134. Pandemic Era Changes in Drug Use and Harm Reduction Behavior Among People who Use Drugs in Rural Illinois

Alex Rains¹, Ellen Almirol², Erin Augustine², Kyle Miller³, Elizabeth Salisbury-Afshar⁴, Wiley Jenkins³, Mai Pho⁵

¹University of Chicago, Pritzker School of Medicine, ²The Chicago Center for HIV Elimination, University of Chicago, Chicago, IL, ³Department of Population Science and Policy, SIU School of Medicine, ⁴Departments of Family Medicine and Community Health and Population Health Sciences, University of Wisconsin School of Medicine and Public Health, ⁵Department of Medicine, University of Chicago

W135. Prevalence of Polysubstance Use Diagnoses in Electronic Health Records Data for Patients Hospitalized With Opioid Use Disorder or Opioid Poisoning at six NYC Public Hospitals

Carla King¹, Yasna Rostam Abadi¹, Noa Appleton¹, Medha Mazumdar¹, Jasmine Fernando¹, Adetayo Fawole¹, Roopa Kalyanaraman Marcello², Caroline Cooke², Johanna Dolle², Charles Barron², Jennifer McNeely¹, Yasna Rostam Abadi³

¹NYU Grossman School of Medicine, ²NYC Health + Hospitals, ³NYU School of Medicine

W136. Open Board

W137. Prep Experience and Willingness in Substance-Using MSM in Higher Incidence Southern U.S. Cities: NIDA Clinical Trials Network Study

Susan Tross¹, Tanja Laschober², Margaret Paschen-Wolff³, Melissa Ertl⁴, C. Mindy Nelson⁵, Lynette Wright⁶, Daniel Feaster⁵, Colby Hankey⁷, David Meche⁸, Chloe Lancaster⁹, Josh Fegley¹⁰, Mauda Monger¹¹, Christina Woodhouse¹², David Forrest⁵, Mary Hatch²

¹Columbia University Irving Medical Center/NYS Psychiatric Institute, ²University of Washington, Addictions, Drug and Alcohol Institute, ³Columbia University Medical Center, ⁴Columbia University and New York State Psychiatric Institute, ⁵University of Miami Miller School of Medicine, ⁶University of Washington Alcohol and Drug Abuse Institute, ⁷Aspire Health Partners, ⁸Louisiana State University School of Social Work, ⁹University of South Florida, ¹⁰Tulane University School of Social Work, ¹¹My Brother's Keeper Inc., ¹²Jasmyn Inc.

W138. PrEP and PEP Experience and Willingness in People who Use Opioids: A NIDA Clinical Trials Network Study in Southern U.S. Cities Where HIV Incidence Is High

Mary Hatch¹, Tanja Laschober², Margaret Paschen-Wolff³, C. Mindy Nelson⁴, Melissa Ertl⁵, Lynette Wright², Daniel Feaster⁴, Susan Tross⁵

¹University of Washington Addictions, Drug and Alcohol Institute, Department of Psychiatry and Behavioral Sciences, Seattle, WA, ²University of Washington, Addictions, Drug and Alcohol Institute, Department of Psychiatry and Behavioral Sciences, ³Division on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center at New York State Psychiatric Institute, New York, New York, ⁴Department of Public Health Sciences, University of Miami Miller School of Medicine, ⁵HIV Center for Clinical and Behavioral Studies, Division of Gender, Sexuality, and Health, Department of Psychiatry, New York State Psychiatric Institute and Columbia University, New York, New York

W139. Childhood Aggression and Adolescent Substance Use Initiation

Nora Satybaldiyeva¹, Erin Delker¹, Gretchen Bandoli¹

¹UC San Diego

W140. Substance Use in Pregnancy is Associated With Attention Deficit Hyperactivity Disorder in Childhood: Findings From the Adolescent Brain Cognitive Development Study

Jennie Ryan¹, Philip Veliz²

¹Thomas Jefferson University, ²Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing

W141. Positive Methamphetamine Urinalysis Result During Treatment Intake is Not Associated With Worst Treatment Outcomes Amongst Opioid Users Initiating Medication-Assisted Opioid Treatment in Rural Communities

Leslie Kenefick¹, Lisa Khairy¹, Luke Hall¹, Nicole Limberg¹, Kibeom Kwon¹, Sterling McPherson¹, Andre Miguel¹

¹Elson S. Floyd College of Medicine

W142. Attachment Insecurity Predicts Poly-Substance use in Individuals With Opioid Use Disorder Reporting Loneliness

Matthew Snyder¹, Lisham Ashrafioun², Tracy Stecker³, Nicholas Allan⁴, Jonathan Umansky⁵

¹Syracuse University, ²University of Rochester, ³VA Center of Excellence for Suicide Prevention; Medical University of South Carolina, ⁴Department of Psychiatry and Behavioral Health, Ohio State University, ⁵University of Rochester Rochester, NY

W143. Habitual Use of Tobacco and Alcohol on Tendency of Depression and Anxiety Evidence from 27,942 Taiwan Biobank Participants

Shaw-Ji Chen¹

¹Taitung MacKay Memorial Hospital

W144. Association of Opioid Analgesics, Benzodiazepines, Gabapentinoids, and Opioid Agonist Treatment With Mortality Among Individuals With Opioid Dependence

Chrianna Bharat¹, Natasa Gisev¹, Sebastiano Barbieri², Timothy Dobbins³, Sarah Larney⁴, Luke Buizen¹, Louisa Degenhardt¹

¹National Drug and Alcohol Research Centre, ²Centre for Big Data Research in Health, UNSW Sydney, Sydney, Australia, ³School of Population Health, UNSW Sydney, Sydney, Australia, ⁴Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Department of Family Medicine and Emergency Medicine, Université de Montréal

W145. Rates of Medication Prescription, Mental Health Disorder, and HCV Diagnoses Among Patients With Comorbid Alcohol and Opioid Use Disorder in Rural Primary Care Clinics

Emily Kan¹, Laura-Mae Baldwin², Larissa Mooney³, Andrew Saxon⁴, Yuhui Zhu⁵, Yih-Ing Hser⁶

¹University of California, Los Angeles, ²University of Washington, ³Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles, ⁴Veterans Affairs Puget Sound Healthcare System, ⁵Semel Institute - UCLA, ⁶UCLA Integrated Substance Abuse Programs

W146. Is Abstinence From Alcohol and Smoking Associated With Better Mood Among People With HIV?

Christina Freibott¹, Breanne Biondi¹, Sowmya R. Rao¹, Elena Blokhina², Greg Patts¹, Julianne Dugas¹, Sally Bendiks³, Evgeny Krupitsky⁴, Natalie Chichetto⁵, Jeffrey Samet⁶, Matthew Freiberg⁷, Michael Stein¹, Hilary Tindle⁷

¹Boston University School of Public Health, ²First Pavlov State Medical University, ³Boston Medical Center, ⁴V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, ⁵University of Florida - Department of Epidemiology, ⁶Boston University School of Medicine, ⁷Vanderbilt University Medical Center

W147. Neural and Behavioral Habituation to Sad Infant Stimuli in Mothers who Use Substances

Li Yan McCurdy¹, Sarah Yip¹, Patrick Worhunsky¹, Sohye Kim², Lane Strathearn³, Marc Potenza¹, Linda Mayes¹, Helena Rutherford¹

¹Yale University School of Medicine, ²University of Massachusetts Medical School, ³University of Iowa, Stead Family Department of Pediatrics

W148. Development of Text Message-Based Intervention Content for People who Inject Drugs: Opportunities and Challenges

Ian Aronson¹, Alex S. Bennett², Selena A. Gilles³, Mary-Andrée Ardouin-Guerrier⁴, Juan Esteban Baus⁴, Brent Gibson⁵

¹New York University, ²New York University College of Global Public Health, ³NYU Rory Meyers College of Nursing, ⁴NYU School of Global Public Health, ⁵Community Research

W149. Motives and Experiences of Psychedelic and Cannabis Co-Use Among Emerging Adult Cannabis Users: A Qualitative Analysis

Bridgid Conn¹, Alisha Osornio², Meagan Suen², Susie Choi², Omolola Odejimi², Janna Ataiants³, Ekaterina Fedorova³, Stephen E. Lankenau³, Carolyn F. Wong²

¹Children's Hospital Los Angeles and University of Southern California, ²Children's Hospital Los Angeles, ³Drexel University

W150. Effects of Target Self-Selection in an App-Based Contingency Management Intervention to Reduce Substance Use

Jesse Fletcher¹, Win Turner², Jody Kamon², Laura Monico³, Maxine Stitzer³, Shannon Gwin Mitchell³

¹Friends Research Institute, Inc., ²Center for Behavioral Health Integration, ³Friends Research Institute

W151. Heroin Use, Non-Medical Prescription Opioid Use, and Injection Drug Use among Urban High School Students Across the US

Himani Byregowda¹, Terrinieka Powell¹, Xinzi Wang¹, Sabriya Linton¹, Renee Johnson¹

¹Johns Hopkins Bloomberg School of Public Health

W152. Drug Use as a Risk Factor for Mortality From HIV, Cirrhosis, and Liver Cancer Among People 15-49 Years old in Uzbekistan

Sergey Soshnikov¹, Azizbek Boltaev²

¹Frankfurt University of Applied Sciences, ²Human Research and Development Center "INSON"

W153. Establishing and Engaging Community Partner Boards That Generate the Research Ideas

Tess Drazdowski¹, Patrick Hibbard¹, Michelle Cruz¹, JEAP Community Boards¹, JEAP Initiative Investigators¹

¹Oregon Social Learning Center

W154. Peer Recovery Center of Excellence Needs Assessment of Minority AIDS Initiative Grantees' Peer Worker Training Needs

Michelle Teti¹, Laurie Krom², Adam Viera², Shannon Roberts², Tanesha Burley², Lena Marceno³

¹University of Missouri, ²University of Missouri- Kansas City, ³Altarum Institute

W155. Preparing the Addiction Workforce to Practice Informed Eclecticism Through Integration of Motivational Interviewing and Cognitive-Behavioral Therapy

Bryan Hartzler¹, Alanna Feltner¹

¹University of Washington

W156. HIV Prevention Intervention Delivery via Facebook With Rural Appalachian Women who Use Drugs: Risk-Related Outcomes During Community Re-Entry Following Incarceration

Megan Dickson¹, Erika Pike¹, Michele Staton²

¹University of Kentucky, ²University of Kentucky, College of Medicine

W157. Identifying Common Drug Abuse Products in Polysubstance and Serious Adverse Events

Paula Bernander¹, Gabrielle Bau¹, Karilynn Rockhill¹, Jennifer Jewell¹, Matthew Ellis², Richard Dart¹, Joshua Black¹, Joshua Black³

¹Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO, USA,

²Washington University in St. Louis, ³Rocky Mountain Poison and Drug Safety

W158. A Systematic Mapping Review of Treatment for Persons who Use Drugs and Alcohol With Histories of Violence: Gaps in Treatment and Future Directors for Research

Sara Beeler¹, Olivia Gerrish¹, Benjamin Aldred²

¹Jane Addams College of Social Work, UIC, ²University Library, UIC

W159. The Use of LSD by Major Depression Status in the U.S.: 2008-2019 Time Trends and Sociodemographic Associations

Claire Walsh¹, Lauren Gorfinkel², Dvora Shmulewitz³, Deborah Hasin³

¹New York State Psychiatric Institute, ²The University of British Columbia, ³Columbia University

W160. Associations Between Harm Reduction Strategy Use and Acute Psychedelic Effects in Spanish Speakers who Used LSD or Psilocybin

Rafael Lancelotta¹, Christopher Timmerman², Ana Maria Ortiz Bernal³, Sandeep Nayak⁴, Nathan D. Sepeda⁴, Aki Nikolaidis⁵, Roland R. Griffiths⁴, Alan K. Davis⁶

¹The Ohio State University, ²Imperial College, ³University of Wisconsin-Madison, ⁴Johns Hopkins University,

⁵Child Mind Institute, ⁶Ohio State University

W161. Differing Approaches to Investigating the Therapeutic Efficacy of Psilocybin Across Diverse Indications

Ryan Lanier¹, Michael Bogenschutz², Emmanuelle Schindler³, Benjamin Kelmendi⁴, Caitlyn Durgin⁵, Judy Ashworth⁵

¹Pinney Associates, ²New York University Grossman School of Medicine, New York, NY, USA, ³VA Connecticut Healthcare System, West Haven, CT, USA, ⁴Yale School of Medicine, New Haven, CT, USA, ⁵Pinney Associates, Inc., Bethesda, MD

W162. Psychiatrists' Personal Use and Social Proximity to Psychedelics Predicts Attitudes Towards Drugs and Drug Users

Adam Levin¹, Paul Nagib¹, Alan K. Davis²

¹Ohio State University, College of Medicine, ²Ohio State University

W163. Hyperarousal/Sleep Disturbance and Inability to Discontinue Chronic Hypnotic Use

Timothy Roehrs¹, Gail Koshorek¹, Thomas Roth¹

¹Henry Ford Health System

W164. Pregnancy and Childbirth in Relation to Receiving the Deferred Prosecution for Amphetamine-Type Substance-Involved Female Offenders in Taiwan

Chuan-Yu Chen¹, Tan-Wen Hsieh², Rosetta Siew¹, Wenmay Rei¹, Sheng-Chang Wang²

¹National Yang Ming Chiao Tung University, ²National Health Research Institutes

W165. Prevalence, Geographic Variation and Racial/Ethnic Disparities in Methamphetamine Associated Heart Failure Among Veterans

Veena Manja¹, Cheng Chen², Alex Sandhu³, Steven Asch⁴, Susan Frayne⁴, Mark McGovern³, Paul Heidenreich⁴

¹Center for Innovation to Implementation, VA Palo Alto Health Care System; Stanford University, ²Center for Innovation to Implementation, VA Palo Alto Health Care Services, ³Stanford University, ⁴Center for Innovation to Implementation, VA Palo Alto Health Care Services; Stanford University

W166. A Pilot Study of 16-Week Intensive Outpatient Treatment for Gay and Bisexual Men With Methamphetamine Use Disorder in Taiwan

Yen-Chun Kou¹, Han-Ting Wei², Yu-Hsiung Chen¹, Chao-Hui Lee³, Sheng-Chang Wang⁴

¹Department of Psychiatry, Linsen, Chinese Medicine, and Kunming Branch, Taipei City Hospital, Taiwan,

²Kunming Prevention and Control Center, Taipei City Hospital, Taiwan, ³Blossom Clinic of Psychosomatic Medicine, Taiwan, ⁴National Health Research Institutes

W167. Hub Disruption in HIV Disease and Cocaine Use Disorder.

Kareem Al-Khalil¹, Ryan Bell², Sheri Towe², Jessica Cohen³, Syam Gadde², Shana Hall², Christina Meade²

¹Duke University, ²Duke University School of Medicine, ³University of North Carolina at Chapel Hill

W168. Open Board

W169. Co-Occurrence of Gaming Disorder and Drug Dependence in People who Use Stimulants During the Era of COVID-19 Pandemic in Taiwan

Tony Szu-Hsien Lee¹, Ming-Chyi Huang², Lian-Yu Chen², Kuen-Hong Wu³, Su-Chen Fang⁴, Cheng-Yi Huang⁵, Chun Lin², Chuan-Hsi Chen⁶, Lien-Wen Su⁷, Yang-Lin Lin³, Yi-Jia Wu², Chia-Chun Hung⁵

¹National Taiwan Normal University, ²Taipei City Hospital, ³Taoyuan Psychiatric Center, ⁴Mackay Medical College, ⁵Bali Psychiatric Center, ⁶National Taipei University, ⁷Taipei Medical University-Shuang Ho Hospital

AUTHOR INDEX

Abadi, Yasna Rostam	103	Bazan, Carolyn	72
Adams, Faith	80	Bazzi, Angela	113
Adams, Joella	123	Bedi, Gillinder	48
Adams, Zachary	51	Bedillion, Margaret	99
Adinoff, Bryon	38, 39	Beeler, Sara	138
Agrawal, Arpana	41	Beitel, Mark	110
Akbarian, Schahram	41	Bell, Ryan	81
Aldridge, Barrett	67	Berger, Alyssa	79
Alexander, Wynta	99	Bernander, Paula	137
Al-Khalil, Kareem	139	Berry, Meredith	40
Almog, Shahar	67	Betancur, Alejandro	129
Alshaarawy, Omayma	35	Bharat, Chrianna	136
Al-Tayyib, Alia	90	Bhatia, Devika	111
Alvarez, Emmanuel	90	Bhondokhan, Fiona	106
Amruthapuri, Rahul	20	Bickel, Warren	39
Ananthan, Subramaniam	44	Biondi, Breanne	102
Anastasio, Noelle	94	Bird, Helen	61
Anderson, Brian	24	Black, Anne	60
Andraka-Christou, Barbara	110	Black, Dominique	84
Angarita, Gustavo	56	Blake, Grace	60
Angelone, Leonardo	33	Blanco, Carlos	33, 48
Annunziato, Erin	59	Bobashev, Georgiy	63
Antoine, Denis	38	Bogenschutz, Michael	43
Apsley, Hannah	66	Bolin, Barrett	134
Ardouin-Guerrier, Mary-Andrée	111	Bolinski, Rebecca	27
Arensdorf, Angela	16	Bolton, Carma Deem	109
Arkell, Thomas	52	Bondy, Emma	85
Armstrong, Stacey B.	95	Bonny-Noach, Hagit	116
Arnold, Rachel	55	Bonson, Katherine	17
Aronson, Ian	136	Bontemps, Andrew	114
Arterberry, Brooke	70	Borja, Ana	80
Ashrafioun, Lisham	86	Borodovsky, Jacob	32
Ashworth, Judy	91	Borquez, Ignacio	72
Austin, Elizabeth	128	Bounds, Dawn	19, 55
Avila, Jaqueline	33	Bozinoff, Nikki	109
Awad, Ashraf	68	Bradley, Brooklyn	83
Azmi, Amirul Danial	117	Brandt, Laura	22, 104
Azzoni, Livio	113	Bremer, Paul	49
Baggott, Matthew	75	Brenneke, Savannah	26, 27
Bailey, Amelia	86	Bristol, Skye	19
Bailey, Katie	131	Brooks, Julia	57
Bailey, Steffani	92	Brown, Timothy	98
Baillet, Emmanuelle	131	Brown, Tracy	83
Baime, Melanie	125	Bruzeliuss, Emilie	101
Baker, Pieter	70	Bryant, Brittany	23
Baldassarri, Stephen	121	Bubier, Jason	48
Baldwin, Aileen	78	Budney, Alan	31, 32
Balise, Raymond	53	Buell, Eden	73
Balter, Dylan	127	Bunting, Amanda	26, 72
Balvanz, Peter	65	Burke, Colin	97
Banks, Devin	25, 26, 51	Burlew, A. Kathleen	23
Banta-Green, Caleb	105	Burwell, Scott	76
Bardwell, Geoff	130	Bushey, Michael	103
Barnes, Autumn	69	Bushnell, Greta	116
Barrington-Trimis, Jessica	30	Busse, Anja	73
Barson, Jessica	44	Butelman, Eduardo	18
Bart, Gavin	18, 54	Buttram, Mance	132
Batchelder, Sydney	126	Byregowda, Himani	137
Bauer, Alexandria	26	Cain, Gloria	23
Bayoumi, Ahmed	124	Calhoun, Stacy	130

AUTHOR INDEX

Calihan, Jessica	80	Datta, Abhishek	34
Campbell, Kaytryn	133	Davis, Alan	116
Carbonaro, Theresa	111	Davis, Chrysanthia	105
Carlson, Hannah	69	Davis, Danielle	37, 133
Carreiro, Stephanie	78	Degenhardt, Louisa	106
Carrico, Adam	50	DeLucia, Alexandra	26
Carter, Jordan	58, 94	de Martell, Sierra Castedo	133
Castillo, Felipe	61	Denis, Cecile	105
Cavazos, Patricia	93	Denson, Rebecca	120
Cazares, Leticia	73	Derminassian, Andrew	97
Cerdá, Magdalena	21	DeVeugh-Geiss, Angela	82
Chai, Peter	77	Devi, Lakshmi	44
Chandler, Corinne	115	Dewey, Jodie	66
Chang, Andy	77	Dewey, William	17
Chao, Thomas Wen-Chi	131	Dickson, Megan	137
Charron, Elizabeth	102	Diggs, Bria-Necole	56
Chatterjee, Avik	66	Dong, Huiru	122
Chattopadhyay, Ankita	89	Drazdowski, Tess	137
Chen, Catherine	84	Driezen, Peter	72
Chen, Chi-Ya	132	Dugosh, Karen	85
Chen, Chuan-Yu	138	Duncan, Alexandra	38
Chen, Lian-Yu	95	Dunn, Kelly	41, 42, 46
Chen, Shaw-Ji	136	Durgin, Caitlyn	62
Chen, Tianzhen	91	Dwoskin, Linda	42
Chen, Wei J.	101	Dwyer, Candice	72
Cheng, Hui	99	Eaton, Ellen	113
Chilcoat, Howard	24	Ebrahimi, Chantel	117
Christine, Paul	60	Eggert, Kathryn	64
Chung, An-Nie	131	Eglovitch, Michelle	89
Chung, Yu-Chu	93	Eisenstein, Toby	17
Cioffi, Camille	124	Ekhtiari, Hamed	44, 45, 62
Claborn, Kasey	35	Elbaz, Hosam	56
Clingan, Sarah	72	Elliott, Luther	127
Cloutier, Renee	20	Ellis, Jennifer	111
Cochran, Gerald	105	Ellis, Robyn	82
Coffin, Phillip	43, 124	Ely, Alice	96
Colledge-Frisby, Samantha	88	Endres-Dighe, Stacy M.	123
Coll, Neasa	92	Estadt, Angela	71
Comer, Sandra	30, 49	Evans, Rachel	21
Conn, Bridgid	137	Evins, Anne Eden	15
Conner, Brad	32	Evonko, Christopher	76
Conway, Caitlin	126	Fahey, Margaret	33
Cook, Christopher	130	Fairbairn, Nadia	122
Cook, Robert	56	Fairman, Brian	58
Cooper, Clinton	90	Falise, Alyssa	86
Cope, Lora	96	Falls, Zackary	114
Copenhaver, Michael	104	Fanucchi, Laura	53, 54
Cordoba-Grueso, Whitney	56	Faster, Daniel	53, 116
Coughlin, Lara	82	Feder, Kenneth	93
Craft, William	65	Feelemyer, Jonathan	91
Crane, Natania	80	Feinstein, Marc Jerome	121
Crimmins, Lauren	63	Fendrich, Michael	124
Cropsey, Karen	90	Fenton, Melissa	119
Crowley, Christina	87	Ferreiro, Andrea Vasquez	61
Cruz, Rick	19	Ferretti, Morgan	119
Cservenka, Anita	81	Fidalgo, Thiago	23
Cunningham, Kathryn	40, 41	Fields, Logan	84
Curtis, Brenda	38, 39	Fink, David	83
Cyr, Kevin	108	Fitzgerald, Nicole	99
Daniulaityte, Raminta	69	Flannagan, Kerry	119

AUTHOR INDEX

Fletcher, Jesse	137	Habersham, Leah	68
Fockele, Callan	106	Habib, Mohammad	119
Fogelman, Nia	72	Haddad, Stephanie	79
Forati, Amir Masoud	123	Hagle, Holly	133
Foster, Daniel	22	Hai, Audrey	110
Foster, Katrina	34	Hammerslag, Lindsey	89
Fox, Evelyn	86	Hammond, Christopher	49
France, Charles	34	Hammond, David	32
Franciotti, Kevin	24	Han, Benjamin	129
Fredericksen, Rob	115	Hanbury, Richard	28
Freeman, Kevin	37	Hand, Dennis	60
Freeman, Patricia	65	Haney, Margaret	15
Freibott, Christina	136	Hansson, Jocelyn	58
Freisthler, Bridget	117	Haque, Lamia	121
Friend, Lindsey	13	Harfmann, Roxanne	90
Frohe, Tessa	36	Harris, Joshua	78
Frost, Madeline	107	Harris, Miriam	68
Frye, Emma	94	Harrison, Eric	123
Fuster, Daniel	75	Harton, Moriah	113
Gaalema, Diann	45, 84	Hartung, Daniel	125
Gagnon, Kelly	85	Hartwell, Karen	133
Gainey, Sarah	62	Hartzler, Bryan	137
Galaj, Ewa	94	Hasin, Deborah	30
Gallivan, Molly	92	Hatch, Mary	135
Garcia, Erik	19	Hawes, Elizabeth	58
Garcia-Romeu, Albert	43	Hawk, Kathryn	127
Gatch, Michael	94	Hayley, Amie	52
Gazzola, Marina Gaeta	91	Heads, Angela	50
Gebru, Neo	19, 120	Heal, David	95
Gehlert, Don	77	Heidari, Omeid	122
Gex, Kathryn	57	Hendricks, Peter	24, 43
Giannini, Jillian	105	Henningfield, Jack	30, 74
Giardino, William	44	Henry, Maxine	110
Gicquelais, Rachel	123	Hernandez-Casas, Daisy	115
Gilbert, Paul	22	Herrera, Maria	60
Giles, Michael	76	Hester, Robert	36
Gilman, Jodi	97	Hides, Leanne	49
Glatfelter, Grant	95	Hill, Justine	84
Glynn, Tiffany	112	Hinckley, Jesse	51
Golde, Jake	78	Hindmarch, Grace	51
Gomez, Alejandro De La Hoz	115	Hiranita, Takato	66
Gonçalves, Priscila	19, 96	Hite, Desislava	75
Gopaldas, Manesh	36, 104	Hite, Michael	46
Gordon, Ellie	76	Hobin, Jennifer	21
Gorfinkel, Lauren	73	Hochheimer, Martin	71
Gosden, Jane	116	Hochstatter, Karli	75
Gould, Errol	68	Hodgson, Kate	64
Grasing, Ken	94	Hoffman, Kim	79
Greiner, Miranda	89	Homsted, Felicity	66
Gross, Ariana	70	Hoover, Daniel	128
Grossman, Daniel	58	Horigian, Viviana	132
Grunevski, Sergej	125	Houghton, David	86
Gryczynski, Jan	87	Howell, Benjamin	102
Guerin, Alexandre	82	Huhn, Andrew	41, 42
Gukasyan, Natalie	116	Humphrey, Jamie	25
Gupta, Abhishek	118	Hung, Chia-Chun	74
Gust, Steve	16	Huskinson, Sally	37
Gutkind, Sarah	131	Ibrahim, Layan	81
Gutowski, Stacie	46	Idrisov, Bulat	124
Guttman, Jeremy	76	Ilgen, Mark	57

AUTHOR INDEX

Islam, Kendall	62	Kou, Yen-Chun	139
Israel, Josh	28	Krause, Alexis	98
Jackson, Logan	69	Krawczyk, Noa	59
Jain, Jennifer	50	Kritikos, Brooke E.	111
James, G. Andrew	28	Krueger, Evan	31
Janes, Amy	15	Kulak, Jessica	33
Jarlais, Don Des	107	Kusi-Boadum, Nana Kofi	58
Jeansonne, Scott	102	Kuzniewicz, Michael	69
Jemberie, Wossenseged Birhane	80	Lacy, Ryan	38
Jimes, Cynthia	76	Lagisetty, Pooja	129
Johnson, Carla	21	Lake, Stephanie	97
Johnson, Matthew	43	Lancaster, Kathryn	58
Johnson, Micah	113	Lancelotta, Rafael	138
Jones, Abenaa	112	Lane, Suzanne	65
Jones, Christopher	33	Langlois, Jenna	70
Jones, Jermaine	42, 107	Lanier, Ryan	138
Jones, Joseph	77	Lankenau, Stephen	119
Jones, Marissa	94	Lapham, Gwen	120
Joseph, Verlin	62	Larochelle, Marc	103
Joshi, Vandana	133	Lauckner, John	128
Kahler, Christopher	50	Lavin, Antonieta	40
Kalmin, Mariah	75	Le, Mylinh	87
Kan, Emily	136	Ledgerwood, David	76
Kang, Augustine	100	Lee, Dustin	74
Kang, Kai-Hsiang	83	Lee, Elizabeth	129
Karamouzian, Mohammad	59	Lee, Kenneth	63
Karavolis, Zoe	115	Lee, Tony Szu-Hsien	139
Karns-Wright, Tara	35	Levin, Adam	138
Karoly, Hollis	99	Levin, Frances	83
Karunakaran, Thiruventhan	95	Levine, Emily A.	110
Kasinather, Vicknasingam	101	Levitsky, Igor	77
Kasson, Erin	65	Li, Anna	120
Katz, Brian	99	Li, Shuwen	57
Kaufman, Marc	77	Li, Wei	121
Kearney-Ramos, Tonisha	67	Li, Yang	41
Keen, Larry	99	Liew, Megan	69
Kehne, Adrienne	90	Lile, Joshua	90
Kelsch, Jordan	130	Lin, Chungqing	64
Kenefick, Leslie	135	Lin, Lewei (Allison)	116
Kennedy-Hendricks, Alene	93	Linden-Carmichael, Ashley	31, 32
Kepner, Wayne	69	Lippi, Stephen	68
Khairy, Lisa	125	Livne, Ofir	56
Khalsa, Rama	133	Lofwall, Michelle	53
Khodaparast, Navid	75	London, Edythe	14
Khokhar, Jibran	15	Lopes, Snehal	63, 91
Khotimchenko, Maksim	78	Lopez, Alexa	59
King, Carla	134	Lopez-Quintero, Catalina	118
King, Thomas	77	Loree, Amy	55
Kiraly, Drew	48	Loya, Jennifer	117
Kirk, Mia	129	Luba, Rachel	35, 49, 85
Kirtadze, Irma	57	Ludwig-Barron, Natasha	124
Kleykamp, Bethea	29, 32, 33	Lukas, Scott	17, 98
Knox, Justin	81	Lundahl, Leslie	81
Knudsen, Hannah	64	Luo, Ting	83
Kock, Loren	84	Lyons, Myla	93
Kong, Grace	84	Macias, Miracle	55
Koob, George	14, 15, 28	Mackesy-Amiti, Mary	64
Korthuis, P. Todd	73, 132	MacLean, Robert	125
Kosgolla, Janaka	113	Madden, Lynn	66, 129
Kouri, Nicole	89	Mallahan, Stephanie	88

AUTHOR INDEX

Malone, Natalie	65	Morrison, Filomene	67
Malone, Samantha	64	Morse, Sophie	65
Manja, Veena	138	Moses, Tabitha	55
Mannes, Zachary	119	Motemayor, Ana Chapa	97
Marchette, Renata	66	Moyers, Susette	35
Marcus, Olivia	74	Mulford, Carrie	51
Marino, Elise	35	Murnane, Kevin	43
Marks, Katherine	104	Murphy, Zoe	73
Marotta, Phil	123	Murray, Conor	82
Marra, Ashton	29	Murray, Laura	100
Martin, Caitlin	124	Myers, Amanda	92
Martin, Erin	98	Myers, Matthew	81
Martinez, Suky	104	Nader, Michael	37
Martins, Daniel	121	Nelson, Erik	25
Martins, Silvia	88	Nesoff, Elizabeth	101
Marziali, Megan	59	Nguyen, Anh	102
Matheson, Justin	120	Nguyen, Diep Bich	106
Mathur, Rahul	100	Nguyen, Tam	78
Mauro, Pia	71	Nielsen, Suzanne	23, 65
Maxwell, Andrea	86	Noggle, Brendan	121
Mbichila, Tinkhani	87	Nordeck, Courtney	103
McCabe, Andrew	88	Novak, Matthew	45, 117
McClure, Erin	82	Obekpa, Elizabeth	106
McCustian, Caravella	24, 61	Obel, Geoffrey	24
McCurdy, Li Yan	136	Oberlin, Brandon	75
McGinty, Jacqueline	40	Ochal, Domenic	125
McGriff, Shelby	95	Ochalek, Taylor	90
McKendrick, Greer	90	O'Dell, Nicole	81
McLellan, A Thomas	28	Odom, Gabriel	53
McLeman, Bethany	128	Oesterle, Tyler	114
McMahan, Vanessa	129	Okita, Kyoji	55
McNeely, Jennifer	54, 110	Oliva, Henrique	62, 94
McPherson, Sterling	127	Oliver, Jeffrey	75
Meacham, Meredith	26, 57	Olszewski, Nathan	85
Meade, Christina	119	Onigbogi, Olanrewaju	84
Meadows, Diamond	71	Oon-arom, Awirut	113
Medina, Maritza Perez	39	Opara, Onumara	85
Meredith, Lisa	51	Ortiz, Cynthia	83
Merritt, Christina	127	Oser, Carrie	63
Mestre, Luis	99	Oviedo-Joekes, Eugenia	22
Metz, Verena	109	Palmisano, Alexandra	58
Mian, Maha	98	Pang, Raina	84
Mihic, Tamara	60	Papa, Carrie	126
Miller, Thomas	78	Pareek, Tanya	80
Miloslavich, Krista	67	Parker, Maria	24, 85
Mitchell, Jennifer	24	Parks, Michael	79
Mitchell, Shannon	64	Parlier-Ahmad, Anna	105
Mitra, Sanjana	69	Parms, Tiffany	121
Mixson, Lyndsey	109	Paschke, Maria	26
Moeller, F. Gerard	40	Pasternak, Annie	77
Moffitt, Trevor	108	Patton, Thomas	107
Mohebbi, Fahimeh	123	Pearlman, Morgan	82
Moline, Margaret	114	Peck, Kelly	61
Montgomery, Barrett	47, 102	Peles, Einat	85
Moore, Debra	20	Perez-Carreno, Juan G	97
Moore, Kelly	126	Perez, Patricio Viera	100
Moreira, Eliseu	74	Perez-Pedrogo, Coralee	72
Moreland, Angela	23, 105	Perron, Lauren	106
Moriceau, Sarah	55	Perse, Artin	79
Morris, Alexis	83	Peters, Erica	38

AUTHOR INDEX

Pham, Huyen	61	Saraiya, Tanya	100
Phillips, Kristina	130	Satybaldiyeva, Nora	135
Pho, Mai	27	Saunders, Elizabeth	100
Picco, Louisa	107	Scarpetta, Maia	112
Pickering, Eleanor	92	Schacht, Joseph	45
Plaitano, Enzo	131	Scheidell, Joy	59
Pollock, Jonathan	41	Schepis, Ty	95
Potter, Jennifer	34	Schermitzler, Brandon	120
Pravetoni, Marco	49	Schmitz, Joy	14, 50
Preston, Thomas	98	Schow, Nicole	123
Pridgen, Bailey	126	Schranz, Asher	111
Pringle, Janice	20	Scott, Pamela	34
Proferes, Nicholas	27	Searcy, Carly	118
Purdon, Patrick	46	Seegulam, Vijaya	98
Pytell, Jarratt	101	Serrano, Vanessa	114
Quarles, Emma	57	Sessler, Nelson	96
Quddos, Fatima	74	Shah, Hridika	68
Rahman, Tahsin	31	Shakhshir, Ali	114
Rains, Alex	27, 134	Shakya, Pooja	61
Ralte, Lalchhanhima	96	Sharma, Anjalee	110
Ramaekers, Jan	52	Shearer, Riley	100
Ramirez, Miranda	119	Shepherd, Justin	84
Ramsey, Kelly	33	Shetty, Shekar	78
Randall-Thompson, Jovita	38	Shulman, Matisyahu	97
Rao, Deepika	60	Shurtleff, David	16
Ray, Lara	45	Siegel, Gregg	76
Reed, Brian	18	Silverstein, Sydney	128
Reed, Derek	40	Silwal, Anita	108
Reed, Megan	128	Singh, Vasudha	92
Reeser, David	46	Skewes, Monica	26
Regan, Timothy	55	Skinstad, Anne	21
Regier, Paul	112	Skogseth, Emma	101
Regnier, Sean	77, 117	Slavin, Melissa	132
Reich, Jeffrey	79	Slosky, Lauren	43
Reif, Sharon	67	Smid, Marcela	68
Richardson, Julia	71	Smith, Danielle	134
Ridenour, Ty	46, 47	Smith, Kirsten	68
Robinson, Athena	78	Smith, Rachel	122
Rocha, Beatriz	30	Smith, Sharon	95
Roehrs, Timothy	138	Smoker, Michael	132
Roman, Benjamin	120	Snyder, Hannah	96
Ross, Che	102	Snyder, Matthew	135
Ross, J. Megan	118	Sokolowska, Marta	30
Rouhani, Saba	67	Sorg, Barbara	40
Rowlett, James	36, 37	Sorkhou, Maryam	118
Roy, Payel	61	Soshnikov, Sergey	137
Russell, Lauren	56	Sosnowski, David	134
Ruth, Avaion	128	Sousa, Jason	49
Ryan, Jennie	135	Spindle, Tory	52
Ryan-Pettes, Stacy	19	Spitz, Stephanie	115
Rzeszutek, Mark	118	Sproule, Beth	103
Saavedra, Lissette	46	Stanton, Cory	73
Sadler, Richard	25	Staton, Michele	86
Sahlem, Gregory	120	Steine, Steven	22
Sakai, Joseph	34	Stein, Lynda	107
Salow, Katheryn	113	Stevens-Watkins, Danelle	26
Samples, Hillary	59	Stoltman, Jonathan	29
Sancho-Domingo, Clara	118	Strait, Matthew	17
Santos, Glenn-Milo	50	Strickland, Justin	39, 40
Santo, Thomas	59	Striley, Catherine	111

AUTHOR INDEX

Strong-Jones, Sienna	122	Wang, Hannah	94
Struble, Cara	30, 31	Wang, Jia Bei	76
Stull, Samuel	125	Wang, Jijiang	56
Sugarman, Dawn	108	Ware, Orrin	72
Sullivan, John	80	Warren, Katherine	129
Sullivan, Kyle	41	Wartko, Paige	108
Surratt, Hilary	70	Washio, Yukiko	58
Suzuki, Joji	104	Weaver, Nicholas	89
Svikis, Dace	69	Webber, Heather	74
Sweeney, Kaylin	91	Webster, Matt	91
Szlyk, Hannah	62	Weiss, Roger	127
Takano, Ayumi	117	Weiss, Susan	16
Tatangelo, Mark	103	Wesley, Michael	126
Terashima, Javier Ponce	106	West, Brooke	88
Teti, Michelle	137	Whistler, Jennifer	48
Thiessen, Karina	97	White, Augustus	124
Thompson, Ronald	28	Whiteside, Lauren	126
Thrul, Johannes	71	Wiese, Anna	120
Tilhous, Alyssa	60	Wightman, Rachel	98
Tillson, Martha	63	Wiley, Rhiannon	100
Timberlake, John	77	Wilkerson, J. Michael	63
Timmons, Patricia	117	Williams, Arthur Robin	125
Tiouririne, Nassima Ait-Daoud	34	Williams, Emily	88
Todesco, Stefanie	131	Williams, Michael	91
Tofighi, Babak	66	Windsor, Liliane	115
Tomko, Catherine	70, 92	Winstanley, Erin	101
Tomlinson, Devin	122	Witcraft, Sara	104
Tonigan, Alexandra	47	Withey, Sarah	83, 106
Torralva, Phillip	42	Wolinsky, David	56
Towers, Eleanor	67	Wolkowicz, Noah	127
Towe, Sheri	82	Won, Hyejung	41
Townsend, Drew	49	Won, Nae	68
Traxler, Haily	96	Wong, Carolyn	97
Treidler, Peter	130	Wong, Jennifer	34
Tross, Susan	135	Woody, George	62
Tsui, Judith	27, 88	Wright, Madison	57
Unterwald, Ellen	17, 18	Wright, Susan	47
Valeri, Jake	80	Wu, Shang-Chi	134
Vallender, Eric	118	Wyse, Jessica	128
Van Dyne, Angelina	112	Xenakis, Stephen	24
Vemuri, Kiran	47	Xin, Yitong	74
Vest, Bonnie	67	Xu, Kevin	87
Vest, Noel	36, 110	Yan, 'Elsie' Xu	98
Vidal, Carol	80	Yanez, Jaime	42
Vidot, Denise	37, 112	Yang, Yang	126
Viera, Adam	107	Yasuma, Naonori	81
Vitaliano, Gordana	79	Yeh, Yu-Hua	73
Volkow, Nora	13, 15, 28	Yip, Sarah	44, 45
Vo, Quynh	99	Young, Samantha	103
Vroom, Enya	89	Zamarripa, Carlos	52
Wagner, Karla	74	Zeid, Dana	94
Wahab, Suzaily	111	Zhang, Chenming	49
Walsh, Claire	138	Zhao, Yihong	57
Wang, Anna	86	Zhou, Yanjiao	48
Wang, Danny	115	Zhu, Yuhui	114

2022-2023 DONORS

Dr. Merideth Addicott
Dr. Judy Ashworth
Dr. Sudie Back
Dr. Jack Bergman
Dr. Qiana Brown
Dr. Kathleen Bucholz
Dr. Alan Budney
Dr. Sandra Comer
Dr. James Cook
Dr. Andrew Coop
Dr. Ziva Cooper
Dr. Linda Cottler
Dr. Richard De La Garza
Evan Dickert
Dr. Kelly Dunn
Dr. Linda Dwoskin
Dr. Linda Dykstra
Dr. Reginald Fant
Dr. Francesca Filbey
Dr. Albert Garcia-Romeu
Dr. Ellen Geller
Dr. Jillian Giannini
Johns Hopkins University Behavioral
Pharmacology Research Unit
Dr. Cassandra Gipson-Reichardt
Dr. Charles Gorodetzky
Dr. Shelly Greenfield
Dr. Margaret Haney
Dr. Deborah Hasin
Dr. Richard Hawks
Dr. Angela Heads
Dr. Jack Henningfield
Dr. Denise Hien
Dr. Frederic Hopf
Jesse Howard
Dr. Amy Janes

Dr. Jermaine Jones
Dr. Scott Lane
Dr. Scott Lukas
Dr. Wendy Lynch
Dr. Bertha Madras
Dr. Paolo Mannelli
Dr. Silvia Martins
Dr. Deborah Mash
Dr. Shayna Mazel
Dr. Heidi Melbostad
Dr. John Mendelson
Dr. Angela Moreland
Dr. Jason Paris
Dr. Robert Pechnick
Dr. Tasha Perdue
Dr. Marco Pravetoni
Dr. James Rowlett
Dr. Sidney Schnoll
Dr. Brian Sherman
Dr. Stacey Sigmon
Dr. Mark Smith
Dr. Lindsay Snyder
Dr. William Stoops
Dr. Eric Strain
Dr. John Strang
Dr. Yung-Fong Sung-Holtzman
Dr. Dace Svikis
Dr. Michael Taffe
Dr. D. Andrew Tompkins
Dr. Judith Tsui
Dr. Annie Umbricht
Dr. Patricio Viera Perez
Dr. Wendee Wechsberg
Dr. Erin Winstanley
Dr. George Woody



**The College *on* Problems
of Drug Dependence**

SAVE THE DATE

86th CPDD Annual Meeting

Montreal, Quebec Canada | June 16 - 19, 2024